Opioid-related side-effects and opioid-induced hyperalgesia by Isherwood, Ruth Jayne
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
n  
 
 
 
 
 
Isherwood, Ruth Jayne (2015) Opioid-related side-effects and opioid-
induced hyperalgesia. MD thesis. 
 
 
http://theses.gla.ac.uk/6598/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
  
 
 
 
Opioid-Related Side-Effects and 
Opioid-Induced Hyperalgesia 
 
 
 
Ruth Jayne Isherwood 
MB ChB, MRCS, MRCGP, MSc 
 
 
 
Submitted in fulfilment of the requirements for the 
degree of MD 
 
Institute of Cancer Sciences 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
January 2015 
 
 
 
 
2 
 
 
ABSTRACT 
 
 
Introduction: Opioids are widely used for the management of cancer and chronic non-
cancer pain and the maintenance management of patients with a history of substance 
misuse.  Increasingly the use of opioids is being scrutinised as patients are prescribed 
opioids for longer periods and the long-term effects of the opioids becomes clinically more 
relevant and evident. Our work has explored the prevalence of opioid-related side-effects 
in patients who are prescribed opioids and explored the clinically relevant phenomenon of 
opioid-induced hyperalgesia. .  
Methods: Patients were recruited who were prescribed opioids for the management of 
cancer and non-cancer pain or substance misuse. Quantitative data was collected to explore 
the prevalence and severity of opioid related side-effects, the impact of opioids on 
cognitive function and the effect of opioids on peripheral nerve function through 
quantitative sensory testing. Testing the sensory processing of patients who are on opioids 
has revealed altered thermal thresholds and the presence of wind-up at non-painful sites 
indicating central sensitisation. Qualitative description was used to explore the patient 
experience of an episode of opioid toxicity. 
Results: Patients have a significant burden of side-effects which have often not been 
recognised by clinicians. Using the Addenbrooke’s Cognitive Examination much more 
cognitive impairment has been revealed than has previously been recognised. Altered 
thermal thresholds and wind-up at non-painful sites suggests altered pain processing as a 
result of opioids. Themes from the qualitative description highlighted the coping strategies 
patients’ develop when managing with significant side-effects and toxicity, the covert self-
management of their pain and the need to exert control. One of the most significant 
findings from the qualitative research was the finding of altered sensation and pain 
description associated with other features of opioid toxicity. 
Conclusions: The impact of opioids on the cognitive function of patients has significant 
implications in terms of patients’ involvement in decision-making and functioning in 
everyday life. The qualitative data reflects the burden of side effects and the descriptions of 
patients suggest that opioid-induced hyperalgesia exists as part of the spectrum of opioid 
toxicity. This finding may help physicians identify patients who are developing opioid-
induced hyperalgesia and allow them to intervene earlier with a proactive approach. 
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CHAPTER 1:  INTRODUCTION 
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1.1 Introduction 
 
 
Opioids are used throughout the world to manage pain and remain a key component of 
pain management. Increasingly we are recognising that there are side effects associated 
with the use of opioids on a long term basis about which we know very little. There are 
many clinically relevant questions relating to opioid usage which require exploration. 
These opioid related effects may impact on the health and well-being of patients but they 
may also affect pain processing. 
 
 
1.2 Definition and Prevalence of Pain 
 
 
The International Association for the Study of Pain define pain as 
 
 
“an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.” (Loeser and Melzack, 1999, page 
1607) 
 
 
Pain is a major health problem worldwide. It is estimated that at any time 15 – 25% of the 
adults across the world are living with pain (Brennan, Carr and Cousins 2007). Some 
diagnoses are associated with pain for example up to 70% of the adults with cancer will 
experience pain (Brennan, Carr and Cousins 2007).  In the UK and in other developed 
nations we have many resources to help manage pain. However across the world to ensure 
everyone has access to pain management there is a need to provide opioids at an affordable 
cost to all, to provide guidance to clinicians about the legal status of the opioids and how to 
safely prescribe them and to educate professionals so that opioids and other pain 
management therapies can be used effectively and safely.  (Brennan, Carr and Cousins 
2007) 
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In a review of symptoms by Miller Reilly and her colleagues in 2013 in people receiving 
active cancer treatment pain was one of the symptoms experienced most frequently (Miller 
Reilly et al, 2013). Cancer pain tends to be multiple in terms of the nature and sites of pain 
experienced by the patient. The pain may be due to the tumour invading adjacent structures 
for example nerves or destroying bony structures or due to the treatments given to manage 
the cancer. Patients with cancer may be restricted in their mobility and this can result in 
pain due to the complications of immobility, for example pressure sores. 
 
 
All pain is recognised as a subjective experience. The individual response to a painful 
stimulus is affected by their previous experiences of pain and the emotional state at the 
time of the pain. In palliative medicine the importance of pain as having spiritual, social 
and psychological components as well as the physical component is well recognised. This 
concept of pain is fundamental to managing cancer pain.  
 
 
When pain is not treated well there are physical and emotional sequelae including poor 
sleep, anxiety and depression, loss of time at work or reduced productivity at work 
(Brennan, Carr and Cousins 2007). 
 
 
1.3 The Assessment of Pain 
 
 
Pain can be described as sharp, burning, aching, dull or stabbing by patients. The 
descriptors used help the clinician form an understanding of the underlying cause of the 
pain. Clinicians may also use pain assessment tools such as numerical rating scales or 
visual analogue scales to help understand the severity of the pain and monitor the response 
to analgesia. Other scales give “multidimensional” information about the pain and describe 
both the severity and the extent to which it impacts on function or quality of life. In 
addition the clinician uses their knowledge of the disease process to recognise and predict 
patterns of pain and other symptoms. Ronald Serlin and colleagues that pain severity and 
interference are linked in a predictable way (Serlin, et al, 1995) however the extent to 
which pain is a subjective response would seem to dispute this. 
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Some authors have called for a classification of pain based on the underlying 
pathophysiology and suggest that this facilitates pain management as physicians could 
target different pathways. It is possible that this approach would facilitate research (Woolf 
et al, 1998) but it largely ignores the emotional element to pain.    
 
 
In a survey of physicians Caraceni explored the link between cancer site and pain. He 
found that primaries of the head and neck, respiratory and upper gastrointestinal tracts had 
pains which were closely related to the primary. For patients with other cancers the pain 
was most likely to be in the low back or sacral area. (Caraceni, 2001) 
 
 
1.4 Pathophysiology of Pain 
 
 
Acute pain results from tissue injury and healing. It serves a physiological purpose in 
helping the body protect itself from further injury and enable healing. Several 
inflammatory mediators and neurotransmitters are released in response to the injury 
including substance P, prostaglandins and endorphins. Endorphins are opioid-like 
structures and they inhibit the pain signal peripherally. (von Gunten 2011; Loeser and 
Melzack,1999) 
 
 
Nociceptors are transducers found in many of the tissues of the body including skin, bones 
and organs such as the bladder. Nociceptors respond to changes in their homeostatic 
environment for example heat, cold, pressure, chemical damage. When the nociceptors are 
activated the signal is transmitted via the A delta fibres which transmit pain signals quickly 
yielding an immediate response to the stimulus and via C fibres which generate a slower 
less localised response. Cancer will cause chronic nociceptive pain when local tumour 
presence causes ongoing stimulation of the receptors. (von Gunten 2011) The nociceptor 
can become sensitised and generate spontaneous firing of pain signals, and they respond at 
lower levels of stimulation. (Portenoy, 1992) 
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From the nociceptor the pain signal travels via the peripheral nerves and then to the brain 
via the contralateral spinothalamic tract. Third order neurones pass from the spinothalamic 
tract to the cerebral cortex where the pain is mapped. (von Gunten 2011) 
 
 
When there is damage to one of the peripheral nerves or part of the central nervous system, 
neuropathic pain is generated. Neuropathic pain is a feature of pain for many cancer 
patients. It is recognised by its anatomical definition and associated features of altered 
sensation for example numbness. 
 
 
Chronic pain can occur due to excitatory effects in the spinal cord which result in altered 
function of the spinal cord. Previous experience and learning about pain are very important 
and will temper the individual’s response to any painful stimulus. 
 
 
1.5 Management of Pain 
 
 
There are many barriers to managing pain well. Some of these are physician related 
barriers for example a reluctance to prescribe opioids, lack of understanding about the 
drugs and the potential for side effects, failure to manage the side effects of opioids. There 
are also patient related barriers for example concern over starting morphine in case it 
heralds a poor prognosis, fear of side effects, concern over a perceived stigma of taking 
opioids. Some patients worry that discussing the pain will distract the physician from 
managing the cancer. Patients may believe pain is inevitable and needs to be tolerated and 
this is more likely if the patient is depressed (Jacobsen et al, 2009). In a literature review 
the importance of social and cultural influences over patients’ responses to pain and their 
use of analgesia were highlighted (Jacobsen et al, 2009). 
 
 
Pain is recognised as a multidimensional experience. As such a multimodal approach to the 
management of pain is required. Due to its availability, cost and the variety of preparations 
available morphine is the first line opioid for the management of pain. Not all pain will 
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respond to opioids and other drugs and pain management interventions are likely to be 
needed also. For example patients may be on adjuvant analgesia such as gabapentin or 
amitriptyline, they may be using a TENS machine and seeking psychological or spiritual 
support. 
 
 
Understanding the pathophysiology of pain enables combinations of drugs and 
interventions to be chosen with a logical approach. Paracetamol and the non-steroidal anti-
inflammatory agents reduce prostaglandin synthesis and will return the medium around the 
nociceptor to its usual state. Opioids act at central and peripheral receptors and reduce 
nociceptor signalling by altering potassium and calcium levels in the neurone. 
 
 
Opioids are key to the management of cancer pain in particular however not all pain is 
opioid-responsive. Neuropathic pain is typically poorly responsive to opioid analgesia. 
Opioid responsive pain implies that the pain responds to opioid analgesia without 
unacceptable side effects. About 10 – 20% of patients will not experience good pain relief 
despite the introduction of opioids. (Hanks and Justins, 1992) 
 
 
Patients who have cancer pain usually have more than one site of pain and more than one 
type of pain. In one study it was reported that 80% of patients with cancer have two or 
more pains and 34% have four or more pains. (Bennett, 2005) It is therefore unlikely that 
cancer patients will be relying on one form of analgesia alone. 
 
 
Some physicians and patients have been concerned that the use of opioids shortens life. In 
a very large study based on the experience of 13 American hospices clinical data from 
1,163 patients was reviewed. The last change in the opioid dose was a mean of 12.46 days 
(+/- 23.11) with a median of 5 days and a range of 0 to 231 days. They found that a higher 
dose was associated with a shorter time to death of the patent but the percentage dose 
change was not associated with shorter time to death. Overall the authors concluded the 
study should reassure clinicians that opioids can be prescribed at the end of life to alleviate 
pain and without concern that death will be hastened. (Portenoy et al, 2006) 
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1.6 Adverse Effects of Opioids 
 
 
Morphine and the other strong opioids have many adverse effects and there is considerable 
overlap between the side effects of morphine and the side effects of the other strong 
opioids. Patients may respond better to one opioid than another. At the moment it is not 
possible to predict response unless a patient has impaired renal and / or liver function in 
which case the metabolism and excretion of certain opioids means they will accumulate 
and cause side effects and toxicity.  
 
 
The side effects of opioids can be grouped into neuropsychiatric, gastrointestinal, 
respiratory, dermatological and pharmacological. (Lawlor and Bruera 1998). Delirium, 
sedation and impaired cognitive function are all in the neuropsychological group. Sedation 
is usually associated with either the initiation of opioid or a dose titration and most reports 
suggest this is a temporary side effect. The impact of opioids on cognitive function is 
discussed in detail in a later section. Overall there are mixed results from the studies done 
and a suggestion that residual pain may counter the effects of the opioids by the arousal it 
causes. The gastrointestinal side effects include nausea and vomiting and constipation. 
Nausea is due to stimulation of the area postrema (also known as the chemoreceptor trigger 
zone). Opioids cause gastroparesis and slow gastrointestinal transit which results in hard 
stool that is more difficult to pass. Constipation is a persistent side effect to which 
tolerance does not develop and ongoing management with laxatives is usually needed. 
Dermatological side effects include pruritus as a result of histamine release. 
 
 
While there is considerable evidence for some of the adverse effects of the opioids, other 
effects are still being described and their implications fully recognised.  Controversy still 
exists around the effects of opioids on the immune and endocrine systems and opioid-
induced hyperalgesia. (Brennan, 2013) 
 
 
Opioid endocrinopathy results from the effect of opioids on the hypothalamic – pituitary – 
gonadal axis and on the hypothalamic – pituitary – adrenal axis. Opioids bind to opioid 
receptors in the hypothalamus and reduce the secretion of gonadotrophic releasing 
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hormone. The opioids therefore exert an effect throughout the whole axis but they also act 
at other levels. The altered axis effects menstrual cycle, reduced sperm production and 
reduced testosterone in the testes. As soon as the patient is commenced on an opioid the 
endocrine system starts to be altered. Up to 90% of patients will have an altered endocrine 
system. Patients may describe reduced libido, infertility, fatigue, anxiety, hot flashes, night 
sweats. Osteoporosis may occur. (Brennan, 2013) There is also thought to be a link 
between hypogonadism and increased pain which may lead to opioid dose increases to help 
alleviate the pain. Low testosterone is the most frequently recognised hormone deficiency 
secondary to opioid prescription. (Ballantyne, 2006) Opioids also reduce the production of 
ACTH from the pituitary and impair the production of cortisol and DHEA by the adrenal 
gland. There have been case reports of patients presenting with Addisonian crisis 
secondary to opioids. (Brennan, 2013) 
 
 
Activation of the hypothalamic-pituitary-adrenal axis causes the release of glucocorticoids 
and noradrenaline release is stimulated by the activation of the sympathetic nervous 
system. Both pathways are activated by opioids. Glucocorticoid and noradrenaline both act 
to suppress lymphocytes. Evidence of immune suppression by opioids is seen in the 
increased risk of infections after burns, risk of metastatic spread after cancer surgery and 
immune response to vaccine. (Hojsted and Sjogren, 2007) The immune system is also 
suppressed by pain (Ballantyne, 2006) and the influence of individual contributions is 
difficult to establish.  
 
 
A proactive approach to the management of opioid side effects is required. Some patients 
will require the prescription of an anti-emetic, often just for a few days. If the side effects 
are not managed with the addition of these other drugs then the patient may need either a 
reduction in the dose of the opioid or to be changed to an alternative opioid. Although 
large studies reviewing the side effect profiles of the different opioids suggest no 
difference at a population level, there is no doubt that individuals respond differently to the 
different opioids. 
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Tolerance to opioids requires the opioid dose to be increased in order to achieve analgesia. 
In cancer patients it can be difficult to know whether the patient is tolerant to the opioid or 
has disease progression causing escalation of pain. In one study patients were found to 
have increased their opioid dose by 640% over a 15-month period with no change in their 
pain scores. 
 
 
“The premise that tolerance can always be overcome by dose escalation is now 
questioned” (Ballantyne, 2007 page 482).    
 
 
Opioid-induced hyperalgesia is increasingly recognised and considered by clinicians who 
prescribe opioids. Opioid-induced hyperalgesia is a paradoxical increase in pain 
experienced by a patient when the dose of opioid is increased. Opioid-induced 
hyperalgesia can present as pain which is distributed beyond the original site of the pain or 
as whole body pain or sensitivity. The diagnosis relies on an awareness of opioid-induced 
hyperalgesia and may sometimes only be recognised by the clinician when the dose of 
opioid has been reduced in order to manage side-effects or features of toxicity and the 
patient’s pain has improved. A review of the published literature pertaining to opioid-
induced hyperalgesia is included in chapter seven. 
 
 
Dependence may be a concern to patients. For some patients the stigma of being perceived 
as an addict outweighs the pain and they may decline opioids despite severe pain. Physical 
dependence manifests as the symptoms of withdrawal when the opioids are stopped 
suddenly for any reason. The symptoms can be avoided by slow reduction of opioids. 
Psychological addiction manifests as a craving for the drug. It was traditionally thought to 
be rare in patients who were prescribed opioids for pain under medical supervision (Lawlor 
and Bruera, 1998) but it is now recognised that the prevalence can be as high as 19%. 
(Ballantyne, 2006) Psychological addiction occurs as a result of the release of dopamine in 
the “reward area” of the brain after opioid has been taken. (Hojsted and Sjogren, 2007) 
 
 
There is no agreed definition of prescription opioid misuse or the development of addiction 
to drugs originally commenced for pain. (Compton and Volkow, 2006; Manchikanti, et al, 
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2010; Hojsted and Sjogren, 2007) The increase in the consumption of prescription opioids 
means there is an inevitable risk of diversion of the drugs to illicit drug users which also 
makes it difficult to interpret the figures.  Patients who are most at risk of addiction to 
prescription drugs are young men, those with a previous history of substance misuse and 
those with mental health issues. (Hojsted and Sjogren, 2007)  
 
 
1.7 Opioid Consumption – cause for concern? 
 
 
Opioids are widely and increasingly used to manage pain, both cancer and non-cancer in 
origin. They are prescribed with the best of intentions which is to improve pain. However 
the prescribing of opioids must be considered in context. There is little evidence about the 
longer-term effects of opioids. Many of the published studies on opioids only follow 
patients for a few short weeks and leave clinicians to extrapolate the longer -term effects. 
Evidence from the United States of America is of increasing addiction to prescription 
painkillers with associated increase in morbidity and mortality. Evidence is emerging about 
the effects of opioids on the endocrine and immune systems of patients. The time has come 
to reconsider our approach to opioids (Stannard, 2013). 
 
 
Palliative medicine has developed as a specialty over the last fifty years. It has traditionally 
been involved in the management of symptoms associated with malignant disease. In more 
recent years there has been a shift towards an involvement with patients with non-
malignant diseases amid recognition that they can have a similar burden of symptoms to 
patients with cancer. 
 
 
Advances in oncology mean that many patients are now living with their disease and some 
will live with complications of treatment for example chemotherapy-induced peripheral 
neuropathy.  Palliative medicine needs to keep pace with advances in oncology and change 
our approaches to the management of patients who are living with cancer and not dying of 
cancer. 
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We have much to learn from our colleagues in chronic pain teams about helping patients 
live with pain and other symptoms but we are not the only ones who must learn. All 
professionals who prescribe strong opioids need to stop and think. This is an opportunity to 
learn from the USA and from our increasing reliance on opioids as painkillers. We need to 
consider the evidence, ask questions and have discussions with our patients that help them 
make informed decisions. 
 
 
When managing pain there is a need to balance the benefits of opioids and the adverse 
effects of the opioids. Over the years medical opinion has shifted massively. Initially there 
were attempts to regulate the prescription of strong opioids, borne of a fear of addiction. 
These regulations were particularly seen in the USA. Later in the 20
th
 Century there were 
calls for the better management of chronic pain. Clinical leaders encouraged the use of 
opioids for chronic pain stating the use was safe despite little evidence to support the view. 
Now views are starting to change again. The evidence base for the use of opioids is being 
questioned in the face of increasing consumption of opioids, increasing deaths related to 
prescription drugs, increasing attendances at accident and emergency departments with 
drug related problems. In an invited review article Jane Ballantyne highlights the evidence 
on which opioids are prescribed for strong pain is based mainly on randomised controlled 
trials of relatively short duration (up to 32 weeks) and doses of morphine that are less than 
many patients are prescribed (approximately 180 mg /day). To establish the longer term 
effects of opioids it is necessary to look to case series. Dr Ballantyne also highlights that 
56% of patients abandoned treatment with opioids because they were not gaining 
improvement in pain or because they were having unacceptable side effects (Ballantyne, 
2007). 
 
 
It is difficult to know how many people are addicted to prescription opioids or are at risk of 
addiction because there is a real lack of clarity and consensus about the diagnosis of 
addiction to prescription opioids.  Cathy Stannard has raised some concerns from the UK 
(Stannard, 2007). While recognising that we do not have the same magnitude of problem in 
the UK she has highlighted the lessons that can be learned from the USA. She recommends 
the practice of “good medicine” (Stannard, 2007, page 347)  – take a careful history, 
ensure relevant health problems are also taken into account when prescribing opioids, 
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Look for behaviours that may indicate the patient is at risk of opioid misuse and above all, 
review the patient to judge effect of the opioid on the pain. This recommendation echoes 
Jane Ballantyne’s recommendations in 2006 that chronic opioid therapy is initiated 
following a detailed review of the pain, consideration of the risk factors for opioid misuse 
and ongoing review of the benefit for the patient’s pain. (Ballantyne, 2006) 
 
 
While opioid misuse is a clear issue on a worldwide basis, the purpose of this thesis is to 
evaluate the physical side effects of opioids, in relation to symptoms and indeed pain itself. 
 
 
1.8 Research in Palliative Care 
 
 
As a specialty palliative medicine is committed to providing the best care for patients and 
their families. It is increasingly necessary to provide the evidence base that the care 
provided is the best for patients, to be able to teach and engage with other specialties 
confident in the knowledge that we provide good care, to have informed conversations 
with patients about the various therapeutic options open to them and the risks and benefits 
that are associated with the different options. 
 
 
There has been a reluctance to engage in research in palliative medicine however. 
Historically the reluctance to engage with research has come from a perception that 
palliative medicine is separate to other specialties – free from the medicalization of the rest 
of modern medicine. Janssens and Gordijn argue that as medicine became increasingly 
interventional and focussed on cure so palliative care separated and focussed more on the 
needs of the individual. As the specialty has come to realise the need to re-integrate with 
other medical specialties there has come the realisation that research is an essential 
component to arguing the value of palliative medicine. (Janssens and Gordijn, 2000) Kaasa 
and Dale argue that establishing the evidence base of palliative medicine is not at odds 
with the ethos of care provision. (Kaasa and Dale, 2005) 
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Hospice care developed from a wish to provide the best care for the dying patient and their 
family. Increasingly now there is a wish to take aspects of hospice care and transfer them 
to other care settings. Establishing an evidence base is an important step to transferring 
care. It can be difficult to persuade colleagues without the evidence.   
 
 
The importance of research in palliative care was eloquently outlined in Research Active 
Hospices (Payne et al, 2013) which calls for collaboration between teams and an up-
skilling of all staff in research skills for example critical appraisal skills. 
 
 
Fine argues that research in patients who are nearing the end of life is “a classical 
deontological – utilitarian conflict” (Fine, 2003, s55) There is conflict between our wish to 
provide the best care for the individual patient, even though taking part in research may 
cause inconvenience at least and harm at worst, and a need to understand how we can 
ensure the best care for all our patients. Janssens provides a similar argument. 
 
 
 “Caregivers in a palliative care setting are faced with a conflict between non-
maleficence (not to harm current patients) and social justice (the societal duty to 
improve medical care for future patients). Both options are imperative and morally 
praiseworthy but at the same time they seem mutually exclusive.” (Janssens and 
Gordijn, 2000, page 56) 
 
 
It is often assumed that patients who have advanced disease and are frail do not wish to 
participate in research but this assumption should be challenged. Patients may wish to 
contribute to research and may find it helpful to contribute although they are unlikely to 
benefit from the results.  (Addington-Hall (ed) 2007, page 6) Particular concern has been 
raised about recruiting palliative care patients into research studies due to the concern 
about their vulnerability. They are a frail group, who are coping with their disease and 
emotions; they may be cognitively impaired as a result of their disease or its treatment. 
Authors have suggested they are at risk of coercion by the professionals they depend on 
and that they may lack capacity to give informed consent. (Addington-Hall (ed) 2007, page 
5) Others have argued that if they have capacity, they should be offered the chance to 
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participate in studies. It would be too paternalistic to not consider them for research. (Fine, 
2003) 
 
 
Fine argues that the ethical principles apply to all types of research and they should not 
alter simply because the patient is less well or nearing the end of life. (Fine, 2003). Is it 
then our own prejudices that colour the view of research at the end of life?  Fine also 
argues that being too protective has stopped palliative medicine developing as a specialty 
and is against patient choice. There has been a tendency to rely heavily on expert opinion. 
(Kaasa and Dale, 2005) but “it is important to generate not just validated but also 
generalizable knowledge” (Aktas and Walsh, 2011, page 461) 
 
 
A further ethical concern that has been raised is that research can take away the hope that 
comes from spending time with family, away from hospitals, and from achieving good 
symptom control and replace it with false hope generated by participation in a trial which 
may be intrusive and time consuming. (Janssens and Gordijn, 2000) 
 
 
Research in palliative care is hindered by inadequate recruitment of patients and attrition 
which may occur as people become increasingly frail or require other interventions which 
mean they are not eligible for the original study or that the research is no longer a priority 
for them. It is important to define the symptom, intervention or outcome adequately 
otherwise there is little opportunity to strengthen research through the conduct of meta-
analysis or systematic reviews. (Addington-Hall (ed) 2007, page 5) Palliative medicine 
research is also limited by confounding factors ie the number of different variables that can 
impact on the experience of a symptom by the patient, their family and other caregivers. 
For example the management of nausea depends on the underlying disease process, the 
multiple causes of nausea and the interventions used. It is much easier to study 
hypertension where there is a clear objective outcome measure.  Randomised controlled 
trials can be difficult to design due to the confounding factors. (Aktas and Walsh, 2011) 
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The lack of consistent definition in the palliative care literature also affects the ability to 
conduct systematic reviews and meta-analysis. For example in one review article the lack 
of consistent definition of “dying” and “terminally ill” was highlighted.  Lack of funding 
has been suggested as a barrier to the conduct of palliative care research. (Kaasa and Dale, 
2005) but it is probably the lack of infrastructure and experienced research personnel 
within an organisation that is more important. (Whalen et al, 2007) 
 
 
Both qualitative and quantitative research methods have a place in palliative research. 
Qualitative research is very positive as it gives the patients and their carers the opportunity 
to discuss their experience and the meaning of the experience for them.  In quantitative 
research alternative methodologies can be useful and in fact offer more chance of 
succeeding at research than trying to follow RCT protocols rigidly.  N = 1 studies have 
been suggested as a useful methodology for palliative care research. Care is still needed 
with case definition in order to allow comparison and aggregation of the studies. If the 
patient’s disease progresses between cycles it can be difficult to judge outcome. (Nikles et 
al, 2011) It is sometimes possible to extrapolate from research done in other care settings 
(Kaasa and Dale, 2005) but this relies on a clear understanding of context of study and on 
the possible limitations of transferring the results of the study to a different disease or stage 
of disease.  It is important to consider that not all research needs to be hospice based in 
order to establish the evidence base for palliative medicine researchers can look to other 
relevant settings. Dialysis units and accident and emergency units have been suggested as 
appropriate settings. (Whalen et al, 2007) Observational studies can be more practical to 
conduct than Randomised Controlled Trials. (Aktas and Walsh, 2011) 
 
 
1.9 Outline of thesis 
 
 
This thesis explores the burden of opioid related side effects and the nature of opioid 
induced hyperalgesia. The research was conducted in three parts initially with the first part 
of the study aiming to provide a point prevalence of side effects and the burden of these in 
the different patient groups. The second part of the study was qualitative research that 
aimed to give voice to patients with cancer pain who had experienced an episode of opioid 
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toxicity. The third part of the study was aiming to provide longitudinal information about 
opioid-induced hyperalgesia. As the study recruited patients and analysis was completed it 
became clear that there was a wealth of data across all the original aims of the study 
provided by the follow-up assessments and that the original division of the study into three 
parts was less relevant than anticipated. The study was providing information on four key 
aspects – opioid related side effects, effect of opioids on cognitive function, opioid-induced 
hyperalgesia and the patient experience of opioid toxicity. It became clear that the thesis 
would most logically follow these chapters. 
 
 
The methods chapter provides an outline of each of the tools used with the details of the 
population in which they were validated, the strengths and limitations of the tool. 
 
 
The same tools were used at each assessment that collected quantitative data and were: 
 
 
 Opioid history and Short Opioid Withdrawal Scale 
 Likert scales for the assessment of side effects of opioids  
 Constipation Score 
 Brief Pain Inventory 
 Hospital Anxiety and Depression Scale 
 Self-completed Leeds Assessment of Neuropathic Pain Scale 
 Addenbrooke’s Cognitive Examination – Revised 
 Bond and Lader analogue scales  
 Quantitative sensory testing. 
 
 
Qualitative description has been used for one part of the study. The use of qualitative 
research within the main study will be explored and the rationale for using qualitative 
description as the method in this study will be discussed along with the results and not in 
the methods chapter. 
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Four chapters will follow, each one exploring one of the themes highlighted above. Each 
chapter starts with a statement of the aims of the section and a review of the relevant 
published literature. The patients who were included in the data analysis of relevance to 
that section will be described and results of the analysis presented. Each chapter will 
include comparison of the results to the literature, a reflection on the limitations of the 
study with particular relevance to the chapter and a brief discussion of the future work 
required. 
 
 
In the chapter exploring the prevalence and burden of opioid-related side effects the 
morphine equivalent daily dose will be used to facilitate analysis of the data and look for a 
possible relationship between dose of opioid and the side effects experienced by the 
patients in the study. The analysis of the data will also explore possible correlations 
between the different strong opioids and rate of titration of the opioid and the side effects 
experienced. The side effects will be compared between the different patient groups. 
 
 
The introduction to the chapter which discusses opioids and cognitive function will provide 
an overview of our current understanding of the impact of opioids on cognitive function. 
Other factors of importance particularly in the cancer group will be briefly considered for 
example biochemical abnormalities and chemotherapy related impairment.  This chapter 
will review the prevalence of opioid related cognitive impairment and will reconsider the 
most clinically relevant assessment tools. The results of the objective and subjective 
measures of cognitive function will be presented and any correlation sought. 
 
 
The published literature regarding opioid-induced hyperalgesia in cancer patients is based 
on case reports currently. The case reports will be examined and common themes 
extracted. The introduction to this chapter will provide a brief summary of the literature 
relating to opioid-induced hyperalgesia and its assessment using quantitative sensory 
testing. The aim of this part of the study is to explore the prevalence of opioid induced 
hyperalgesia and possible associations including opioid, dose and rate of titration of opioid. 
The quantitative sensory thresholds will be compared over time and between patient 
groups. Morphine equivalent daily dose will again be used to facilitate comparison. 
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Patients who show features suggestive of opioid-induced hyperalgesia will be reviewed to 
look for possible contributory factors. The findings of this part of the study will be 
summarised and compared to the published literature. 
 
 
The introduction to the qualitative research chapter will present a critical review of the 
published literature on patients’ views of opioid toxicity. The process of developing codes 
and identifying themes will be described. The main themes found after analysis of the data 
will be presented and the implications for the care of future patients considered. 
 
 
1.10 Summary 
 
 
Pain is a subjective experience that is affected by the patient’s previous experiences of pain 
and healthcare. Pain will have physical and psychological consequences if not managed 
well. The prevalence of pain throughout the world requires us to consider our approaches 
to the management of pain and ensure everyone has access to analgesia and support. 
 
 
Strong opioids such as morphine are considered the mainstay of pain management 
especially in cancer pain. Traditionally opioids have been prescribed for patients with 
cancer with the expectation of fully controlling the pain and with the advice to 
professionals that there is no “ceiling dose”. There has been increasing recognition in 
recent years about the lack of evidence about the effects of opioids over the long term but 
emerging understanding that opioids adversely impact on the endocrine and immune 
systems. This study aims to add to this literature with data about the burden of side effects, 
the impact of opioids on cognitive function and opioid induced hyperalgesia. Palliative 
medicine is shifting to keep pace with the developments made by our colleagues in 
oncology and we are involved in the management of patients who are living, not dying, 
with cancer. It is no longer acceptable to use opioids without serious regard for the future. 
Now is the time to review opioids and the way in which they are prescribed. 
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1.11 Aims of the Study 
 
 
The aims of the study are detailed below. 
 
 
To assess the prevalence and severity of side effects of prescribed opioids 
To compare the symptom burden due to strong opioids in different patient groups 
To assess the impact of strong opioids on cognitive function 
To explore the patient experience of opioid toxicity 
To estimate the prevalence of opioid-induced hyperalgesia 
To describe the clinical features of opioid-induced hyperalgesia and thus enable 
clinicians to better recognise opioid-induced hyperalgesia  
To identify factors which may predict patients at risk of developing opioid-induced 
hyperalgesia  
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CHAPTER 2:  METHODS 
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2.1 Introduction 
 
 
This is an exploratory research study which represents a longitudinal review of patients 
who are prescribed strong opioids with the aims of assessing the burden of opioid-related 
side-effects and of characterising opioid-induced hyperalgesia. The study was planned and 
conducted in three parts. However as described in the introduction to the thesis the results 
which emerged from the different studies defined the chapters. The methods chapter 
describes each of the research tools used with an outline of the strengths and limitations of 
each tool. The same research tools were completed by all patients at all assessments. 
Information regarding demographic details and disease status were confirmed and updated 
at subsequent assessments.  
 
 
2.2 Outline of Study 
 
 
Multi-centre ethical approval was obtained and the study had the support of the Research 
and Development teams in each of the health boards from which patients were recruited. 
The approval numbers for the study were MREC: 09/S1103/11 and Research and 
Development project identification number: 2009/W/AN/03. Approval letters have been 
included as Appendix A. 
 
 
Eligible patients were identified by the clinicians leading their clinical care. Patients were 
attending oncology clinics in the cancer centre, attending chronic pain or substance misuse 
clinics or under the care of the specialist palliative care team – either the one of the 
community clinical nurse specialists or the day hospice team. Once patients had been 
identified as eligible the possibility of participating in a research study was discussed and 
they were given a patient information leaflet which outlined the study. The patient was 
then contacted by a member of the research team in order to answer any questions they 
may have and to confirm their eligibility for the study. Patients who wished to participate 
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provided informed written consent prior to commencing the study. The patient information 
sheet and consent form for the study have been included as Appendix B and Appendix C 
respectively. 
 
 
Patients were given a choice about where the study was completed. The majority of 
patients were seen in their own homes and usually chose to have a close family member 
with them. The exceptions to this were the patients with a history of substance misuse. 
They were seen in the substance misuse clinic. The assessments took between thirty and 
sixty minutes to complete at each visit. The majority of patients were seen once, some 
patients completed two or three assessments.  
 
 
2.3 Patient Groups 
 
 
Patients are prescribed opioids for several reasons as outlined in the introduction to the 
thesis. In order to provide comparisons between different patient groups it was necessary to 
recruit patients who were prescribed opioids with different indications. Patients were 
recruited who were prescribed opioids as part of the management of cancer pain, chronic 
non-cancer pain or to manage their substance misuse. In order to provide a comparison 
group for the quantitative sensory testing, a group of patients with chronic non-cancer pain 
but who were not prescribed opioids were also recruited. These patients were attending one 
of the chronic pain clinics in Lothian (n = 25). The majority of patients with cancer pain 
were recruited from Strathcarron Hospice. Additional patients with cancer pain were 
recruited from the Beatson West of Scotland Cancer Centre (n = 8) and the Western 
General Hospital, Edinburgh (n = 1). Patients with non-cancer pain and those with non-
cancer pain who were not on opioids were mainly recruited from the chronic pain clinics in 
NHS Lothian. Additional patients in these groups were recruited from Strathcarron 
Hospice (n= 13). Patients with a history of substance misuse were recruited from NHS 
Lothian (n = 25). 
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A group of healthy volunteers without chronic pain or opioids were also recruited in order 
to provide the population normal values for the quantitative sensory testing. The healthy 
population who did not have chronic pain and were not prescribed strong opioids were 
recruited from the staff and volunteers of Strathcarron Hospice (n = 102). They completed 
a questionnaire to confirm eligibility and collect basic demographic information. The 
quantitative sensory testing undertaken in this group provides a control group of 
quantitative sensory testing in healthy people. Approximately the same number of 
volunteers and patients was required to provide adequate comparison.  
 
 
2.4 Inclusion and exclusion criteria 
 
 
Patients were all aged over 18 years of age and able to communicate in written and verbal 
English. Some of the tools chosen for the study were only available in English. Patients 
must have an estimated prognosis of at least three months. Patients who were very frail or 
confused were excluded. It would not have been ethical to recruit patients who were 
confused as they would not have been able to give informed consent or to provide the 
information required during the assessments. Very frail patients were excluded as it was 
unlikely they would be able to complete two or three assessments with six to eight week 
intervals between assessments. 
 
 
The initial three parts of the study are detailed in the diagram. The diagram shows the 
number of patients from each patient group who completed each assessment.  
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Figure 1: Number recruited in each patient group and the number of assessments 
completed by patients in each patient group 
 
 
 
All patients had to have been prescribed and taking a strong opioid for at least a week prior 
to recruitment.  Patients were required to be on at least 60mg of morphine each day or an 
equivalent dose of an alternative strong opioid in order to complete the full study i.e. 
assessments at three time points. The dose of 60mg was chosen as the majority of patients 
with cancer pain will be effectively managed at this dose of morphine or an equivalent 
dose of another opioid (From Oxford Textbook of Palliative Medicine, 4
th
 Edition. Ed. 
Hanks, Cherny, Fallon et al). It therefore represents a clinically relevant dose rather than an 
extreme. Patients who were prescribed less than 60mg or an equivalent dose of an 
alternative strong opioid were eligible to complete the assessment on one occasion only. 
Some patients who were recruited to complete three assessments managed fewer than 
planned assessments due to increasing frailty which was usually due to progression of their 
cancer. 
 
 
A third group of patients was recruited for the qualitative research component of this 
mixed methods study. All patients who were recruited for the qualitative research study 
were also participating in the quantitative research study. We purposively recruited patients 
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who had previously been opioid toxic. Eligibility for this part of the study was identified 
by the referring clinician or by the researcher when conducting the other assessments and it 
became clear the patient had been toxic previously. Patients recruited for this part of the 
study participated in semi-structured interviews. 
 
 
2.5 Assessment Tools 
 
 
Basic demographic data for all those who participated in the study was recorded. This 
included the patient’s age, sex and ethnicity. The underlying diagnosis and treatments 
which had been completed or were ongoing were noted for example chemotherapy or 
hormone therapy. For those patients with cancer, the primary site and site of any 
metastases was noted. A detailed pain history was documented including the type of pain, 
duration of the pain and relevant investigations. Non-pharmacological interventions which 
had been tried and whether there had been any benefit in terms of improvement in pain 
were recorded. Past medical history and psychiatric history were also documented. 
 
 
The patients recruited for the study all completed the research tools at each assessment 
during participation in the quantitative research study. An explanation of each of the 
research tools used and the reasons for choosing them is given below. 
 
 
2.5.1 Opioid History 
 
 
A comprehensive opioid history was obtained through questioning the patients about the 
opioid they were prescribed over the last six months. When the patient was unable to recall 
the opioid history with certainty, the details were clarified from notes and previous 
prescriptions. The patient was asked to state how long they had been on opioids and details 
about which opioids they had tried and the reasons behind any change of opioid. 
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The opioid, formulation i.e. instant release or modified release, route of administration and 
dose were all recorded. The number of doses of instant release opioid used in a 24-hour 
period were also recorded. The number doses of instant release opioid imply how well the 
patients’ pain is controlled.  The detail of the opioid history was necessary to enable the 
morphine equivalent daily doses to be calculated. It was also key to many of the planned 
statistical analyses as the analysis has explored possible relationships between strong 
opioid, dose and dose titration. 
 
 
The reasons for taking the opioid were recorded and the patient was asked whether they 
had any concerns about becoming dependent on the opioid. The use of any non-prescribed 
drugs including opioids was documented. The features of opioid withdrawal were assessed 
using the Short Opioid Withdrawal Scale (SOWS). 
 
 
The Short Opioid Withdrawal Scale comprises ten questions each with four possible 
responses. The responses indicate the presence of any of the symptoms in the last 24 hours 
and are graded from none (score zero) to severe (score three). A score is obtained out of a 
possible total of thirty. The Short Opioid Withdrawal Scale provides a subjective measure 
of the symptoms associated with withdrawal from any of the strong opioids. The symptoms 
included in the SOWS include feeling sick, stomach cramps, heart pounding and yawning. 
 
 
The SOWS was developed from a 32-point questionnaire after analysis showed that some 
items were not needed. The questionnaire was reduced to 20 and then further to ten items. 
Questions were dropped when they were show to overlap with other questions or when 
patients found them unclear. The ten items which remained were all shown to have 
relevance and value when measuring withdrawal. The author of the SOWS suggests that 
presenting the mean of the scores is one way to present the results (Gossop, 1990). 
 
 
 
 
47 
 
There are both objective and subjective measures of opioid withdrawal. Originally 
clinicians completed objective tools but one research team were keen to consider the 
addicts perspective (Cohen, Klett, Ling, 1983). In 1983 they looked at 150 male veterans 
on methadone and asked them to complete a self-report questionnaire during 
detoxification. They were asked questions about the frequency with which symptoms 
occurred, the duration of the symptoms and the timing of the symptoms during the episode 
of withdrawal. Some symptoms were experienced by most patients. These were 
restlessness, lack of energy, craving for the drug, difficulty sleeping and aching bones and 
joints. 
 
 
The Clinical Opiate Withdrawal Scale (COWS) was developed by clinicians in 1999. The 
COWS assesses 11 symptoms of withdrawal and assigns a variable score to each question. 
The maximum score possible is 42. A score of five to 12 indicates mild withdrawal and a 
score of 36 or greater indicates severe withdrawal symptoms. The symptoms assessed 
include sweating, gastrointestinal upset, bone or joint aches, runny nose and yawning so 
there is an expected overlap with the Short Opioid Withdrawal Scale. Resting pulse rate 
and pupil size are also required for the COWS though. Although grounded in clinical 
experience the questions were not refined through any validation studies until 2009. At this 
time the COWS was compared to the Clinical Institute Narcotics Assessment a tool which 
has been criticised due its reliance on pulse and BP measurement (see paragraph below) 
and which it has also been suggested is easy for patients to manipulate the questions and 
subsequent score obtained. The two studies were compared in a double-blind placebo-
controlled study involving the administration of morphine to healthy volunteers and then 
the administration of either naloxone or placebo. The validation of the COWS has 
therefore not been undertaken in relevant patient groups (Tompkins et al, 2009). 
 
 
Objective measures include measurement of pupil dilatation, heart rate and blood pressure. 
In a study by Turkington and Drummond however these objective measures were shown to 
be unreliable measures.  Comparisons were also made between objective and subjective 
measures and it was noted that there is poor correlation between the two (Turkington and 
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Drummond, 1989).  
 
 
Overall the Short Opioid Withdrawal Scale offers the more meaningful and reliable 
subjective measure of the symptoms of opioid withdrawal when compared to the other 
available tools. It has also been more robustly validated than the other available tools. 
None of the tools to measure opioid withdrawal have been validated in patient groups other 
than those with a history of substance misuse and therefore any tool chosen is limited in its 
application to patients who are prescribed opioids for the management of cancer and non-
cancer pain. 
 
 
2.5.2 Summary: Opioid History and Short Opioid Withdrawal Scale 
 
 
A detailed history of the opioids which had been prescribed and taken over the six months 
prior to assessment was documented. A subjective measure of the symptoms of opioid 
withdrawal was used given the poor correlation between subjective and objective measures 
and the importance for this study of establishing the burden of side effects on patients. The 
Short Opioid Withdrawal Scale has been included as Appendix D. 
 
 
2.5.3 Morphine Equivalent Daily Dose 
 
 
Strong opioids are prescribed for cancer and non-cancer pain. Different opioids are 
available and individual patients can find particular opioids are more effective for their 
pain or that there are fewer side effects. Patients may be prescribed opioids by different 
routes also for example oral, transdermal, buccal or subcutaneous. In order to be able to 
compare the opioids used by patients for the purposes of research the opioids are converted 
to a morphine equivalent daily dose in milligrams (MEDD). “The equianalgesic dose is 
defined as that dose at which two opioids (at steady state) provide approximately the same 
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pain relief.” (Shaheen et al, 2009) 
 
 
Some opioids have established conversions which are used clinically and have relevance to 
healthcare professionals. Other opioids do not have established conversions and it was 
necessary to use a conversion which we found clinically meaningful. The fast acting short 
acting preparations of fentanyl are in this category. If the opioid conversions are not 
accurate the analysis will be open to bias. 
 
 
There are many different opioid conversion tables available. The conversions used in this 
study are those which most closely represent clinical practice in the areas from which 
patients were recruited.  The wide variation in opioid conversion tables has been 
highlighted in the literature. (Shaheen et al, 2009) The main concerns highlighted by 
Shaheen and colleagues are clinical and the potential for significant harm to patients from 
inaccurate dose calculations. (Shaheen et al, 2009) 
 
 
O’Bryant and her colleagues highlight that many studies are not transparent about the 
opioid conversions used and simply present the MEDD and the results based on it. The 
data is then likely to be interpreted according to the reader’s usual clinical practice. Results 
may be wrongly interpreted due to false assumptions. (O’Bryant et al, 2008) 
 
 
It is most complex to convert from one opioid to methadone or from methadone to a 
different opioid. Methadone is a strong opioid which is also an N-Methyl – D –Aspartate 
antagonist. This dual action lends methadone clinical utility beyond other strong opioids 
however renders it difficult to convert between opioids and methadone. There are many 
different suggested protocols to manage patients who require methadone to be commenced. 
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There is sparse guidance on how to convert methadone to morphine (or any other strong 
opioid). A pragmatic approach was taken based on the best available evidence. (Wong and 
Walker, 2012; Pollock et al, 2011; Lawlor et al, 1997; Walker et al 2008) 
 
 
2.5.4 Summary: Use of MEDD 
 
 
Various strong opioids are prescribed for patients and the opioids may also be taken by 
different routes. The morphine equivalent daily dose represents a conversion to a single 
opioid and route and has been used to facilitate statistical analysis. The opioid conversion 
chart used in the study has been included as Appendix E. 
 
 
2.5.5 Likert Scales 
 
 
Likert scales were used to assess the presence of symptoms. There are validated tools that 
would explore patient’s symptoms for example the EORTC QLQ-C30 (Aaronson et al, 
1993) however these can be extensive and are not specifically designed to look for the side 
effects of opioids. A pragmatic approach was therefore taken of using Likert scales written 
particularly for this study which therefore had not been tested or validated but were 
specific to meet the aims of the study. 
 
 
Patients were asked to think about the seven days prior to the assessment and to think 
about the frequency of each of five symptoms. Each of the symptoms was a recognised 
side effect of opioids. The symptoms included were nausea, vomiting, dry mouth, 
myoclonus and hallucinations. There were five possible responses to each statement about 
the presence and frequency of the symptom moving through very often, quite often, 
occasionally, very rarely and none. 
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Likert scales are frequently used in studies and are therefore a familiar tool for many in the 
general population. The familiarity brings an intrinsic value. However they are not without 
problems. It has been suggested that Likert scales are less responsive to change than visual 
analogue scales and that Likert scales may be harder for those with a lower educational 
achievement to complete. There is no consistent advice on how many possible responses 
should be available for each question but it appears that too few or too many responses 
result in poor completion of the questions. (Hassan and Arnetz, 2005) 
 
 
In a study designed to compare Likert scales with visual analogue scales Hassan and 
Arnetz recruited participants through the use of a website for those seeking advice on stress 
management and self-motivation. Recruitment bias is immediately clear given the 
population involved however they went on to exclude students, unemployed and 
pensioners in order to make the group as homogeneous as possible. They found Likert 
scales and visual analogue scales to be similar but the results of this study must be 
questioned given the clear bias. (Hassan and Arnetz, 2005) 
 
 
The optimum number of responses in a Likert scale is five or seven. Maximum information 
is extracted from the results if a scale with at least 20 responses is used. Scales with only 
two or three possible responses are not useful. (Preston and Colman, 2000) 
 
 
The analysis of Likert scales is contentious and the subject of several articles. In 2004 
Jamieson (Jamieson, 2004) argued that the responses given by study participants are 
ranked with unequal intervals between them. If this is not recognised, some of the value of 
the responses can be lost. The comparative validity of alternative scales to measure the 
intensity of symptoms was discussed in the section describing the Brief Pain Inventory. 
Through the study we have used a variety of measures. 
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The EORTC-QLQ-C30 would have offered a more robust measure of symptoms than the 
Likert scales. It was validated in 305 patients with lung cancer and found to be a reliable 
measure of quality of life (Aaaronson et al, 1993). Importantly it is not used in patients 
with non-cancer or substance misuse however. Although the tool includes questions about 
nausea, vomiting, constipation and some questions relevant to cognitive function, anxiety 
and depression, it does not provide any measure of the other side effects of opioids or the 
depth of assessment gained from using tools to assess the other research questions 
specifically eg the Hospital Anxiety and Depression Scale.  
 
 
2.5.6 Summary: Likert Scales 
 
 
Likert scales were written for this study to assess the frequency with which patients 
experienced opioid-related side-effects. This was a pragmatic approach given the number 
of research tools being used at each study assessment. The Likert scales had five responses 
and were analysed using a Spearman rank correlation which requires no assumption about 
the equality of the intervals between responses. The Likert scales have been included as 
Appendix F. 
 
 
2.5.7 Assessing Presence of Constipation  
 
 
The constipation score provides information about the frequency of bowel movements, the 
ease with which the patient can move their bowels and the consistency of their stool. Each 
response is scored from zero to two. A score of four or more represents normal bowel 
function and a score of three or less indicates constipation. (Fallon and Hanks, 1999) 
 
The tool was developed during a study of constipation in patients who were prescribed 
morphine. All the patients in the study had advanced cancer and had been referred to the 
specialist palliative care team in a cancer centre. The purpose of the study was not to 
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validate the constipation score and it has not been subject to a validation study since. It is 
therefore not possibility to comment on construct validity, sensitivity, specificity or 
predictive values of the tool.  (Fallon and Hanks, 1999) It is also a tool that was developed 
for use in a palliative care patient group yet we have used it as an outcome measure in all 
patient groups recruited for the study. 
 
 
In a review article Clark and Currow reviewed the available outcome measures for 
constipation in palliative care patients. The lack of a definition of constipation in palliative 
care is discussed. There is also lack of guidance about how best to measure constipation – 
even whether this should be with objective or subjective measures. (Clark and Currow, 
2013) The lack of a validated tool is also clear in the Cochrane review on opioid-induced 
constipation (Candy et al, 2011). The authors of the review (Clark and Currow, 2013) 
suggest the Rome Criteria which were developed and are used by gastroenterologists could 
be used when looking at constipation in palliative care. In reviewing the various outcome 
measures used to assess constipation in palliative care the authors found six themes used to 
define constipation in the literature. These were “time between bowel actions, time 
between bowel actions with concurrent opioid use, opioid use, use of laxatives, self-report 
or health professional’s opinion (Clark and Currow, 2013).” The lack of consistency of 
definition of constipation in patients who were prescribed opioids for the management of 
non-cancer pain was also highlighted in a review by Panchal and colleagues in 2007 
(Panchal, Muller-Schwefe, Wurzelmann, 2007). The tool used in this study overlaps with 
some of the less comprehensive tools used in the literature.  
 
 
The Rome criteria provide clear diagnostic criteria with both subjective and objective 
measures of constipation. The constipation score we have chosen successfully addresses 
some of the Rome criteria. The Rome Criteria for the diagnosis of functional constipation 
require the presence of sufficient symptoms to meet the criteria for at least three months 
with the onset of symptoms at least six months prior to diagnosis. Although the criteria are 
robust and well defined they are specifically designed to provide consistency around the 
diagnosis of functional constipation and are less well suited to opioid-induced constipation 
due to the time stipulations.  
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2.5.8 Summary: Use of Constipation score 
 
 
The constipation score provides a total score based on three questions. A score of three or 
less indicates constipation. An un-validated tool was chosen as it offers a patient- centred 
approach to the assessment and a priority of this study is to assess the burden of opioid-
related side effects on patients. The constipation score has been included as Appendix G. 
 
 
2.5.9 Measuring anxiety and depression 
 
 
Various tools exist for the purposes of screening of anxiety and depression. These include 
the Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory, 
Edinburgh Depression Scale and Distress Thermometer.   
 
 
The Beck Depression Inventory (BDI) was developed in 1961. It can be used as a 
screening tool in both psychiatric and non-psychiatric populations. It was designed to be 
completed by an interviewer but is widely used as a self-completed tool. (Beck, Steer and 
Garbin, 1988) The BDI consists of 21 questions each with four possible responses. A 
spectrum of cut-off values for the diagnosis of varying severity of depression are provided. 
Questions include those around fatigue, appetite and concern about health that could be 
difficult for patients with physical illness. However the BDI has shown to be a valid and 
reliable screening tool when compared to the HADS in patients with cancer (Mystakidou et 
al, 2006) and to have good construct validity and internal consistency in patients with 
chronic pain (Harris and D’Eon, 2007). 
Ultra-short methods of screening (for example the distress thermometer) for anxiety and 
depression were also considered given the number of assessments and questionnaires 
patients were asked to complete at each research visit. However in a large review of 38 
analyses exploring the accuracy of these methods in cancer patients the ultra-short 
screening methods were found to lack sufficient accuracy to be used as screening tools 
(Mitchell, 2007).  
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Given the inclusion of somatic symptoms of depression in the BDI and the apparent lack of 
reliability of short methods the use of the HADS for the purposes of identifying anxiety 
and depression in this study were explore further. 
 
 
The hospital anxiety and depression scale (HADS) is widely used in palliative medicine 
both as a screening tool and as an outcome measure in research in several patient groups. 
The popularity of the HADS has been in part as a result of its non-reliance on the somatic 
symptoms of anxiety and depression as these can significantly overlap with the physical 
symptoms of illness. 
 
 
The HADS tool has been designed to be completed by the patient and the wording of each 
question was considered and revised in order to ensure patients could understand the 
question. The use of English colloquialisms has been criticised as these do not translate 
well into other languages and the value of the HADS could be lost. 
 
 
Patients are asked to complete fourteen questions. Each question has four possible 
responses. Each response is a descriptive term with an attributed score of zero to three. A 
score of three indicates the presence of one of the symptoms suggestive of anxiety or 
depression and that the symptom is severe. Two total scores are then obtained – one for 
anxiety and one for depression. The HADS was designed to provide separate score for 
anxiety and depression and not to provide a total score which would represent distress as a 
more global concern. Much has been written about the use of the individual scores and the 
validity of this approach. This will be discussed further. 
 
 
The questions ask about the patient’s experience of the last week. The score provided is 
therefore very contemporary. The authors of the HADS suggested that the HADS can be 
used at time intervals in order to review the patient’s progress. 
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Annunziata and colleagues recruited 512 consecutive hospitalised cancer patients to 
address the question of whether the HADS scores are best used as separate scores for 
anxiety and depression or as a combined score. They also wanted to identify the 
appropriate cut-off scores. 544 patients were recruited but 32 were excluded because the 
HADS forms were not properly completed. No further detail about the incomplete forms 
was provided. It is therefore not clear whether 5.8% of the patients recruited for the study 
found the forms too difficult – which would have implications for the use of the HADS – 
or whether there were patient related factors which precluded completion of the form, for 
example fatigue, difficulty reading the questions due to eyesight or comprehension 
difficulties. In this study of cancer patients in hospital the use of two scores ie anxiety and 
depression rather than one global score was found to be the “best fit.” Of note the HADS 
was valid in an Italian population and its usefulness had survived the translation process. 
The study recruited a relatively large sample of patients but generalizability may be limited 
by the fact they were all in hospital (Annunziata, Muzzatti, Altoe, 2011) 
 
 
Mari Lloyd Williams and her colleagues looked at the HADS in a population of patients 
who all had metastatic malignant disease (Lloyd-Williams and Friedman, 2001). They 
recognised the difficulties of diagnosing depression in frail patients.  They specifically 
recruited patients with a limited prognosis (estimated to have less than six months to live). 
The study compared the accuracy of the HADS in diagnosing anxiety and depression with 
present states examination interviews which require specialist training to conduct but are 
regarded as a gold standard diagnostic tool and therefore chosen for the validation of other 
screening tools. Lloyd Williams argued that in patients with advanced malignancy higher 
cut-off scores should be used and that the highest sensitivity and specificity came from 
using the HADS as a one factor tool ie with a total score calculated. They recommended a 
cut-off total score of 19.  
 
 
Alex Mitchell and colleagues also looked at how well the HADS performs in those with 
cancer or under the palliative care team. A meta-analysis was conducted. He concluded the 
HADS performed better earlier in the disease trajectory but there were few studies which 
could be included in this part of the meta-analysis and a small sample size therefore 
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caution is applied to the finding. Overall they recommended the HADS for use as a 
screening too (Mitchell, Meader, Symonds, 2010). This conclusion was also discussed by 
Luckett in 2010 in a systematic review of the use of HADS in English-speaking patients. 
This review only looked at papers published in the last ten years. They assumed that 
anything described more than ten years ago had been superseded by a better tool. This is a 
fundamental flaw and source of significant inclusion bias. The results must therefore be 
interpreted with caution. The review suggests that there is some evidence to support the 
use of HADS rather than other screening tools, the HADS appears to perform better earlier 
in the cancer journey and that a total score is useful. Overall they recommended using the 
HADS anxiety, depression and total scores to describe the patient’s distress (Luckett et al, 
2010). 
 
 
Johnston et al reviewed the use of the HADS in different patient populations. They 
concentrated on the internal consistency of the HADS ie how well it performs in different 
patient groups. They concluded the HADS has good internal consistency with 13 of the 14 
questions leaning to the psychological, rather than somatic, symptoms of anxiety and 
depression. The question “I feel as if I am slowed down” was a poor predictor of distress in 
all patient groups (Johnston, Pollard, Hennessey, 2000). A meta-analysis published by 
Brennan et al found that the HADS performs as well as other screening tools in primary 
care populations (Brennan et al, 2010). 
 
 
In a group of patients with lung cancer the most helpful HADS cut-off for diagnosing 
depression was 8. If the cut-off was increased to 11, the number of false positives 
increased from one to three. This increase was thought to be more reassuring for clinicians 
than the possibility of failing to recognise some patients with depression. This study was 
very small with only 53 patients and was conducted in Italy (Castelli, 2009). The Italian 
version of the HADS has appeared valid in a larger group though (Annunziata, Muzzatti, 
Altoe, 2011). 
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Ultra- short screening tools have been suggested as valid by some practitioners. These 
tools rely on five or fewer questions to make the diagnosis. A review of the ultra-short 
methods of detecting anxiety and / or depression in cancer patients found that although 
they were popular with clinicians they can only be relied upon to “rule-out” that patients 
have anxiety and depression and could not be relied upon to “rule-in” the diagnoses 
(Mitchell, 2007). This study did not use an ultra-short screening tool due to the lack of 
reliability. 
 
 
2.5.10 Summary: Use of HADS 
 
 
The Hospital and Anxiety Scale was therefore chosen for the study due to its internal 
consistency and known validity in different patient groups. Cut-off values for anxiety and 
depression have been used in accordance with the recommendations of the authors of the 
HADS in the absence of clear guidance to the contrary. In addition for those patients with 
cancer a total cut off score of 19 was also used. The HADS questionnaire has been 
included as Appendix H.  
 
 
 
 
 
2.5.11 Measuring pain severity and interference 
 
 
There have been two significant reviews of the use of tools to measure pain. The 
IMMPACT recommendations reviewed the use of outcome measures for chronic pain 
studies. They considered the use of visual analogue scales, numerical rating scales and 
verbal rating scales, and several tools which explore pain and its impact on function. This 
consensus meeting and subsequent paper recommended the use of the Brief Pain 
Inventory. (Dworkin et al, 2005) In a paper on behalf of the European Association of 
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Palliative Care (Caraceni et al, 2002) both the McGill Pain Questionnaire and the Brief 
pain Inventory were found to be valid multidimensional research tools. 
 
 
The validity of single dimension pain scores was considered in a study by Ferreira-Valente 
and colleagues in 2011. They compared the visual analogue scale (VAS), numerical rating 
scale (NRS), Faces Pain Scale – Revised (FPS-R) and the verbal rating scale (VRS). All 
four provide a measure of pain intensity. The study recruited healthy volunteers and 
subjected them to acute cold pressor pain. It therefore fails to include the important 
emotional aspects of chronic pain and the authors recognised this important limitation. 
Overall there was little difference between the four scales. (Ferreira-Valente, Pais-Ribeiro, 
Jensen, 2011) Although the use of a visual analogue scale would only have addressed one 
dimension of pain and a tool which addressed the multiple dimensions was preferred it is 
helpful to note the validity of the visual analogue scale in general given that they have been 
used to address other research questions. In addition the visual analogue scale has not been 
shown to be responsive to change especially when the pain is decreasing (Carlsson, 1983).  
 
 
The Brief Pain Inventory (BPI) is a self-completed pain assessment tool which measures 
both intensity of the pain and the interference of pain on everyday activities. It was 
developed by Professor Charles Cleeland in response to a call for better documentation of 
cancer pain, better management and better understanding of the epidemiology of cancer 
pain. In the 1970s when the BPI was developed, patients reported that the existing tools 
were too long and complex. Some of the questions were felt to lack relevance to the cancer 
pain group. The BPI was the result of refinement of earlier drafts. It has largely been 
validated in patients with cancer pain which is unusual. Most tools are initially validated in 
patients with non-cancer pain and then transferred to the cancer pain setting. The first 
version of the BPI was called the Wisconsin Brief pain Inventory. It was tested in 667 
patients with cancer and 32 patients with rheumatoid arthritis. Following some refinement 
the questions were looked at in 1200 patients. The test – re-test characteristics were looked 
at. (BPI 1) The validation studies were robust in terms of the numbers of patients included. 
The internal consistency has been confirmed in subsequent studies. (Cleeland, 2009) 
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Two forms of the BPI exist. The long form is used in clinical trials but its length means it 
is burdensome. The short form is used in clinics and most research studies. For the most 
part, where the BPI is used it can be assumed to be the short form. (Cleeland, 2009) 
 
 
The scores provided by the Brief Pain Inventory (Cleeland, 2009) were recommended for 
use in all trials looking at aspects of the management of chronic pain by the IMMPACT 
panel. The BPI provides best, worst, average and current pain scores – each question about 
the severity of their pain is given a score from zero to ten by the patient. The worst and 
average scores can be used as standalone scores or the mean of the four scores can be 
presented. There are seven questions which measure the interference with daily activities 
for example walking, enjoyment of life and sleeping. Each of the seven interference 
questions is also given a score by the patient from zero to ten. The mean of the seven 
scores is presented as the measure of interference. The mean of the interference scores is 
valid provided four or more of the seven questions has been answered. (Cleeland, 2009) 
The European association of Palliative Care recommend the use of pain tools which are 
multidimensional and completed by patients not observers given that pain is a very 
subjective experience. (Caraceni et al, 2002) 
 
 
The interference questions can be divided into two groups – known as WAW and REM. 
Much has been written about the use of the BPI as a three factor research tool. 
 
 
WAW includes the questions on walking, general Activity and ability to do normal Work. 
It is the activity sub dimension of the BPI.  REM includes the questions on relations, 
enjoyment and mood. It is the affective sub dimension of the BPI. (BPI 1) The question on 
the interference of pain on sleep does not seem to fit clearly with either of the sub 
dimensions. Published studies keep sleep separate when looking at the validity of the three 
factor approach. (Atkinson et al, 2011; Cleeland, 2009; Wu et al, 2010; Zalon, 2006) 
 
 
In a study by Wu both the two and three factor model was shown to be valid. Wu and 
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colleagues used confirmatory factor analysis in 258 patients with cancer pain due to bone 
metastases. Removing sleep from the analysis improved the internal consistency (Wu et al, 
2010) and was consistent with other studies in the removal of sleep. The authors of the 
study suggested that sleep may not be subject to the same interference by pain as the other 
factors if physical splinting is used at night to support the painful body part, patients may 
spend longer in bed to make up for disrupted sleep and opioids may affect the patient’s 
sleep. All these factors were thought to mask the real effect of pain on sleep. (Wu et al, 
2010) 
 
 
Some authors favour one approach or other – ie either a two or three factor approach. A 
study in acute pain supported the two factor use of the BPI. However this study was in 
patients with acute pain so is limited in relevance to my study. (Lapane et al, 2014) A 
study in men with castration-resistant prostate cancer favoured the three factor use 
however it should be noted that this study recruited relatively small numbers (n=184) of 
men with a single diagnosis (Atkinson et al, 2012). The strength of the study in recruiting 
such a homogenous group limits its transferability to other studies. 
 
 
Of more relevance was the study conducted by Atkinson and colleagues who looked at 364 
patients with either HIV/AIDS related pain or cancer pain. Using confirmatory analysis 
they found that either the two or three factor approach was valid. They highlighted that the 
three factor model could be particularly useful in different clinical situations. For example, 
in patients with a limited prognosis the affective component of the BPI would be most 
relevant for patients for whom the priority was spending quality time with their families. 
The authors of this study also highlighted that the question about the interference of pain 
on the ability to carry out normal work is a difficult question for patients with a diagnosis 
such as cancer which affects this ability for many reasons including but not limited to pain. 
(Atkinson et al, 2011) 
 
 
Tan et al evaluated the use of the BPI over time and found it detects improvement in pain. 
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The BPI was used when patients attended for out-patient review with a mean of 27.73 days 
between assessments. (Tan et al, 2004) Keller also found the BPI is sensitive to change 
when used over time (Keller et al, 2004). Dworkin suggested that a change of one point on 
the pain interference scale is the minimal clinically important change. (Dworkin et al, 
2005) 
 
 
2.5.12 Summary: Measuring Pain Severity and Interference 
 
 
The Brief Pain Inventory measures both pain intensity and the extent to which it interferes 
with the patient’s daily activities. It can be used as either a two factor or three factor tool. 
When used as a three factor tool it provides a mean severity score, an affective sub 
dimension (mean of three interference scores) and an activity sub dimension score (mean 
of three further interference scores). The BPI has been validated in cancer patients and is 
available for use in different countries and languages. The Brief Pain Inventory has been 
included as Appendix I. 
 
 
2.5.13 Quantitative Sensory Testing 
 
 
Quantitative sensory testing (QST) provides a functional assessment of the peripheral 
nervous system. There is some variation in protocols used which is discussed below, but 
QST is the only method of clinicians assessing peripheral nerve function in an objective 
manner. 
 
 
“QST measures the detection threshold of accurately calibrated sensory stimuli.” (Shy 
et al, 2003) 
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QST provides an objective stimulus which generates a subjective response. In this study 
patients were asked to compare sensations between index and control areas and record the 
sensation at the index site as “no change, increased, significantly increased, decreased, 
significantly decreased or not detected.” They were also asked to provide a pain score for 
each of the sensations tested using a numerical scale from zero (no pain) to ten (severe 
pain). The sensations tested were light touch with a brush, cool and warm sensation, 
detection and pain threshold using Von Frey filaments, pinprick sensation and the presence 
of wind-up. 
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Table 1:  Different thresholds are tested and provide information about different 
sensory pathways 
 
 
The information in the table has been drawn from two papers – Zaslanski and Yarnitsky, 
1998; Yarnitsky, 1997    
 
Sensory modality Fibres conveying signals 
Cold sensation Small myelinated fibres (Aδ) 
Warm sensation Unmyelinated warm specific C-fibres 
Cold pain Cold fibres and Small myelinated and 
unmyelinated nociceptors 
Heat pain Small myelinated and unmyelinated 
nociceptors  
Vibration Large myelinated fibres 
 
 
In clinical neurological examination the examiner looks for discrepancies between the 
affected and unaffected sides where possible. The patient becomes their own control. The 
same approach is taken in QST. Clinical examination is not standardised though. QST aims 
to standardise the process and to quantify the response. (Gruener and Dyck, 1994) We used 
an index area and wherever possible a contra-lateral area to provide the control data. At 
times it was not feasible to test the index site for example a patient who had intra-oral pain. 
Patients who were in the study and prescribed opioids to manage their substance misuse 
did not usually have pain. In both these clinical situations the forearm was used as the 
index site. 
 
 
A standardised approach to the test is vital. The way the stimulus is delivered is as 
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important as the stimulus if the results are to be reliable over time. Several authors have 
highlighted the importance of this. We conducted each QST assessment in the same order 
of sensory modalities and used the same wording to explain the testing to the patient. 
Wherever possible subsequent testing in the same patient was also conducted by the 
researcher. One advantage of QST is that the stimuli used are relevant to life and to the 
patients’ experience of situations which may trigger their pain, for example, cold. (Gruener 
and Dyck, 1994) 
 
 
We used the method of levels which requires the participant to remain concentrated for the 
duration of the test but does not require them to make a rapid decision so it is easier for 
fatigued patients who may be fatigued due to their pain or disease or both. Normal values 
for QST are determined by the stimulus used – and can vary between different 
manufacturers – age, sex and ethnicity of the patient. Although values are available in the 
published literature which give normal values most authors recommend using normal 
values from the population patients are drawn from. (Gruener and Dyck, 1994; Shy et al, 
2003; Yarnitsky, 1997) When this is not possible then researchers can look to the literature 
but accept the limitations of the approach. 
 
 
Other QST protocols have been developed and validated however the protocol we used 
takes much less time to complete. This is an important consideration in a patient group 
who are likely to be fatigued due to cancer or other chronic disease. The German team who 
provided much of the normal data used a protocol which took three hours to complete and 
required the participants to either have closed eyes or remain fixed and looking at a single 
spot on the wall. It would seem unlikely that participants’ concentration remained constant 
throughout the whole test. It seems more likely that in the later stages of the test the 
responses were tempered by tiredness or inability to concentrate further. One hundred and 
eighty healthy volunteers were recruited for the main study which provided the normative 
data. They were recruited from ten different sites in Germany. Although the study aimed to 
provide consistency across the testing, two different thermal kits were used and given the 
number of different sites there must have been at least as many testers. Both factors 
introduce inconsistency and therefore bias to the study. (Rolke et al, 2006) The protocol 
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used by the team is more comprehensive than the one we used. Although it provides more 
information the length of time to complete the protocol would be difficult in our patient 
group. They found that there is significant difference between sensory thresholds at 
different sites of the body. Body site was more important than age, sex or ethnicity of the 
patient. They recommended that testing is done at both index and control site to provide 
best comparison data. (Rolke et al, 2005; Rolke et al, 2006) 
 
 
In a further validation study which recruited patients who were thought to have small fibre 
pathology due to their use of descriptors including “tingling, prickling and burning” QST 
improved the sensitivity of diagnosing the underlying pathology. The team found that 
thermal thresholds were the least useful modality in “detecting small fiber dysfunction” 
and noted variation when patients were re-tested. The authors of this study argued against 
using thermal thresholds alone as a diagnostic tool and suggested they were most useful in 
following –up patients with a known diagnosis. This study was very small with only 15 
patients and it is therefore possible that the findings were due to chance and not a real 
difference.  (Tobin, Giuliani, Lacomis 1999) 
 
 
QST can be used to provide a diagnosis and treatment approach to pain by characterising 
the somatosensory changes observed and therefore understanding the underlying aetiology. 
(Rolke et al, 2006) The authors of one review article called for all chronic pain subtypes to 
be phenotyped using QST in order to provide clarity around diagnosis. 
 
 
Nerve conduction studies also provide information on the peripheral nervous system and 
altered signalling within the system. However to undertake nerve conduction studies 
requires specialist training and it is not a portable investigation. QST is easier for the non –
specialist to perform.  (Zaslanski and Yarnitsky, 1998) Pain scores alone are commonly 
used as outcome measures in clinical trials but using QST adds more value and depth if the 
relevant sensory thresholds are studied. For example the authors of one paper (Stubhaug 
2002) suggest using heat and pain thresholds to assess the effect of non-steroidal anti-
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inflammatory agents. 
 
 
2.5.14 Summary: Quantitative Sensory Testing 
 
 
Quantitative Sensory Testing provides a subjective response to an objective sensory 
threshold. QST thus provides information on the functioning of the peripheral nervous 
system. A consistent approach to the delivery of sensory testing and questions asked of the 
patients is very important to ensure the results are valid. We used index and contralateral 
control areas where possible. If it was not possible to test the painful area directly the 
forearm was used. In order to provide normal data from our own population we also 
recruited 103 healthy volunteers who also underwent QST of the forearm. The chart used 
to record the quantitative sensory testing protocol is included as Appendix J. 
 
 
2.5.15 Measuring Cognitive Function 
 
 
Cognitive function is an important outcome measure in the study. It was important to 
provide both subjective and objective measures of cognitive function. Cognitive function 
can be impaired by delirium, dementia and age-related “cognitive impairment not 
dementia”. (Woodford and George, 2007) Many of the measures of cognitive function 
require specialist training or assess specific aspects of function, for example the finger 
tapping test, trail making test. A priority when choosing a tool for this study was the ability 
to provide a global assessment of cognitive function and to be clinically relevant in order 
to facilitate application of results to the clinical setting. 
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2.5.16 Objective measure of cognitive function 
 
 
The use of a clinically relevant tool that had been validated in different patient groups was 
a priority for the research study given that one of the main objectives was to assess the 
impact of opioids on cognitive function. A review and meta-analysis by Baldacchino 
explored the neuropsychological consequences of chronic opioid use (Baldacchino et al, 
2012) and found that the cognitive domains most likely to be affected were those of 
working memory, verbal fluency and cognitive impulsivity. The use of a tool which 
measured these domains was therefore key. Ismail and colleagues reviewed the available 
screening tools and their validity in screening for dementia. This review provided useful 
information and comparison of the available tools for assessing cognitive function. (Ismail, 
Rajji, Shulman, 2010) Based on these papers the Addenbrooke’s Cognitive Examination, 
the Mini-mental State Examination and the Montreal Cognitive Assessment were explored 
further. Many authors have used more specific tests of psychological function which lack a 
comprehensive overview of cognitive function (for example Kendall et al, 2010). These 
findings are discussed further in the chapter on the impact of opioids on cognitive function. 
 
 
The Montreal Cognitive Assessment assesses short-term memory, visuospatial abilities, 
executive function, attention and concentration, language and orientation to time and place. 
It has been validated in a memory clinic and an elderly out-patient population. It is 
available in several languages including Arabic and Korean. Of note in one study in a 
British memory clinic the specificity of the Montreal Cognitive Assessment to detect 
dementia was just 50% (Smith, Gildeh and Holmes, 2007), although the specificity has 
been higher in other studies. Overall the Montreal Cognitive Assessment has been 
recommended for use in conjunction with the Mini-mental State Examination and that it 
can be a useful additional screening tool for patients with a Mini-mental State Examination 
score greater than 25 out of 30 (Ismail, Rajji, Shulman, 2009; Smith, Gildeh and Holmes, 
2007). This approach would not have been as useful for the study as it would have added 
burden in terms of number of tools and the need to score one tool and then decide whether 
to carry out a second cognitive assessment in some patients. Overall this approach did not 
consistent with the objectives of the study and the Addenbrooke’s Cognitive Examination 
– Revised (ACE-R) was chosen. 
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The Addenbrooke’s Cognitive Examination – Revised (ACE-R) was chosen to measure 
cognitive function objectively. It provides a comprehensive assessment of cognitive 
function. In addition it is user-friendly and does not require specialist training. It takes ten 
to fifteen minutes to complete the ACE-R. The ACE-R is based on the mini-mental state 
examination which has been a very popular means of assessing cognitive function. The 
mini-mental state examination remains widely used in many clinical settings despite 
widespread acceptance that it is limited in the information that it provides. In their article 
outlining the use of the ACE-R Bak and Mioshi explain that the mini-mental state 
examination only verbally assesses memory and attention. “It is insensitive to frontal-
executive dysfunction and visuospatial deficits.” (Bak and Mioshi, 2007, page 246) The 
mini-mental state examination therefore provides limited information on cognitive function 
and is unable to differentiate between different pathologies. (Bak and Mioshi, 2007; Kipps 
and Hodge, 2005; Larner, 2007; Woodford and George, 2007) The ACE-R provides a 
score out of 30 based on the items from the mini-mental state examination and a score out 
of 100. The original Addenbrooke’s cognitive examination was developed in 2000 and was 
more heavily weighted towards memory and less weighted towards visuospatial abilities. 
The revised version was published in 2006. The majority of the published literature which 
provides the evidence for using the ACE or ACE-R is actually based on the ACE. However 
the ACE-R is the tool which is now more widely used. (Crawford et al, 2011; Mathuranath 
et al, 2000) 
 
 
The ACE-R has been designed for use by the non-specialist. It provides information on 
five domains of cognitive function and normative values based on age and education of the 
subject. The quality of the information provided enables the user to distinguish between 
causes of dementia. There are three versions of the ACE-R and subsequent assessments 
should be carried out using different versions. (Bak and Mioshi, 2007) 
 
 
The domains of cognitive function which are assessed are – attention and orientation, 
verbal fluency, language, visuospatial and memory. Using a cut-off score of 82 / 100 has a 
sensitivity of 84% and a specificity of 100%. (Bak and Mioshi, 2007) Cut-off scores of 75 
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and 88 / 100 have also been used. 
 
 
The possibility that a patient with severe dementia could have a normal mini-mental state 
examination was noted during early clinical studies using the ACE-R (Bak and Mioshi, 
2007) and has since been highlighted by other authors (Jones et al, 2010). During an early 
study using the original version of the Addenbrooke’s Cognitive examination a cut-off 
score of 24 /30 on the mini-mental state examination missed dementia in up to 50% of 
cases as compared with a cut-off value of 83 on the ACE. The need to assess the patient 
further if a normal mini-mental state examination score is obtained despite clinical concern 
about cognitive function has been discussed. This is particularly important if the patient 
has a “high educational background” (Jones et al, 2010). A meta-analysis and results from 
the national dementia research register have shown the ACE-R to be a superior diagnostic 
tool to the mini-mental state examination. (Larner and Mitchell, 2014; Law et al, 2013) 
 
 
In a review of 100 patients attending a memory clinic the ACE-R was found to be 
acceptable to the patients and to have “excellent diagnostic accuracy”. (Larner, 2007) The 
author of this paper also used a lower cut-off value than the one suggested by the authors 
of the ACE-R. A cut-off of 75 / 100 showed a sensitivity and specificity of >0.9. The lower 
cut-off value was used to improve the specificity associated with cut-off values of 82 or 88 
/ 100. In a further study Larner also explored the use of the ACE-R over time and found it 
to be useful in assessing cognitive function over time. This was a very small sample though 
with only 23 patients completing more than one ACE-R. (Larner, 2006) In patients with 
established Alzheimer’s disease however the mini-mental state examination has been 
shown to be as useful as the ACE-R in monitoring change in cognitive function. (Law et al, 
2013) In patients with established Parkinson’s disease the ACE-R has been shown to be 
useful at monitoring changes in cognitive function. (Ritman et al, 2013) The value of the 
ACE-R over time in a palliative care population has not been demonstrated. 
Another study found that the ACE-R correlated well with quality of life of the patient 
when assessed by the carer and the patient. (McColgan et al, 2012)  
 
 
 
71 
 
Although only a small number of patients were recruited a study by Ahmed and colleagues 
showed the ACE-R to have a high discriminatory ability when used in elderly patients with 
normal and mildly impaired cognitive function. The ability of the ACE-R to detect mild 
cognitive impairment is relevant to this study. (Ahmed, de Jager, Wilcock 2011) 
 
 
A systematic review of the ACE and ACE-R in the diagnosis of dementia (Crawford et al, 
2011) highlights that education was found to affect the score obtained when using the 
ACE. This finding was noted in only one paper and other studies had failed to report on the 
educational attainments of the patients. This is one area of importance when interpreting 
the ACE and ACE-R which needs clarifying. Two of the nine studies included in this 
review described the internal consistency and convergent validity of the tools. No studies 
have yet looked at inter or intra-rater reliability. (Crawford et al, 2011) 
 
 
There have been no studies published which report on the use of the ACE-R in a palliative 
care population. 
 
 
2.5.17 Summary: Use of Addenbrooke’s Cognitive Examination – Revised 
 
 
The ACE-R provides a comprehensive assessment of cognitive function for the non-
specialist clinician. It has been shown to be of excellent diagnostic accuracy in patients 
with dementia and it is able to provide information on particular aspects of cognitive 
function which enables the clinician to distinguish between types of dementia. The ACE-R 
has not been used in a palliative care population previously. There are some limitations to 
its use. The lack of evidence for inter-rater and intra-rater reliability is of obvious 
importance to this study given the number of staff assessing patients.  The ACE-R is 
available on-line for anyone who wishes to use the tool. A cut-off score of 85 was used for 
this study.  The Addenbrooke’s Cognitive Examination has been included as Appendix K. 
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2.5.18 Subjective measure of cognitive function 
 
 
A subjective measure of cognitive function was also felt to be very important in this study. 
Palliative medicine is a patient-centred speciality with an emphasis placed on the patient 
experience and opinion. The Bond and Lader scales were chosen in part due to previous 
experience of their use in patients who were prescribed strong opioids. 
 
 
Bond and Lader published their experience and development of the analogue scales in 
1974. (Bond and Lader, 1974) The authors describe the benefits of analogue scales. They 
are straightforward for patients to complete and allow for very fine discrimination by the 
patient. They enable small changes in mood and feelings to be detected when other tests 
would be likely to overlook the change. In their initial work sixteen 100 mm scales were 
given to 500 participants for completion. All subjects were healthy volunteers with an age 
range of 16 – 64 years (mean 27 years) (Bond and Lader, 1974). 
 
 
The sixteen scales are anchored at each end by positive and negative descriptors of an 
emotion for example alert and drowsy, attentive and dreamy. The patients are asked to 
make a mark anywhere along the 100 mm line indicating the strength with which they 
respond to the emotion. Some of the scales are anchored with the positive emotion at the 
left hand side and some at the right hand side. The scales require inversion before analysis 
to ensure all are read from the left hand side. The scales can be divided into four groups. 
 
Mental sedation or intellectual impairment 
Physical sedation or bodily impairment 
Tranquillization or calming effects 
Other types of feelings or attitudes (from Bond and Lader, 1974) 
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The scales are completed by the patient on the basis of how they feel at the time of 
completion. They are sensitive to changes when used to assess response to medication for 
example. Several studies have used them to assess medication including butobarbitone 
sodium and flurazepam in healthy volunteers (Bond and Lader, 1974), temazepam in 
healthy volunteers (Begg, Drummond, Tiplady, 2001), mirtazapine and paroxetine in 
healthy subjects (Ruwe et al, 2001) and tetrahydrocannabinoid in healthy volunteers 
(Kleinloog et al, 2014). All the studies showed the Bond and Lader scales to be useful in 
assessing subjective responses of mood and feelings to medication. 
 
 
The cognitive failures questionnaire provides a description of self-reported failures in 
perception, memory and motor function. Patients answer 25 questions that are rated from 
four (very often) to zero (never). The questions pertain to the six months prior to 
completion of the questionnaire and are designed to be ecologically relevant ie close to real 
life. (Broadbent et al, 1982) Wagle and Berrios suggested that the cognitive failures 
questionnaire may correlate highly with stress (Wagle and Berrios, 1999). This could make 
interpretation in a group of patients with life limiting illness more challenging. Although 
recognising the positive aspect of the tool’s ecological validity Wagle and Berrios also 
questioned its ability to measure change (Wagle and Berrios, 1999).  
 
 
A further option for the measurement of the subjective view of cognitive function would 
have been to use verbal rating scales or visual analogue scales anchored by terms relevant 
to this study. Klepstad and colleagues took this approach (Klepstad et al, 2002). They also 
relied on the cognitive function domain of the EORTC QLQ-30.  As with the Likert scales 
used to assess opioid related side effects this approach would have offered relevance to the 
study objectives but lacked validity.  
 
 
The EORTC QLQ-30 (Aaronson et al, 1993) was one of the tools used by the studies 
included in a review of objective and subjective cognitive impairment following 
chemotherapy for cancer (Hutchinson et al, 2012). Semi-structured interviews and the 
cognitive failures questionnaire were also commonly used in the included studies. 
Although the EORTC QLQ-30 is a well-validated and relevant tool the cognitive function 
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scale relies on the responses to two questions only. Overall therefore the Bond and Lader 
analogue scales offer a validated relevant assessment that has been shown to be responsive 
to change after the administration of medications. 
 
 
2.5.19 Summary: Use of Bond and Lader analogue scales 
 
 
The Bond and Lader analogue scales provide a contemporary view of the patient’s mood 
and emotions. They are easy for patients to complete and have been used in other studies 
looking at the effect of medications on functioning. The Bond and Lader Scales have been 
included as Appendix L. 
 
 
2.5.20 Assessing the nature of the pain 
 
 
Clinicians are able to distinguish between types of pain based on the history and 
examination of the patient. Patient descriptors, distribution of the pain and associated 
features such as altered sensation or colour all guide the clinician and the management of 
the pain. For the purposes of research however a tool to provide quantitative evidence of 
the quality of the pain was required. The tools which have been developed are compared to 
clinician diagnosis of the presence of neuropathic pain. Clinician diagnosis is regarded as 
the gold standard for the diagnosis of neuropathic pain (Hardy et al, 2013). 
 
 
PainDETECT, Self-completed Leeds Assessment of Neuropathic Symptoms and Signs (S-
LANSS), Neuropathic Pain Questionnaire, Douleur Neuropathique en 4 questions (DN4) 
and ID – pain are all measures of neuropathic pain. In a review of the available screening 
tools Bennett et al outlined the tools and their sensitivity and specificity (Bennett et al, 
2007). The tools share a reliance on the sensory changes which suggest neuropathic pain 
for example a description of electric shocks or shooting, pins and needles or tingling, and 
numbness. All the tools were validated in heterogeneous chronic non-cancer pain settings 
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and were compared with clinician diagnosis in the validation studies. All the tools result in 
a total score with defined cut-off values which indicate neuropathic pain. Only the LANSS 
(ie original version) has been looked at over time and in one study (Khedr et al, 2005) was 
shown to be responsive to the effects of treatment. There is little to discriminate between 
the tools in terms of sensitivity or specificity (Bennett et al, 2007). However the S-LANSS 
has recently been studied in a group of patients with cancer and this adds strength to our 
choice of tool (Hardy et al, 2013). 
 
 
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) tool was developed 
in 2000 to facilitate early accurate diagnosis of pain with neuropathic features and thus 
ensure appropriate management. (Bennett, 2001)  The S-LANSS was developed from the 
LANSS. It is designed to be completed by the patient ie Self-completed. (Bennett et al, 
2005) 
 
 
The S-LANSS comprises seven questions about their pain and patients are required to 
choose one of two possible answers which they feel best describes their pain and the 
symptoms and signs they experience. The answers are weighted and therefore contribute 
different values to the total score. A pain is regarded as neuropathic if the total score is 
above 12. The total score is 24. 
 
 
The LANSS was developed in patients with chronic pain who were attending a pain 
management clinic in England. Patients with pain which was clearly either nociceptive or 
neuropathic were recruited. Patients with more complex pain were excluded. The study 
recruited eight patients with cancer out of a total of 60 patients. The exclusion of patients 
with mixed pain has clear implications for the use of the S-LANSS in patients with cancer 
pain as the majority of them have mixed pain and pure neuropathic pain is uncommon. The 
LANSS was shown to have good internal consistency. Some of the descriptors had better 
discriminant ability when the patient used them without prompt than when the LANSS 
required them to consider their pain. This applies to “burning” and “shooting” which are 
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often used by patients with neuropathic pain. Of note the LANSS has never been tested in 
a mixed pain population. (Bennett, 2001) 
 
 
The S-LANSS was developed from the LANSS with the aim of making the tool more 
useful to researchers by removing the need for examination by a clinician. Instead the S-
LANSS requires the patient to rub the affected area themselves and then answer questions. 
The S-LANSS was tested in a clinic and by postal survey. (Bennett et al, 2005) Patients 
were recruited from a pain management clinic in the UK and a primary care population in 
Scotland. The S-LANSS was found to have construct validity with each item contributing 
positively to the total score. It was shown to be acceptable to patients in both settings. 
 
 
In a further study using the S-LANSS Bennett and colleagues explored the use of the S-
LANSS in determining the extent to which pain is neuropathic. They found that an 
increasing S-LANSS score correlated with a clinicians rating of the likelihood that a pain 
was unlikely or very likely to be neuropathic. (Bennett et al, 2006) This is relevant to our 
study and patient population although again only a minority of those recruited had 
malignant disease (17 out of 200 recruited). 
 
 
In 2013 Janet Hardy and colleagues undertook an analysis of a group of patients with 
cancer pain which was difficult to manage and who had been recruited for a study 
exploring the use of ketamine. Patients with mixed pain as reported by a clinician were 
excluded from the analysis so there is still a lack of evidence regarding the use of the S-
LANSS in this group. However when the S-LANSS was used for patients with either 
neuropathic or nociceptive pain it was found to have “excellent diagnostic properties” 
(Hardy et al, 2013).  
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2.5.21 Summary: Use of the Self-completed Leeds Assessment of 
Neuropathic Symptoms and Signs 
 
 
The S-LANSS provides a useful measure of the nature of the patient’s pain with a score of 
12 or greater indicting a neuropathic component to the pain. There is also some evidence 
that a higher S-LANSS score indicates that the pain is predominantly neuropathic and this 
may be helpful in this study where patients in the cancer pain group are likely to have pain 
of mixed character.  The S-LANSS is included as Appendix M. 
 
 
2.6 Summary of Chapter 
 
 
This chapter has provided an outline of the research tools used to collect the quantitative 
data and to address the aims of the study pertaining to the assessment of opioid-related 
side-effects, impact of opioids on cognitive function and exploration of opioid-induced 
hyperalgesia. The qualitative research methodology used to explore the patient experience 
of having been opioid toxic is described in the relevant chapter of the thesis. 
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CHAPTER 3:  CHARACTERISTICS OF THE 
PATIENTS RECRUITED FOR THE STUDY 
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3.1 Characteristics of the Patients Recruited 
 
 
This chapter provides a description of the patients recruited for the study. Patients were 
recruited who were prescribed opioids for the management of either cancer or non-cancer 
pain or to manage substance misuse. Patients were also recruited who had non-cancer pain 
but were not prescribed opioids.  
 
 
One hundred and two healthy volunteers were recruited as a control group for the 
quantitative sensory testing.  
 
 
A total of 178 patients were recruited. Figure 2 shows the number recruited in each patient 
group and the number of assessments completed by patients in each patient group. Only 
the cancer pain patients were asked to complete three assessments. In part this was a 
pragmatic approach as many of the patients in the other groups were working or had other 
commitments which meant time was more limited for them. The cancer patients were in a 
more structured follow-up system which facilitated research assessments also. The patients 
with chronic non-cancer pain were attending specialist clinics less frequently and 
managing other personal commitments. In addition, more changes in medication were 
expected in the cancer pain group. The cancer pain patients welcomed the opportunity to 
continue with further assessments. 
 
 
Less than ten patients declined to take part in the study after reading the patient 
information leaflet. A screening log was found to be impractical and inaccurate given the 
number of clinicians who could potentially refer patients to the study.  
 
 
The first patient was recruited on 20
th
 August 2010. The majority of patients were recruited 
by 16
th
 January 2012. One patient (chronic non-cancer pain, not on opioids) was recruited 
on 23
rd
 May 2014 just prior to full statistical analysis in order to complete the planned 
recruitment of 25 patients in the particular patient group.  
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Inevitably there was attrition in the cancer pain group. This is expected given the nature of 
the diagnoses. The attrition indicates that patients were becoming less well and less able to 
complete the assessments. It is important to note that their commitment to the study 
persisted. The recruitment of frailer patients could limit the extrapolation of results to a 
more general population who are under the care of a specialist palliative care team but at 
an earlier stage in their illness. However the study draws some conclusions based on the 
impact of opioids in all the different patient groups ie the effect is by drug not diagnosis. 
These results are more generalisable to other patients who are prescribed opioids. 
 
 
Assessments were carried out every six weeks. In situations where this was not possible 
due to other patient commitments the assessment was carried out as close as possible to the 
planned date. In an ideal situation all patients would have had at least three research 
assessments however this proved easier for the cancer patients as they are followed up 
more frequently and in a more structured way compared to some of the chronic non-cancer 
pain patients who were attending specialist clinics more sporadically and in some cases 
also trying to return to work or care for families.  
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Figure 2:  Number recruited in each patient group and the number of assessments 
completed by patients in each patient group 
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3.2 Demographics 
 
 
Table 2:  Characteristics of the patients recruited where n = 178 
Age (years) 
Range 18 to 88  
Mean 55.5  
SD 13.9  
Gender 
Female   n = 84 47.2% 
Male n = 94 52.8% 
Primary Cancer Site (n = 89) 
Breast 14 15.7 
Myeloma 13 14.6 
Lung 12 13.5 
Prostate 9 10.1 
Colorectal 6 6.7 
Ovarian 6 6.7 
Bladder 5 5.6 
Pancreatic 4 4.5 
Other 20 22.5 
 
 
 
The table above shows the demographic details of the patients recruited for the study. 
Approximately equal number of males and females were recruited. The age of those 
recruited ranged from 18 years to 88 years with a mean of 55.5 years and a median of 57.0 
years. Cancer diagnoses relating to only one patient have been grouped together in the 
“other” group. This group includes cervical, laryngeal and melanoma amongst others. 
 
 
At assessment one 68 (76.4%) of the patients with a cancer diagnosis had metastatic 
disease; 12 (13.5%) had loco-regionally advanced disease and others had local malignant 
disease.  
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In addition to the patients who were recruited with cancer pain, four patients had a 
previous history of cancer but were known to be disease free at the time of recruitment to 
the study and their pain was due to non-cancer causes. The patients had a past diagnosis of 
bladder, breast, colorectal and oral cancers. For the purposes of the analysis these patients 
were included in the group with chronic non-cancer pain. 
 
 
3.3 Pain History 
 
 
The pain history for 151 patients is presented below. Twenty-five patients with a history of 
substance misuse were excluded from this analysis as they did not have a history of 
longstanding or significant pain. Two patients had data missing from the pain history and 
were also excluded from this analysis.  
 
 
Table 3:  Duration of pain in weeks for patients with cancer and non-cancer pain 
where n = 151 
 Duration (weeks) 
 N Min Mean Median Max 
Non-cancer 62 24 381 268 1700 
Cancer 89 1 68 36 999 
All 151 1 197 75 1700 
 
 
The minimum duration of cancer pain is one week. Patients reported more than one pain so 
it may be that patients describing pain of short duration also had a pain which had present 
for a longer time. Patients with non-cancer pain had a much longer duration of pain in 
general. Three patients described pain lasting longer than 1000 weeks. These patients were 
managed without opioids at the time of the study. 
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Table 4:  Pain types based on descriptors used by patient for 229 pain reports at first 
assessment where n = 151 
 All Non-cancer Cancer 
 N Percent N Percent N Percent 
Bone 52 22.7 8 7.4 44 36.4 
Central 1 0.4 1 0.9 - - 
Fibromyalgia 1 0.4 1 0.9 - - 
Inflammatory 9 3.9 2 1.9 7 5.8 
Mixed 48 21.0 22 20.4 26 21.5 
Musculoskeletal 17 7.4 12 11.1 5 4.1 
Neuropathic 70 30.6 43 39.8 27 22.3 
Post-surgical 5 2.2 5 4.6 - - 
Visceral 18 7.9 7 6.5 11 9.1 
Other 8 3.5 7 6.5 1 0.8 
       
All 229 100.0 108 100.0 121 100.0 
 
 
Overall the most common pain types were bone, neuropathic and mixed pain types. 70 
(30.6%) patients had neuropathic pain based on the descriptors they used. In the cancer 
pain group the number of patients with neuropathic pain was lower (n = 27, 22.3%) and the 
number of patients with bone pain was much higher than the patient group overall (n = 44, 
36.4% in the cancer pain group). Interestingly, the number of patients reporting a mixed 
pain picture was almost the same in the two patient groups ie 20.4% in the non-cancer pain 
group compared to 21.5% in the cancer pain group. 
 
 
Table 5 shows the frequency of pain occurring at each of the anatomical sites coded in the 
database. Many patients recorded pain at a site other than the originally identified sites but 
the provision of free text enables the sites to be identified as hips (n = 8), abdomen (n = 7), 
legs (n = 6), headache (n = 3) and ankles (n = 3). Other sites of pain included “joints”, 
“ear” and “whole body”. 
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Thirty-six patients reported pain at a site that was not an anatomical site coded for in the 
database. Twenty-two of these patients had cancer pain. 
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Table 5:  The frequencies of reporting 28 pain sites in database list in descending 
order 
Site No. of patients reporting pain at site 
Back 51 
Other 36 
Anterior abdominal wall 16 
Anterior chest wall 15 
Neck 13 
Anterior knee 11 
Posterior chest wall 10 
Arm  8 
Whole leg  8 
Anterior thigh  7 
Inguinal region  7 
Shoulder  7 
Face  6 
Anterior lower leg  5 
Scalp  4 
Posterior abdominal wall  3 
Plantar aspect of foot  2 
Posterior thigh  2 
Unknown  2 
Axilla  1 
Dorsum of foot  1 
Fingers  1 
Hands   1 
Oral/mouth  1 
Perineum  1 
Posterior knee  1 
Posterior lower leg  1 
Upper limb stump  1 
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Table 6:  Patient responses to questions 2 to 5 of the Brief Pain Inventory reflecting 
pain severity at assessment one where n = 146 
 N Mean Median Min Max 
Cancer Pain  
Worst pain in last 24 h 88 5.3 6 0 10 
Least pain in last 24 h 89 2.5 2 0 8 
Average pain 88 4.2 4 0 9 
Current pain 89 3.0 2 0 9 
Non-cancer Pain, On Opioids  
Worst pain in last 24 h 33 7.6 8 0 10 
Least pain in last 24 h 33 4.4 4 0 10 
Average pain 33 6.2 6 0 10 
Current pain 33 5.5 6 0 10 
Non-cancer, non-opioid   
Worst pain in last 24 h 24 5.9 6 0 10 
Least pain in last 24 h 24 2.7 2 0 10 
Average pain 24 4.9 5 0 10 
Current pain 24 4.5 5 0 10 
ALL three groups  
Worst pain in last 24 h 145 5.9 7 0 10 
Least pain in last 24 h 146 3.0 3 0 10 
Average pain 145 4.8 5 0 10 
Current pain 146 3.8 4 0 10 
 
 
The table above shows the responses to the questions from the Brief pain Inventory which 
describe the severity of the pain. In all patient groups there were patients who were pain-
free with the analgesia they had been prescribed and patients who still had very severe pain 
despite analgesia. The patients with cancer pain have lower mean and median pain scores 
for each of the four questions than patients in the other two groups. 
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The table below shows the same information at assessment two. The patients with cancer 
pain have lower mean and median pain scores for each of the severity questions. A t-test 
was used to explore possible significance of the change in mean score between 
assessments one and two for each of the four measures in each group. Of the 12 t-tests only 
two were significant current pain in cancer patients had a p value of 0.026 and average 
pain in non-cancer pain group with a p value of 0.004. 
 
 
Table 7:  Patient responses to questions 2 to 5 of the Brief Pain Inventory reflecting 
pain severity at assessment two where n = 90 
 N Mean Median Min Max 
Cancer  
Worst pain in last 24 h 50 4.7 5 0 10 
Least pain in last 24 h 50 2.3 2 0 8 
Average pain 50 4.1 4 0 9 
Current pain 50 2.0 1 0 8 
Non-cancer  
Worst pain in last 24 h 24 6.9 7 3 9 
Least pain in last 24 h 24 3.8 4 0 9 
Average pain 24 5.4 6 2 8 
Current pain 24 4.5 5 0 9 
Non-cancer, non-opioid   
Worst pain in last 24 h 16 6.3 7 0 10 
Least pain in last 24 h 16 3.5 3 0 10 
Average pain 16 5.3 6 0 10 
Current pain 16 4.4 5 0 10 
ALL three groups   
Worst pain in last 24 h 90 5.6 7 0 10 
Least pain in last 24 h 90 2.9 3 0 10 
Average pain 90 4.7 5 0 10 
Current pain 90 3.1 2 0 10 
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Table 8:  Average of responses to seven questions about pain interference in Brief 
Pain Inventory at assessments 1 and 2 where n = 146 at assessment 1 (Ass 1) and n= 
90 at assessment 2 (Ass 2) 
 
 N 
missing 
N Mean SD Median Min Max 
Cancer   
Interference score(Ass1) 24 65 6.0 2.0 6.3 1.0 9.4 
Interference score(Ass2) 14 36 5.4 1.9 5.4 1.0 10 
Non-cancer   
Interference score(Ass1) 3 30 7.4 2.0 7.4 2.6 10.0 
Interference score(Ass2) 1 23 7.0 2.1 7.6 1.1 9.4 
Non-cancer, non-opioid  
Interference score(Ass1) 3 21 5.1 2.3 4.8 2.0 10.0 
Interference score(Ass2) 2 14 6.6 1.8 6.9 3.5 9.4 
All three groups  
Interference score(Ass1) 30 116 6.2 2.1 6.4 1.0 10.0 
Interference score(Ass2) 17 73 6.1 2.1 6.0 1.0 10.0 
 
 
The mean of the interference scores is valid provided four or more of the seven questions 
has been answered. (Cleeland, 2009) The average score is therefore recorded as missing if 
fewer than three out of seven items have been scored. In the cancer pain group many of the 
patients did not manage to complete the Brief Pain Inventory.  The patients found it 
difficult to recall a time at which they had not been in pain and also found it difficult to 
separate the effect of pain on activity from the effects of other symptoms they were 
experiencing. The patients with cancer pain who managed to complete the questions 
reported a lower level of interference due to pain than patients with non-cancer pain who 
were prescribed opioids. At assessment one the patients with non-cancer pain who were 
not prescribed opioids reported the lowest mean interference score. At assessment two the 
patients with cancer pain reported the lowest mean interference score. 
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There were no significant changes in mean pain interference scores between assessments 
one and two. 
 
 
Table 9:  Total morphine equivalent daily dose (MEDD) in the 24 hours prior to 
assessment and at each assessment by patient group where n = 147 at first assessment 
and patients with non-cancer pain who were not prescribed opioids and those with 
pain and substance misuse history were excluded 
 
MEDD 
  N Mean Median SD Min Max 
 
Assessment 
No 
       
1 Cancer 89 191.7 130 209.2 20 1120 
Non-cancer 33 343.9 200 483.2 25 2440 
Substance misuse 25 412.2 300 367.0 36 1350 
All 147 263.4 160 328.8 20 2440 
2 Cancer 51 215.7 140 210.2 40 1120 
Non-cancer 23 358.0 160 529.9 60 2400 
Substance misuse 1 80.0 80 . 80 80 
All 75 257.5 140 343.7 40 2400 
3 Cancer 34 219.9 140 217.6 20 1120 
Non-cancer 5 268.0 220 196.3 60 520 
Substance misuse 1 92.0 92 . 92 92 
All 40 222.8 140 211.5 20 1120 
        
 
The table above shows that patients with cancer pain are on lower total opioid doses than 
patients with non-cancer pain. The mean MEDD for patients with cancer pain was 191.7 
mg and the mean MEDD for patients with non-cancer pain was 343.9 mg. Patients with a 
history of substance misuse are on the highest doses of opioid with a mean MEDD of 
412.2 mg. For all patient groups the range of MEDDs was large and overall the MEDD 
range was from 20 mg to 2440 mg. From assessment one to three the mean MEDD 
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increased for the patients with cancer pain. For patients with non-cancer pain the mean 
MEDD decreased from assessment one to two. A further decrease was seen for the few 
patients in this group who had a third assessment also. Only one patient in the substance 
misuse group had more than one assessment. Patients who were on a dose of 20mg to 
60mg MEDD were only eligible for a single assessment. Patients on 60mg MEDD were 
eligible for the follow-up assessments. 
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Table 10:  Distribution of the total Morphine Equivalent Daily Dose (MEDD) for the 
four main opioids prescribed at assessment one where n = 167 and over the six 
months prior to recruitment to the study 
 
Total MEDD dose 
(regular + breakthrough) 
  N Mean Median SD Min Max 
Opioids in 
last 24 
hours 
Fentanyl 23 266.5 129 409.4 20 1800 
Methadone 27 508.5 300 412.4 56 1500 
Morphine 65 121.9 90 101.0 10 480 
Oxycodone 52 227.9 150 256.3 16 1120 
Opioids in 
last 7 
days 
Fentanyl 25 243.3 111 399.0 10 1800 
Methadone 26 539.6 375 422.5 56 1500 
Morphine 67 119.9 90 99.6 10 400 
Oxycodone 49 244.7 160 260.3 10 1120 
Opioids in 
last 4 
weeks 
Fentanyl 19 338.5 150 502.7 20 1800 
Methadone 25 558.9 375 590.1 135 2813 
Morphine 71 114.7 80 98.4 10 400 
Oxycodone 45 232.8 160 250.2 16 1120 
Opioids in 
last 2 
months 
Fentanyl 17 370.5 180 523.4 36 1800 
Methadone 23 511.3 263 432.6 135 1500 
Morphine 57 125.4 90 136.2 10 860 
Oxycodone 39 237.7 150 263.8 20 1120 
Opioids in 
last 4 
months 
Fentanyl 18 347.9 155 515.6 36 1800 
Methadone 22 548.2 375 425.2 135 1500 
Morphine 51 144.3 100 133.7 10 600 
Oxycodone 29 224.3 150 221.9 40 1120 
Opioids in 
last 6 
months 
Fentanyl 18 427.3 203 655.7 36 2400 
Methadone 22 501.1 413 363.4 90 1500 
Morphine 46 124.8 85 120.8 10 600 
Oxycodone 26 259.8 190 247.8 24 1120 
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In this study the four most frequently prescribed opioids were fentanyl, methadone, 
morphine and oxycodone. One hundred and sixty-seven reports were reviewed. The total 
MEDD dose reflects the regular opioid and the breakthrough opioid used in 24 hours. 
There will be patients for whom the opioids used regularly and as breakthrough will not be 
the same and this accounts for the number of reports being higher than the number of 
patients who were on opioids. Patients who are prescribed methadone are on a much higher 
MEDD than patients who are prescribed the other opioids. Patients who were prescribed 
oxycodone were on a higher MEDD than patients who were prescribed morphine. The 
range of MEDD for morphine is lower than for the other opioids with a maximum at any 
time point of 600 mg compared to a maximum MEDD of oxycodone of 1200 mg and a 
maximum MEDD of fentanyl of 2400. 
 
 
Not all patients had been on opioids for six months. One hundred and twelve opioid reports 
were reviewed for the time pint six months prior to recruitment to the study. Over the six 
months prior top recruitment there had been an increase in the use of morphine and 
oxycodone. The mean MEDDs of the opioids prescribed did not vary much over the six 
months. 
 
 
The same information was recorded at assessment two and is shown in the table below. At 
assessment two a shorter opioid history was recorded. The MEDD of methadone is much 
lower than at assessment one but is based on data from only two patients. The MEDD of 
morphine is higher at all the time points recorded at assessment two. 
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Table 11:  Distribution of the total Morphine Equivalent Daily Dose (MEDD) for the 
four main opioids prescribed at assessment two where n = 85 and over the four weeks 
prior to recruitment to the study 
 
 Total MEDD dose (regular + breakthrough) 
 
  N Mean Median SD Min Max 
 
Opioids in 
last 24 
hours 
Fentanyl 17 279.3 150 442.2 10 1800 
Methadone 2 65.6 66 13.3 56 75 
Morphine 33 150.9 110 127.2 10 600 
Oxycodone 33 242.7 160 239.2 20 1120 
Opioids in 
last 7 days 
Fentanyl 15 312.3 180 462.1 10 1800 
Methadone 2 65.6 66 13.3 56 75 
Morphine 32 160.3 130 134.1 50 600 
Oxycodone 35 235.0 160 233.2 6 1120 
Opioids in 
last 4 
weeks 
Fentanyl 15 306.0 180 463.7 10 1800 
Methadone 2 65.6 66 13.3 56 75 
Morphine 36 155.1 100 140.4 10 600 
Oxycodone 31 261.6 160 232.7 40 1120 
 
 
3.4 Summary of Patient Characteristics 
 
 
This chapter describes the patients recruited for the study and provides information on the 
site and nature of the pain they were experiencing. The severity of the pain and the extent 
to which it interfered with their lives were described using the Brief Pain Inventory. The 
opioid drugs and doses prescribed have been outlined. 
 
 
Neuropathic pain was the most common type of pain reported by patients who were 
involved in the study. Bone and mixed pain were also common. Back pain, pain of the 
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anterior abdominal wall or chest wall and neck pain were the most frequently reported sites 
of pain. 
 
 
Cancer pain appeared better controlled amongst patients recruited and the patients reported 
lower scores on the Brief Pain Inventory. Not all the patients with cancer pain were able to 
complete the interference scores on the Brief pain Inventory. This could mean the patients 
did not feel the scores were relevant to them. At the time of assessment many patients 
commented that they had become used to living with pain every day. For many patients 
there were other reasons for example nausea, fatigue or altered body image which were 
also interfering with the activities and social relationships scored by the Brief pain 
Inventory. This is an interesting finding given that the Brief Pain Inventory was developed 
in cancer patients initially. It may be that this patient group was frailer in general than the 
patients included in the original studies. The patients with cancer pain who were able to 
complete the scores reported a lower level of interference by pain than patients in the other 
groups. 
 
 
Patients with cancer pain were on lower morphine equivalent daily doses of morphine than 
patients with non-cancer pain. Patients with a history of substance misuse were prescribed 
the highest MEDDs. Methadone was the opioid with the highest MEDD. These two results 
are not unexpected based on clinical experience but may also reflect the liberal conversion 
used from morphine to methadone.  
 
 
It is interesting to note the lower MEDD when morphine was prescribed compared to 
oxycodone. This may be due to patients having more complex pain and that the opioid was 
switched in an attempt to better control the pain. It is also interesting to note that the non-
cancer patients on opioids were on higher opioid doses than the cancer patients. In addition 
the cancer patients had overall better pain control. 
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The substance misuse group appeared to be on the highest opioid doses; however they 
were on methadone, which has the added complication of conversion to oral morphine 
equivalent dose. 
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CHAPTER 4:  OPIOID-RELATED SIDE 
EFFECTS 
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Outline of chapter: 
 
 
 Explains the pathophysiology of opioid-related side effects and the management of 
the side effects. 
 Describes the role of morphine and its metabolites in causing the opioid-related 
side-effects and introduces the role of genetics. 
 Describes the burden of opioid-related side-effects in patients recruited for this 
study and compares the burden of side-effects between different patient groups. 
 
 
4.1 Hypothesis 
 
 
Patients who are prescribed strong opioids will experience side effects due to the opioids 
and the prevalence of side effects will vary according to the opioid and dose which has 
been prescribed 
 
 
4.2 Aims 
 
 
 To assess the opioid-related side effects of patients who are prescribed opioids for 
different indications 
 To compare the prevalence of side effects between the different groups 
 To explore possible factors which may contribute to the presence of side effects 
including choice of opioid, opioid dose and the effect of titration of the opioid 
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4.3  Introduction 
 
 
Several authors have discussed the lack of convincing evidence about the side effects of 
opioids prescribed for pain including the prevalence of the side effects and the most 
effective approach to their management. Many of the trials of opioids do not have side 
effects as an end-point and in addition the trials may not be long enough to determine 
whether side effects persist and how this impacts on the patients. (McNicol, 2008) In an 
editorial in 2010 Colette Reid and Geoff Hanks reflected on the Opioid Conference held in 
Bristol in 2010 at which experts from Specialist Palliative Care across Europe presented 
several systematic reviews. The evidence regarding the use of opioids and the side effects 
they can cause was found to be lacking and the authors of the editorial concluded the 
“reviews must surely represent a “call to arms” for the palliative medicine research 
community.” (Reid and Hanks, 2010) 
 
 
It is well documented that not all pain will respond to opioids. Schrivers suggested up to 
20% of cancer patients fall into this group. (Schrivers, 2007) For some patients it is the 
side effects caused by the opioids that limit the effectiveness. Up to 22% of patients who 
are prescribed opioid to manage chronic non-cancer pain will discontinue therapy due to 
intolerable side effects (McNicol, 2008). The side effects of the opioids and the subsequent 
limits on analgesia may cause poor quality of life. (Harris, 2008) In order to manage the 
side effects three main strategies are suggested: the dose of the opioid can be reduced if 
possible while also maintaining efficacy of analgesia; the opioid can be changed to an 
alternative; or further medication can be added to manage the side effects of the opioid. It 
is often the final strategy that is used by clinicians and this approach results in 
polypharmacy with the risk of further side effects, drug-drug interactions and poor 
compliance with an increasing number of medications (Harris, 2008; Glare, 2006; 
McNicol, 2008). 
 
 
Most authors and reviews on the topic suggest that patients become tolerant to the side 
effects over time and particularly if the opioid is titrated slowly to achieve optimum 
analgesia (McNicol, 2008). Constipation is the exception to this and is known to persist 
over time (Fallon, 1999). Different patient groups may find different side effects more or 
 
 
100 
 
less tolerable for example McNicol describes sedation as being more acceptable to cancer 
patients than those with non-cancer pain who are more likely to have an expectation of 
being able to drive and work. (McNicol, 2008) 
 
 
4.4 Specific Opioid-Related Side-Effects 
 
 
4.4.1 Nausea and vomiting 
 
 
Nausea and vomiting are frequently attributed to morphine. In cancer patients particularly 
it is likely that multiple factors are contributing to the symptoms of nausea and vomiting 
and it can be difficult for the clinician to determine how much of the symptom is due to the 
opioid. Studies suggest between ten and 40% of patients on opioids will have nausea and 
that it is most frequent at opioid initiation and titration. (McNicol, 2008 ) Harris provides a 
clear summary of the pathophysiology of nausea and the various receptors involved in 
nausea and vomiting. The chemoreceptor trigger zone, cerebral cortex, gastrointestinal 
tract and vestibular apparatus all have a role in opioid-induced nausea and vomiting. 
(Harris, 2008; Lawlor and Bruera, 1998; McNicol, 2008; Laugsand, Kaasa, Klepstad, 
2011; Smith and Laufer, 2014) The chemoreceptor trigger zone (CTZ) lies in the floor of 
the fourth ventricle. At this site the blood-brain barrier allows many toxins to cross from 
the systemic circulation and the CTZ is therefore directly stimulated by drugs and toxins. 
(Porreca and  Ossipov, 2009) The cortex probably has a role in modulating nausea and 
vomiting based on patents previous experiences. The vestibular apparatus is also directly 
stimulated by the opioids. Mu, delta and kappa opioid receptors are all found in the inner 
ear. (Porreca and Ossipov, 2009) 
 
 
Nausea and vomiting may also be due to biochemical abnormalities such as 
hypercalcaemia, raised intracranial pressure due to primary or secondary brain tumours, or 
due to the oncological interventions being used to treat underlying malignancy. Patients 
with non-malignant disease may experience nausea and vomiting as a result of the chronic 
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pain, following surgery or investigations, and as a side-effect of other drugs they are 
prescribed alongside the opioid.  
 
 
In patients with chronic non-cancer pain gastrointestinal side effects are one of the most 
common reasons for discontinuing opioids (Porreca and Ossipov, 2009). The prevalence of 
nausea and vomiting in patients with non-cancer pain who are prescribed opioids varies 
from 10 to 50% (Porreca and Ossipov, 2009). 
 
 
Haloperidol and metoclopramide are both frequently used first line in the management of 
opioid-induced nausea and vomiting. Given the multiple receptors involved it is not 
unusual to require more than one anti-emetic to control severe nausea and vomiting and 
non-pharmacological measures may also be helpful. (Harris, 2008; Lawlor and Bruera, 
1998; McNicol, 2008; Laugsand, Kaasa, Klepstad, 2011) 
 
 
In a systematic review of the “Management of opioid-induced nausea and vomiting in 
cancer patients” Eivor Laugsand and colleagues reviewed the available evidence with the 
stated objective of providing guidance on the use of anti-emetics.   (Laugsand, Kaasa, 
Klepstad, 2011) They identified 56 papers which described the management of opioid-
induced nausea and vomiting. Many of the studies identified were of limited relevance due 
to patient group for example patients prescribed spinal opioid or were of poor methodology 
for example small sample size or retrospective case note review. In many of the included 
studies the effect on nausea and / or vomiting was the secondary or even tertiary outcome 
of the study. Although there was some evidence to support the use of metoclopramide, 
tropisetron and olanzapine the evidence was not sufficiently to make recommendations on 
their use. Evidence is also lacking for the other strategies that are available for the 
management of opioid –induced nausea and vomiting in patients with cancer such as 
change of opioid and change of route of administration. 
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4.4.2 Constipation 
 
 
Opioid-related constipation also occurs due to several mechanisms (Fallon, 1999, Choi and  
Billings 2002; Yuan and Foss 2000). Opioids cause delayed gastric emptying and reduced 
peristalsis. The tone of the ileocaecal valve and the anal sphincter tone are increased. There 
is evidence of disrupted defaecation reflex although this is probably most relevant in 
patients who are prescribed opioids and have pelvic malignancy. Patients are also likely to 
be on other constipating drugs such as anti-cholinergics and to be less mobile than 
previously due to pain or other co-morbidities. (Fallon, 1999; Choi and Billings 2002) 
Constipation in rats has been shown to occur at 25% of the opioid dose required to cause 
analgesia (Yuan and Foss, 2000). The combination of constipation, increased gastric reflux 
(due to delayed gastric emptying) and bloating are known as “opioid bowel dysfunction” 
(McNicol, 2008; Choi and Billings 2002; Becker, Galandi, Blum 2007) and are thought to 
occur in 25 to 50% of patients with cancer and 15 to 40% of those with non-cancer pain 
(McNicol, 2008). As constipation is unlikely to resolve with ongoing opioid therapy it is 
recommended that patients are commenced on regular laxatives (Harris 2008; McNicol, 
2008).  
 
 
Constipation can be distressing for patients and cause bloating, abdominal pain, nausea and 
vomiting (Choi and Billings, 2002). As well as the impact on the patient, the effect on 
healthcare services has been recognized with a need for nursing and medical time and 
sometimes hospital admission required to manage constipation. (Fallon, 1999) 
 
 
There are opioid receptors in the gastro-intestinal tract but opioids also have a central role 
in mediating constipation via an effect on the autonomic nervous system (Yuan and Foss 
2000) The opioid receptors in the gastrointestinal tract can be inferred to have an effect on 
gut function from the finding that loperamide – an opioid which does not cross the blood-
brain barrier – can be used to manage diarrhoea. (Yuan and Foss, 2000) The presence of 
opioid receptors in the bowel provides a therapeutic opportunity and the use of peripherally 
acting opioid antagonists has developed. Prescribing a low dose of the opioid antagonist 
naloxone will reverse the gastrointestinal effects of the opioid without adversely affecting 
the analgesia. Methylnaltrexone is another opioid antagonist which has the additional 
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benefit of not crossing blood brain barrier so there is no risk of reduced analgesia effect. 
(Harris, 2008; Yuan and Foss 2002) It has been shown to reverse opioid induced slowing 
of smooth muscle in laboratory situations. (Yuan and Foss, 2000) There is evidence to 
support the role of the peripherally acting opioid antagonists in mediating constipation in 
those with cancer pain (Becker, Galandi, Blum 2007). In palliative care patients with an 
estimated prognosis of less than six months and who had not had a bowel movement for 48 
hours, methylnaltrexone  resulted in a bowel movement in approximately one hour with no 
loss of analgesia. (Gevirtz, 2007) 
 
 
4.4.3 Other Opioid-Related Side –Effects 
 
 
Respiratory depression and difficulty passing urine are usually associated with acute use or 
accidental overdose of opioids (Lawlor and Bruera 1998) and have not been considered 
further in this study. Opioid-induced itch is described by 1% of patients who are prescribed 
opioids. The use of spinal opioids causes pruritus to worsen. Itch is thought due to 
histamine release or activation of serotonin receptors. Dry mouth is a common side-effect 
and is also usually attributed to several different causes including opioids. Salivary gland 
pathology, post radiation damage and other drugs such as the anticholinergics are likely to 
be contributing. It seems the dry mouth may be due to an anti-muscarinic effect of opioids. 
Dry mouth appears to persist over time and the patient does not become tolerant. (McNicol 
2008) Vanegas et al reported that in their experience methadone caused less dry mouth 
than morphine. (Vanegas  et al, 1998)  
 
 
There is no evidence to guide the management of myoclonus due to opioids. Most 
clinicians would try to reduce the dose if this could be achieved while maintaining pain 
control, alternatively a change of opioid may be required. Case reports and case series in 
the literature did not provide any conclusive evidence. (Stone and Minton, 2010) 
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Although opioid switching to manage the adverse effects of opioids is common in clinical 
practice there is little evidence to support this. While individuals may respond differently 
to a change of opioid it is also possible that the improved side effect profile is due to the 
placebo effect. (Dale, Moksnes, Kaasa, 2010)   
 
 
4.5 Importance of Opioid Metabolites 
 
 
Morphine is metabolized in the liver to several metabolites. The two most important 
metabolites are morphine-6-glucoronide (M6G) and morphine-3-glucoronide (M3G). 
Between 44 and 55% of morphine is metabolized to M3G and 9- 10% is metabolized to 
M6G. 8 – 10% of morphine is excreted unchanged in the urine (Andersen, Christrup, 
Sjogren 2003).  M6G is the active metabolite which binds with the mu opioid receptor and 
is thought to contribute much of the analgesic effect of morphine. M3G does not bind at 
the mu opioid receptor (Faura et al, 1998) and its role in the clinical effects of morphine 
has been debated (Gretton et al, 2013; Andersen, Christrup, Sjogren 2003). It was 
previously thought to be responsible for the myoclonus and hyperalgesia although the 
evidence is mainly from animal studies and is not conclusive. (Andersen, Christrup, 
Sjogren 2003) In humans when there was an association between hyperalgesia, myoclonus, 
allodynia and M3G there was also a high concentration of the parent drug. (Andersen, 
Christrup, Sjogren 2003) 
 
 
Morphine is also metabolized at extra-hepatic sites but these are of less significance. Extra-
hepatic sites of metabolism include kidney, gastrointestinal tract and brain. (Andersen, 
Christrup, Sjogren 2003) Liver dysfunction causes a reduction in glucuronidation of 
morphine, although it seems likely that the extrahepatic sites of metabolism become more 
prominent in this situation, and thus prolonged action of the parent drug. In renal 
impairment morphine and its metabolites will accumulate. (Andersen, Christrup, Sjogren, 
2003) 
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Several groups have studied the role of morphine and its metabolites in causing opioid side 
effects. The evidence is inconsistent though. In a systematic review published in 1998 
Faura and colleagues reviewed 57 studies and based their conclusions on 1232 patients. 
Although the systematic review was based on a large sample size, the included papers were 
on the whole small studies. The mean sample size was just 12 patients with a range of one 
to 136 patients. The review highlights the difficulties in conducting the studies needed to 
explore the relationship between serum concentrations of morphine and its metabolites and 
opioid related side effects. (Faura et al, 1998) 
 
 
Two more recent studies are discussed in more detail. They are based on larger samples 
and better define the clinical situation – a further flaw in other studies that have been 
published.  
 
 
In 2003 Pal Klepstad published the findings of a study which recruited 300 patients the 
majority of whom (n = 263) were on oral morphine. The remainder of patients were on 
subcutaneous morphine or a combination of routes (n = 2). The median dose of morphine 
orally was 80 mg / 24 hours which was lower than the dose taken subcutaneously which 
was 110mg / 24 hours. The study divided patients into treatment failures and successes. 
The treatment failures were those patients with opioid-related side effects and inadequately 
relieved pain. The study did not find any association between level of pain, nausea, 
constipation or cognitive impairment and the concentrations of plasma morphine, M6G and 
M3G. (Klepstad et al, 2003) The authors recognize the difficulty in addressing the 
contribution of morphine and metabolite concentrations to both pain and adverse effects 
when there are so many variables contributing especially in cancer patients.  
 
 
Sophie Gretton and her colleagues conducted a prospective study in 2013 and recruited 
patients with cancer related pain who were on oral morphine. On the basis of pain control 
and the presence of side effects they divided the group into patients who were responders 
and those who were non-responders. Blood was taken from the patients between two and 
four hours following a dose of morphine. They recruited 228 patients and analysed blood 
from 212 of those recruited. Although this study recruited larger numbers than many other 
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palliative care studies the number of patients with the side effects was very small. The 
authors suggested that central opioid effects are associated with a higher ratio of morphine 
metabolite to morphine ratio. However comments and conclusions on the association 
between morphine metabolite and morphine ratios are based on only seven patients with 
myoclonus and thirteen patients with severe confusion and / or hallucinations. Forty-two 
patients had severe drowsiness which represented 20% of the study group and are therefore 
more likely to represent real rather than chance findings. (Gretton et al, 2013) 
 
 
The role of genetics in opioid-related side effects was explored in a study which was 
completed by 114 twin pairs. The twin pairs received intravenous alfentanil and then saline 
infusion (or vice versa) in a randomized double-blind placebo-controlled study. The 
authors found that respiratory depression, nausea and a disliking for the opioid were all 
inherited traits. Sedation, itch and a liking for the drug were all strongly associated within 
family units which may indicate inherited traits but may also be due to the twins having 
been exposed to the same environmental influences and experiences. Although the study is 
of direct relevance to the use of opioids in the acute setting for example in the 
perioperative setting this study shows that well conducted studies are possible to address 
the cause of opioid effects and to assess to what extent genetics determines how patients 
respond to opioids. (Angst et al, 2012; Fillingim, 2012) 
 
 
Pharmacogenomic studies have identified some possible polymorphisms that may be 
contributing to the development of side-effects. These include genes which code for 
proteins involved in opioid receptor binding, transport of opioids and pathways of nausea 
and vomiting. (Smith and  Laufer, 2014) However none of the pharmacogenomics is yet 
ready to translate into clinical practice. 
 
 
4.6 Patient Acceptance of Opioids and Side effects 
 
 
A qualitative study recruited eleven patients who were reluctant to increase the dose of 
opioid to improve management of their cancer pain and explored the reasons for the 
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reluctance. The patients were part of an earlier study evaluating a pain management 
intervention. Despite receiving education about their pain and the opioids the patients 
declined to take a higher dose. When the nurses who were delivering the education spoke 
with patients the interviews were recorded and transcribed. The research team recognised 
that within these interviews was a significant data which explained why patients did not 
always want to titrate their analgesia. The interviews were conducted as part of the 
education programme. They were therefore clinical interactions and not research 
interviews. The main reasons given were fear of addiction to opioids and previous personal 
history of misuse of prescription drugs, strongly held beliefs about drugs and previous 
experience of severe opioid-related side effects. Although the numbers were small and the 
interviews had been conducted with a clinical purpose which may have limited their 
research potential the themes extracted from the data are strong and clinically relevant. 
(Schmacher et al, 2002) 
 
 
In a study which explored patient satisfaction with analgesia in acute pain secondary 
outcomes from a Randomised Controlled Trial were used. The methodology was one 
which could possibly be adapted for other palliative care research questions although there 
are intrinsic disadvantages for example the inability to explore fully some of the possible 
confounding factors. Although the patients had acute pain, the findings may still be 
relevant as the outcomes are about decision-making and acceptability of analgesia rather 
than the efficacy of the analgesic. The study showed that patients take into account several 
aspects when making decisions about analgesia including pain control and side effects of 
drugs. . The patients found the opioid-induced symptoms of nausea and fatigue were the 
least acceptable. (Jensen et al, 2004) 
 
 
In a study designed to measure the acceptability of side effects to patients who have acute 
or chronic pain and require opioids to manage the pain Razmic Gregorian and colleagues 
also found that nausea, and in this study vomiting, were the least acceptable side effects to 
patients. Both professionals and patients placed significant value on the presence of side 
effects when choosing opioids to manage pain. In the study the patients with both chronic 
and acute pain had previous experience of opioid-related side effects and were 
experiencing two or more side effects at the time of the study. (Gregorian et al, 2009) 
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4.7 Methods  
 
 
As in other parts of the study patients were recruited from three different clinical groups so 
that the prevalence of side effects in each group could be compared. Patients with chronic 
pain who were not prescribed a strong opioid were also recruited in order to provide a 
further comparison. Patients with cancer pain who were prescribed 60mg of morphine or 
an equivalent daily dose of an alternative opioid were invited to complete the assessments 
on up to three occasions. The majority of patients with chronic non-cancer pain who were 
prescribed an opioid and those who were not prescribed an opioid completed the 
assessment on two occasions. Patients with a history of substance misuse completed only 
one series of assessments.  
 
 
After providing information about their pain and opioid history patients were asked about 
the presence and severity of symptoms.  Likert scales had been constructed for the purpose 
of the study. Patients were asked to reflect on the week prior to the assessment and record 
whether the symptoms had been present very often, quite often, occasionally, very rarely or 
never. Five statements asked the patients about the symptom using non-technical language. 
Many patients read and completed the scales themselves so it was important to describe the 
symptom rather than use technical names such as myoclonus or hallucinations. The results 
have been presented using the questions that were put to participants. The symptoms 
included were nausea, vomiting, dry mouth, myoclonus and hallucinations. A member of 
the research team was always with the patient to clarify questions as needed. Quintiles of 
opioid dose were used to enable a descriptive presentation of frequency of symptoms. The 
symptoms were further presented as a distribution of the frequency of each symptom 
according to dose increase or reduction. Spearman rank correlations were used to explore 
the possible association between opioid dose or titration of the opioid and the frequency of 
the side effect.  
 
 
The patients then completed the questions about the presence and severity of constipation. 
The constipation score includes clear instructions for patients and again they are asked to 
think about the week prior to the assessment. There are three questions, each with 
statements from which the patient chooses the one they most identify with. Two of the 
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questions have three options and the third question has four possible answers. The 
questions are scored from zero to two or three and a maximum score of seven is obtained. 
A score of three or less signifies constipation. Patients were identified as constipated or not 
constipated after completion of the score. Basic descriptive statistics including mean, 
standard deviation and standard error were used to explore possible association between 
opioid dose and titration and constipation status.  
 
 
4.8 Results 
 
 
Figure 3:  Number recruited in each patient group and the number of assessments 
completed by patients in each patient group 
 
 
 
 
The presence of opioid related side effects was assessed at each time point in the study 
schedule. 178 patients were recruited and completed at least one set of assessments. The 
data for patients with substance misuse and chronic pain has been excluded from the 
analyses here due to the very small numbers recruited. The data for these patients has been 
presented separately in the chapter “Patients with Pain and a History of Substance Misuse”. 
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Ninety patients completed two assessments. The numbers from the different patient groups 
who completed each assessment have been detailed in the chapter “Patient 
Characteristics”. 
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Table 12:  Distribution of symptoms at assessment 1 by quintiles of dose in last 24 
hours where n=147 
 
  Never Very 
rarely 
Occasion-
ally 
Quite 
often 
Very 
Often 
All 
 N Percent Percent Percent Percent Percent Percent 
 
 Nausea 
Quintiles of dose in last 24 hours 
1 29 48 31 3 14 3 100 
2 29 34 28 31 7 0 100 
3 29 41 28 21 10 0 100 
4 30 40 23 10 17 10 100 
5 30 33 23 23 10 10 100 
 Vomiting 
Quintiles of dose in last 24 hours 
1 29 76 10 14 0 0 100 
2 29 76 17 7 0 0 100 
3 29 79 17 3 0 0 100 
4 30 73 7 10 7 3 100 
5 30 50 20 20 10 0 100 
 Dry mouth 
Quintiles of dose in last 24 hours 
1 29 14 3 31 31 21 100 
2 29 10 14 24 10 41 100 
3 29 14 7 21 24 34 100 
4 30 23 7 10 10 50 100 
5 29 21 7 31 17 24 100 
 Myoclonus 
Quintiles of dose in last 24 hours 
1 29 59 10 17 14 0 100 
2 29 45 14 14 24 3 100 
3 29 38 14 31 10 7 100 
4 30 30 13 20 13 23 100 
5 30 27 3 37 23 10 100 
 Hallucinations 
Quintiles of dose in last 24 hours 
1 29 93 0 3 3 0 100 
2 29 72 7 7 10 3 100 
3 29 72 14 7 3 3 100 
4 30 60 10 17 3 10 100 
5 30 80 3 17 0 0 100 
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There are 147 patients thus the first three quintiles each represent 29 patients, and last 
two quintiles represent 30 patients.  
 
 
At the lowest doses of opioid represented by the first quintile 52% of patients reported 
nausea in the week prior to assessment. The percentage of patients reporting nausea 
remained at above 50% in all quintiles. At the highest doses of opioid 66% of patients 
reported nausea and 20% of patients reported nausea had been present either quite often or 
very often. It is interesting to note that the prevalence of nausea is similar in the three 
quintiles representing higher doses of opioid. 
 
 
Overall the presence of vomiting is less than the presence of nausea in all quintiles of 
opioid dose.  The percentage of patients reporting vomiting in the last week is highest in 
the final quintile. However there are still 20 to 50% of patients in each quintile reporting 
vomiting in the week prior to assessment representing significant symptom burden. 
 
 
The percentages of patients reporting dry mouth are the highest of all symptoms 
documented. Between 70 and 83% of patients reported dry mouth at least occasionally in 
the week prior to assessment. 
 
 
Myoclonus is present at least occasionally in 31% of patients in the lowest dose quintile 
and this rises to 70% of patients in the highest dose quintile. 
 
 
Hallucinations are the least prevalent of all the symptoms. In the fourth quintile 10% of 
patients reported hallucinations very often. This was a higher percentage than reported 
hallucinations at the same frequency at the highest dose of opioid.   
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Table 13:  Distribution of symptoms at assessment two by quintiles of dose in last 24 
hours where n=74 
  Never Very 
rarely 
Occasion-
ally 
Quite 
often 
Very 
Often 
All 
 N Percent Percent Percent Percent Percent Percent 
 
 Nausea 
Quintiles of dose in last 24 hours 
1 15 27 33 40 0 0 100 
2 15 67 20 7 7 0 100 
3 15 27 20 47 7 0 100 
4 15 27 33 20 7 13 100 
5 14 36 7 21 21 14 100 
 Vomiting 
Quintiles of dose in last 24 hours 
1 15 67 27 7 0 0 100 
2 15 80 13 7 0 0 100 
3 15 67 20 13 0 0 100 
4 15 53 27 13 0 7 100 
5 14 50 14 21 7 7 100 
 Dry mouth 
Quintiles of dose in last 24 hours 
1 15 7 20 33 13 27 100 
2 15 13 7 20 13 47 100 
3 15 7 7 27 27 33 100 
4 15 7 13 20 27 33 100 
5 14 14 21 14 14 36 100 
 Myoclonus 
Quintiles of dose in last 24 hours 
1 15 53 13 20 0 13 100 
2 15 53 13 13 7 13 100 
3 15 33 20 20 20 7 100 
4 15 33 13 33 20 0 100 
5 14 21 36 29 14 0 100 
 Hallucinations 
Quintiles of dose in last 24 hours 
1 15 73 13 7 0 7 100 
2 15 93 0 7 0 0 100 
3 15 87 0 13 0 0 100 
4 15 80 13 0 7 0 100 
5 14 71 14 7 7 0 100 
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The numbers in table 13 are much smaller than in table 12. Again they represent quintiles 
of opioid dose and are based on patients prescribed opioids for cancer and non-cancer pain 
and substance misuse.  At assessment two, nausea is more frequent in four of the five 
quintiles than at assessment one. Dry mouth remains the most frequently reported 
symptom. Myoclonus has also persisted with 53% of patients in the fourth quintile 
reporting myoclonus at least occasionally and 43% of patients in the fifth quintile reporting 
the symptom at the same frequency. Hallucinations remain the least frequent symptom 
overall.    
 
 
Table 14:  Spearman rank correlations of opioid dose in last 24 hours at assessment 1 
with side effects as measured on Likert scales at assessment 1 where n = 147 
  
 
 
Side effect 
Correlation 
with dose 
in last 
24 hours 
 
 
P 
value 
Cancer (N=89) Nausea 0.003 0.974 
Cancer (N=89) Vomiting -0.001 0.996 
Cancer (N=89) Dry mouth -0.046 0.667 
Cancer (N=89) Myoclonus 0.252 0.017 
Cancer (N=89) Hallucinations 0.131 0.220 
    
Non- Cancer pain  (N=33) Nausea 0.331 0.060 
Non- Cancer pain  (N=33) Vomiting 0.406 0.019 
Non- Cancer pain  (N=33) Dry mouth 0.198 0.269 
Non- Cancer pain  (N=33) Myoclonus 0.004 0.982 
Non- Cancer pain  (N=33) Hallucinations 0.142 0.431 
    
Substance misuse (N=25) Nausea 0.554 0.004 
Substance misuse (N=25) Vomiting 0.675 0.000 
Substance misuse (N=25) Dry mouth 0.249 0.240 
Substance misuse (N=25) Myoclonus 0.659 0.000 
Substance misuse (N=25) Hallucinations 0.142 0.499 
    
All (N=147) Nausea 0.155 0.060 
All (N=147) Vomiting 0.220 0.007 
All (N=147) Dry mouth -0.026 0.752 
All (N=147) Myoclonus 0.278 0.001 
All (N=147) Hallucinations 0.125 0.132 
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In the results table 14 a positive correlation means worse symptoms with higher dose and a 
negative correlation means better symptoms with higher dose of opioid.  
In the substance misuse group of patients there are the strongest correlations in particular 
between higher dose and more severe nausea, vomiting and myoclonus.  These correlations 
are statistically significant. 
 
 
In the non-cancer patients there is some correlation between higher dose of opioid and 
severity of nausea and vomiting reported by the patients but this is less than in the 
substance misuse group. Only the correlation between higher dose of opioid and vomiting 
is statistically significant however.  
 
 
In the cancer patients there is least correlation between higher dose of opioid and severity 
of symptoms. Myoclonus shows the strongest correlation with opioid dose and this is 
statistically significant with a p value of 0.017.  
 
 
When all the data was analysed together there are weak correlations between higher dose 
of opioid and severity of symptoms however two of the correlations are statistically 
significant – vomiting and myoclonus. Dry mouth is a negative correlation suggesting this 
symptom improves with higher dose of opioid.  
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Table 15:  Spearman rank correlations of opioid dose in last 24 hours at assessment 
two with side effects as measured on Likert scales at assessment two  where N=74 
  
 
 
Side effect 
Correlation 
with dose 
in last 
24 hours 
 
 
P 
value 
    
Cancer (N=50) Nausea -0.001 0.994 
Cancer (N=50) Vomiting 0.096 0.506 
Cancer (N=50) Dry mouth -0.036 0.806 
Cancer (N=50) Myoclonus 0.156 0.279 
Cancer (N=50) Hallucinations 0.074 0.609 
    
Non- Cancer  pain (N=23) Nausea 0.479 0.021 
Non- Cancer pain  (N=23) Vomiting 0.399 0.059 
Non- Cancer pain  (N=23) Dry mouth 0.078 0.724 
Non- Cancer  pain (N=23) Myoclonus 0.047 0.832 
Non- Cancer  pain (N=23) Hallucinations -0.009 0.966 
    
All (N=74) Nausea 0.194 0.098 
All (N=74) Vomiting 0.221 0.059 
All (N=74) Dry mouth -0.005 0.966 
All (N=74) Myoclonus 0.160 0.172 
All (N=74) Hallucinations 0.059 0.617 
 
 
The “All patients” group includes the only patient with substance misuse to have had 
follow up assessments. Two patients had follow up assessments but had missing data from 
the Likert scales and are therefore excluded from this analysis (one patient with non-cancer 
pain and one patient with cancer pain). 
 
 
In this analysis the strongest correlation between symptom severity and opioid dose is with 
nausea in patients with non-cancer pain. The Spearman rank correlation is 0.479 and is 
statistically significant with a p value of 0.021. As in the previous analysis dry mouth has a 
negative correlation with opioid dose but the correlation is weaker in this analysis. 
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Table 16:  Spearman rank correlations of titration in last 7 days with side effects at 
assessment one as measured on Likert scales where n = 147 patients 
  
 
 
 
Side effect 
Correlation 
with dose change 
between 
7 days ago and last 
24 hours 
 
 
 
P 
value 
    
Cancer (N=89) Nausea 0.073 0.494 
Cancer (N=89) Vomiting -0.093 0.383 
Cancer (N=89) Dry mouth 0.114 0.289 
Cancer (N=89) Myoclonus 0.041 0.703 
Cancer (N=89) Hallucinations 0.120 0.263 
    
Non- Cancer  pain (N=33) Nausea -0.023 0.901 
Non- Cancer  pain (N=33) Vomiting 0.044 0.806 
Non- Cancer  pain (N=33) Dry mouth -0.056 0.758 
Non- Cancer  pain (N=33) Myoclonus -0.003 0.985 
Non- Cancer  pain (N=33) Hallucinations 0.080 0.657 
    
Substance misuse (N=25) Nausea 0.155 0.461 
Substance misuse (N=25) Vomiting -0.064 0.761 
Substance misuse (N=25) Dry mouth 0.281 0.184 
Substance misuse (N=25) Myoclonus 0.091 0.666 
Substance misuse (N=25) Hallucinations -0.143 0.496 
    
All (N=147) Nausea 0.070 0.396 
All (N=147) Vomiting -0.054 0.517 
All (N=147) Dry mouth 0.101 0.223 
All (N=147) Myoclonus 0.038 0.645 
All (N=147) Hallucinations 0.067 0.422 
 
 
In the analysis above a positive correlation means an increased dose of opioid in the last 
seven days was associated with worse symptoms and a negative correlation means an 
increased dose of opioid in the last seven days was associated with better symptoms. 
 
 
 
 
 
 
118 
 
The analysis shows there is no clear correlation between recent titration of the dose of 
opioid and the severity of symptoms. The correlations are all very weak with values close 
to zero. None of the correlations achieve statistical significance though. 
 
 
Some of the correlations are negative indicating the symptom actually improved when the 
dose of opioid increased. Several symptoms show negative correlation in the different 
patient groups. Only vomiting shows a negative correlation in the analysis of all patients 
together. 
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Table 17:  Spearman rank correlations of opioid dose titration in the last 4 weeks 
with side effects as measured on Likert scales where n = 147 
  
 
 
 
Side effect 
Correlation 
with dose change 
between 
4 weeks ago and 
last 24 hours 
 
 
 
P 
value 
    
Cancer (N=89) Nausea -0.044 0.690 
Cancer (N=89) Vomiting -0.047 0.669 
Cancer (N=89) Dry mouth 0.045 0.681 
Cancer (N=89) Myoclonus 0.044 0.685 
Cancer (N=89) Hallucinations 0.041 0.706 
    
Non- Cancer pain (N=33) Nausea -0.033 0.854 
Non- Cancer pain  (N=33) Vomiting 0.131 0.468 
Non- Cancer  pain (N=33) Dry mouth -0.062 0.734 
Non- Cancer  pain (N=33) Myoclonus -0.140 0.438 
Non- Cancer  pain (N=33) Hallucinations 0.018 0.920 
    
Substance misuse (N=25) Nausea 0.033 0.877 
Substance misuse (N=25) Vomiting 0.012 0.954 
Substance misuse (N=25) Dry mouth 0.172 0.421 
Substance misuse (N=25) Myoclonus 0.201 0.336 
Substance misuse (N=25) Hallucinations -0.164 0.433 
    
All (N=147) Nausea -0.049 0.561 
All (N=147) Vomiting -0.009 0.917 
All (N=147) Dry mouth 0.025 0.769 
All (N=147) Myoclonus 0.039 0.640 
All (N=147) Hallucinations -0.021 0.805 
 
 
In the analysis above a positive correlation means an increased dose of opioid in the last 
seven days was associated with worse symptoms and a negative correlation means an 
increased dose of opioid in the last seven days was associated with better symptoms. 
 
 
All the correlations between titration of the opioid dose over the four weeks prior to 
assessment and the symptoms reported by the patients are weak. None achieve statistical 
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significance. Some of the correlations are negative. In the “All patient” group, nausea, 
vomiting and hallucinations are all negative associations but with values very close to zero 
indicating a weak relationship. 
 
 
Table 18:  Spearman rank correlations of opioid dose titration in the last 6 months 
with side effects as measured on Likert scales where n = 147 
  
 
 
 
Side effect 
Correlation 
with dose change 
between 
6 months ago and 
last 24 hours 
 
 
 
P 
value 
    
Cancer (N=89) Nausea 0.143 0.337 
Cancer (N=89) Vomiting 0.050 0.741 
Cancer (N=89) Dry mouth -0.090 0.548 
Cancer (N=89) Myoclonus 0.274 0.062 
Cancer (N=89) Hallucinations -0.039 0.765 
    
Non- Cancer pain  (N=33) Nausea 0.099 0.583 
Non- Cancer pain  (N=33) Vomiting 0.148 0.410 
Non- Cancer  pain (N=33) Dry mouth 0.037 0.837 
Non- Cancer  pain (N=33) Myoclonus -0.070 0.699 
Non- Cancer  pain (N=33) Hallucinations 0.055 0.762 
    
Substance misuse (N=25) Nausea -0.003 0.990 
Substance misuse (N=25) Vomiting -0.072 0.749 
Substance misuse (N=25) Dry mouth -0.041 0.857 
Substance misuse (N=25) Myoclonus 0.161 0.475 
Substance misuse (N=25) Hallucinations -0.265 0.233 
    
All (N=147) Nausea 0.103 0.303 
All (N=147) Vomiting 0.045 0.656 
All (N=147) Dry mouth -0.022 0.824 
All (N=147) Myoclonus 0.176 0.077 
All (N=147) Hallucinations -0.053 0.600 
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In the analysis a positive correlation means an increased dose of opioid in the last seven 
days was associated with worse symptoms and a negative correlation means an increased 
dose of opioid in the last seven days was associated with better symptoms. 
The correlations are generally weak with values close to zero. Several of the correlations 
are negative suggesting symptoms improved as the dose of opioid was titrated.  
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Table 19:  Distribution of symptoms at assessment one by titration of opioid dose 
between 7 days ago and last 24 hours where n = 147 
 
  Never Very 
rarely 
Occasion-
ally 
Quite 
often 
Very 
Often 
All 
 N % % % % % % 
Nausea 
Percent change 7 days to 24 hours 
Negative (dose 
decreased)                  
30 47 17 20 10 7 100 
No change 91 38 31 16 11 3 100 
Positive (dose 
increased) 
26 35 23 19 15 8 100 
Vomiting 
 
Percent change 7 days to 24 hours 
Negative (dose 
decreased)                  
30 67 17 13 3 0 100 
No change 91 70 14 12 3 0 100 
Positive (dose 
increased) 
26 77 12 4 4 4 100 
Dry Mouth 
Percent change 7 days to 24 hours 
Negative (dose 
decreased)                  
30 23 3 20 10 43 100 
No change 90 17 10 26 21 27 100 
Positive (dose 
increased) 
26 8 4 19 19 50 100 
Myoclonus 
Percent change 7 days to 24 hours 
Negative (dose 
decreased)                  
30 37 10 27 10 17 100 
No change 91 44 9 26 15 5 100 
Positive (dose 
increased) 
26 27 19 12 31 12 100 
Hallucinations 
Percent change 7 days to 24 hours 
Negative (dose 
decreased)                  
30 77 0 13 3 7 100 
No change 91 78 8 10 3 1 100 
Positive (dose 
increased) 
26 65 12 8 8 8 100 
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The table show results of patients prescribed opioids for all reasons. Of the total patient 
group 30 patients had the dose of opioid reduced in the week prior to assessment. The 
patients still experienced symptoms despite opioid dose reduction. 37% of patients in this 
group reported nausea was present at least occasionally in the last week. 13% of patients 
reported vomiting; 73% reported dry mouth; 54% reported myoclonus and 23% reported 
hallucinations at least occasionally in the week prior to the assessment. 
 
 
The opioid dose of 26 patients had been titrated in the week prior to assessment.  The 
numbers of patients reporting symptoms at least “occasionally” are very similar in the two 
groups of patients i.e. those that had the dose increased and those that had a dose reduction. 
42% reported nausea, 12% reported vomiting, 88% reported dry mouth, 55% reported 
myoclonus and 24% reported hallucinations.  
 
 
The same analysis was carried out for two different historical time points. This aimed to 
provide a measure of the speed of change of the opioid dose and an attempt to differentiate 
between a rapid change of opioid and a slower change of opioid. For example if the dose of 
opioid is increased by 25% in a week this would be expected to have more impact on the 
patient than if the dose increased by 25% over 4 weeks or six months. From the data 
recorded it is not possible to know whether the opioid dose changed steadily or suddenly 
between any stated time points however the analysis provides an attempt at this. 
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Table 20:  Distribution of symptoms at assessment one by titration of dose between 4 
weeks ago and last 24 hours where n = 144 
 Never Very 
rarely 
Occasion-
ally 
Quite 
often 
Very 
Often 
All 
 N % % % % % % 
Nausea 
Percent change 4 weeks to 24 hours 
Negative (dose 
decreased)                  
36 33 25 25 8 8 100 
No change 69 42 29 13 12 4 100 
Positive (dose 
increased) 
39 41 23 21 13 3 100 
Vomiting 
Percent change 4 weeks  to 24 hours 
Negative (dose 
decreased)                  
36 69 19 8 3 0 100 
No change 69 70 14 12 4 0 100 
Positive (dose 
increased) 
39 74 10 10 3 3 100 
Dry Mouth 
Percent change 4 weeks to 24 hours 
Negative (dose 
decreased)                  
36 22 6 28 11 33 100 
No change 69 14 7 20 25 33 100 
Positive (dose 
increased) 
38 16 11 24 13 37 100 
Myoclonus 
Percent change 4 weeks to 24 hours 
Negative (dose 
decreased)                  
36 42 8 19 25 6 100 
No change 69 42 10 29 13 6 100 
Positive (dose 
increased) 
39 33 13 21 15 18 100 
Hallucinations 
Percent change 4 weeks to 24 hours 
Negative (dose 
decreased)                  
36 75 11 8 3 3 100 
No change 69 75 4 16 4 0 100 
Positive (dose 
increased) 
39 77 8 3 3 10 100 
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The table shows the presence of symptoms by dose titration over the last four weeks. It 
includes results from 147 patients as some patients were relatively opioid naïve. A larger 
number of the patients have had the dose of opioid adjusted in the four weeks prior to 
assessment. 39 (27.1%) patients have had the dose increased from four weeks ago 
compared to 26 (17.7%) patients with a dose increase in the previous week. The numbers 
of patients reporting the symptoms remains similar to the previous table however. Dry 
mouth remains the most frequently reported symptom, hallucinations remains the least 
frequently reported. 41% of patients with a reduced opioid dose reported nausea at least 
occasionally, 37% of patients with an increased opioid dose reported nausea. 50% of 
patients with a reduced opioid dose reported myoclonus at least occasionally and 54% of 
those with an increased dose also reported myoclonus.  
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Table 21:  Distribution of symptoms at assessment one by titration of dose between 6 
months ago and last 24 hours where n = 102 
 Never Very 
rarely 
Occasion-
ally 
Quite 
often 
Very 
Often 
All 
 N % % % % % % 
Nausea 
Percent change 6 months to 24 hours 
Negative (dose 
decreased)                  
36 50 25 14 6 6 100 
No change 23 39 35 13 9 4 100 
Positive (dose 
increased) 
43 35 26 23 12 5 100 
Vomiting 
Percent change 6 months  to 24 hours 
Negative (dose 
decreased)                  
36 78 14 6 3 0 100 
No change 23 70 9 17 4 0 100 
Positive (dose 
increased) 
43 72 14 5 7 2 100 
Dry Mouth 
Percent change 6 months to 24 hours 
Negative (dose 
decreased)                  
36 19 6 17 22 36 100 
No change 23 22 13 26 9 30 100 
Positive (dose 
increased) 
43 14 5 26 21 35 100 
Myoclonus 
Percent change 6 months to 24 hours 
Negative (dose 
decreased)                  
36 42 11 31 8 8 100 
No change 23 48 9 26 13 4 100 
Positive (dose 
increased) 
43 33 7 23 26 12 100 
Hallucinations 
Percent change 6 months to 24 hours 
Negative (dose 
decreased)                  
36 78 6 11 3 3 100 
No change 23 78 0 13 9 0 100 
Positive (dose 
increased) 
43 81 2 9 5 2 100 
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The table represents 102 patients. Not all patients in the study were on opioids six months 
prior to recruitment. The results show again the number of patients with symptoms. A 
minority of patients in each group were free of the symptom. Nausea was the most frequent 
symptom with at least 50% of patients in the three opioid titration groups reporting nausea 
in the week prior to assessment. 
 
 
Table 22:  Median symptom severity of symptoms in last 24 hours by regular drug at 
assessment one where n = 147 
  Nausea Vomiting Dry 
mouth 
Myoclonus Halluc- 
inations 
 N Median Median Median Median Median 
 
Drug       
Alfentanil 2 0.5 0.5 1.0 0.0 0.0 
Buprenorphine 3 0.0 0.0 0.0 0.0 0.0 
DHC 1 0.0 0.0 0.0 0.0 0.0 
Diamorphine 1 1.0 2.0 2.0 3.0 2.0 
Fentanyl 15 1.0 0.0 3.0 0.0 0.0 
Hydromorphone 4 2.5 0.0 4.0 1.5 0.0 
Methadone 21 1.0 0.0 2.0 2.0 0.0 
Morphine 59 1.0 0.0 3.0 1.0 0.0 
Oxycodone 40 0.0 0.0 2.0 2.0 0.0 
 
 
The table shows the median values of the Likert scales for each of the drugs and indicates 
the frequency at which the patient experienced the symptom. A median of zero indicates 
the symptom had not been present in the last week. A median of 2.0 indicates the symptom 
had been present on occasion in the last week. A median of 4.0 indicates the symptom has 
been present “very often” in the last week. The most frequent symptom was dry mouth 
experienced by patients who were on hydromorphone. Dry mouth was the most frequent 
symptom experienced by patients on all the different opioids. Myoclonus appears to be the 
next most frequent symptom and was most common in patients who were prescribed 
diamorphine and methadone. 
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Table 23:  Median severity of symptoms in last 24 hours by patient group at 
assessment 1 where n = 147 
 Nausea Vomiting Dry 
mouth 
Myoclonus Halluc- 
inations 
 N Median Median Median Median Median 
 
Cancer  89 1.0 0.0 3.0 1.0 0.0 
Chronic 
non-
cancer 
pain  
33 1.0 0.0 3.0 2.0 0.0 
Substance 
misuse                     
25 1.0 0.0 2.0 2.0 0.0 
 
 
The table above shows the symptoms present in each of the different patient groups. Dry 
mouth is the most frequently present symptom. Patients with non-cancer pain have the 
most frequent symptoms with nausea, dry mouth and myoclonus all present. Myoclonus is 
also present frequently in all patient groups. 
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Table 24:  Symptom frequency reported by patients in the week prior to assessment 
by patient group where n = 147 
 Cancer 
pain 
Non-cancer 
pain 
Substance 
misuse 
 
Nausea    
Never – Occasionally %                            84.3 72.7 95.8 
Quite/Very Often %                            15.7 27.3 4.2 
Vomiting    
Never – Occasionally %                            97.8 87.9 100.0 
Quite/Very Often %                            2.2 12.1 - 
Dry mouth    
Never – Occasionally %                            46.1 33.3 70.8 
Quite/Very Often %                            53.9 66.7 29.2 
Myoclonus    
Never – Occasionally %                            76.4 72.7 66.7 
Quite/Very Often %                            23.6 27.3 33.3 
Hallucinations    
Never – Occasionally %                            93.3 90.9 91.7 
Quite/Very Often %                            6.7 9.1 8.3 
 
 
The table above divides symptoms by patient group and frequency. Symptoms were 
divided into two groups representing the lowest three frequency options on the Likert 
scales or the highest two frequencies on the scales. In this table more patients with non-
cancer pain had nausea more frequently than patients with cancer pain or substance misuse. 
Patients with substance misuse had nausea less frequently than either of the other two 
patient groups. Vomiting was less frequently experienced by either cancer pain or 
substance misuse patients. Dry mouth was the most frequently reported symptom in all 
patient groups. The symptom was still lower in substance misuse than in other groups. Less 
than 10% of patients in all three patient groups reported hallucinations either quite or very 
often. 
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Table 25:  Symptom frequency in last week by opioid dose in last 24 hours at 
assessment one where n = 147 
 MEDD dose in last 24h 
 
 Low 
 
Medium High 
 
Less than two symptoms quite/very often  (n)                             24 58 25 
Two or more symptoms quite/very often (n) 4 24 12 
    
Less than two symptoms quite/very often (%)                           85.71 70.73 67.57 
Two or more symptoms quite/very often (%)                             14.29 29.27 32.43 
 
 
In this table the frequency of symptoms in all patients according to the morphine 
equivalent daily dose is presented. In this analysis a morphine equivalent daily dose of 
60mg or less is regarded as low; between 60mg and 300mg is regarded as medium; and a 
dose of 300mg or greater is regarded as high. Most patients were on a medium dose of 
morphine (or equivalent dose of another opioid).   At each range of morphine equivalent 
daily doses the majority of patients are experiencing less than two symptoms quite or very 
often. As the dose range increase from low through medium to high, the percentage of 
patients experiencing two or more symptoms quite or very often increases. 
 
 
Table 26:  Symptom frequency in last week by regular opioid drug in last 24 hours at 
assessment one where n = 147 
 Less than two 
symptoms 
quite/very often 
Two or more 
symptoms 
quite/very often 
 N % N % 
 
Alfentanil 2 100.0 0 0 
Buprenorphine 2 66.7 1 33.3 
DHC 1 100.0 0 0 
Diamorphine 1 100.0 0 0 
Fentanyl 9 60.0 6 40.0 
Hydromorphone 1 25.0 3 75.0 
Methadone 17 81.0 4 19.0 
Morphine 43 72.9 16 27.1 
Oxycodone 31 77.5 9 22.5 
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Patients on methadone seem to have a lower symptom burden than patients on other 
opioids with 17 (81%) of the patients reporting less than two symptoms present at the 
higher frequencies in the week prior to assessment. Patients who were prescribed fentanyl 
were more evenly spread in this table. Nine (60.0%) had less than two symptoms present at 
the higher frequencies, and 6 (40.0%) had two or more symptoms present at the higher 
frequencies. No patients on alfentanil, dihydrocodeine and diamorphine had two or more 
symptoms present at the higher frequencies. 
 
 
Table 27:  Morphine equivalent daily dose in the last 24 hours by constipation status 
for patients in different clinical groups and for all patients who were taking opioids 
where n = 147 
Dose in last 24 hours 
 
 
  N Mean SD SE Median Minimum Maximum 
 
 Constipation 
Cancer 
(N=89) 
No 56 200.4 202.5 27.1 128 20 1120 
Yes 33 177.0 222.6 38.8 140 20 1120 
         
Non-
cancer 
(N=33) 
No 21 371.9 540.3 117.9 200 56 2440 
Yes 12 295.0 379.9 109.7 188 25 1400 
         
Substance 
misuse 
(N=25) 
No 14 232.1 169.0 45.2 188 36 750 
Yes 11 641.4 427.7 129.0 525 80 1350 
         
All No 91 244.9 314.8 33.0 151 20 2440 
Yes 56 293.5 351.1 46.9 160 20 1400 
 
 
Overall 56 (38.1%) of the patients were constipated. 11(44%) of patients with substance 
misuse were constipated compared to 12 (36.4%) of patients with non-cancer pain and 33 
(37.1%) of those with cancer pain. There was no association between constipation and 
opioid dose. When the patient groups were combined P=0.39 on a t test. The mean 
difference in MEDD dose between those with & without constipation was 49, with a 
standard error of 56. 
 
 
132 
 
Table 28:  Opioid titration in the last 7 days by constipation status for patients in 
different clinical groups and for all patients who were taking opioids where n = 147 
% change 7 days to 24 hours  
 
  N Mean SD SE Median Minimum Maximum 
 
 Constipation 
Cancer 
(N=89) 
No 56 5.5 35.7 4.8 0 -38 200 
Yes 33 1.5 20.5 3.6 0 -33 100 
         
Non-
cancer 
(N=33) 
No 21 1.1 14.8 3.2 0 -33 50 
Yes 12 -0.6 21.3 6.2 0 -44 48 
         
Substance 
misuse 
(N=25) 
No 14 32.7 143.1 38.3 0 -67 525 
Yes 11 -6.6 22.4 6.8 0 -67 24 
         
All No 91 8.7 62.4 6.5 0 -67 525 
Yes 56 -0.5 20.9 2.8 0 -67 100 
 
 
Patients in the substance misuse group had the most significant dose titration. 
 
 
There is no statistically significant association between titration of opioid dose in the week 
prior to assessment and constipation status. P=0.29 for t-test of mean difference (when the 
groups are combined) 
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Table 29:  Opioid titration in the last 4 weeks by constipation status for patients in 
different clinical groups and for all patients who were taking opioids where n = 147 
 
% change 4 weeks to 24 hours  
 
  N Mean SD SE Median Minimum Maximum 
 
 Constipation 
Cancer 
(N=86) 
No 55 15.3 44.2 6.0 0 -40 200 
Yes 31 5.1 33.4 6.0 0 -58 150 
         
Non-
cancer 
(N=33) 
No 21 -3.0 18.9 4.1 0 -39 50 
Yes 12 -1.5 24.4 7.0 0 -57 48 
         
Substance 
misuse 
(N=25) 
No 14 99.4 205.9 55.0 0 -33 525 
Yes 11 13.2 63.2 19.1 0 -67 130 
         
All No 90 24.1 92.6 9.8 0 -40 525 
Yes 54 5.3 39.2 5.3 0 -67 150 
 
 
Again it is the patients in the substance misuse group who have had the greatest change in 
opioid dose. 
 
 
There is no statistically significant association between titration of opioid dose in the four 
weeks prior to assessment and constipation status. P=0.16 for t-test of mean difference 
(when the groups are combined) 
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Table 30:  Opioid titration in the last 6 months by constipation status for patients in 
different clinical groups and for all patients who were taking opioids where n = 147 
 
% change 6 months to 24 hours  
 
  N Mean SD SE Median Minimum Maximum 
 
 Constipation 
Cancer 
(N=47) 
No 28 133.6 369.1 69.8 22 -67 1900 
Yes 19 18.8 91.9 21.1 -10 -67 265 
         
Non-
cancer 
(N=33) 
No 21 50.1 243.9 53.2 0 -64 1100 
Yes 12 63.8 146.1 42.2 17 -57 488 
         
Substance 
misuse 
(N=22) 
No 13 89.2 222.8 61.8 0 -67 525 
Yes 9 30.0 115.8 38.6 0 -67 317 
         
All No 62 96.0 301.6 38.3 0 -67 1900 
Yes 40 34.8 114.3 18.1 0 -67 488 
 
 
When reviewing the last six months it is the cancer patients who have had the greatest 
change in opioid dose. 
 
 
There is no statistically significant association between titration of opioid dose in the six 
months prior to assessment and constipation status. P=0.22 for t-test of mean difference 
(when the groups are combined) 
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Table 31:  Constipation status by regular drug in last 24 hours at assessment 1 
 Constipation 
 
Constipation 
 No 
 
Yes No Yes 
 N 
 
N Percent Percent 
Drug     
Alfentanil 2 0 100.0 0 
Buprenorphine 2 1 66.7 33.3 
DHC 1 0 100.0 0 
Diamorphine 0 1 0 100.0 
Fentanyl 10 5 66.7 33.3 
Hydromorphone 2 2 50.0 50.0 
Methadone 12 9 57.1 42.9 
Morphine 37 22 62.7 37.3 
Oxycodone 24 16 60.0 40.0 
     
All 90 56 61.6 38.4 
 
 
Some of the drugs were only prescribed for very small numbers of patients making it 
difficult to draw conclusions. Fentanyl, methadone, morphine and oxycodone were the 
most frequently prescribed. Fentanyl appears to cause less constipation than the other 
drugs. Methadone appears to cause the most constipation. However a chi-squared test 
comparing rates of constipation between the four main drugs, Fentanyl, Methadone, 
Morphine & Oxycodone gives P=0.94, so the variation is not statistically significant. 
 
 
4.9 Discussion 
 
 
4.9.1 Summary of Main Findings 
 
 
Patients were asked about the frequency of known opioid-related side effects in the week 
prior to assessment. Overall the patients are displaying clinically significant burden of side 
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effects from the opioids which have been prescribed. Hallucinations were the least 
common side effect. Dry mouth was the most common side effect in all patient groups ie 
cancer pain, non-cancer pain and substance misuse patients. Patients with non-cancer pain 
appear to have a higher side-effect burden than patients with either cancer pain or 
substance misuse. 
 
 
Overall there were weak correlations between symptoms and opioid dose with myoclonus 
and vomiting being statistically significant. Patients with substance misuse showed a 
statistically significant correlation between opioid dose and nausea, vomiting and 
myoclonus. In the non-cancer group only vomiting was significantly associated with opioid 
dose. No correlation was observed between opioid titration and frequency with which the 
patients reported opioid-related side-effects.  Titration over the seven days prior to 
assessment, four weeks and six months were all explored and no correlation was found. 
Patients reported similar levels of side-effects when the dose of opioid had been reduced as 
when it had been increased.  
 
 
Constipation was common and 56 (38.1%) of the total study population were found to be 
constipated with a score of three or less on the constipation score. Patients with substance 
misuse were more likely to be constipated than other patient groups. There was no 
statistically significant association between dose and constipation. There was no 
association between titration of the opioid dose and constipation. This was explored at 
several time points prior to the assessment. In this study fentanyl was the least constipating 
of the opioids. Methadone was the most constipating. However there was not a statistically 
significant difference between the drugs. 
 
 
4.9.2 Comparison with the Published Literature 
 
 
In a study with some similarities to our own work Glare, Walsh and Sheehan recruited 42 
patients who completed at least one assessment and thirty patients completed the 
assessments every week for four weeks. The patients were all known to the palliative 
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medicine team and had been on morphine for at least week at the time of recruitment. The 
authors of this study used a questionnaire designed to elicit the presence of opioid-related 
side effects. The median dose of morphine at the start of the study was 144mg per day with 
a range of 50 – 3600 mg / day. The authors calculated the point prevalence of the different 
side-effects based on the 30 patients who completed four questionnaires. 23 (77%) of the 
patients reported a dry mouth, 7 (23%) reported constipation, 13 (43%) reported 
myoclonus, 3 (10%) reported nausea and 1 (3%) reported hallucinations. There was a non-
significant trend for nausea, dizziness and myoclonus to be worse with higher doses of 
morphine. In this group of patients nausea was usually mild and did not persist. Myoclonus 
was also usually mild and not persistent. The study benefits from the use of the specific 
questionnaire designed to identify all opioid-related side effects however it is limited by its 
duration of only four weeks. (Glare, Walsh, Sheehan 2006) 
 
 
Although traditionally clinicians are most concerned about opioid-induced nausea and 
vomiting at the introduction of the opioid or when the dose is titrated a longitudinal study 
of patients in the USA found that for some patients the nausea and vomiting persisted. The 
data came from an open-label uncontrolled study which followed patients for up to three 
years. All patients were on modified release oxycodone for the management of non-cancer 
pain. The mean dose of oxycodone was 52.5 mg with a range of 10.0 to 293.5mg. Patients 
were managed according to local guidelines and their pain. The study imposed a few 
limitations on the management of patients, for example twice daily dosing only, and 
required an assessment every three months to collect study data. 44% of the 233 patients 
who enrolled in the study required dose titration within the first three months. The need for 
dose titration reduced with time. The incidence of side effects was greatest in the first three 
months of the study. Forty one (18%) of the patients discontinued oxycodone due to side 
effects. The incidence of constipation declined from 9.7% at one-three months to 3.2% at 
three- six months and declined further through the study. The incidence of nausea declined 
from 11.0% at one-three months to 4.2% at three- six months. However for a small number 
of patients the side-effects persisted over the three years of follow-up. (Portenoy et al, 
2007) 
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The prevalence of opioid-related side effects in patients with a history of substance misuse 
and non-cancer pain who are prescribed methadone was discussed in a paper by Rhodin 
and colleagues in 2006. In a study of 48 patients dry mouth was reported by 19 (39.6%) 
patients, nausea by 10 (20.8%) and constipation by 9 (18.7%) of patients. The patients in 
this cohort more commonly experienced the less typical side effects of opioids including a 
combination of sweating, weight gain, fatigue, sedation and sexual dysfunction. (Rhodin et 
al, 2006) 
 
 
As part of a study evaluating a pain management programme 174 patients with cancer and 
bone metastases were asked about their opioid use and experience of opioid-related side-
effects.  In this study constipation was much less prevalent in patients who were not on an 
opioid and most prevalent in those who were on regular opioid and using breakthrough 
doses. Nausea was more prevalent in patients who were taking regular and as required 
doses of opioid than regular opioid alone. In this study the opioid dose correlated with the 
severity of nausea, vomiting and constipation.  (Villars et al, 2007) 
 
 
“A systematic review of oxycodone in the management of cancer pain” published in 2011 
found no evidence that oxycodone is more or less effective than morphine. The review also 
discussed a meta-analysis which had previously been published and found no difference in 
side-effect profile between the side-effect profiles of the two opioids. (King et al 2011) A 
similar review also published in 2011 found no significant differences between 
hydromorphone and morphine (Pigni, Brunelli, Caraceni, 2011). A review from the series 
compared transdermal opioids and oral morphine and found a reduction in constipation but 
no apparent benefit in terms of analgesia efficacy (Tassinari D et al, 2011). 
 
 
In patients with advanced cancer the prevalence of nausea ranges from 11 to 78%, and the 
prevalence of vomiting in the same population is 7 to 49%. (Laugsand, Kaasa, Klepstad 
2011) In cancer patients, opioid-induced nausea and / or vomiting is reported by up to 40% 
of patients (Laugsand, Kaasa, Klepstad, 2011). Our results also showed that nausea tended 
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to be mild indicated in our study by the patients reporting they had felt nauseous either 
very rarely or occasionally in the week prior to assessment. In our patient group myoclonus 
appeared to be more prominent. The myoclonus persisted over time and was present six to 
eight weeks later at assessment two. Hallucinations were the least frequent symptom in our 
patient group which is consistent with the findings of the other studies.  
 
 
Laugsand et al looked at whether changing the opioid prescribed for patients with cancer 
pain and whether this had any impact on the nausea and vomiting reported. The 
conclusions were based on six studies only and all were of smaller sample size than this 
study. There was some evidence to suggest oral morphine caused more nausea than 
intravenous morphine or oxycodone either orally or intravenously. Changing to 
hydromorphone from morphine also resulted in an improvement in nausea. Methadone 
appeared to cause less nausea than transdermal fentanyl. The authors concluded that there 
was weak evidence to support a change of opioid from morphine to either oxycodone or 
hydromorphone in order to better manage patients with opioid-induced nausea. (Laugsand, 
Kaasa, Klepstad 2011) Porreca and Ossipov also commented there was some evidence that 
transdermal fentanyl causes less constipation than oral opioid in patients with non-cancer 
pain. (Porreca and Ossipov 2009) There is also a lack of evidence guiding the use of anti-
emetics in patients with non-cancer pain. (Porreca and Ossipov 2009) 
 
 
Constipation is recognised as one of the most frequent side effects of opioids with a 
prevalence of between 40% and 50% in patients with metastatic cancer who are prescribed 
strong opioids. (Choi and Billings, 2002) There are several factors which influence bowel 
habit in cancer patients and opioids are just one of the factors contributing. Choi and 
Billings suggested that opioids were accounting for approximately 25% of the constipation 
in frail patients. (Choi and Billings 2002) 
 
 
In a study which recruited 50 patients with cancer who were referred to a specialist 
palliative care team 70% of the patients were constipated at the time of referral. Eight of 
the patients were not an opioid at the initial assessment. With the use of laxatives the 
 
 
140 
 
number of patients who were constipated at four weeks reduced to 26%. With findings 
similar to our results, the published study did not show any correlation between opioid 
dose and constipation. Instead it was the frailer patients who had the more resistant 
constipation. (Fallon and Hanks, 1999) Other authors have suggested a relationship 
between opioid dose and constipation. (Choi and Billings 2002) The published study used 
the same constipation score as this study.  (Fallon and Hanks, 1999) The authors also 
reported that at six months twelve of the 50 patients were still being followed up. Of these 
12 patients, four were prescribed an opioid but were not constipated and were not requiring 
a laxative and a further six of the 12 were prescribed a laxative were on a strong opioid and 
were not constipated. The authors concluded that morphine dose and constipation are not 
correlated and that the patients’ performance state better predicts the development of 
resistant constipation. (Fallon and Hanks, 1999) 
 
 
In a prospective survey of 100 hospice in-patients 47 patients had experienced visual 
hallucinations within the four weeks prior to assessment.  Of the patients who described 
recent hallucinations 28% experienced hallucinations several times a week and 25% had 
hallucinations every day.  The study explored the type of hallucination and found that 43% 
of patients saw a person either on waking or on going to sleep. The hallucinations were 
twice as likely to occur in patients who were sleepy or confused. Patients with 
hallucinations were more likely to be on opioids than the patients who were not prescribed 
opioids with an odds ratio of 4.45 although the author noted the wide confidence interval 
of the odds ratio. (Fountain 2001).  
 
 
Porreca and Ossipov quoted a study from the UK which recruited general practitioners 
(GPs). 74% of the 569 GPs who completed the survey thought the side-effects of the pain 
medication prevented adequate pain control of non-cancer pain (Porreca and Ossipov 
2009). They also quoted another study which suggested that patients with opioid-related 
side-effects may feel their doctor does not understand how best to manage their pain 
(Porreca and Ossipov 2009). 
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4.10 Conclusions 
 
 
The findings of this study are consistent with the published literature in showing that 
patients who are prescribed strong opioids have a significant burden from opioid-related 
side effects. Nausea and constipation are frequently reported by patients despite long-term 
opioid use. There was no correlation with opioid titration or with morphine equivalent 
daily dose. 
 
 
Although the small number of patients who were prescribed some of the drugs for example 
alfentanil makes it difficult to draw conclusions on the data regarding specific opioids this 
study benefits from a larger sample size than most of the literature. However this study has 
other advantages over many of the published studies. The data provides direct comparison 
between three clinically distinct patient groups and over a longer time period than many 
studies have done previously.  
 
 
These data help inform a proactive management plan for different patient groups taking 
opioids. These side effects can  impact significantly on quality of life and discussion with 
patients and relatives is key to ensuring clinicians are fully aware of the extent to which the 
patient is experiencing side effects and that the most appropriate and effective management 
plan is decided.  
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CHAPTER 5:  THE EFFECT OF OPIOIDS ON 
COGNITIVE FUNCTION 
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Outline of chapter: 
 
 
 Defines cognitive function and explains how impaired cognitive function can 
impact on the patient. 
 Definition of delirium with an outline of the prevalence, presentation, causes and 
management of delirium. 
 Considers the impact of opioids on cognitive function in patients with cancer pain 
and non-cancer pain. 
 Describes the use of the Addenbrooke’s Cognitive Examination -Revised in a 
population with pain. 
 Demonstrates that significantly more morbidity due to cognitive impairment is 
detected when using the ACE-R.  
 
 
5.1 Hypothesis 
 
 
Opioids affect cognitive function and this differs between patient groups who are 
prescribed opioids for different indications. 
 
 
5.2 Aims 
 
 
 To assess the cognitive function of patients who are prescribed opioids for different 
indications 
 To compare the cognitive impairment between the different groups 
 To explore possible factors which may contribute to impaired cognitive function 
including opioid drug, opioid dose and the effect of titration of the opioid 
 To describe the use of the ACE – R in a group of patients with pain or substance 
misuse and who are prescribed opioids.  
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5.3 Definitions of Cognitive Function 
 
 
“Cognitive function has been described as the brain’s acquisition, processing, storage 
and retrieval of information.” (Moriarty, McGuire, Finn 2011) 
 
 
“The term “executive function” is used as an umbrella for various complex processes 
and sub-processes. Most attempts to define executive function resort to a list of 
examples (such as task-switching, planning) or that other useful umbrella “working 
memory”, which reflects the fact that executive function is by no means a unitary 
concept.” (Elliott, 2003) 
 
 
Cognitive function is a complex process involving memory, attention, visuospatial 
awareness, language and fluency.  When any aspect of cognitive function is impaired it 
will adversely impact on the patient. For example if the patient’s language is impaired it 
will affect their ability to converse with their family, can cause frustration when they 
cannot find the words to express themselves, can cause them to become socially isolated 
rather than face people with whom they find it hard to communicate. When memory and 
attention are affected patients can find it difficult to be involved in discussions with family 
or health professionals and there may be safety concerns about how they will manage 
medications or being on their own at home. Many authors have commented that impaired 
cognitive function leads to impaired quality of life. As such it is important to consider the 
prevalence and presentation of impaired cognitive function and the possible reasons for the 
impairment. For some patients the impairment may be wholly or partially reversible. In 
this chapter there will be a description of some of the factors that can impact on cognitive 
function in cancer patients and then a more systematic consideration of the impact of 
opioids on cognitive function. 
 
 
Cognitive function can be affected by several neuropsychiatric disorders for example age-
related cognitive decline, delirium, dementia and affective disorders. Differentiating 
between the causes relies on a comprehensive history from the patient and obtaining a 
collateral history from their carers and other health professionals. The importance of 
recognising delirium lies with the potential for reversibility if any of the causes can be 
found and the need to manage the symptoms of delirium which can cause distress for both 
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the patient and their family. Age associated cognitive decline is separate to any disease 
related cognitive impairment. Intelligence traits are present from early life and are still 
relevant in later life. They must be taken into account when assessing cognitive function 
and the assessments of cognitive function are therefore best done over time rather than at a 
single time point (Deary et al, 2009; Michaud, Burnand, Stiefel 2004). It is a change in 
cognitive function that is important rather than any individual result. 
 
 
5.3.1 Definition of Delirium 
 
 
Delirium is a term often used interchangeably with acute confusion or acute confusional 
state in the literature. Delirium is a clinical diagnosis which is defined as: 
 
 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
diagnostic criteria for delirium is as follows
 
:  
 
 
“Disturbance in attention (ie, reduced ability to direct, focus, sustain, and shift attention) 
and awareness.” 
 
 
“Change in cognition (eg, memory deficit, disorientation, language disturbance, 
perceptual disturbance) that is not better accounted for by a preexisting, established, or 
evolving dementia.”  
 
 
“The disturbance develops over a short period (usually hours to days) and tends to 
fluctuate during the course of the day.” 
 
 
“There is evidence from the history, physical examination, or laboratory findings that 
the disturbance is caused by a direct physiologic consequence of a general medical 
condition, an intoxicating substance, medication use, or more than one cause.” 
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5.3.2 Delirium and Palliative Care 
 
 
The prevalence of delirium in palliative care populations varies with the patient group 
studied. For example in a review of patients admitted to a general cancer hospital Doriath 
and colleagues found that 11.8% (95% confidence interval: 9.7 – 14.2%) of patients were 
acutely confused (Doriath et al, 2007). However in a review article Centeno found the 
prevalence can be between 26% and 44% of patients with “terminal cancer” admitted to 
either hospital or hospice. (Centeno, Sanz, Bruera 2004) There was wide variation amongst 
the included studies in terms of diagnostic criteria, care setting, age and timing of study 
which is likely to explain this spread of prevalence.  The lack of consistency in definition 
is not limited to delirium and was discussed in the introduction when considering research 
in palliative care more generally. 
 
 
Delirium may present as hypoactive, hyperactive or mixed forms.  The patient may be 
quiet, still and withdrawn or can be restless, agitated and hallucinating. All forms of 
delirium are distressing for the patient but there is more risk of the hypoactive from being 
overlooked by professionals. (Centeno, Sanz, Bruera 2004; Michaud, Burnand, Stiefel 
2004) The patient may be disorientated in time, place or person. Hallucinations or sleep 
disturbances may be apparent.  
 
 
When delirium is present it can make it harder to assess the patient and gain an 
understanding of the other symptoms which they may be experiencing for example pain, 
nausea, shortness of breath. There are several tools available which can help assess the 
patient, particularly with respect to pain and in a discussion paper Mary Wheeler provides 
a useful summary of them. (Wheeler 2006) 
 
 
Delirium may be caused by hypoxia, biochemical abnormalities such as hypercalcaemia or 
hyponatraemia, sepsis or drugs. The presence of intracerebral pathology including 
metastatic disease or recent haemorrhage can cause delirium. Many drugs have been 
implicated and examples include opioids, steroids, benzodiazepines and anticholinergic 
drugs.  (Michaud, Burnand, Stiefel 2004) Serotonin toxicity is an increasing problem in 
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palliative care and is probably not always recognised. Cancer affects serotonin levels and 
when drugs which also increase serotonin levels in the blood for example anti-depressants 
are prescribed there is a risk of serotonin toxicity. The features include hyperreflexia, 
clonus, agitation, anxiety and altered mental state. (Dvir and Smallwood 2008; Isbister and 
Buckley 2005) 
 
 
Chemotherapy drugs are increasingly implicated in cognitive impairment and as such 
warrant particular consideration. 
 
 
5.4 Chemotherapy-induced cognitive impairment 
 
 
Cognitive impairment in cancer patients who received chemotherapy is recognised in a 
growing body of literature. Increasing recognition of cognitive impairment after 
chemotherapy is in part due to the increased survival of patients after chemotherapy. Given 
the increasing numbers of people who will be diagnosed with cancer during their lifetime 
and that there are new interventions which will continue to improve survival rates 
cognitive impairment is set to become a significant concern for those in oncology and 
palliative medicine. (Argyriou et al, 2011; Simo et al, 2013) 
 
 
Chemotherapy-induced cognitive function is also called “chemobrain” and “chemo-fog”. It 
occurs during treatment with chemotherapy and can persist long after the treatment has 
finished (Argyriou et al, 2011). The prevalence of chemobrain in studies varies between 
14% and 85%. It has been reported to last between two and ten years after the 
chemotherapy has been completed.  (Argyriou et al, 2011; Hodgson et al, 2013).  Females 
who have been treated for breast cancer appear to be the most commonly affected patient 
group. Other patient groups most commonly affected are those who have been treated for 
lung, prostate and ovarian tumours. (Argyriou et al, 2011) In one study a third of patients 
had cognitive impairment before chemotherapy was commenced (Hodgson et al, 2012).  
The type of chemotherapy and the duration of the treatment most likely to cause 
chemobrain remain unknown. (Cheung, Chui, Chan, 2012) 
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In a review in 2011, Argyriou and colleagues discussed that the aetiology of chemobrain is 
largely unknown but probably due to a combination of factors.  Many of the chemotherapy 
drugs cannot cross the blood-brain barrier normally, however there is some genetic 
variation in permeability and there may be a genetic susceptibility to chemobrain. Other 
chemotherapy drugs can cross the blood-brain barrier, for example 5-fluorouracil, and thus 
there is a risk of direct neurotoxicity. Hormone changes related to cancer treatment 
including reduced oestrogen and testosterone levels can also affect cognitive function 
adversely. (Argyriou et al, 2011) 
 
 
Emotional distress, fatigue and hormonal therapies have all been recognised by authors as 
confounding factors. (Argyriou et al, 2011) Opioids and other drugs used for the 
management of other side effects of chemotherapy and the sequelae of a cancer diagnosis 
have not been mentioned as possible confounders in the chemobrain literature. As with 
other clinical situations including the impact of opioids on cognitive function there is no 
consensus on the most appropriate method of testing cognitive function in order to assess 
and support patients with chemobrain. Subjective assessments tend to report more severe 
cognitive impairment than the objective measures of psychological performance. (Jansen 
2013) This may reflect “real life” ie the subjective assessments reflect more closely the 
difficulties patients have in everyday functioning. Alternatively the subjective assessments 
may be more affected by anxiety or depression than the objective measures.  
 
 
The importance of cognitive impairment that predates chemotherapy and therefore should 
not be wrongly attributed to chemotherapy is discussed by several authors (Hodgson et al, 
2012; Schagen et al, 2014; Vardy and Tannock 2007). It may be that some of the cognitive 
impairment attributed to chemotherapy is due to other cancer related factors. Opioids may 
have a part to play but none of the studies reviewed reported on the patients’ use of opioids 
or other analgesia. 
 
 
Patient reports of cognitive impairment within qualitative research studiesreveals the 
impact of the cognitive impairment on patients. (Kohli et al, 2007; Von Ah et al, 2013; 
Myers 2013) Von Ah and colleagues interviewed 22 patients with breast cancer who were 
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between one and twelve years post treatment. The patients were aware of the change in 
cognitive function during their chemotherapy but more concerned with other side effects at 
the time for example nausea. The cognitive impairment was more important to them when 
the other side effects had either subsided or been appropriately managed. They appeared to 
recognise the chemotherapy as the cause of the cognitive impairment. (Von Ah et al, 2013) 
In contrast a review by Myers (Myers, 2013) found that not all patients had identified 
chemotherapy as the cause of their impaired cognitive function. Some were fearful of 
dementia as the cause. Patients in this review described withdrawing from social situations, 
adverse effect on work and the development of coping strategies. (Myers, 2013) 
 
 
5.5 Effect of Opioids on Cognitive Function in Patients with Cancer Pain 
 
 
The published literature about the effects of opioids on cognitive function of patients with 
cancer pain is reviewed in this section. The numbers of confounding factors which are also 
likely to impact on cognitive function in this patient group make it difficult to evaluate 
well.  
 
 
A literature search was carried out using the OVID database. The search was carried out 
within Medline (1946 – 2014), Embase (1947 – 2014) and Health and Psychosocial 
Instruments (1985 – 2014). The table below shows the search strategy used. Words in 
columns were combined using the Boolean term OR; words in rows were combined using 
the Boolean term AND. The papers obtained in the literature search and the process of 
including and excluding papers for the literature review are shown in the chart below. 
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Table 32:  Search strategy used to identify papers for the literature review regarding 
the effects of opioids on the cognitive function of patients with cancer pain 
Opioi$ Cancer Cogniti$ Function$ 
Opiat$ Malignan$  
Morphine   
Oxycodone   
Methadone   
Hydromorphone   
 
Figure 4:  Papers identified for the literature review regarding the effects of opioids 
on the cognitive function of patients with cancer pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 articles identified initially 
102 articles remain after removing 
duplicates 
Initial screening - excluded animal studies, non-
cancer pain, healthy volunteers and studies which did 
not have assessment of cognitive function as one of 
the main study outcomes  
30 papers reviewed in full  
Excluded review articles from the extraction of 
themes 
18 papers included 
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5.5.1 Summary of Main Themes from Literature Review 
 
 
Aspects of importance across all the studies have been extracted and presented in a series 
of tables in order to provide comparison across the studies. 
 
 
The papers included in the review provide data on patients from across the world. Patients 
have been recruited who are attending outpatient clinics and who are hospice in-patients. It 
is likely that the care setting from which they have been recruited is of relevance to the 
outcomes of assessment. It is likely that hospice in-patients are frailer than those attending 
an oncology outpatient clinic particularly in countries where a poor prognosis is a 
requirement for admission to hospice. 
 
 
In general the studies are small. The two large studies (Andreasson et al, 2012; Kurita et al, 
2011) are both based on the European Pharmacogenetic Opioid Study (EPOS). Kurita and 
colleagues presented the results of the cognitive assessments of 1915 patients representing 
a significant achievement. The patients were recruited from 17 centres in 11 countries so it 
is likely that the number of investigators involved has introduced inter-observer bias. This 
large study also lacked follow-up data so although there is a wealth of data collected at a 
single point it is difficult to extrapolate to clinical settings.  
 
 
There was a lack of longitudinal data in most of the studies. Most of the studies rely on 
single assessments of cognitive impairment in order to draw conclusions. While there may 
be some validity in this approach for studies exploring the effect of breakthrough doses of 
opioid, the results of studies aiming to explore the effects of regular or long-term opioids 
on cognitive function are open to question if they rely on a single assessment. Bruera et al 
(Bruera et al, 1989) presented 2 days of data; Clemons et al reviewed their patients for two 
weeks and up to three weeks for some (Clemons, Regnard, Appleton, 1996). Maddocks 
and McNamara also presented data over a two-week period (Maddocks et al, 1996; 
McNamara, 2002). 
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Vainio in 1995 used tests that were specifically designed for the assessment of driving- 
highly relevant to the research question being explored (Vainio et al, 1995). Other authors 
used specific tests of psychological function. Some of the tests require special training or 
equipment in order to apply and interpret the test appropriately. Indeed some of the studies 
had psychologists as part of the research team. The use of such tests inevitably limits the 
relevance to clinicians who wish to apply the results of the studies within busy clinical 
practice. 
 
 
Five of the eighteen studies outlined did not report on the presence of other symptoms that 
could be attributed to opioids for example nausea, vomiting, sedation or dry mouth. Failure 
to report on the side effects of opioids takes the cognitive function assessments out of 
clinical context. 
 
 
The studies took different approaches to exploring the impact of opioids on cognitive 
function. Some of the studies measured the serum concentration of morphine and its 
metabolites and looked for possible correlation between the concentrations and cognitive 
impairment. Some of the studies screened a cohort of patients for the development of 
delirium. The majority of the papers recruited patients who were on opioid and assessed 
their cognitive function and looked for possible contributory factors to cognitive 
impairment in the opioid history. Some went on to switch to an alternative opioid or route 
and to look for possible change in the cognitive impairment as a result of the intervention. 
These studies address highly relevant research questions as these are situations which 
clinicians face every day and questions which patients ask. 
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Table 33:  Table which shows the features extracted from the studies exploring the impact of opioids on cognitive function in cancer patients 
Author, Date Andreassan, 2012 Ashby, 1997 Bruera, 1991 Bruera, 1989 
Care Setting,  Country 
 
 
Majority in-patients, some 
out-patients, 17 centres in 
11 European countries 
Hospice in-patients, 
Australia 
In-patients, specialist 
palliative care unit, 
Canada 
Unclear on setting, Canada 
Number of Patients 450 patients 36 patients 4 patients 40 patients 
Method of Assessing 
Cognitive Function 
MMSE 
(score < 23 = cognitive 
failure) 
Clinical diagnosis Mini-mental state 
questionnaire 
Finger tapping, arithmetic, 
reverse memory of digits, 
visual memory 
Control Group Grouped according to 
CYP2D6 genotype 
No comparison group No Two groups – stable opioid 
dose and following opioid 
titration 
Opioid 
 
 
Oxycodone Morphine 
MEDD 20 – 600mg, 
median 110mg 
Hydromorphone 
 
Morphine, oxycodone, 
hydromorphone and codeine 
Other Symptoms 
Assessed 
Nausea, tiredness Nausea, vomiting, 
confusion 
No Pain, nausea, drowsiness, 
confusion, depression and 
activity  
Longitudinal 
Assessment 
No No Only regarding presence of  
hallucinations 
2 consecutive days 
Timing of Opioid and 
Assessment 
 
 
Serum oxycodone 
measured at “trough level” 
ie prior to routine dose 
No fixed time after 
morphine dose 
No fixed time, all patients 
were requiring  opioid 
titration 
Assessment 1: immediately 
before opioid 
Assessment 2: 45 minutes 
after opioid 
Impact on Cognitive 
Function 
 
None found 
Median MMSE scores for 
2 groups were 28 and 29 
9 / 36 had confusion but 
also had increased 
creatinine level 
Hallucinations with no 
other change in cognitive 
function 
Titration of opioid associated 
with  drowsiness and 
impaired cognitive function 
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Table 34:  Table which shows the features extracted from the studies exploring the impact of opioids on cognitive function in cancer patients 
Author, Date Clemons, 1996 Gagnon, 2000 Gaudreau, 2006 Kamboj, 2005 
Care Setting,  Country 
 
In-patients and out-patients, UK In-patient unit, Canada Hospital patients, Canada In-patients and out-patients, 
UK 
Number of Patients 
 
29 recruited 89 patients 114 patients 14 patients 
Method of Assessing 
Cognitive Function 
 
 
Multiple measures including 
adult reading test, logical 
memory test, reaction time, 
grammatical reasoning test 
Confusion Rating 
Scale and Blessed 
Memory 
Concentration Test 
Nursing Delirium 
Screening Tool 
Multiple Objective and 
subjective measures 
Control Group 
 
 
Healthy volunteers and patients 
with cancer pain not taking 
opioids 
No No Crossover study, placebo arm 
Opioid 
 
 
Morphine Information lacking re 
opioid and method of 
conversion to MEDD 
Multiple opioids, MEDD 
presented 
Instant release opioid 
Other Symptoms 
Assessed 
 
Alertness, anxiety, pain, 
depression, concentration, 
clearheadedness 
No No Dry mouth, anxiety and 
depression, pain 
Longitudinal 
Assessment 
Yes – 2 weeks follow up, some 
participants up to 3 weeks 
Yes – screened three 
times / day until death 
Yes – mean 16 days No 
Timing of Opioid and 
Assessment 
1.5 hours after instant release 
morphine, 4 hours after modified 
release morphine 
Not known Not stated 45 minutes after 
administration of either 
instant release opioid or 
placebo 
Impact on Cognitive 
Function 
 
Yes. Seen in grammatical 
reasoning test, alertness and 
stroop colour-word test 
Prevalence of delirium 
varied apparently with 
MEDD 
Delirium more frequent 
with MEDD > 90mg 
Impaired memory 
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Table 35:  Table which shows the features extracted from the studies exploring the impact of opioids on cognitive function in cancer patients 
Author, Date Klepstad, 2003 Kurita, 2008 Kurita, 2011 Maddocks, 1996 
Care Setting,  Country 
 
 
Hospital in-patients Cancer and pain out-
patients, Brazil 
In-patients and out-
patients, 11 European 
countries 
Hospice in-patients, Australia 
Number of Patients 
 
 
300 patients 26 patients 1,915 patients 19 patients recruited only 13 
patients completed study 
Method of Assessing 
Cognitive Function 
Mini-mental state 
examination 
Mini-mental state 
examination and others 
Mini-mental state 
examination 
Clinical assessment of 
cognition 
Control Group No No No No 
Opioid 
 
Morphine, stable use Multiple opioids, MEDD 
used for comparisons 
Multiple opioids, MEDD 
used for comparisons 
Oxycodone 
Other Symptoms 
Assessed 
EORTC-QLQ Beck Depression 
Inventory 
EORTC – QLQ –C30, Nausea and vomiting, itch 
Longitudinal Assessment No Yes – of depression No Yes – 6 days 
Timing of Opioid and 
Assessment 
 
 
No consistent timing Not stated Not stated At commencement of 
oxycodone infusion, after 24 
hours with no dose change, 
after 6 days 
Impact on Cognitive 
Function 
 
No association between 
serum morphine and 
morphine metabolites and 
cognitive function 
No association between 
MMSE score and opioid 
found but other tests 
suggested impairment 
Impaired cognitive 
function associated with 
MEDD > 400mg 
(compared with MEDD < 
80mg) 
Reduction in delirium when 
change to oxycodone from 
morphine 
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Table 36:  Table which shows the features extracted from the studies exploring the impact of opioids on cognitive function in cancer patients 
Author, Date McNamara, 2002 Morita, 2002 Sjogren, 2000 Sjogren, 1989 
Care Setting,  Country 
 
Hospice in-patients, UK Hospice in-patients, Japan Hospital out-patients, 
Denmark 
Hospital in-patients, 
Denmark 
Number of Patients 19 patients 8 patients 130 patients 14 patients  
Method of Assessing 
Cognitive Function 
 
 
Cognitive function drug 
research assessment, DSM 
– IV criteria for delirium 
Presence of DSM – IV 
criteria for delirium 
Continuous reaction time, 
finger tapping test, paced 
auditory serial addition 
task 
Continuous reaction time 
Control Group 
 
 
No No Yes – 5 groups according 
to pain, opioid and 
performance status  
Yes – healthy controls 
Opioid 
 
 
Morphine changed to 
fentanyl 
Morphine infusion Multiple opioids, MEDD 
used 
Multiple opioids changed 
during study to epidural 
opioid 
Other Symptoms 
Assessed 
 
Nausea, vomiting, 
constipation, myoclonus 
and dizziness 
No Pain, sedation Pain, sedation 
Longitudinal Assessment 
 
Yes – 14 days No No Before and after initiation of 
epidural morphine 
Timing of Opioid and 
Assessment 
Patients on transdermal 
opioid 
Patients on continuous 
morphine infusion 
Consistent time of day Time between last opioid 
dose and testing included in 
analysis 
Impact on Cognitive 
Function 
 
Change to fentanyl led to 
improved concentration, 
working memory and 
speed of memory 
Patients had increased 
morphine metabolites seen 
after delirium developed  
Long – term opioid 
treatment did not seem to 
adversely affect the tests 
of neuropsychological 
function 
No change in continuous 
reaction time with change of 
route of opioid 
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Table 37:  Table which shows the features extracted from the studies exploring the impact of opioids on cognitive function in cancer patients 
Author, Date Vainio, 1995 Wood, 1998 
Care Setting,  Country Out-patients, Finland Hospice in-patients, 
Australia 
Number of Patients 
 
49 patients 
(7 patients did not 
complete) 
18 patients 
Method of Assessing 
Cognitive Function 
 
 
Psychomotor tests 
designed for assessment of 
professional drivers 
National adult reading test, 
Williams delayed recall 
test, immediate memory 
for digits, trail making test 
Control Group 
 
 
Yes – 24 patients on 
morphine, 25 patients not 
on opioid 
No 
Opioid Morphine Morphine 
Other Symptoms 
Assessed 
No No 
Longitudinal Assessment No No 
Timing of Opioid and 
Assessment 
 
Tests started 90 minutes 
after taking modified 
release opioid 
Not stated 
Impact on Cognitive 
Function 
 
Balancing ability with 
closed eyes was the only 
test affected significantly 
by morphine 
Impaired concentration 
and attention, delayed 
recall and conceptual 
tracking 
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5.5.2 Critical Review of Included Studies 
 
 
Bruera, Schoeller and Montejo described a series of four patients who had visual 
hallucinations which were attributed to opioid. (Bruera, Schoeller, Montejo 1992) The case 
series is interesting as the hallucinations appeared without other features suggestive of the 
central side effects of opioids or delirium. Three of the patients responded to a change of 
prescribed opioid and the introduction of haloperidol. There were no other apparent drug 
causes and biochemical abnormalities were excluded. The authors therefore concluded the 
opioid was responsible. However the response may have been due to the haloperidol and 
the change of opioid did not necessarily contribute to the benefit seen.  A case series of 
four patients, although well described, can only be of interest and not conclusive. 
 
 
Gaudreau et al recruited hospital cancer patients from an episode of delirium while they 
were in hospital. (Gaudreau et al, 2007) The episode of delirium regarded as the index 
episode was not necessarily their first episode therefore – it represented a convenience 
episode. The patients were followed up until they were discharged. Unfortunately the study 
is further flawed as the final data collected does not represent the outcome of the delirium. 
This study used the Nursing delirium Screening Scale which scores various aspects of 
delirium and results in a score from zero to ten where a score of greater than two indicates 
delirium. The study measured the NuDESC score three times each day. Any positive score 
was recorded as delirium. The study fails to provide any information on the duration of 
delirium. If the NuDESC score is positive on the subsequent day, the authors regarded this 
as a recurrent episode of delirium. A further flaw of this study is the failure to recognise 
that the interpretation of data does not distinguish between one episode of delirium lasting 
for ten days or ten daily episodes of delirium. They looked at specific doses and grouped 
the doses of the drugs above and below specific doses. Morphine was coded as above or 
below 90mg morphine equivalent daily dose. They found a statistically significant 
association between morphine dose greater than 90mg and delirium.  The conclusion of 
this paper has to be tempered by the flawed assumptions described earlier. 
 
Maddocks, Somogyi and colleagues wished to explore the hypothesis that a change of 
opioid can improve opioid-related delirium. They recruited 19 patients who had previously 
experienced morphine related delirium, however only 13 patients completed the study. The 
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patients were converted from morphine to subcutaneous continuous infusion of oxycodone 
and were monitored for features of delirium twice each day. All patients showed a 
reduction in delirium over the few days following the switch. The study is limited by the 
sample size, the lack of a validated tool and inter-observer bias given the number of 
observers involved in collecting the data (Maddocks et al, 1996). 
 
 
Kamboj and colleagues conducted a very well thought through study which looked at the 
effect of instant release opioid on cognitive function. They developed their hypothesis 
from the traditional view that it is either initiation of opioids or a change in the dose of 
opioids that cause the side effects. They recruited 14 patients and included those with 
cancer and non-cancer pain, in-patients and out-patients and a variety of opioids which 
were given by three different routes. Although the premise of the study was good this 
heterogeneity in patients recruited makes it difficult to draw any meaningful conclusions as 
there are too many possible confounding factors that cannot be controlled for. They chose 
tests which had “ecological validity” which was another very positive aspect of the study. 
Ecological validity aims to ensure that tests are meaningful representations of real life. 
They used the Bond and Lader scales and the HADS. They found that instant release 
morphine causes impaired memory with a slight impairment in immediate recall and a 
more obvious impairment in delayed recall. The authors suggest that opioids have an effect 
on information retrieval and put forward the thought that instant release morphine 
 
 
“exposes the patients to cognitive “reserve capacity” limitations – already there due to 
cancer, age and background opioids” (Kamboj et al, 2005) 
 
 
Klepstad explored whether serum concentrations of morphine or its metabolites M3G and 
M6G could be useful clinically. He recruited 300 patients who were in hospital and on a 
stable dose of morphine for at least three days prior to recruitment. They recruited 263 
patients on oral morphine and 35 patients on a continuous subcutaneous infusion of 
morphine. A further two patients were receiving morphine by more than one route 
regularly. 91 patients were also requiring instant release morphine for breakthrough pain. 
The study found that morphine, M3G and M6G concentrations do not correlate with 
nausea, constipation or cognitive failure. The authors suggested that other factors were 
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responsible for example receptor properties and genetic variability in opioid pharmacology 
(Klepstad et al, 2003). 
 
 
In a study published in 1989, Bruera and colleagues reviewed 40 patients with cancer and 
pain admitted to the hospital. There was no information on the reason for admission to 
hospital or the prescription of other drugs which could have influenced delirium although 
the authors stated that “none (of the patients) had evidence of other cause of delirium.”  
The paper stated that 40 consecutive admissions were included but then excluded patients 
who were prescribed either a long-acting opioid or a continuous infusion of opioid. It was 
therefore unclear how the 40 patients were identified. The patients were divided into two 
groups. Twenty patients were on a stable dose of opioid and had no dose change for at least 
seven days. Twenty of the patients were on a dose of opioid which had been titrated by at 
least 30% in the three days or less prior to the assessment. Both groups then underwent the 
same series of tests on two consecutive days. The first test of the day was done 
immediately before the routine of dose of opioid and the second test was done 45 minutes 
after the routine opioid dose. Both groups had a reduction in pain and an increase in 
sleepiness after the opioid dose. Additionally finger tapping speed and an arithmetic test 
were impaired after the dose of opioid in the opioid titrated group. This study was limited 
by lack of information on other possible contributory factors and the small numbers 
recruited. The study is also limited by only recruiting patients on short-acting opioids and 
by the use of a battery of very specific psychological tests which may be less easy for 
clinicians to use in everyday clinical practice. The authors recognised some of the 
limitations of the study and felt that future work was needed to clarify the implications for 
informed consent, driving and involvement in making decisions. (Bruera et al, 1989) 
 
 
Michael Ashby and colleagues conducted a study in Australia in 1997. Overall this is a 
very flawed study. The research team collected blood samples from 36 hospice patients at 
the same time as taking venous blood for other clinical analyses. Morphine, morphine -3-
glucoronide and morphine-6-glucoronide were measured in the venous samples. There was 
no information on the patients recruited and how they were identified for the study. All the 
patients were on morphine for at least three days prior to being included in the study. There 
was no consistency about opioid usage and the timings of blood tests in relation to opioid 
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administration was not recorded. Overall the results suggested that the patients who 
experienced nausea, vomiting and impaired cognitive function may have done so as a 
result of renal impairment or accumulation of morphine metabolites. (Ashby et al, 1996) 
 
 
In 2002 (Morita et al, 2002) another study was published which aimed to establish the 
impact of morphine metabolites on cognitive function. Although Morita’s study was more 
robust than Ashby’s study it still demonstrates clearly the problems in studying this area. 
The research team took samples of venous blood from patients who were on a continuous 
infusion of morphine – either subcutaneous or intravenous infusion - for at least 24 hours 
and in whom there was no evidence of cognitive impairment. It was not clear from the 
paper how it was decided that the patient had cognitive impairment. If delirium developed 
later in the patient’s journey further blood samples were taken, this time within 24 hours of 
recognition of delirium. Of 258 patients admitted to the hospice, 131 patients were eligible 
ie were prescribed continuous infusion of morphine but the study only generated results for 
eight patients. All eight patients had delirium which was attributed to multi-organ failure 
on the basis of biochemistry results and recognised diagnostic criteria. The study suggested 
that morphine metabolites may accumulate in patients who do not have renal failure. 
Overall the study protocol did not seem well designed to address the hypothesis and role of 
morphine or metabolites in delirium. There was a risk that the levels of morphine and / or 
metabolites were fluctuating and that any findings were due to chance. Discussion was 
based on eight sets of results only and there was no consistency about relationship of initial 
sample to episode of delirium (Morita et al, 2002). 
 
 
Sjogren and colleagues recruited 130 patients with cancer who were attending out-patient 
clinics. They excluded any patient with a poor performance status which clearly 
immediately limits the relevance of the findings of the study to many palliative care 
patients. The patients recruited were divided into five groups on the basis of performance 
status, pain and use of opioids. The patients completed a series of tests which included 
finger tapping test, Continuous Reaction Time (CTT) and Paced auditory serial addition 
task (PASAT). The tests assess non-specific cerebral function, vigilance and working 
memory respectively. The tests were chosen as they assess high order functioning and 
reflect information processing. The study showed that opioids did not affect the patients 
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functioning with the neuropsychological test. Patients with a lower performance status 
tended to have a slower CRT. When pain was more severe the patients performed less well 
on PASAT. The authors suggested that pain may have an arousal effect which helps 
patients function better. It is important to note though that 45% of all those recruited were 
unable to even complete the PASAT. As well as the exclusion of frailer patients and the 
use of specialised neuropsychological tests, the study is limited as there are no longitudinal 
data. The authors recognised this and stated: 
 
 
“It is well known that longitudinal studies in this population are difficult to conduct 
mainly because of a large number of drop-outs”. (Sjogren et al 2000) 
 
 
Two of the papers included in this literature review were drawn from the results of the 
European Pharmacogenetic Opioid Study (EPOS) which is a multi-centre study which has 
recruited patients from 17 centres in 11 European countries. Andreassen et al described a 
subgroup of the patients recruited for EPOS. Data on 461 patients who were taking 
oxycodone was extracted from the main study. This paper addressed very clearly stated 
research questions but was limited like so many of the papers by lack of follow-up and 
longitudinal data. Patients were grouped according CYP2D6 genotype and grouped 
according to speed of oxycodone metabolism ie extensive, poor or ultra-rapid metabolisers. 
92% of those recruited were extensive metabolisers. The authors observed that CYP2D6 
genotype affected oxycodone metabolism but not efficacy and that CYP2D6 genotype was 
not associated with opioid related adverse events including cognitive impairment as 
measured by the mini-mental state examination (Andreassen et al, 2012). 
 
 
Another paper based on the EPOS study was written by Kurita et al in 2011. This paper 
analysed data on 1915 patients clearly benefitting from significant numbers recruited but 
again lacking longitudinal information. The EPOS study used the mini-mental state 
(MMSE) to measure cognitive function. MMSE scores of less than 23 out of 30 were taken 
to indicate definite cognitive impairment, scores of 24 to 27 to indicate possible cognitive 
impairment and scores of greater than 27 to indicate normal cognitive function. The 
authors found that poor performance status, increased age and short time since diagnosis 
(15 months) and lower MMSE scores were all associated. Overall one third of patients had 
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possible or definite cognitive impairment as indicated by a MMSE score of 27 or less.  A 
morphine equivalent daily dose of 400 mg / day or greater was associated with a 1.75 times 
greater odds of having a low MMSE compared to a morphine equivalent daily dose of  less 
than 80mg. Patients with breakthrough pain had 0.73 times lower odds of a low MMSE. 
The authors of this paper also highlighted the lack of cut-off scores for the more specialist 
neuropsychological tests to indicate clinically relevant cognitive dysfunction (Kurita et al, 
2011). 
 
 
McNamara conducted a small study which was published in 2002. The study explored 
whether changing patients to transdermal fentanyl would improve their cognitive function 
and other opioid related side effects. None of the results obtained were statistically 
significant but this was not surprising given the small sample size. Only 19 patients were 
recruited over a two year period and of the 19 recruited only nine completed the fourteen 
days of the study. Several of the patients who did not complete the study became too 
unwell or had an adverse event about which there was no detail. The patients were changed 
from morphine to transdermal fentanyl because of morphine toxicity. The patients reported 
an improvement in well-being that was not apparent to the researcher. The researcher did 
observe an improvement in drowsiness, working memory, attention and power of 
concentration. The small sample size and lack of completion of the protocol clearly limit 
the conclusions that can be drawn from the study (McNamara, 2002). Also of note is the 
rapid titration of fentanyl which would be unusual in most hospices. The transdermal 
fentanyl was titrated by 25 mcg / hour every 72 hours which would be considered too rapid 
by many clinicians. 
 
 
Eighteen patients who were prescribed morphine and were hospice in-patients were 
recruited to assess their cognitive function on morphine. This study used the National 
Adult Reading Test to establish pre-morbid intellectual functioning and this showed that 
the patients were of average intelligence. However they showed an impaired ability to 
retain information and reduced ability on conceptual tracking test. There was a statistically 
significant correlation between immediate memory and attention and plasma morphine 
concentration. The patients in this paper were on lower dose of morphine than several of 
the other papers with a mean daily dose of 100 mg per 24 hours. (Wood et al, 1998) This 
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paper is of interest because the authors established the pre-morbid intellectual functioning 
and it was noted that the patients had not appeared confused to the clinical team but most 
had evidence of cognitive impairment on formal testing.  
 
 
One of the key papers mentioned when discussing opioids and cognitive function was 
written by Vainio and colleagues in 1995. This paper addressed the safety of patients with 
cancer who are prescribed opioids to drive. The study used a battery of tests designed to 
assess professional drivers. Two groups were recruited for the study. Twenty four patients 
had cancer and were on twice daily sustained release morphine. The dose of morphine had 
been stable for at least two weeks. Also recruited were 25 patients with cancer but who did 
not have pain and were not prescribed opioids. Seven of the 49 patients recruited did not 
complete the tests due to either fatigue or problems with the equipment (Vainio et al, 
1995).  
 
 
“However, we cannot ignore the tendency of the morphine group to show slower 
reaction times, make more mistakes, and process visual information and perform the 
motor sequences more slowly than the control group.”……”In conclusion, long-term 
analgesic medication with stable doses of morphine does not have psychomotor effects 
of a kind that would be clearly hazardous to driving in traffic.”  (Vainio et al, 1995, 
pages 669, 670)  
 
 
The two quotes from the paper appear at odds and it would seem there are risks when 
patients on morphine (and presumably other opioids) are driving. 
 
 
All consecutive patients admitted to a hospice in Canada were screened for delirium using 
the confusion rating scale (CRS). Eighty-nine patients were followed from admission to 
the hospice until they passed away with a mean follow-up of 12 days. Patients who were 
positive for screening for delirium on CRS had the diagnosis confirmed or excluded using 
the Confusion Assessment Method. Of the 55 patients in the cohort who had a delirium 
only the dose of opioid prescribed was different from those who did not have a delirium. 
The patients had a higher morphine equivalent daily dose for regular analgesia (p = 0.080) 
and for their breakthrough pain (p = 0.097). (Gagnon et al, 2000) 
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In a pilot study exploring cognitive impairment in patients with cancer on opioids Kurita 
describes the assessment of two groups of patients (Kurita and de Mattos Pimenta, 2008). 
Fourteen patients who were prescribed opioids are compared to 12 patients who were not 
taking opioids. Only a small number of patients were recruited and attrition was high. The 
study aimed for three assessments over a month but only 13 of the patients recruited were 
able to complete all three assessments. The study assessed many aspects of cognitive 
function including attention, mental flexibility, concentration, working memory, short-term 
recall and long term memory. There was no difference found between the two groups 
recruited and no correlation between cognitive function and opioid dose. (Kurita and de 
Mattos Pimenta, 2008)  
 
 
Clemons et al also found no difference in cognitive function between patients with cancer 
who were prescribed opioids and those who were not. There was a difference between the 
patients and healthy volunteers. This study was very small with only six patients in the 
cancer, not on opioids group and seven patients in the cancer and on opioids group. 
Although the study was well thought through it is possible that the findings are due to 
chance. The authors did not recognise this but did not consider that the results were biased 
due to recruitment only from a hospice in-patient population. (Clemons, Regnard, 
Appleton 1996) 
 
 
Sjogren and Banning recruited fourteen patients with cancer pain who were on oral opioids 
and in whom there was to be a planned switch to epidural morphine because the patient 
was either experiencing inadequate pain control or unwanted sedation. (Sjogren and 
Banning 1989) Prior to cognitive function testing the patients were on a stable dose of 
opioid although fluctuations of 10% either way were allowed within this definition. This 
study used the continuous reaction time (CRT) and the patients reported their pain and 
sedation using a visual analogue scale. When the patients were changed to epidural opioid 
there was no statistically significant improvement in CRT and although the median VAS 
results for sedation and pain were lower there was an inevitable range and the results were 
not significantly positive. The study did not show significant with a change to epidural 
opioid but the sample size was small and there was no data to describe how long the 
 
 
166 
 
patients had been on opioid ie were they chronic opioid users? There were differences 
found between controls and patients CRT scores though (Sjogren and Banning 1989). 
 
 
In 2003 Klepstad measured serum morphine, morphine-3-glucoronide and morphine-6-
glucoronide concentrations and looked for possible correlations with symptoms. There was 
no correlation with the serum concentration of morphine or its metabolites and cognitive 
function, pain, nausea or constipation. The patients were only on a stable dose of morphine 
for 3 days and should have reached steady state however there was no consistency in 
timing between sample time and symptom assessment which may limit the conclusions. 
Some patients were using breakthrough analgesia and the analysis was repeated without 
these patients to all for the effect of breakthrough doses on stable dose.  The authors 
suggest that it is not the concentrations of opioid or metabolite that are important per se 
and that receptor properties or intracellular pharmacodynamics is involved.  The results 
and conclusions are in line with other authors. (Klepstad et al, 2003) This is an important 
clinical conclusion as we often see a time lag between reducing, stopping or switching an  
opioid and an improvement in cognition. 
 
 
5.6 Effect of opioids on cognitive function in patients with non-cancer pain 
 
 
In an industry- sponsored study designed to assess neuropsychological effects of opioids in 
patients with chronic back pain Jamison and colleagues provided data over a 180-day 
period. This represents the longest period of data collection identified in the literature. One 
hundred and forty four patients were included in this analysis and represented a subset of a 
larger study. All the patients had back pain and required opioids to manage their pain. The 
patients were prescribed either oxycodone with acetaminophen or transdermal fentanyl. 
They were prescribed the analgesia for 90 days and then crossed over to the other 
treatment. Only 68.8% completed the intended study assessments. Psychological 
performance was assessed using the trail making test and the digit substitution test. 
Together these tests are a useful indicator of fine motor speed, dexterity and reaction time. 
Unfortunately the trail making test is affected by age and also shows a practice effect. Both 
factors could have influenced the results. Although many of the patients showed 
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improvement in psychological function with improved concentration and hand-to-eye 
coordination, 16 - 25% of the participants showed deterioration in psychomotor function. 
The deterioration was linked to increased age and less pain at the start of the study. 
(Jamison et al, 2003) 
 
 
In a study that recruited 40 non-cancer patients Sjogren and colleagues used the continuous 
reaction time, finger tapping test and paced auditory serial addition test to assess the 
neuropsychological function of patients who were on a stable dose of opioid. (Sjogren, 
Thomsen, Olsen 2000) The tests were chosen to reflect higher order functions and the 
ability to process information. Functioning in all the tests was impaired.  The morphine 
equivalent daily dose was moderate with a range of 15 to 300mg and 12 of the patients 
were on methadone. Interestingly the study participants had a significant degree of anxiety 
and depression but no correlation was found between these morbidities and the ability to 
complete the neuropsychological tests. The authors suggested that there is a balance to be 
achieved between the effects of pain on arousal (ie increased) and concentration (ie 
decreased) and that the effects of the opioids are a part of this balance.  
 
 
Tassain comments that the cognitive effects of opioids are less well studied in patients with 
non-cancer pain than in those with cancer pain. (Tassain et al, 2003) In a well-designed 
study Tassain and his colleagues sought to assess the effects of opioids on cognitive 
function in an observational study designed to reflect the realities of clinical practice. The 
participants of the study were opioid naïve but already on other forms of analgesia and 
anxiolytics or antidepressants as needed. Thirty two patients were identified and 28 
consented for the study. The morphine was titrated to analgesic effect and the mean dose at 
3 months was 62mg, at 6 months was 65mg and at 12 months was 72mg. Ten of the 
patients discontinued the morphine shortly after starting due to unacceptable side effects 
mainly constipation and sedation. Only 11 patients completed the final series of 
assessments at 12 months. The patients were required to complete a battery of assessments 
which measured mood, pain, quality of life, memory, attention and tests of fine motor 
speed and reaction time. The patients’ pain responded to the morphine and there was no 
significant change in the cognitive function measures although there was some 
improvement in information processing. This study was useful as it approximates clinical 
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practice however the patients are on a relatively small dose of opioid and the numbers 
involved are very small. The number of patients who were unable to tolerate morphine 
represented a significant proportion of the study sample. (Tassain et al, 2003) 
 
 
In a review article Chapman and co-authors recognised the importance of clarifying the 
effect of opioids on cognitive function. In healthy volunteers opioids have been shown to 
adversely affect motor speed even after one dose. Other studies have contradicted the 
finding and the balance between the effects of pain and opioids on arousal, anxiety and 
inhibition is discussed. The authors highlight the difficulties of comparing the findings 
from the studies which have been carried out due to the variation in outcome measures 
used. Inevitably given the available evidence the conclusion of this comprehensive review 
was that further research is needed to fully understand the role of opioids in cognitive 
functioning. (Chapman, Byas-Smith, Reed 2002) 
 
 
In a review of the “extent of neurocognitive dysfunction in a multidisciplinary pain centre 
population” (Landro et al, 2013) the authors highlighted some key points. Cognitive 
impairment may be recognised by patients but not reported to a professional and when it is 
reported it may be wrongly attributed to anxiety or depression. In their study Landro and 
colleagues found that 20% of the patients had impaired cognitive function at baseline 
although it was not clear from the paper how many of this group were on pain medications. 
The difficulties in recruiting for this type of study were also clear – they recruited 73 
patients from the total 123 patients who were screened. The research team used the 
everyday working memory questionnaire which assesses general memory and attention as 
well as several other measures of psychological function. They found that objective and 
subjective measures of cognitive impairment correlated. (Landro et al, 2013) 
 
 
Kurita and colleagues recruited 49 patients after screening 137 patients. They used a 
battery of neuropsychological tests including the mini-mental state examination, trail 
making test, continuous reaction time. The patients recruited had been on opioids for many 
years (mean 6.8 years) and were on a moderate dose of opioid with a mean morphine 
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equivalent daily dose of 252mg / day. They found that a lower dose of opioid correlated 
with worse performance on the digit span test (Kurita et al, 2012). 
 
 
5.7 Opioids and driving 
 
 
Patients and professionals consider the question of whether it is safe to drive when taking 
strong opioids. 
 
 
“Safe operation of a motor vehicle is a learned activity demanding the complex 
interaction of physical, cognitive, perceptual skills and abilities.” (Galski, Williams, 
Ehle 2000) 
 
 
The ability to drive can maintain independence and quality of life and the implications of 
driving, if it is not safe to do so, are clearly significant. Despite this there is a lack of 
studies which address the question. In a review in 2012 Angela Mailis – Gagnon describes 
the inconsistencies in the conclusions drawn from the few studies that have been carried 
out and argues that previous reviews had not been able to safely conclude that patients on 
opioids are safe to drive. She argues that there many confounders such as concomitant 
medications, pain and sleepiness which are not properly allowed for in the analysis. The 
review identified only four studies which assessed driving or a driving simulator but these 
were limited not only by failure to address the confounders but also by the small sample 
size. The studies recruited 23, 16, 33 and 21 patients. Further bias was introduced by the 
recruitment of patients who responded to general calls to be involved. The recruitment of 
this self-selected group may indicate the recruitment of patients who were confident in 
their driving ability and those who knew they had difficulties decided to not be involved. 
(Mailis-Gagnon et al, 2012) Although recognising the lack of evidence regarding safety to 
drive an editorial by James Zacny argued that to preserve patients quality of life was the 
priority when the evidence was not conclusive (Zacny, 2006). He suggested putting the 
decision about driving back to the patient. In a structured review of the evidence Fishbain 
and colleagues also concluded that there was no evidence to support the restriction of 
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driving but recommended that patients should not drive for four or five days after the dose 
of opioid has been increased or if they ever feel sedated. (Fishbain et al, 2003) 
 
 
In a study in 2005, Byas-Smith and colleagues evaluated the patients driving in the 
community and around an obstacle course. They only recruited 32 patients with a history 
of pain, 11 of whom were not taking opioids. The patients were experienced drivers with 
around 30 years’ experience. Thirty of the 32 patients who agreed to take part were taking 
medication other than opioids which had the potential to impact on cognitive function. 
Also of note, the patients who volunteered for the study – only 15% of the initial patient 
group approached – were paid $75 (Byas-Smith et al 2005). In Galski’s study (Galski, 
Williams, Ehle 2000) 16 patients were compared with 327 patients who had known 
cerebral compromise from a variety of causes including dementia, frail elderly and 
cerebrovascular accident. Small size and confounders make it difficult to draw any 
conclusions but the authors found no loss of visuospatial abilities in the patient group who 
were on opioids. However this group made more mistakes on tasks which rely on speed 
and accuracy together. It is also possible that the small number of participants from the 
population contacted represents a biased sample – those who knew they were having 
difficulties driving may have chosen to not become involved in the study (Galski, 
Williams, Ehle 2000). 
 
 
5.8 Summary of the Literature 
 
 
The literature regarding the effects of opioids on cognitive function is limited in particular 
by studies of small sample size and a lack of longitudinal data. The lack of clinically 
relevant and user accessible research tools limits the ability of the clinician to assess 
cognitive function in clinical rather than research settings. There is a need for a tool to 
assess cognitive function which can be used without specialist training, is not too onerous 
for the patient and has been shown to detect cognitive impairment in patients with pain or 
substance misuse and who are prescribed opioids.  
 
 
 
171 
 
5.9 Methods Specific to Effect of Opioids on Cognitive Function  
 
 
Patients were recruited from three different clinical groups so that the impact of cognitive 
function could be assessed and compared between the groups. Patients with cancer pain 
who were prescribed 10mg of morphine (or an equivalent daily dose of an alternative 
opioid) completed assessments at one time point. Patients with cancer pain who were 
prescribed 60mg of morphine or an equivalent daily dose of an alternative opioid 
completed the assessments at two or three time points. Patients with chronic non-cancer 
pain who were prescribed opioid and those who were not prescribed opioid completed the 
assessment on two time points mainly. Patients with a history of substance misuse 
completed assessments at one time point only.  
 
 
The Addenbrooke’s Cognitive Examination-Revised (ACE-R) takes ten to fifteen minutes 
to complete. There are three versions available that have different names and addresses in 
each in order to prevent learning of the address on subsequent tests. The three versions are 
ACE-R A, B and C and they were used in that order at assessments one, two and three of 
the study. There are several questions for the patient to complete and the researcher or 
clinician scores each. The patient’s responses to each of the questions can be recorded at 
the time and then the test can be scored at a later time. This avoids the patient being aware 
of scoring zero which could possibly cause them distress. The questions are clearly worded 
in order that there is no ambiguity for the patient and little chance of inter-observer bias 
due to more prompting within the question. Each question or small group of questions has 
the heading of the aspect of cognitive function that is being assessed. Each question has a 
maximum possible score that is written into a small box on the right hand side of the page. 
If the question was taken from the mini-mental state examination this is indicated by the 
presence of a shaded box also on the right hand side. The clinician can then add up the 
scores out of 30 or 100. Most of the questions are very straightforward to score for 
example “What is the day, date, month, year and season?” Each correct item scores one out 
of a possible total five for the question. Other questions such as the clock-drawing test 
require more consideration in order to ensure a consistent approach to scoring. A scoring 
sheet is available which provides helpful information on the scoring of each question.  
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The Addenbrooke’s Cognitive Examination-Revised (ACE-R) provides a score out of one 
hundred that reflects five domains of cognitive function. The 30-point score of the mini-
mental state examination can be extracted from the ACE-R and allows a comparison 
between the two tools. I compared the results of the two cognitive function tools in order to 
look for possible discrepancy in assessing cognitive function in our study groups. The five 
domains of cognitive function were explored in order to assess the domain which is most 
affected by opioids. The impact of opioid dose and opioid titration on cognitive function 
was explored using both Spearman and Pearson Correlation Co-efficients.   
 
 
The table below has been constructed to show the different domains of cognitive function 
assessed by the two tests. It facilities a comparison between the two and highlights the 
extent to which the mini-mental state examination relies on assessment of attention and 
orientation and does not provide an adequate assessment of the other domains. For 
example the MMSE only provides a score out of three for memory and the ACE-R 
provides a score out of 26. The difference in scores comes directly from the very different 
number of questions in each of the two assessments. 
 
 
Table 38:  The table shows the different domains of cognitive function assessed by the 
two tests 
Cognitive Domain Mini-Mental State 
Examination 
Addenbrooke’s Cognitive 
Examination  - Revised 
 
Attention and Orientation 
 
18 18 
Memory 
 
3 26 
Visuospatial abilities 
 
1 16 
Language 
 
8 26 
Fluency 
 
0 14 
Total 
 
30 100 
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The Bond and Lader analogue scales were used to provide a subjective measure of 
cognitive function. The Bond and Lader scales consist of sixteen 100 mm horizontal lines 
which are anchored at each end by a positive and negative aspect of an emotion. The 
patient is asked to place a vertical line across the horizontal line so that the intersection 
marks the degree to which they agree with the particular emotion. The Bond and Lader 
scales provide a subjective response to 16 individual emotions but they can also be 
grouped into four variables – mental sedation, physical sedation, calming effects and other 
feelings. The results of the analogue scales are presented and have been analysed to 
explore possible correlation between objective and subjective measures of cognitive 
function. Both Pearson and Spearman correlations have been provided. The Spearman 
correlation depends on the order or ranking of the values and does not assume consistent 
intervals. If the correlations show strong disagreement the research team would need to 
look for an extreme value that may be skewing the Pearson correlation. 
 
 
Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. 
The HADS is widely used in many healthcare settings. There are fourteen questions – 
seven of which relate to anxiety and seven to depression. Each question is given a score 
from zero to three according to the response of the patient. The scores are not visible on the 
question sheet and some of the statements are inverted in order to reduce the risk of 
patients simply ticking the same box for each statement. The statements have been 
carefully constructed to reflect colloquial statements for example “butterflies in the 
stomach” which should be familiar descriptors to many patients and provide illustration to 
statements that could otherwise be hard to interpret. 
 
 
Pain and interference due to pain were assessed using the Brief Pain Inventory. The Brief 
Pain Inventory starts with questions which identify the patient’s pain as more than an 
“everyday pain” and identifies the pain using a body chart. Patients are then asked for four 
scores which reflect the severity of the pain in the 24 hours prior to the assessment – the 
worst, best and average pain scores and to provide a pain score at the time of completing 
the assessment. The BPI goes on to ask seven questions which reflect the interference by 
the pain on various activities. Again this reflects the 24 hours prior to the assessment. From 
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the two different groups of questions, two scores are obtained. These are the mean pain 
severity score and the mean pain interference score.   
 
 
Anxiety, depression and pain are all known to impact on cognitive function and therefore 
the scores of the ACE-R have been analysed with the scores from the Hospital Anxiety and 
Depression Scales and the Brief Pain Inventory to assess if there is any correlation and 
evidence of impact in these patient groups. 
 
5.10 Results 
 
 
Cognitive function was assessed at each time point in the study schedule. 178 patients were 
recruited and completed at least one set of assessments. The data for patients with 
substance misuse and chronic pain has been excluded from the analyses here due to the 
very small numbers recruited. The data for these patients has been presented separately in 
the chapter “Patients with Pain and a History of Substance Misuse”. 
Ninety patients completed two assessments. The numbers from the different patient groups 
who completed each assessment have been detailed in the chapter “Patient 
Characteristics”. 
 
  
Figure 5:  Number recruited in each patient group and the number of assessments 
completed by patients in each patient group 
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Table 39:  Cognitive impairment as assessed by ACE-R vs MMSE at assessment 1  
  ACE-R 
 
 MMSE < 85    >=85 All 
 
Cancer 
       
 
Definite (<=23) 
 
14 
 
0 
 
14 
Possible (24-27)         19 2 21 
None (>=28)              17 37 54 
All 50 39 89 
    
Non-cancer pain         Definite (<=23) 1 0 1 
Possible (24-27)          4 3 7 
None (>=28)               4 21 25 
All 9 24 33 
    
Substance misuse    Definite (<=23) 5 0 5 
Possible (24-27)          4 0 4 
None (>=28)               4 10 14 
All 13 10 23 
    
Non-cancer pain,        
Non-opioid    
Definite (<=23) 1 0 1 
Possible (24-27)          3 2 5 
None (>=28)               2 17 19 
All 6 19 25 
    
All Definite (<=23) 21 0 21 
Possible (24-27)          30 7 37 
None (>=28)               27 85 112 
All 78 92 170 
 
 
Table 42 shows a comparison of cognitive function scores obtained when using the 
Addenbrooke’s Cognitive Examination – Revised (ACE-R) compared to the Mini-Mental 
State Examination (MMSE). In table 42 it can be seen that 50 (56.2%) of the 89 patients 
with cancer pain had impaired cognitive function as measured by the ACE-R. When the 
MMSE was used to assess cognitive function only 35 (39.3%) patients were found to have 
globally impaired cognitive function. In the chronic pain patients who were prescribed 
opioids 9 (27.3%) patients out of the total 33 patients had impaired cognitive function on 
the ACE-R; 8 patients (24.2%) had impairment detected by the MMSE. In the group of 
patients with substance misuse the ACE-R detected cognitive impairment in 13 (56.5%) 
out of 23 patients; the MMSE detected cognitive impairment in nine (39.1%) patients.  In 
the group of patients with chronic pain who were not prescribed opioids there are six 
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(24.0%) patients with impaired attention out of the total 25 patients. In this group of 
patients both tools detected the same prevalence of cognitive impairment. 
 
 
Table 40:  ACE_R subscales and MMSE at assessment 1 where n = 170 
 
Attention impairment as assessed by ACE-R vs MMSE 
 
  Attention 
 
 MMSE < 17    >=17 All 
 
Cancer 
       
 
Definite (<=23) 
 
14 
 
0 
 
14 
Possible (24-27)         8 13 21 
None (>=28)              2 52 54 
 
P value 0.002 
All 24 65 89 
 
     
Non-cancer          Definite (<=23) 1 0 1 
Possible (24-27)          3 4 7 
None (>=28)               1 24 25 
 
P value 0.046 
All 5 28 33 
     
Substance misuse    Definite (<=23) 5 0 5 
Possible (24-27)          2 2 4 
None (>=28)               1 13 14 
 
P value 0.083 
All 8 15 23 
     
All Definite (<=23) 21 0 21 
Possible (24-27)          17 20 37 
None (>=28)               4 108 112 
 
P value <0.0001 
All 
 
42 128 170 
 
 
 
Table 43 shows the results for attention which is one of the specific domains of cognitive 
function assessed by the ACE-R. The results show that patients may present a normal 
MMSE despite impaired attention. This is seen particularly in the cancer group where 24 
patients had impaired attention detected by the ACE-R but only 14 patients had definite 
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cognitive impairment detected by the MMSE and a further 21 had possible cognitive 
impairment detected by the MMSE. The ACE-R is more accurate in assessing domains of 
cognitive function individually when compared to the MMSE in assessing cognitive 
function globally.  
 
 
In patients with non-cancer pain there was less impairment of attention detected than in the 
cancer pain group. Five patients had impaired attention detected by the ACE-R and eight 
patients had possible or definite global cognitive impairment detected by the MMSE. In the 
substance misuse group eight patients had impaired attention and nine patients had global 
cognitive impairment detected by the assessments.  
 
 
The findings were statistically significant when McNemar’s test was applied to the results. 
P values are shown in the table. 
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Table 41:  Memory impairment as assessed by ACE-R vs MMSE where n = 170 
 
 Memory 
 
 MMSE < 19    >=19 All 
 
Cancer        
Definite (<=23) 
 
13 
 
1 
 
14 
Possible (24-27)         17 4 21 
None (>=28)              24 30 54 
All 54 35 89 
    
Non-cancer          Definite (<=23) 1 0 1 
Possible (24-27)          5 2 7 
None (>=28)               4 21 25 
All 10 23 33 
    
Substance misuse    Definite (<=23) 5 0 5 
Possible (24-27)          3 1 4 
None (>=28)               5 9 14 
All 13 10 23 
    
Non-opioid, non-cancer      Definite (<=23) 1 0 1 
Possible (24-27)          2 3 5 
None (>=28)               3 16 19 
All 6 19 25 
    
All Definite (<=23) 20 1 21 
Possible (24-27)          27 10 37 
None (>=28)               36 76 112 
All 83 87 170 
 
 
The results show that over half the patients with cancer pain had memory loss detected 
when the ACE-R was used. Fifty-four patients out of the total 89 patients had memory 
impairment in this patient group. When the MMSE was used 24 (44.4%) patients from a 
total of 54 patients would have had apparently normal cognitive function ie a normal 
MMSE score and the memory loss would have been missed.  The proportion of patients 
with memory impairment was less in the group with non-cancer pain. In this group ten 
(30.3%) of the 33 patients had memory impairment with a preserved MMSE score.  In the 
substance misuse group 13 (56.5%) of the patients had impaired memory. Fourteen 
(60.1%) patients had apparently normal cognitive function with the MMSE and only nine 
(39.1%) of the patients would have had their cognitive impairment recognised if the 
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MMSE was relied on. This is a lower proportion of patients with recognition of global 
impairment of cognitive function than the ACE-R is able to detect with specific memory 
loss.    
 
 
Table 42:  Fluency impairment as assessed by ACE-R vs MMSE where n = 170 
 Fluency 
 
 MMSE < 8    >=8 All 
 
Cancer        
Definite (<=23) 
 
12 
 
2 
 
14 
Possible (24-27)         13 8 21 
None (>=28)              11 43 54 
All 36 53 89 
    
Non-cancer          Definite (<=23) 1 0 1 
Possible (24-27)          0 7 7 
None (>=28)               1 24 25 
All 2 31 33 
    
Substance misuse    Definite (<=23) 5 0 5 
Possible (24-27)          2 2 4 
None (>=28)               0 14 14 
All 7 16 23 
    
Non-opioid , non-cancer     Definite (<=23) 1 0 1 
Possible (24-27)          1 4 5 
None (>=28)               0 19 19 
All 2 23 25 
    
All Definite (<=23) 19 2 21 
Possible (24-27)          16 21 37 
None (>=28)               12 100 112 
All 47 123 170 
 
  
Patients in the cancer pain group have been shown to have reduced fluency. Thirty-six 
(40.4%) of the patients had reduced fluency in this group. In the non-cancer pain group 
fluency was much less affected and only two (6.1%) of the patients had reduced fluency. 
This low proportion was repeated in the group of patients with pain who were not 
prescribed opioids where two (8%) of the patients had reduced fluency. Interestingly in the 
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substance misuse group seven (30.4%) of the patients had reduced fluency and all the 
patients had possible or definite cognitive impairment on the MMSE. 
 
 
Table 43:  Language impairment as assessed by ACE-R vs MMSE where n = 170 
 Language 
 
 MMSE < 21    >=21 All 
 
Cancer 
 
 
Definite (<=23) 
 
11 
 
3 
 
14 
Possible (24-27)         0 21 21 
None (>=28)              2 52 54 
All 13 76 89 
    
Non-cancer          Definite (<=23) 1 0 1 
Possible (24-27)          0 7 7 
None (>=28)               0 25 25 
All 1 32 33 
    
Substance misuse    Definite (<=23) 4 1 5 
Possible (24-27)          2 2 4 
None (>=28)               1 13 14 
All 7 16 23 
    
Non-opioid, non-cancer      Definite (<=23) 1 0 1 
Possible (24-27)          0 5 5 
None (>=28)               0 19 19 
All 1 24 25 
    
All Definite (<=23) 17 4 21 
Possible (24-27)          2 35 37 
None (>=28)               3 109 112 
All 22 148 170 
 
 
Language was the domain of cognitive function least affected in all groups of patients. 
Overall 22 (12.9%) of patients had impaired language abilities detected by the ACE-R. 
Patients in the non-cancer pain and non-cancer pain and not taking opioids groups were 
least likely to have reduced language abilities. Language was the domain of cognitive 
function most likely to be reflected by the MMSE. Seventeen (77.3%) of the 22 patients 
with impaired language abilities were in the possible or definite cognitive impairment 
groups when the MMSE was relied on.   
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Table 44:  Visuospatial impairment as assessed by ACE-R vs MMSE where n = 170 
 
 Visuo-spatial 
 
 MMSE < 14    >=14 All 
 
Cancer        
Definite (<=23) 
 
14 
 
0 
 
14 
Possible (24-27)         8 13 21 
None (>=28)              10 44 54 
All 32 57 89 
    
Non-cancer          Definite (<=23) 1 0 1 
Possible (24-27)          2 5 7 
None (>=28)               3 22 25 
All 6 27 33 
    
Substance misuse    Definite (<=23) 4 1 5 
Possible (24-27)          1 3 4 
None (>=28)               2 12 14 
All 7 16 23 
    
Non-opioid, non-cancer   Definite (<=23) 1 0 1 
Possible (24-27)          3 2 5 
None (>=28)               0 19 19 
All 4 21 25 
    
All Definite (<=23) 20 1 21 
Possible (24-27)          14 23 37 
None (>=28)               15 97 112 
All 49 121 170 
 
 
Visuospatial abilities can be seen to be impaired in the patient groups overall but 
particularly in the cancer pain group. Forty-nine (28.8%) of the total 170 patients had 
reduced visuospatial abilities. This was most pronounced in the cancer pain group where 
32 (36.0%) of the group were affected.  Despite the reduction in visuospatial abilities 54 
(60.7%) of the 89 patients had apparently normal cognitive function when using the 
MMSE. In the non-cancer pain group six (18.2%) of the patients had reduced visuospatial 
awareness. Again this was a similar finding in the non-cancer patients who were not taking 
opioids. In this group four (16.0%) of the 25 patients had impaired visuospatial abilities.  
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Table 45:  McNemar tests of agreement between impairment on ACE-R subscale and 
definite impairment on MMSE where n = 170 
 Subscale 
 
 Attention Memory Fluency Language Visuospatial 
 
  
P 
 
P 
 
P 
 
P 
 
P 
Group      
Cancer 0.002 0.000 0.000 0.655 0.000 
Non-cancer 0.046 0.003 0.317  0.025 
Substance 
misuse 
0.083 0.005 0.157 0.317 0.317 
Non-opioid 0.046 0.025 0.317  0.083 
All 0.000 0.000 0.000 0.739 0.000 
 
 
The table shows the McNemar tests of agreement between impairment on ACE-R subscale 
and definite impairment on MMSE. There was little impairment of language in any of the 
groups. The other domains of cognitive function however show significant disagreement 
between assessment on MMSE and assessment on the ACE-R subscales. 
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Table 46:  Distribution of ACE-R and MMSE by regular opioid drugs used in last 4 
weeks where n =134 
 
 Used in last 
 
 24 hours 4 weeks 
 
 N Median 
ACE-R 
Median 
MMSE 
N Median 
ACE-R 
Median 
MMSE 
 
Alfentanil 2 90 29 3 88 28 
Buprenorphine 2 81 28 2 82 28 
Dihydrocodeine 1 81 26 3 88 29 
Diamorphine 1 83 28 1 83 28 
Fentanyl 15 87 28 13 89 28 
Hydromorphone 4 86 27 3 93 29 
Methadone 19 87 29 18 85 29 
Morphine 54 85 28 57 85 28 
Oxycodone 36 87 28 32 87 29 
 
 
The table shows little variation in the median ACE-R and MMSE by the different opioids 
which were prescribed. Alfentanil has a much higher median ACE-R at 24 hours than the 
other opioids however the result is from only two patients so it is not possible to draw any 
conclusions from this result. The numbers of patients on each opioid at the two time points 
are very similar suggesting that most patients were on the same opioid at the each time 
point and the data therefore suggests that cognitive impairment is not just a feature of the 
initiation of opioids.  
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Table 47:  Distribution of ACE-R subscale scores by regular opioid drugs used in last 
4 weeks  
 Memory 
(max 26) 
Attention 
(max 18) 
Fluency 
(max 14) 
Language 
(max 26) 
Visuo-
spatial 
(max 16) 
 Median 
 
Median Median Median Median 
24 hours      
 Alfentanil 21 18 12 25 16 
 Buprenorphine 20 17 8 23 14 
 DHC 20 17 9 20 15 
 Diamorphine 16 17 10 25 15 
 Fentanyl 20 18 10 25 16 
 Hydromorphone 20 16 11 25 16 
 Methadone 20 18 10 25 15 
 Morphine 18 18 11 25 15 
 Oxycodone 19 18 9 25 15 
      
4 weeks      
 Alfentanil 20 17 10 25 15 
 Buprenorphine 19 18 9 25 12 
 DHC 20 17 9 25 15 
 Diamorphine 16 17 10 25 15 
 Fentanyl 20 18 10 25 16 
 Hydromorphone 23 17 11 25 16 
 Methadone 18 18 10 25 15 
 Morphine 18 18 10 25 15 
 Oxycodone 19 18 10 25 15 
 
 
The results show that the median scores for each of the domains of cognitive function 
assessed by the ACE-R are similar for the different opioids prescribed. The maximum 
scores for each domain are shown in the heading of the table in brackets. Diamorphine has 
the lowest median score for the domain of memory. Methadone, morphine and oxycodone 
also have low median scores for this domain. The median scores for attention are similar 
across all the different opioids prescribed. Dihydrocodeine, buprenorphine and oxycodone 
have the lowest median scores for the domain of fluency. The results of dihydrocodeine 
and buprenorphine are based on very few patients though. It is the same two drugs which 
show impairment at the language subscale and again this result may to be a chance finding 
given the small numbers of patients involved. The median scores for the visuospatial 
domain are similar for all opioids except buprenorphine.  
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Table 48: Distribution of ACE-R subscale scores by regular opioid drugs used in last 
4 weeks.  (Cancer patients only)  
 Memory 
(max 26) 
Attention 
(max 18) 
Fluency 
(max 14) 
Language 
(max 26) 
Visuo-
spatial 
(max 16) 
 Median 
 
Median Median Median Median 
24 hours      
 Alfentanil 20 18 9 24 15 
 Fentanyl 18 18 8 23 14 
 Hydromorphone 16 15 10 24 16 
 Morphine 18 18 10 24 15 
 Oxycodone 18 18 8 25 15 
      
4 weeks      
 Alfentanil 20 18 10 25 15 
 Buprenorphine 15 17 8 23 10 
 Fentanyl 18 18 8 25 14 
 Hydromorphone 18 16 10 25 16 
 Morphine 18 18 9 24 15 
 Oxycodone 18 18 9 25 15 
 
 
The table above shows the median scores for each of the specific domains of cognitive 
function assessed by the Addenbrooke’s Cognitive Examination-Revised. These results are 
for patients with cancer pain only. Although the medians appear slightly lower overall 
there is no significant difference between the cancer patients and the study patients as a 
whole. The results show there is no association between the opioid prescribed and the 
cognitive impairment. 
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Table 49:  Correlations of cognitive scores at assessment 1 with total dose in last 24 
hours 
 
Variable 
Correlation 
with dose 
 
P 
 
ALL PATIENTS ON OPIOIDS 
 
ACE_R 0.032 0.711 
MMSE -0.012 0.888 
Memory 0.062 0.476 
Attention -0.113 0.196 
Fluency 0.029 0.740 
Language 0.083 0.342 
Visuo-spatial -0.025 0.777 
   
 
CANCER PATIENTS ONLY 
  
   
ACE_R 0.122 0.280 
MMSE 0.116 0.304 
Memory 0.177 0.115 
Attention 0.012 0.917 
Fluency 0.085 0.448 
Language 0.127 0.259 
Visuo-spatial -0.078 0.489 
 
 
The results show the correlation between the scores obtained from assessing cognitive 
function and the total dose of opioid prescribed in the 24 hours prior to assessment. The 
correlations are shown for all patients in the study who were prescribed opioids and then 
separately for the patients with cancer pain. The opioid drugs and doses have been 
converted to the morphine equivalent daily dose (MEDD) to facilitate this analysis. None 
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of the correlations approach one, indicating there are no positive correlations. Dose of 
opioid does not appear to affect the cognitive function when assessed using the ACE-R. 
 
 
Table 50:  Correlations of cognitive scores at assessment 1 with titrations  
Variable Correlation with 
percent 
change 7 days to 24 
hours 
 
P 
Correlation with percent 
change 4 weeks to 24 
hours 
 
P 
     
ACE_R 0.056 0.520 -0.086 0.328 
MMSE 0.029 0.744 -0.027 0.758 
Memory 0.063 0.469 -0.048 0.585 
Attention -0.017 0.847 0.007 0.938 
Fluency 0.018 0.833 -0.151 0.086 
Language 0.071 0.417 -0.034 0.705 
Visuo-spatial   0.043 0.627 -0.058 0.509 
 
 
The table above shows the results of correlation between domains of cognitive function 
and opioid titration. The MEDD has again been used to facilitate the analysis. None of the 
correlations approach one indicating that there is no correlation between titration of the 
opioid and the degree of cognitive impairment as measured by the ACE-R. 
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Table 51:  Correlation of ACE_R cognitive scores with Bond and Lader scales at Assessment 1 
 
 
Assessment 
 
 
Group 
 
 
Variable 
Pearson 
correlation 
with ACE_R 
 
 
P 
Spearman 
correlation 
with ACE_R 
 
 
P 
1       
Cancer Mental sedation -0.149 0.186 -0.171 0.129 
Cancer Physical sedation -0.059 0.604 -0.150 0.186 
Cancer Calming effects -0.102 0.369 -0.115 0.311 
Cancer Other feelings -0.081 0.475 -0.134 0.237 
      
Non-cancer Mental sedation -0.034 0.856 -0.059 0.751 
Non-cancer Physical sedation -0.104 0.577 -0.100 0.593 
Non-cancer Calming effects -0.129 0.488 -0.154 0.409 
Non-cancer Other feelings -0.064 0.734 -0.117 0.530 
      
Substance misuse Mental sedation -0.728 0.000 -0.648 0.003 
Substance misuse Physical sedation -0.594 0.007 -0.635 0.003 
Substance misuse Calming effects -0.697 0.001 -0.703 0.001 
Substance misuse Other feelings -0.497 0.031 -0.449 0.054 
      
Non-opioid Mental sedation 0.110 0.617 0.124 0.574 
Non-opioid Physical sedation -0.051 0.816 -0.060 0.786 
Non-opioid Calming effects -0.253 0.244 -0.260 0.231 
Non-opioid Other feelings 0.024 0.915 -0.110 0.618 
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Table 52:  Correlation of ACE_R cognitive scores with Bond and Lader scales at Assessment 2  
  
 
 
Assessment 
 
 
Group 
 
 
Variable 
Pearson 
correlation 
with ACE_R 
 
 
P 
Spearman 
correlation 
with ACE_R 
 
 
P 
2       
Cancer Mental sedation -0.188 0.222 -0.176 0.252 
Cancer Physical sedation -0.030 0.846 -0.085 0.583 
Cancer Calming effects 0.073 0.637 0.009 0.953 
Cancer Other feelings 0.147 0.340 0.076 0.623 
      
Non-cancer Mental sedation 0.009 0.968 0.095 0.692 
Non-cancer Physical sedation -0.285 0.223 -0.200 0.397 
Non-cancer Calming effects -0.197 0.406 -0.117 0.622 
Non-cancer Other feelings -0.006 0.718 -0.073 0.758 
      
Non-opioid Mental sedation -0.093 0.751 -0.093 0.751 
Non-opioid Physical sedation -0.169 0.564 -0.195 0.501 
Non-opioid Calming effects -0.160 0.586 -0.251 0.386 
Non-opioid Other feelings -0.016 0.957 -0.265 0.360 
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Table 52 shows the results of the Bond and Lader scales which have been grouped into the 
four classes of feelings. The data has been presented for each of the four patient groups and 
for the first two assessments. Only cancer patients had three assessments and the data are 
not presented here. The scores for each of the classes of subjective feeling have been 
correlated with the ACE-R score. Both Pearson and Spearman correlations have been used. 
Only the patients with substance misuse show any correlation between subjective and 
objective measures of cognitive function. This is statistically significant with both the 
correlations. The other patient groups do not show a correlation between objective and 
subjective measures. 
 
 
Table 53 shows the correlation between the mini-mental state examination and the Bond 
and Lader scales. Again the data are presented for each of the four classes of subjective 
feelings and for two assessments. The patients with a history of substance misuse are the 
only patient group who show a correlation between objective and subjective measures of 
cognitive function. The correlation is present when both Spearman and Pearson 
correlations are used but is not as strong as the correlation with the ACE-R. The correlation 
between MMSE and subjective measures does not reach statistical significance.  
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Table 53:  Correlation of MMSE cognitive scores with analogue scales at Assessment 1 
 
 
Assessment 
 
 
Group 
 
 
Label 
Pearson 
correlation 
with MMSE 
 
 
P 
Spearman 
correlation 
with MMSE 
 
 
P 
1       
Cancer Mental sedation -0.146 0.198 -0.166 0.142 
Cancer Physical sedation -0.100 0.380 -0.223 0.047 
Cancer Calming effects -0.143 0.207 -0.099 0.383 
Cancer Other feelings -0.054 0.634 -0.080 0.483 
      
Non-cancer Mental sedation -0.059 0.754 -0.033 0.860 
Non-cancer Physical sedation -0.067 0.721 -0.015 0.935 
Non-cancer Calming effects -0.032 0.865 -0.063 0.736 
Non-cancer Other feelings 0.023 0.904 0.029 0.876 
      
Substance misuse Mental sedation -0.649 0.003 -0.581 0.009 
Substance misuse Physical sedation -0.527 0.020 -0.435 0.062 
Substance misuse Calming effects -0.501 0.029 -0.525 0.021 
Substance misuse Other feelings -0.413 0.079 -0.346 0.147 
      
Non-opioid Mental sedation 0.180 0.410 0.222 0.309 
Non-opioid Physical sedation 0.033 0.880 0.123 0.576 
Non-opioid Calming effects -0.081 0.715 0.049 0.823 
Non-opioid Other feelings 0.172 0.433 0.210 0.336 
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Table 54:  Correlation of MMSE cognitive scores with analogue scales at Assessment 2 
 
 
 
Assessment 
 
 
Group 
 
 
Label 
Pearson 
correlation 
with MMSE 
 
 
P 
Spearman 
correlation 
with MMSE 
 
 
P 
2       
Cancer Mental sedation 0.055 0.722 0.034 0.827 
Cancer Physical sedation 0.147 0.341 0.098 0.529 
Cancer Calming effects 0.230 0.133 0.135 0.383 
Cancer Other feelings 0.207 0.178 0.115 0.458 
      
Non-cancer Mental sedation 0.223 0.344 0.179 0.450 
Non-cancer Physical sedation -0.010 0.968 0.012 0.961 
Non-cancer Calming effects 0.008 0.974 -0.015 0.950 
Non-cancer Other feelings 0.035 0.882 0.018 0.941 
      
Substance misuse Mental sedation . . . . 
Substance misuse Physical sedation . . . . 
Substance misuse Calming effects . . . . 
Substance misuse Other feelings . . . . 
      
Non-opioid Mental sedation -0.175 0.550 -0.238 0.412 
Non-opioid Physical sedation -0.268 0.354 -0.310 0.280 
Non-opioid Calming effects -0.125 0.671 0.005 0.987 
Non-opioid Other feelings -0.021 0.944 -0.076 0.795 
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Table 55:  Correlations of ACE-R cognitive scores with analogue scales 
 
 
Assessment 
 
 
Label 
Pearson 
correlation 
with 
ACE_R 
 
 
P 
Spearman 
correlation 
with 
ACE_R 
 
 
P 
      
1 Mental sedation -0.190 0.019 -0.175 0.031 
1 Physical sedation -0.142 0.079 -0.176 0.029 
1 Calming effects -0.185 0.022 -0.218 0.007 
1 Other feelings -0.077 0.345 -0.148 0.067 
      
2 Mental sedation -0.059 0.605 -0.081 0.479 
2 Physical sedation -0.126 0.270 -0.130 0.253 
2 Calming effects  0.030 0.793 -0.023 0.843 
2 Other feelings  0.068 0.549 0.004 0.974 
 
 
The table above shows there is no correlation between the ACE-R and the subjective 
measure provided by the Bond and Lader scales when all the patients are grouped together. 
None of the correlations approaches one which would indicate the two variables were 
correlated. The same results are shown in the table below which explores possible 
correlation between the MMSE score and the subjective measures. Again all patients have 
been grouped together. 
 
 
Table 56:  Correlations of MMSE cognitive scores with analogue scales 
 
 
Assessment 
 
 
Label 
Pearson 
correlation 
with MMSE 
 
 
P 
Spearman 
correlation 
with MMSE 
 
 
P 
      
1 Mental sedation -0.173 0.032 -0.124 0.126 
1 Physical sedation -0.151 0.062 -0.155 0.055 
1 Calming effects -0.155 0.055 -0.125 0.124 
1 Other feelings -0.035 0.672 -0.035 0.663 
      
2 Mental sedation 0.106 0.352 0.047 0.681 
2 Physical sedation 0.048 0.678 0.006 0.956 
2 Calming effects 0.167 0.141 0.072 0.529 
2 Other feelings 0.154 0.175 0.073 0.521 
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Table 57:  Correlation of ACE_R cognitive scores with anxiety and depression scores 
(HADS) at assessment 1 
 
 
Group 
 
 
Variable 
Pearson 
correlation 
with 
ACE_R 
 
 
P 
Spearman 
correlation 
with 
ACE_R 
 
 
P 
 
Cases with ACE_R=0 excluded     
Cancer Anxiety 0.032      0.780            0.103      0.360 
Cancer Depression -0.052      0.648           -0.054      0.634 
      
Non-cancer Anxiety -0.117      0.562           -0.108      0.590 
Non-cancer Depression 0.002      0.990            0.022      0.913 
      
Substance misuse Anxiety 0.105      0.659           -0.044      0.855 
Substance misuse Depression -0.273      0.245           -0.297      0.203 
      
Non-opioid Anxiety -0.275      0.194           -0.238      0.263 
Non-opioid Depression -0.142      0.508           -0.227      0.286 
 
 
Table 58:  Correlation of ACE_R cognitive scores with anxiety and depression scores 
(HADS) at assessment 2 
 
 
Group 
 
 
Variable 
Pearson 
correlation 
with 
ACE_R 
 
 
P 
Spearman 
correlation 
with 
ACE_R 
 
 
P 
 
Cases with ACE_R=0 excluded     
Cancer Anxiety 0.011      0.946           -0.064      0.682 
Cancer Depression -0.090      0.571           -0.216      0.170 
      
Non-cancer Anxiety -0.084      0.725           -0.039      0.869 
Non-cancer Depression -0.186      0.447           -0.166      0.497 
      
Substance misuse Anxiety . . . . 
Substance misuse Depression . . . . 
      
Non-opioid Anxiety -0.664      0.013           -0.523      0.067 
Non-opioid Depression -0.218      0.453           -0.244      0.400 
 
 
The tables above show the correlation of the ACE-R scores with the presence of anxiety 
and depression scores at assessment one and two. The four different patient groups have 
been presented. As before both Spearman and Pearson correlation co-efficients have been 
presented. None of the variables appears to correlate. Anxiety and the ACE-R score appear 
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to have some degree of correlation in the group of patients with pain who were not on 
opioids at assessment two however the number in this patient group are small so this may 
be due to chance. Substance misuse patients only had one assessment hence the lack of 
results at assessment two for this patient group. 
 
 
Table 59:  ACE_R and MMSE by HADS score over 15 
 ACE_R ACE_R MMSE MMSE 
 
 HADS Score HADS Score HADS Score HADS Score 
 
 <=15 >15 <=15 >15 <=15 >15 <=15 >15 
 
 Mean Mean Median Median Mean  Mean Median Median 
 
Assessment 1 
Cancer 77.7 70.9 81 83 26.1 23.8 28 28 
Non-
cancer 
83.7 89.3 90 91 26.9 28.8 28 30 
Substance 
misuse 
67.4 74.2 87 83 22.8 24.7 28 28 
Non-
opioid 
85.5 87.5 92 90 27.3 28.6 30 29 
All 79.6 77.3 87 85 26.2 25.5 28 28 
         
Assessment 2 
Cancer 78.7 69.6 85 85 25.4 22.7 28 28 
Non-
cancer 
72.2 82.3 90 90 23.2 26.2 29 28 
Substance 
misuse 
92.0 . 92 . 28.0 . 28 . 
Non-
opioid 
94.2 81.0 95 93 28.8 25.7 30 29 
All 79.5 76.8 90 88 25.4 24.6 29 28 
 
 
The Hospital Anxiety and Depression score can also be used as a total score with a score of 
greater than 15 suggesting anxiety or depression. The patient group has been divided 
according to score on the HADS. The mean and median ACE-R and MMSE scores have 
then been given for each of the patient groups. There appears to be a difference between 
the mean ACE-R scores of those cancer patients who score greater than 15 on the HADS 
and those who score 15 or less. There also appears to be a difference between patients with 
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a history of substance misuse who score more highly on the HADS indicating anxiety and / 
or depression is present. The differences appear less clear when the MMSE is used to 
provide the objective measure of cognitive function. Both the mean and the median are 
reported because the distribution of the ACE-R is negatively skewed.  
 
 
Table 60:  Correlation of ACE_R cognitive scores with average pain (BPI) scores at 
Assessment 1 
 
 
grp 
 
 
Variable 
Pearson 
correlation 
with 
ACE_R 
 
 
P 
Spearman 
correlation 
with 
ACE_R 
 
 
P 
 
Cases with ACE_R=0 excluded     
Cancer Average pain (BPI 
Q4) 
0.015                 0.895            0.008      0.946 
Cancer Average pain 
interference score 
(BPI) 
-0.101      0.452           -0.120      0.368 
      
Non-
cancer 
Average pain (BPI 
Q4) 
-0.233      0.200           -0.265      0.142 
Non-
cancer 
Average pain 
interference score 
(BPI) 
-0.043      0.822           -0.078      0.682 
      
Substance 
misuse 
Average pain (BPI 
Q4) 
0.231      0.582 0.157      0.711 
Substance 
misuse 
Average pain 
interference score 
(BPI) 
-0.275 0.655 -0.600 0.285 
      
Non-
opioid 
Average pain (BPI 
Q4) 
-0.268 0.205 -0.238 0.263 
Non-
opioid 
Average pain 
interference score 
(BPI) 
-0.378 0.082 -0.407 0.060 
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Table 61:  Correlation of ACE_R cognitive scores with average pain (BPI) scores at 
assessment 2 
 
 
 
grp 
 
 
Variable 
Pearson 
correlation 
with 
ACE_R 
 
 
P 
Spearman 
correlation 
with 
ACE_R 
 
 
P 
 
Cases with ACE_R=0 excluded     
Cancer Average pain (BPI 
Q4) 
-0.078      0.615           -0.084      0.588 
Cancer Average pain 
interference score 
(BPI) 
-0.033      0.861           -0.109      0.567 
      
Non-
cancer 
Average pain (BPI 
Q4) 
-0.311      0.182           -0.294      0.208 
Non-
cancer 
Average pain 
interference score 
(BPI) 
-0.242      0.305           -0.118      0.621 
      
Substance 
misuse 
Average pain (BPI 
Q4) 
. . . . 
Substance 
misuse 
Average pain 
interference score 
(BPI) 
. . . . 
      
Non-
opioid 
Average pain (BPI 
Q4) 
    
Non-
opioid 
Average pain 
interference score 
(BPI) 
    
 
 
The table above show the ACE-R scores of the patients in the different patient groups. Two 
questions from the brief pain inventory have been used to look for possible correlation 
between cognitive function as measured by the ACE-R and pain. The questions which have 
been used are the average pain severity score and the average pain interference pain score. 
It is demonstrated that in this study there is no association between pain and the score 
obtained on the ACE-R 
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5.11 Discussion 
 
 
5.11.1 Summary of Main Findings 
 
 
The use of the Addenbrooke’s Cognitive Examination-Revised is more likely to detect 
cognitive impairment in our patient groups studied than the mini mental state examination. 
The higher detection of cognitive impairment was true for both the group as a whole and 
for the different patient groups recruited. The most noticeable difference was in the group 
of patients with cancer pain who were prescribed opioids, where 56.2% of patients had 
cognitive impairment detected by the ACE-R compared to 39.3% of patients with 
cognitive impairment detected by the MMSE. The disagreement between the two 
assessments of cognitive function was statistically significant when McNemar’s test was 
applied. In the group of patients with non-cancer pain who were not prescribed opioids the 
two tests detected the same prevalence of cognitive impairment.  
 
 
The results of this study showed that attention, memory, fluency and visuospatial 
awareness were all impaired. Language was not significantly affected in any of the patient 
groups. It is interesting to note that the MMSE relies mainly on attention and orientation in 
its assessment of cognitive function and yet it still failed to detect the same number of 
patients with cognitive impairment as the ACE-R.  
 
 
Patients in the cancer and substance misuse groups had the greatest degree of cognitive 
impairment. The patients with cancer pain showed evidence of impaired cognitive function 
in all domains but particularly in the memory domain with 60.1% of patients exhibiting 
memory loss. 
 
 
Possible correlations between cognitive function and the opioid prescribed were explored 
using the median values of the Ace-R and the MMSE. There was no evidence that 
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particular opioids have more impact on cognitive function however the sample sizes for 
some of the opioids were very small. 
Possible correlations between the dose of opioid and the cognitive function scores were 
explored and the results showed no evidence of a correlation. Similarly there was no 
evidence to support the hypothesis that titration of the dose of the opioid contributes to 
cognitive impairment.  
 
 
The objective and subjective measures of cognitive impairment did not correlate well in 
this study.  
 
 
5.12 Bias and limitations 
 
 
This study has provided longitudinal data however there are necessary gaps of time 
between assessments which will have limited the responsiveness of the data and lead us to 
rely on trends over time. The assessments we have used have been task-focussed and our 
study has this in common with other published work. While we have found a clinically 
relevant and accessible tool it remains a tool and may not adequately detect how patients 
function in everyday life. Qualitative research which was presented in chapter six of the 
thesis has furthered our understanding of this everyday functioning but further research 
could more specifically explore the issues for patients especially those who may also be 
trying to care for families or maintain employment while on opioids. 
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5.13 Comparison with Published Literature 
 
 
5.13.1 Sample Size and Longitudinal Data 
 
 
This study recruited 178 patients in different clinical groups. This sample size was larger 
than most of the published studies.  Only Klepstad and the two papers based on data from 
the European Pharmacogenetic Opioid Study had larger sample sizes (Andreasson et al, 
2012; Klepstad et al, 2003; Kurita et al, 2011) Klepstad recruited 300 patients but they 
were all hospital in-patients which may limit the relevance of the conclusions to other 
patients. The European Pain and Opioid Study recruited a very large number of patients 
but they were recruited in 11 different countries which must have introduced inter-observer 
bias to the results. In addition there may have been cultural variations in response to pain, 
interpretation of the questionnaires used (Kurita et al, 2011). 
 
 
A further strength of this study is the longitudinal data that has been generated and the 
careful phenotyping of the patients. Gagnon (Gagnon et al, 2000) and Gaudreau (Gaudreau 
et al, 2006) both presented longitudinal data but most of the studies draw their conclusions 
from point prevalence and single assessments of cognitive function. The mean follow-up 
time in Gaudreau’s study was 16 days which is significantly less than the follow-up time in 
our study where assessments were six to eight weeks apart and many of the cancer patients 
had three assessments. The nature of the multiple factors which can influence cognitive 
function especially in the cancer pain group mean there is almost certainly inaccuracy 
introduced by using only single assessments. For example if the patient was very fatigued 
on the day of the study. 
 
 
In one of the few studies that provide longitudinal data, Tassain et al followed a small 
cohort of patients with chronic non-cancer pain over a 12 month period. This study is 
significant because patients were recruited when they were opioid-naïve and assessed prior 
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to commencing them on opioids. The numbers involved were small – only 28 patients were 
recruited and ten of these dropped out due to side effects or lack of benefit on their pain. 
These patients were asked to continue in the study in order to provide control data. Eleven 
patients on opioids continued to the 12-month assessment. The main side-effects causing 
patients to discontinue opioid were constipation and sedation. The researchers found no 
difference in memory, attention, verbal fluency and reaction time between the two groups 
and no apparent adverse effect from the introduction of opioid (Tassain et al, 2003). 
 
 
Our study also derives strength from the recruitment of patients with cancer and non-
cancer pain, a history of substance misuse and a history of chronic non-cancer pain but 
who were not on opioids. Completing the same research tools with the different groups of 
patients has enabled a useful comparison between different clinical groups which is not 
usually available in the literature. 
 
 
5.13.2 Prevalence of cognitive impairment 
 
 
The European Pharmacogenetic Opioid Study recruited 1915 patients who were prescribed 
opioids for the management of their cancer pain. Using the MMSE this study found that 
one in three of the patients had impaired cognitive function (Kurita et al, 2011). Although 
the sample size of the EPOS paper is much larger than our study the prevalence of 
cognitive impairment is quite similar. The MMSE detected impaired cognitive function in 
39.3% of cancer patients, 24.2% of non-cancer patients and 39.1% of patients with a 
history of substance misuse. In his review of “Opioids and cognition in cancer patients” 
Lawlor referred to studies which had shown prevalence of cognitive impairment between 
14 and 77% of patients (Lawlor, 2002) although the definitions of impairment varied and 
the highest prevalence was in patients who had a transient “impaired mental status” 
(Lawlor, 2002, page 1837). It is when the ACE-R was used in our study that the extent of 
the cognitive impairment was revealed however.  
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In a review of the published literature regarding the impact of opioids on the cognitive 
function of patients with chronic non-cancer pain Kendall and colleagues found generally 
poor quality studies and inconsistent findings. They recommended advising patients that 
opioids may adversely impact on cognitive function and that tests would be specific to the 
domains of cognitive function most likely to be affected. They recognised that the mini-
mental state examination was probably not the most appropriate tool (Kendall et al. 2010).  
 
 
In patients with substance misuse, Shane Darke and his colleagues found that patients who 
are on a maintenance programme perform less well than matched controls whether they 
were on methadone or buprenorphine maintenance (Darke 2012). Patients completed a 
series of tests which tested different cognitive domains including working memory, 
executive function and information processing speed.  The authors felt the level of 
impairment may require additional help and support from clinicians when managing this 
group of patients (Darke 2012). 
 
 
Importantly in their study in 1998 Wood and colleagues recognised that patients who 
appear cognitively intact with no evidence of sedation or confusion may still have impaired 
memory, attention and / or concentration (Wood et al, 1998). This finding, taken with our 
results about the prevalence of cognitive impairment, highlights the importance of 
screening for cognitive impairment in a systematic way rather than relying on gross 
assessment during clinical consultation.  
 
 
5.13.3 Impact of Confounders on Cognitive Function 
 
 
Possible correlation between the Addenbrooke’s Cognitive Examination - Revised (ACE-
R) and anxiety and depression as separate scores taken from the Hospital Anxiety and 
Depression Score was explored. No correlation was found in this study. When the HADS 
was used as a whole with a score above 15 indicating potential case of anxiety or 
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depression the ACE-R scores were less in those patients with a high score indicating 
anxiety and / or depression. This association was not detected by the MMSE. 
 
 
Depression and cognitive impairment are both prevalent in patients with pain, both cancer 
and non-cancer pain (Brown, Glass, Park 2002) and it is difficult to separate them. Pain 
itself also affects cognitive function. Pain is known to adversely affect attention, the ability 
to form memories and reaction times (Moriarty, McGuire, Finn 2011). 
 
 
5.13.4 Correlation between the objective and subjective measures of 
cognitive function 
 
 
In this study there was no apparent correlation between the objective and subjective 
measures of cognitive function. The Bond and Lader analogue scales did not appear to be 
sensitive to the changes patients noticed in their cognitive function. The patients who were 
involved in the qualitative research were very aware of impairment in their memory and 
word-finding abilities and this was highlighted in the themes extracted from the transcribed 
interviews (see Chapter 6).  
 
 
In a study published in 2013 Nils Inge Landro and colleagues recruited patients with 
chronic non-cancer pain who were attending a pain clinic in Norway. They highlighted that 
patients who discuss cognitive impairment with their pain specialist may find these 
symptoms are attributed to depression or anxiety and that the cognitive function is not fully 
assessed (Landro et al, 2013). The mean BPI score in this group was 6.2 which was higher 
than in our patient group. Interestingly Landro and his colleagues excluded the current pain 
score from the calculation of the mean pain severity domain of the Brief pain Inventory. In 
the published study they found: 
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 “About 20% of the patients presented neuropsychological problems that might 
influence daily psychosocial functioning in work settings demanding high degree of 
attentional control.”  (Landro et al, 2013, page 975)  
 
 
47% of the patients exhibited a degree of cognitive impairment (Landro et al, 2013). The 
research team used specific tests of psychological function despite recognising that the 
reason patients are often not properly assessed is the lack of experience of clinicians with 
the specialist tests.  They used a “Matrix Reasoning and Vocabulary” test and assessed 
psychomotor speed and attention using the Stroop test – ie the colour -word interference 
test. Furthermore in this published study the authors used the Everyday Memory 
Questionnaire and the objective and subjective measures were found to correlate (Landro 
et al, 2013).   
 
 
In a series of studies in the late 1990’s W. M. O’Neill and his colleagues used the Bond 
and Lader analogue scales. They used the scales to measure “alertness, calmness and 
contentment” (O’Neill et al, 1995, page 449) as part of the assessment of the impact of 
morphine, lorazepam, dextropropoxyphene and placebo on healthy volunteers. They found 
that morphine improved calmness and reduced alertness (Hanks et al, 1995; O’Neill et al, 
1995; O’Neill et al, 2000). The authors of these studies found the Bond and Lader scales 
helpful for reasons which may reflect the differences between healthy volunteers and 
patients who are on long-term opioids for either pain or substance misuse. It may be that 
patients who are on opioids become accustomed to the calming and sedating effects of the 
opioids. It could also be that pain is having an arousal effect on the patient and 
counteracting the effects of the opioid (Kendall et al, 2010; Sjogren Thomsen, Olsen, 
2000). 
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5.13.5 Specific cognitive domains affected 
 
 
The results of this study showed that attention, memory, fluency and visuospatial 
awareness were all impaired. Patients appear to be aware of memory impairment (Landro 
et al, 2013). The Addenbrooke’s Cognitive Examination – Revised (ACE-R) provides a 
more comprehensive assessment of memory than the Mini-Mental State Examination 
(MMSE) with a score of 26 out of 100 in the ACE-R relating to memory compared to just 
three out of 30 in the MMSE. 
 
 
Using some of the specific neuropsychological tools can result in little cognitive 
impairment being revealed for example despite a comprehensive series of tests. Kurita and 
de Mattos Pimenta found that only two of the assessments revealed a difference in patients 
with pain and taking opioids compared to those with pain and not on opioids (Kurita and 
de Mattos Pimenta, 2008). They found a difference between the patient groups when 
assessing memory, attention and executive function (Kurita and de Mattos Pimenta, 2008). 
Similarly in a study which recruited patients with chronic non-cancer pain who were on 
oral opioids with a median morphine equivalent daily dose of 60 mg the authors found that 
attention, working memory and psychomotor speed were adversely affected in patients 
with pain who were on opioids (Sjogren, Thomsen, Olsen, 2000). While there may be 
issues with sample size in some of the studies and it is also recognised that cognitive 
impairment is multi-factorial and any impairment is unlikely to be attributable solely to 
opioids (see introduction to this chapter) it seems that the choice of tool is key. The 
discrepancy between the pathology detected by the two tools may be related to sample size 
or that the specific aspects of cognitive function affected are not well assessed by the 
MMSE.  
 
 
5.13.6 Importance of Opioid and Route of Administration 
 
 
Our results did not show an association between either the dose of the opioid or titration of 
the dose and the impact on cognitive function. Other studies have shown contradictory 
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results. In the paper based on the European Pharmacogenetic Opioid Study Kurita and her 
colleagues found that higher doses of opioids were associated with more significant 
cognitive impairment.   
 
 
“Patients receiving doses of morphine greater than 400 mg in 24 hours or the equivalent 
dose of an alternative opioid had 1.75 (95% CI, 1.25 to 2.46) times higher odds of 
having lower MMSE scores compared with those receiving daily doses less than 80 
mg.” (Kurita et al, 2011, page 1297) 
 
 
Sjogren and Banning did not find any benefit when they changed patients from oral opioids 
to epidural opioid. The sample size was small though with just 14 patients. The patients 
recruited for the study were experiencing either unwanted sedation or inadequate pain 
control or both on oral opioids. As a group the patients gained little benefit from the 
change of opioid route (Sjogren and Banning, 1989).  
 
 
In a study published in 1989, Eduardo Bruera showed that titration of the opioid was 
associated with a negative effect on cognitive function. He recruited twenty patients who 
were on a stable opioid dose and 20 patients who had a recent titration of opioid. He found 
adverse impact on memory, arithmetic tests, and visual analogue scales for sedation and 
nausea. The findings were statistically significant despite small numbers (Bruera, 1989). 
 
 
5.14 Conclusion 
 
 
We have used the Addenbrooke’s Cognitive Examination – Revised to assess the cognitive 
function of patients from different clinical groups who are prescribed opioids. This is a tool 
which can be used by clinicians and does not rely on specialist psychological expertise to 
use it correctly. Using the ACE-R we have revealed the extent of cognitive impairment is 
greater than previously recognised when the MMSE has been relied on. We did not show 
an association between opioid dose or titration of the opioid which is consistent with some 
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of the published literature.  Qualitative research revealed that patients are very aware of the 
cognitive impairment. 
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CHAPTER 6:  HOW DO PATIENTS 
EXPERIENCE OPIOID TOXICITY? 
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Outline of chapter: 
 
 
 Pain is prevalent in patients with cancer and is likely to be managed with opioids. 
 Some patients will experience opioid toxicity which includes myoclonus, sedation, 
confusion, hallucinations and peripheral shadows. 
 Qualitative description is a methodology which can be used to explore the patient 
experience of opioid toxicity.  
 Opioid-induced hyperalgesia may be present with the symptoms of opioid toxicity. 
This has not previously been recognised. 
 Patients also report significant impairment of cognitive function and covert self-
management of the symptoms of opioid toxicity. 
 
 
6.1 Aim 
 
 
To explore the patient experience of an episode of opioid toxicity 
 
 
6.2 Introduction 
 
 
6.2.1 Opioid side effects and toxicity 
 
 
Opioids have an essential role in the management of cancer and non-cancer pain but for 
some patients the side effects will outweigh the improvement in their pain. Opioid toxicity 
represents the more severe end of the spectrum of side effects and is a potentially 
distressing experience for both the patient and those who care for them. Studies have 
explored patients’ views on being prescribed strong opioids but there has not been an 
attempt to explore the patient experience of opioid toxicity. This study provides the first 
description of the experience of patients with cancer pain who have previously been opioid 
toxic. 
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It is now well recognised that opioids have a role in the management of pain of patients 
with both malignant and non-malignant disease. Opioids are used at higher doses and at an 
earlier stage of disease than before. About 80% of patients with cancer will experience 
moderate to severe pain during their illness and for the majority of these patients the pain 
will be successfully managed using opioid analgesia. However some patients (10 – 30%) 
will not experience effective pain relief on strong opioids because analgesia is not adequate 
or the side effects of the medications limit adequate titration (Daeninck and Bruera, 1999; 
Cherny et al, 2001). 
 
 
Patients vary in their experience of opioid side effects and the extent to which the side 
effects limit drug titration. Opioid side effects include nausea, vomiting, pruritus, 
constipation. Mild opioid toxicity may not be recognised by healthcare professionals or 
may not be reported by the patient. The effect of the opioids may only be recognised 
therefore when the patient develops severe opioid toxicity with myoclonus (muscle jerks), 
hallucinations, respiratory depression and marked confusion or cognitive impairment. 
Opioid switching to improve analgesia and minimise side effects is common but there is 
little evidence for its use (McNicol et al 2003; Dale et al, 2011) 
 
 
6.2.2 Qualitative Research 
 
 
“Qualitative research is an approach that allows you to examine people’s experiences in 
detail, by using a specific set of research methods such as in-depth interviews, focus group 
discussions, observation, content analysis, visual methods, and life histories or 
biographies.” Qualitative research is used to address the “How” and “Why” research 
questions. “It gives voice to the issues of a certain study population” and “provides depth, 
detail, nuance and context to the research issues” (Hennink M, Hutter I, Bailey A. 
Qualitative research Methods. Sage Publications 2011) It is not intended to be 
generalizable but it may be relevant or applicable to other patient groups. 
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Patients with advanced disease do not appear to find qualitative research too burdensome 
and responded positively when asked about participating in qualitative research. Gysels et 
al found that participants found being interviewed helpful as it allowed them to tell their 
story. This was therapeutic for the majority of participants when assessed after interviews 
conducted to address other research questions (Gysels, Shipman, Higginson, 2008) 
 
 
In qualitative research researchers are active participants in the creation of data 
(Addington-Hall et al (ed) Research Methods in Palliative Care. Oxford University Press, 
2009). Qualitative research requires an open mind. It should not be conducted with 
prejudice or pre-conceived ideas about what the patients may report. This can be 
challenging to the researcher who is already familiar with the literature on a particular 
subject and already has experience of managing patients with the symptoms or condition 
being investigated.  
 
 
When conducting the interviews issues start to become apparent. The next interview 
explores the issue further and the interviewer askes more specific and probing questions in 
order to elicit more detail. Subsequent interviews follow the exploration and respond to 
new subjects and concerns as they are mentioned by participants. When no new 
information is being reviewed or elicited information saturation had been reached. 
Although there may be an instinct that suggests saturation has been reached this will only 
be confirmed once the data has been analysed.  
 
 
Qualitative research differs from quantitative research in that it allows analysis of the data 
to start as soon as collection of data starts. This is a natural process as the researcher starts 
to process the data intuitively. The researcher will start to recognise keywords and phrases 
and to instinctively label these keywords as data. There is a benefit of one interviewer 
conducting all research interviews as this initial analysis allows subsequent interviews to 
draw out and explore whether themes discussed with one patient are of importance or 
relevance to other patients. Conversely if there is more than one interviewer they will 
almost certainly hear different cues while interviewing participants and this will lead to 
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different themes being explored. Involvement of more than one researcher has the potential 
to bring validity to the study. 
 
 
Purposeful recruitment is valid in qualitative research. It is legitimate to actively seek those 
who have had a particular experience or fall into a particular group.  The study was not 
looking at the prevalence of opioid toxicity but giving voice to those who had previously 
been opioid toxic.  In this study we sought males or females who were aged over 18 years 
and who had a cancer diagnosis. The participants needed to be prescribed strong opioids 
and have been previously opioid toxic.  
 
 
6.2.3 Qualitative Description 
 
 
Qualitative description provides a rich description of an experience. “The final product is a 
description of informants’ experiences in a language similar to the informants’ own 
language.” The aim is to sort and code the data and stay true to it.   There is transparency 
of data in qualitative description that should be valued as there has been no attempt to infer 
or impose meaning, simply a description of the results (Neergaard et al, 2009; 
Sandelowski, 2000) 
 
 
“Table 1: Analytic strategies in qualitative description (taken from Neergaard MA, Olesen 
F, Andersen RS et al, Proposed by Miles et al) 
 
 
a. Coding of data from notes, observation or interviews 
b. Recording insights and reflections on the data 
c. Sorting through the data to identify similar phrases, patterns, themes, sequences and 
important features 
d. Looking for commonalities and differences among the data and extracting them for 
further consideration and analysis 
e. Gradually deciding on a small group or generalizations that hold true for the data 
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f. Examining these generalizations in the light of existing knowledge” 
 
 
Several authors have argued the value of qualitative description is in its simplicity and the 
reporting of data in a very transparent way. There are no attempts to interpret the data or 
generate an underlying theory. 
 
 
Sandelowski argues that qualitative description is a useful research method in its own right 
and does not need to be seen as a starter for other methods.  
 
 
“Researchers conducting qualitative descriptive studies stay closer to their data and to 
the surface of words and events than researchers conducting grounded theory, 
phenomenologic ethnographic or narrative studies. In qualitative descriptive studies, 
language is a vehicle of communication, not itself an interpretive structure that must be 
read. Yet such surface readings should not be considered superficial, or trivial and 
worthless. I intend the word surface here to convey the depth of penetration into, or the 
degree of interpretive activity around, reported or observed events. There is nothing 
trivial or easy about getting the facts, and the meanings participants give to those facts, 
right and then conveying them in a coherent and useful manner.” (Sandelowski, 2000) 
 
 
6.2.4 Consideration of other methodologies 
 
 
Research questions that address individual experiences are best addressed through the 
interview method of data collection. Fieldwork approaches, which require a close 
interaction with participants and observation of behaviour over a period of time, were not 
appropriate to my research question. Individual interviews were chosen rather than focus 
groups as it would be challenging to bring together a group of patients who have malignant 
disease and are often attending oncology clinics, having chemotherapy or attending day 
hospice for the purpose of group discussions. It can be problematic to require this group of 
patients to travel at a particular time and date to a central location. In addition, I wanted to 
give voice to the individual and explore the individual’s experience of opioid toxicity. It is 
easier to explore more sensitive issues on an individual basis rather than in a group 
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Therefore it was felt individual interviews were more appropriate (Addington-Hall et al 
(ed) Research Methods in Palliative Care. Oxford University Press, 2009). 
 
 
Qualitative research covers several different methodologies including phenomenology, 
ethnology. There can be a pressure to make qualitative research fit a mould and generate a 
central theory. The pressure comes from comparisons between quantitative and qualitative 
research and the value of the different methodologies. For some studies this is appropriate 
but for others this forces the study into a new direction.  The pressure can result from a 
tendency to view qualitative research as somehow inferior to quantitative research and 
researchers feel a need to overdo the methodology. This can be counter-productive. The 
research methodology should be appropriate to the research question and what is already 
known about the subject (Sandelowski, 2000; Mays and Pope, 2000) Qualitative 
description is a useful methodology for exploratory studies. 
 
 
Accuracy of the data will be improved by comparing the recording and transcription of the 
interview. If the participant is able to read their own transcription accuracy will be further 
enhanced. 
 
 
The use of quotes in qualitative research enables others to consider the data and the 
categories that have been generated. They can decide if the themes are applicable to their 
own patient group and whether the categories are appropriate given the data presented. 
 
 
Reflexivity is “sensitivity to the ways in which the researcher and the research process 
have shaped the data collected.” (Mays and Pope, 2000) Qualitative research both accepts 
and values the influence of a researcher on the “creation of research data” (Hennink, 
Hutter, Bailey. Qualitative Research Methods. 2011). In qualitative research the researcher 
interprets the data with a subjective view based on their own ideals and background and 
assumptions. (Hennink, Hutter, Bailey. Qualitative Research Methods. 2011)
 
However it is 
reaching an understanding the experience from the participants’ perspective that is 
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important. The researcher must reflect on the study and make it clear how participants’ 
response to them may have influenced the study.  
 
 
6.3 Method  
 
 
6.3.1 Participant Selection 
 
 
Participants were recruited who were part of the main study. While discussing the study 
and seeking consent for involvement participants were identified who had previously been 
opioid toxic. Others were identified to the researcher as having experienced opioid toxicity 
by the clinician who suggested they participate in the main study. Participants who had 
experienced hallucinations, myoclonus, sedation and peripheral shadows were invited to 
take part in the qualitative study. The diagnosis of opioid toxicity was made on the basis of 
the symptoms reported by the participant and on the resolution of symptoms coinciding 
with a reduction in the strong opioids prescribed. The diagnosis of an episode of opioid 
toxicity required both these aspects to be present before inclusion in this part of the study. 
 
 
The aim of the project was explained to participants. The interview process was explained, 
including that the interview would be recorded and then transcribed. The use of quotes to 
illustrate themes was explained to participants and they were reassured they would not be 
identifiable from any quotes used. Written consent was obtained for the qualitative study. 
 
 
Only participants for whom the episode of opioid toxicity had already resolved were 
recruited. It would not have been appropriate to recruit those who were still experiencing 
opioid toxicity as it is likely that their capacity would be impaired or that they were 
distressed with the symptoms they were experiencing.  
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At the time of inclusion in the main study therefore participants were identified who had 
previously been opioid toxic. Participants needed to meet the inclusion criteria for the main 
study. They had a cancer diagnosis, aged 18 years or over and had a prognosis of at least 
three months. They had been prescribed and were taking a strong opioid. The interview 
was conducted at a different time to the completion of other study assessments where 
possible and unless the patient preferred otherwise. This was done to avoid tiring the 
participant. 
 
 
Appropriate ethical permission had been granted and research and development approval 
was in place. 
 
 
The safety of the researcher was considered and the lone worker policy was adhered to.  
 
 
It was made clear to participants at the point of informed consent that if there were ongoing 
symptoms or features that suggested opioid related side effects these would not be 
managed by the researcher but contact would be made with the appropriate health 
professional to arrange review of the patient and instigate a management plan. 
 
 
6.3.2 Data Collection 
 
 
Semi structured interviews were undertaken with a question schedule which was drafted 
before recruitment commenced. As data emerged the questions were refined and became 
more detailed and structured. This is a recognised and valid part of data collection in 
qualitative research. When writing the interview guide open questions were formulated and 
language was chosen which was non-technical and understandable by participants. 
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Recruitment continued until saturation was considered to have been reached and that 
interviews were not revealing any new data or themes. The decision that saturation had 
been reached was confirmed at the time of data analysis.  
 
 
The recorded interviews were transcribed not by the interviewer but by a colleague 
experienced in transcription of qualitative data. There was a short time interval between 
recording and transcription which enabled the researcher to review previous interviews. 
This allowed familiarity with the data to develop and learning from the conduct of 
interviews to take place. Transcription of the interviews by the researcher would have 
contributed further to immersion in the data however due to time constraints and the 
number of patient assessments required for the study as a whole it was not possible for the 
primary researcher to also undertake transcription. It was felt that familiarity with the data 
would result from the relatively small number of interviews and non-use of coding 
software.  
 
 
Anonymity of the participants has been ensured by the use of numbers rather than any 
identifiable data. 
 
 
6.4 Analysis 
 
 
Six of the seventeen interviews were initially read and codes developed. The codes were 
modified as data analysis progressed. Deductive and inductive codes were produced. 
Inductive codes are those which emerge from the data and are derived from the language 
of the participants. Deductive codes come from the researcher’s familiarity with the 
published literature and in this study the clinical phenomena being researched. Deductive 
codes are used to inform the development of the interview questions. The interviews were 
read several times and the researcher became immersed in that data in order that codes start 
to emerge. Words were underlined and the interviews annotated. Initial thoughts were 
noted and the data was questioned and interrogated to find the underlying meaning. Codes 
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were named and defined. To ensure validity a co-researcher has reviewed a sample of the 
interviews and the coding has been agreed between the two. 
 
 
The purpose of the analysis was to explore the research question. The results must be 
grounded, that is, supported by the data and having come from the data. Transparency is 
ensured by the use of quotes. 
 
 
The first reading of the transcribed interviews was quite passive but some codes were 
generated. Active reading and a search for meaning in the interviews revealed many more 
codes. These were refined and merged and then the codes were compared and categorized 
to produce themes. 
 
 
 
Saturation was confirmed on completion of the data analysis. Once coding had been 
completed and agreed by both researchers involved in the coding the themes were 
explored. Both researchers agreed that no new codes or themes were emerging from the 
interviews conducted most recently. The codes were starting to repeat. 
 
 
6.5 Results 
 
 
Although the main study was open to patients who were prescribed opioids for non-cancer 
pain or substance misuse, the qualitative research part was open only to those with cancer 
pain. All the patients who were identified as eligible and were approached to take in the 
qualitative research were interested in participating.  
 
 
Several key themes emerged from the data. There is significant impact on the participants 
and their family with rich description of impaired cognitive function and of altered pain 
experience. Participants describe the strategies that helped them to cope with the symptoms 
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of opioid toxicity. Participants were very accepting of the side effects that the opioids 
caused them. 
 
 
6.5.1 Patients recruited 
 
 
Seventeen participants were recruited and semi-structured interviews conducted.  Eight 
participants were female and nine were male with an age range of 45 – 68 (mean 55.7) 
years. The characteristics of the participants recruited are described in table 2. The patients 
had a variety of primary tumours. Breast cancer was the most common primary 
malignancy. Lung and multiple myeloma were the next most frequent diagnoses. These 
three diagnoses accounted for ten of the patients malignancies. 
 
 
All those who were approached to participate in this part of the study consented to be 
involved. All interviews were conducted by the same researcher (the author) and all but 
two of the interviews were conducted in the patient’s own home. The interviews generated 
between 11 and 42 pages of transcribed text each with a mean length of text of 24.6 pages. 
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Table 62:  Characteristics of the participants recruited to explore their experience of 
opioid toxicity where n=17 
Patient ID Age, Sex Primary malignancy Metastases present 
Patient 1 51, M Lung Bone, Lung 
Patient 2 45, F Breast Bone, Lung, Nodes 
Patient 3 66, F Ovary Bowel, Omentum 
Patient 4 45, F Breast Bone, Nodes 
Patient 5 60, M Prostate Bone 
Patient 6 59, F Ovary Omentum 
Patient 7 51, F Breast Bone, Liver 
Patient 8 60, M Chronic Lymphocytic 
Leukaemia 
 
Patient 9 51, F Lung Nodes 
Patient 10 62, M Multiple Myeloma  
Patient 11 48, F Colorectal Omentum, Nodes 
Patient 12 53, M Lung Lung 
Patient 13 52, M Multiple Myeloma  
Patient 14 61, M Multiple Myeloma  
Patient 15 68, M Prostate  Bone 
Patient 16 58, F Breast Bone, Nodes 
Patient 17 57, M Bladder Lung, Nodes 
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Table 63:  Opioid History prior to Episode of Toxicity where n = 17 
Patient ID Opioid, Route, Dose Duration of 
episode 
Associated with changes in 
opioid? 
Patient 1 
 
Morphine, oral, 90mg 
bd 
Symptoms 
present over 3 
months 
Associated with titration  
Patient 2 
 
Oxycodone , oral, 80mg 
bd 
Symptoms 
present for six 
weeks 
Associated with dose 
titration 
Patient 3 
 
Oxycodone, CSCI, 
20mg  
Symptoms 
present for 3 
weeks 
Associated with initiation 
and titration of opioid 
Patient 4 
 
Fentanyl, TD, 
75mcg/hour 
2 weeks Associated with addition of 
adjuvant analgesic 
Patient 5 
 
Morphine, oral,100mg 
bd 
Intermittent Associated with use of 
multiple breakthrough doses 
Patient 6 
 
Morphine, oral, 30mg 
bd 
Few weeks Started chemotherapy  
Patient 7 
 
Morphine, oral & 
hydromorphone, oral, 
24mg bd  
Months  Opioid being titrated 
Patient 8 
 
Oxycodone, oral, 15mg 
bd 
24 hours No change in opioid or other 
factor identified 
Patient 9 
 
Morphine, oral, 30mg 
bd 
Few weeks Titration of opioid 
Patient 10 
 
Oxycodone, oral, 80mg 
bd 
Weeks  Titration of opioid 
Patient 11 
 
Morphine, oral, 40mg 
bd 
Few days Dose of opioid titrated 
Patient 12 
 
Morphine, oral, 30mg 
bd 
Few weeks At initiation of opioid 
therapy 
Patient 13 
 
Patient unable to recall 6 – 8 weeks Patient unable to recall 
 
Patient 14 
 
Morphine, CSCI, dose 
not known 
24 hours No change in opioid or other 
factor identified 
Patient 15 
 
Oxycodone, oral, 
160mg bd 
Few days Associated with trial switch 
to morphine 
Patient 16 
 
Morphine, oral, 120mg 
bd 
Worsening 
features over 3 
months 
At initiation of opioid 
Patient 17 
 
Oxycodone, oral, 20mg 
bd 
Few days  Associated with titration to 
oxycodone 30mg bd 
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Table 63 shows that most patients were on morphine or oxycodone when they developed 
features of opioid toxicity. The patients were on very moderate doses of opioids. Not all 
patients were able to recall the dose of opioid that was associated with toxicity. The table 
also shows that although some patients sought help quickly others persevered with their 
symptoms for weeks or months before asking for advice. 
 
 
Table 64:  The site and nature of the pain experienced where n = 17 
Patient ID Site of Pain Number of Pain 
Sites 
Nature of Pain 
Patient 1 Arm  1 Neuropathic  
Patient 2 
 
Knees, ankles, 
back 
3 Bony  
Patient 3 Lower limbs 2 Mixed 
Patient 4 Arm  1 Neuropathic  
Patient 5 
 
Pelvis, knee, 
lower leg 
3 Bony, some 
neuropathic 
Patient 6 Abdominal 1 Visceral  
Patient 7 Back 1 Bony 
Patient 8 Coccyx  1 Neuropathic  
Patient 9 Chest wall 1 Mixed  
Patient 10 
 
Back, 
shoulders 
2 Musculoskeletal  
Patient 11 
 
Abdomen and 
perineum 
2 Visceral and 
neuropathic 
Patient 12 Chest  1 Mixed 
Patient 13 Back, hips 3 Bony and neuropathic 
Patient 14 Lower back 1 Bony 
Patient 15 Lower limb 1 Mixed 
Patient 16 Neck and arm 1 Neuropathic  
Patient 17 Back 1 Neuropathic  
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Table 64 shows the variety of sites at which patients had pain. Six of the seventeen patients 
had more than one site of pain. Eight patients had neuropathic pain and four of the patients 
described a mixed pain. 
 
 
6.6 Themes extracted 
 
 
6.6.1 Impact of side effects on Person 
 
 
Participants described the return to normality after being debilitated with the episode of 
opioid toxicity. They described with amazement how much more they could now achieve 
for example making lunch for friends or going shopping.  One participant admitted she had 
thought “2010’ll not exist for me” and “When am I gonnae start feeling okay?”   
(Participant 3) 
 
 
Participants recalled a difficulty when others saw them and noticed the side effects. For 
example one man would fall asleep in the bathroom and his wife would find him there.  
Others were concerned what strangers would think if they saw them in the street and they 
either had myoclonus or memory loss. One participant described not wanting to see other 
people because she didn’t have the energy or interest for conversation. She felt guilty that 
she was unable to respond to people’s kindness.  
 
 
Myoclonus was one symptom that caused distress due to the potential for danger.  For 
example hot drinks and pans of hot food were spilt. Participants made efforts to modify 
their activities to keep themselves and others safe however this was limiting for those who 
lived alone or were on their own for long periods during the day. 
 
 
One participant described feeling too affected by the drugs to really feel able to participate 
in decision making. Altered cognitive function and poor memory also caused distress.  
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 “Because the patient sometimes is too spaced out on their own situation to really take 
in what’s coming…..”   (Participant 10) 
 
 
There were limitations on abilities due to the side effects. For example hobbies were no 
longer possible. Crossword completion and enjoyment of crafts such as card making and 
knitting was limited by the myoclonus. Participants were anxious about driving even 
though they had not all been specifically advised to stop driving. Some participants 
regulated their driving themselves. One participant avoided the use of breakthrough opioid 
during the day in order to be able to keep driving. 
 
 
“And if I’m driving I’m not allowed to the other one (indicated breakthrough opioid) 
anyway seemingly… so I don’t touch that one unless it’s at night and I know I’m no 
going to be driving” (Participant 12) 
 
 
Another participant described recognising she was not safe to drive. “Because when I was 
on the morphine, the, well most of the time I didn’t drive, cos I knew I wasn’t safe to drive, 
cos ma head felt fuzzy, and… no, it just wasn’t, know like, I wasn’t as alert as I should be, 
know, like, so I knew I couldn’t drive. But I’ve been driving now on the methadone” 
(Participant 7). This participant recognised an improvement in herself and returned to 
driving.  
 
 
Only one of the participants felt the side effects had been of benefit. She described being 
an observer rather than a participant whilst on higher doses of morphine and she felt this 
had allowed her some “space” from everything else. 
 
 
“And I think, oh that’s something I forgot to say when I was on the morphine erm…high 
dosage and I’d come off it that was what friends have said I seemed to be a spectator…. to 
their visit and the events and not a participant and when I went down to the 10mg more 
than one of them on different occasions had said you’re more involved em…whereas 
before you seem to.. the visit happened to me.” (Participant 6) 
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6.6.2 Impact on the participant’s family 
 
 
The impact of side effects on the friends and family of the participants was reflected upon 
by several of the participants. Participants recognised that witnessing some of the 
symptoms of opioid toxicity must have been distressing for those that care about them.  For 
example one participant reported that nausea and vomiting had been prominent symptoms 
and she was concerned that the distressing symptoms would be a lasting memory for her 
young children. For participants who lived alone family members still needed to support 
them. One participant (participant 3) recalled her friend’s distress when he could not 
contact her by telephone despite calling seven times in one hour because she had been too 
sleepy to respond to the telephone. 
 
 
Participants reflected on the physical and emotional impact of the episode of opioid 
toxicity, recognising that carers became physically exhausted with providing care. 
Hallucinations and sleep disturbance due to the opioid meant that carers often had broken 
sleep too. Family members were called upon to help manage the physical symptoms due to 
the strong opioids. For example, one participant recalled falling asleep whilst shopping 
with her daughter. She needed to lie down in the changing room of a shop until she was 
able to travel home. At times when hallucinations were prominent, family members were 
called upon to provide reassurance when these had been frightening and to help distinguish 
reality from hallucinations. 
 
 
“Because as in that necessarily as in I was keeping her awake, but as in, what I say, 
there was a couple of points where I really jumped and she was frightened in case 
maybe I done something to myself….” (Participant 1) 
 
 
Carers had a responsibility for the medication. They were often the ones administering the 
medication whilst also retaining responsibility for recognising the side effects and seeking 
help from a healthcare professional in order to better manage the pain and side effects. One 
participant declined to read the information leaflet provided with the medication and 
delegated all responsibility to his partner.  
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Participants relayed that carers had their own anxieties about the symptoms and possible 
causes.  One participant felt that symptoms of opioid toxicity that caused distress to his 
wife would limit his use of strong opioids more than his own experience. Another 
participant knew that his wife was fearful for him because of the side effects she was 
witnessing. 
 
 
6.6.3 Altered Cognitive Function 
 
 
The impact of the opioid on cognitive function was of great importance to the participants. 
Participants described forgetfulness and altered behaviour. They were very aware of their 
poor memory. The cognitive impairment described included a slowing of mental function 
for example being less able to do simple mathematics, disorientation in time and a 
difficulty in differentiating real from unreal.  Memory loss was a source of concern for 
those who experienced it. This impacted on conversations. Conversations were also 
described as “wandery” rather than straightforward. Participants clearly described 
forgetting midway through a sentence what they were trying to say. 
 
 
“….anything people told me I just forgot right away and then they’d say to me later on, 
“Remember I told you that.” (Participant 13) 
 
 
The memory loss affected their ability to give a clear history when attending for out-patient 
review. For example one participant had forgotten about headaches she had been 
experiencing and therefore failed to report a potentially significant symptom. 
One participant was able to describe very clearly that it was his short-term memory that 
was affected but another participant was unable to recall names of those people that had 
been known for a long time.  There was immediacy to the memory loss and an inability to 
retain information even for a few minutes.  
 
 
The participants described the use of coping strategies to help manage the memory loss 
including the use of a whiteboard to write memos, reliance on partner, keeping notes and 
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copies of documents. The impact of the memory loss on family members was outlined. For 
example participants relied on family members to give information when attending 
appointments, to remember information given to them.  
 
 
There was difficulty in social situations. The participants became frustrated with being able 
to communicate their needs due to an inability the words or recall names of people or 
objects. One participant described very slurred speech which resolved when the opioids 
were reduced and word-finding difficulties. 
 
 
“It was difficult to find the words, find the words I was looking for and er… that was 
probably why I was it was coming out slurred because I was finding it difficult to find 
the wards I was looking for…I was getting quite annoyed with that aye….I’d tend to 
just stop speaking..” (Participant 17) 
 
 
The altered cognitive function was of great concern to participants. They felt it reflected 
badly on them as a person and were concerned how others perceived them. They were also 
concerned about the implications of impaired cognitive function and whether there was 
underling dementia. 
 
 
“….because you begin to wonder if you (participant laughs) you’re hanging on to your 
facility [sic] …. Yeah, it reflects back on you a little more than the other ones do, you 
know.”  (Participant 5) 
 
 
“I have to write everything down, everything, absolutely everything……because I just 
completely and utterly forget….”   (Participant 9) 
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6.6.4 Altered Pain experience 
 
 
An altered pain description was reported by six of the seventeen participants. One 
participant described a pain all over which was felt as a dullness in the body. This resolved 
as the opioids were reduced. 
 
 
“..…I felt my whole body kin’ o’ sore and tired.”    (Participant 3) 
 
 
Other participants described a sensitivity of their skin such that they experienced pain 
when someone touched the skin over their back and their clothes felt painful against their 
skin. Other participants noted altered skin sensitivity and a prickly heat feeling. These 
changes resolved when the dose or type of opioid that had been prescribed was changed. 
 
 
“My skin was quite sen…is almost, not like, well almost, like a prickly heat feel…” 
(Participant 5) 
 
 
“I’ll say “I cannae wear that hooded top cause it’s too sair………..I can’t keep my 
dressing gown on because it feels like a ton weight” (Participant 9) 
 
 
“I was sensitive to things yes I think…. the bedding I didn’t….mum gave me a blanket 
and there was no way I could take the blanket…… I don’t think I liked rough textures” 
(Participant 6) 
 
 
“It was a weird sensation, it was as if you had pins and needles …… it was like nerve 
endings or something, you know.”     (Participant 2) 
 
 
Participants were also aware that the pain was not resolving despite escalation in their 
opioid doses and that the rescue medication was not resolving the pain when they took it. 
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“The pain oh well see I had the pain when I was on the lower dose and he gave me a 
higher dose to kill all the pain but to me at the time it didnae kill the pain…” 
(Participant 12) 
 
 
6.6.5 Acceptance of drugs and side effects 
 
 
Participants described some very difficult experiences due to opioid toxicity however 
opioids were still viewed as an essential part of their pain management. Although they 
would be wary of future changes in the dose of the opioids and the possibility that the risk / 
benefit ratio would shift, none of the patients had approached healthcare professionals to 
discontinue their opioid medication or to seek an alternative. There was a general 
acceptance that the severity of their pain was such that opioids were required.  
 
 
“And with the side-effects I would’ve just said, right I’ll just deal with the side-
effects….I definitely wouldnae have stopped taking it…. Because I was in so much pain 
that I would’ve took anything that was going” (Participant 2) 
 
 
“No I just put up with it aye, aye just part of the parcel know what I mean....” 
(Participant 12) 
 
 
Potential changes in the dose of the opioids were a source of anxiety for many. The 
symptom that had been most prominent for them became the focus of that anxiety. For 
example if nausea had been severe there was a concern that nausea would become 
overwhelming. If hallucinations had been prominent there was a fear about the return of 
these.  
 
 
“……is just the feeling that the side effects are going to take over and I don’t feel well 
enough to do things…and everyday, everyday tasks…..and just be with the family so 
that’s what really puts me off when they keep upping the drugs and not being able  [to] 
just feel normal….”  
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Some participants highlighted they felt more confidence when a specialist in palliative 
medicine managed their pain rather than a general healthcare professional. They voiced 
how well supported they felt by their usual medical team but felt that they did not have the 
expertise to manage their pain with strong opioids. Confidence in their abilities was 
maintained for other aspects of symptom control. 
 
 
Some participants had an expectation of a particular side effect but their own experience 
was felt to be worse than they had expected. 
 
 
“…and I just thought oh well I’ll probably end up with nausea or the usual ones but I 
wasn’t expecting the hallucinations like that and that really scared me……” (Participant 
4) 
 
 
One participant described his expectation of opioid-related side effects and medical error. 
 
 
“But my old brain was telling me that, I mean they are strong drugs that you’re giving 
me and you know there is risk so you know I don’t think I really need to be told that 
sort of thing. I would expect that something might happen and you can’t get it right all 
the time.”  (Participant 14) 
 
 
6.6.6 Control 
 
 
Control was mentioned in several different contexts. Participants described the need to be 
in control over aspects of their pain management. For example being able to choose which 
analgesia to use at a particular time or for a particular type of pain was reported positively.  
 
 
Coping with memory loss was also important in taking control. Keeping notes, informing 
spouses of information and appointments all help to keep the patient involved and in 
control. 
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An involvement in discussions over the titration of analgesia would give control to 
participants. One participant highlighted that if side effects had been included in the 
discussion about his analgesia he could have made different (and informed) decisions 
about changing dose of his opioid.  
 
 
Understanding the reason for taking other prescribed drugs and the safe limit within which 
to adjust these was also felt to be helpful. For example, participants could adjust the dose 
of their aperient if experiencing opioid- induced constipation. 
 
 
A lack of information when introducing opioids left the patients feeling out of control. 
Knowledge of the possible side effects that strong opioids may cause and knowing who to 
contact if the side effects occurred helped to put the participant back in control.  
 
 
“I think I’m more aware of the side-effects now and I’d speak out sooner” (Participant 
7) 
 
 
“That’s the point that somebody hadn’t said you know we’re giving you these extra 
tablets and that but you could go in and if you start to go into that stop it immediately… 
and then I would’ve done that but nobody told me anything at all so I just kept on taking 
them like a monkey” (Participant 13) 
 
 
Control was also mentioned when discussing driving and the need to feel mentally in 
control enough to drive. One participant avoided taking rescue doses of opioids when she 
knew needed to drive and then took the medication later. Another participant adjusted the 
dose of her opioids herself and decided to take an asymmetric dose of her long-acting 
opioid. She took control of the side effects she was experiencing by reducing her morning 
dose. Balancing the dose and side effects put her back in control of her situation. 
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“But I was trying to avoid the ones that made you sleepy obviously for driving…. And 
then once I got home then I would take them sort of when I got home later on in the 
afternoon and then later on in the evening so I wasn’t going anywhere else if I fell 
asleep on the couch well that’s fine…”  (Participant 4) 
 
 
“…as soon as I could, as soon as I got all the side effects and things I was trying to get 
away with the three and to see if that still stopped the pain erm… what I found was that 
if I took three in the morning and four in the evening it wasn’t so bad cause I’d be 
sleeping in the evening so it still got rid of the pain during the night so I could handle, I 
could handle that cause it was only when I was awake that I was worried…about any 
side effects.”  (Participant 11) 
 
 
When describing an episode of severe nausea and vomiting which was due to opioids, one 
participant found the loss of control extremely distressing.   
 
 
“I felt like I was out of control, I have no control, they had no control [her family] and 
they were helpless to help me…”  (Participant 4) 
 
 
6.6.7 Coping Strategies 
 
 
Humour was one of the coping strategies used to cope with the episode of opioid toxicity. 
For example falling asleep in the supermarket queue was described with laughter. 
Hallucinations were shared with family members. 
 
 
Practical solutions to manage the memory loss were described by several participants. 
These included writing down messages while on the telephone, involving spouse or partner 
in giving information to health professionals and decision-making. Avoidance of certain 
activities was another strategy adopted to manage the symptoms. For example avoiding 
carrying hot drinks or plates of food, and avoiding taking breakthrough doses when they 
needed to drive.  
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Having enough information and knowing who to contact when problems arose helped 
patients cope with managing their opioids generally. They had often not known whom to 
contact during the episode of opioid toxicity and it had therefore persisted longer than 
necessary. 
 
 
A degree of familiarity with a symptom also helped people cope with a particular 
symptom. For example if something had been experienced previously it caused less 
anxiety than a new symptom. New symptoms generated anxiety when the cause was 
unknown. There was anxiety in case it may be due to the cancer and in particular whether 
it represented disease progression.  
 
 
6.6.8 Future changes 
 
 
One participant had experienced symptoms particularly while on one opioid. Resolution of 
the symptoms had come when he changed drug as well as dose. His usual medical team 
had asked him to go back to the original strong opioid and he had agreed to this to see if it 
would improve his pain. However he experienced the same severe side effects again. 
Participants had a great deal of faith in their usual medical team and a willingness to try 
their suggestions. The severity of the pain often dictated a “try anything” approach. 
 
 
A few participants reflected that not everyone has the same experience with drugs. They 
recognised that there was something individual about the response to strong opioids. 
 
 
There was a general acceptance of the need to take strong opioids to manage their pain. 
The pain was such that they couldn’t tolerate it without the medication. 
 
 
There was also a general anxiety amongst participants that if the dose of their opioid were 
increased again they would experience side effects from the opioids. They expressed 
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concern about this.  This was not universal though – one participant described a more 
relaxed and trusting attitude.  
 
 
“I trust everybody so I’ll do what I’ve got telt and that’s it.” (Participant 16) 
 
 
“…sometimes you get a wee bit sort of apprehensive of, you know, if they say they are 
going to up the drug…cause I always think, oh, going to up the drug. What’s going to 
happen, is it going to make me feel worse or is it going to start again or is something 
else going to happen that I don’t know about. So it does make me feel a wee bit kind of 
anxious about it…” (Participant 4) 
 
 
6.7 Discussion 
 
 
6.7.1 Summary of main findings 
 
 
This study provides the first description of the patient experience of an episode of opioid 
toxicity. Several themes have emerged from the data that may be helpful for professionals 
managing other patients who are prescribed strong opioids.  
 
 
Participants were clearly able to describe an altered pain experience that suggests opioid 
induced hyperalgesia. The altered pain experience and a sensitivity of the skin were 
described along with other symptoms of opioid toxicity. The symptoms resolved when the 
other symptoms of opioid toxicity resolved. It is important to question patients about 
altered pain when assessing their opioids.  
 
 
Participants tried to self-manage their symptoms and were keen to be involved in decision-
making about the management of their pain. Participants understood the need to achieve a 
balance between the benefits that strong opioids have for their pain and the side effects that 
may occur. The participants in the study were interested in the side effects of opioids and 
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in helping minimise the adverse effects for other patients. However none of the participants 
sought advice on possible alternatives to systemic opioids. There was covert self-
management by the participants rather than active engagement and involvement by the 
healthcare professionals. 
 
 
Carers as well as participants felt the burden of side effects. They had responsibility for 
administering the medication which caused the participant to be less well, for seeking 
medical support and involvement in making decisions.  
 
 
6.7.2 Comparison with published literature 
 
 
Several authors have reported that patients link with pain with disease progression and may 
be anxious about reporting the pain or accepting morphine. (Schumacher et al, 2002; 
Flemming, 2009; Reid, Gooberman-Hill, Hanks, 2008; Coyle, 2004; Blake et al, 2006) 
 
In 
2002 the barriers questionnaire was revised by a team in the USA. (Gunnarsdottir et al 
2002) The original questionnaire identified barriers to adequate pain management 
including fear of addiction and tolerance, concern over side effects, fatalism, a feeling that 
patients should “be good” and not distract their doctor, a fear of injections and a perceived 
link between pain and disease progression. The questionnaire needed to be revised as it is 
now recognised that pain and disease progression are often linked and this is not always a 
misconception. Also much fewer drugs are given by injection when managing pain and the 
likelihood is that other routes will be available. In revising the questionnaire the authors 
found that the patients still fear addiction to painkillers and are concerned about side 
effects. They also still believe that “good” patients are those who do not complain about 
pain. The questionnaire was validated in patients with cancer and the results are therefore 
very relevant to patients in this study.  
 
 
In 2008 Reid and colleagues conducted a qualitative research study exploring participants’ 
views on commencing strong opioids. The study was also part of a larger quantitative 
study comparing the management of cancer using a traditional three-step analgesia ladder 
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with a new two-step approach. They approached 29 potential participants and 18 took part 
(Reid,
 
Gooberman-Hill, Hanks, 2008). In the study described here all those approached 
were interested in participating. 
 
 
The study identified four key themes with a link between themes of “morphine as the last 
resort”. The participants described an association between increasing pain and concern that 
the cancer was progressing which was also voiced by participants in this study. They had 
faith in healthcare professionals, particularly those who took time with them and appeared 
knowledgeable. The impact of pain on the participant and their carers was of importance. 
In contrast this group of patients thought morphine would cause loss of function and hasten 
death. In this study participants viewed the side effects as causing loss of function. 
Schumacher and colleagues used pain management autobiographies as a tool to explore 
and demonstrate patient barriers to the use of opioids. They recruited patients with cancer 
who were part of a pain management programme and who were reluctant to take analgesia 
despite poorly controlled pain. Patients were reluctant to take opioids if they had previous 
experience of side effects which had been unpleasant which correlates with our results. 
Patients also had some long held beliefs about opioids and the best way to manage to their 
own pain for example using as little analgesia as possible. (Schumacher et al, 2002) 
 
 
Coyle interviewed seven patients with cancer over a period of time with between two and 
six interviews with each patient. The patients interviewed felt that pain “was a reminder of 
progression of disease and the imminence of death”. However without previous experience 
of opioid toxicity this group of patients wanted their opioids to be increased to guarantee a 
peaceful death when they were at the end of life (Coyle, 2004) 
 
 
In a study exploring the experiences of patients who were prescribed strong opioids for 
non-cancer pain Blake et al described four major themes - the impact of pain, attitudes to 
strong opioid medication, coping strategies and the relationship with the General 
Practitioner. Although these patients had non-cancer pain there were still some similarities 
in the thoughts expressed about opioids in particular the importance of a healthcare 
professional who could support them, in this case their general practitioner. Chronic pain 
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had placed limitations on their abilities and caused them to become socially isolated. They 
did not have the same experience of side effects but were concerned about disease 
progression as were the patients in this study (Blake et al, 2006) 
 
 
In a study in 2010 Gregorian and colleagues looked at the trade-off between side effects 
and pain relief which patients were prepared to accept. They also looked at the trade- off 
from the physician’s perspective. They recruited patients with acute and chronic pain. Both 
patients and physicians regarded nausea and vomiting as the most unacceptable side 
effects. Patients were more likely than the physicians to accept some drowsiness if they 
had better pain control. Some of the patients who completed this theoretical modelling 
study had previously experienced the side effect they were being asked about and some 
patients had no prior experience. There was no other significant difference in the two 
groups. The patients in this study were anxious about the recurrence of side effects which 
they had previously experienced. They expressed anxiety about opioid dose changes in the 
future (Gregorian et al, 2010). It may be that cancer patients are also experiencing side 
effects of their oncology treatments and that the opioid related side effects are the ones that 
they feel should be managed well or avoided by the professional. Future work would 
explore why cancer patients appear to feel differently about the trade-off. 
 
 
Impaired cognitive function was noted by patients who participated in a study 2007.  The 
authors reviewed 595 cancer patients who were having active cancer treatments. These 
patients also reported memory and concentration problems. The conclusions of this study 
were that the cognitive impairment was probably due to the oncology treatments however 
the analysis did not include analgesia. This study comments on the presence of the 
impairment at the start of the treatment. It may be that drugs had some part to play in the 
clinical presentation. It may also be that cancer itself affects cognitive function. (Kohli et 
al, 2007) 
 
 
Von Ah explored “the impact of perceived cognitive impairment” using a qualitative 
research methodology (Von Ah, 2013). Questionnaires were posted to 25 women who had 
cognitive impairment following chemotherapy. Interviews were conducted and the data 
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was analysed using qualitative description. Memory loss was highlighted as the main 
concern of the women recruited. Other aspects of concern were “speed of processing, 
attention and concentration, language, and executive functioning.” The participants 
reported feeling slower than usual or “foggy”. Word-finding difficulties were described.  
All those recruited had breast cancer. The women spoke of the impact their cognitive 
impairment had on their families and the distress it caused themselves. 60% of the women 
in the study felt there had been adverse stress on a close relationship. Again the cognitive 
impairment had been assumed to be due to the chemotherapy but there is no evidence of 
consideration that opioids have contributed. An important finding of this study was that 
most of the women did not discuss the cognitive impairment with a professional and those 
that did discuss the impairment did not receive much support. The most helpful response 
received was that of “validation” ie an explanation that the concerns were justified and had 
a cause. There were many similarities between this study and the results of the qualitative 
research I undertook including the methodology.  
 
 
The importance of patient involvement in decision – making has been debated widely and 
the variation in the degree to which patients wish to be involved has been recognised 
(Blake et al, 2006; Say and Thomson, 2003).
 
 More specifically Cheatle and Savage 
discussed the need to consider informed consent when commencing opioids (Cheatle and 
Savage, 2012) They highlighted some of the barriers to effective pain management 
including fear by the clinician of the associated risks including side-effects and diversion. 
Some specialists in chronic non-cancer pain are using opioid treatment agreements. Opioid 
treatment agreements encourage information-sharing and establish goals of treatment. 
Goals of treatment are decided and may include improvement in pain, increase in 
activities, aspects of mood and involvement with social activities. It may be that some of 
the participants in the study would have welcomed opioid treatment agreements and the 
information and involvement in decision-making that results. However Cheatle and Savage 
argued that the use of opioid treatment agreements may promote the view of opioids as 
risky. 
 
 
Much of the literature on opioid-induced hyperalgesia (OIH) is from three groups – healthy 
volunteers, opioid addicts on methadone maintenance programmes, and patents receiving 
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opioids at the time of surgery. Authors have described an alteration in the pain with the 
pain becoming less well defined in site and nature as OIH develops. The literature on OIH 
in cancer patients is limited to case reports and small case series. (Lee et al, 2011; Fishbain 
et al, 2009; Angst and Clark, 2006;) In the chapter exploring opioid induced hyperalgesia a 
series of case studies are outlined. The studies have all been published and postulate 
opioid-induced hyperalgesia as the cause of the patients’ symptoms. All the patients had 
cancer pain and most of them were on very high doses of opioids. Rapid titration was also 
a prominent theme. The patients in this study describe altered pain and hypersensitivity 
with much milder symptoms of opioid toxicity than the patients in the published literature. 
The patients in this study were on much more moderate doses of opioids and rapid titration 
to very high doses was not a feature. It may be that OIH is present in milder cases of opioid 
toxicity than has previously been recognised.  
 
 
6.7.3 Reflexivity 
 
 
Qualitative research interviews are often thought of as very similar to clinical interviews 
by novice researchers. This is due to not recognising the different purposes of the 
interview. The clinical interview needs to find an answer, often within a time limited 
consultation, that fits a recognised pattern ie to provide a diagnosis. The research interview 
is not constrained by time and should allow the patient to express their views in whichever 
direction makes sense to them. (Mays and Pope, 2000) 
 
 
As a novice qualitative researcher, this research approach was not instinctive. It was 
initially difficult to detach from searching for facts and simply allow information and 
meaning to emerge. The transcription of the first interview revealed the interview had been 
too closely related to a medical history. Attention was paid to changing the conduct of the 
interview to enable a freer flow of information and allowing the participant to direct the 
conversation whilst still addressing the agenda.  
 
 
 
 
240 
 
Field notes were not recorded. This was also due to the newness of this research 
methodology. The presence of a more experienced qualitative researcher may have 
enhanced the depth of interviews and made it possible to record field notes. The presence 
of two researchers at each interview was not possible due to resource limitations. If field 
notes had been recorded additional data may have been available through non-verbal cues 
and the noting of emotional responses. 
 
 
In palliative medicine it could be argued that the two interviews are closer than in other 
specialties as palliative medicine clinicians often have much more time to spend with the 
patient and allow then to tell their story in the order they wish. Palliative medicine 
clinicians enable their patient to prioritise their symptoms and needs in any order they wish 
and help find solutions to problems that suit the patient. We are more used to practicing an 
individually tailored approach to medicine. 
 
 
The interviews were mainly conducted in the participant’s homes.  This was done in order 
to inconvenience the participants as little as possible. It is possible that the place in which 
an interview is conducted shifts the boundaries and power balance between interviewer and 
participant. In their own home the participant should feel more in control of the situation 
and in a position of natural power. This should enable them to voice their opinions more 
freely. None of the participants stated that they had found the home visit intrusive or to the 
detriment of their participation in the study. All those who participated in the study valued 
the chance to be involved. 
 
 
There is potential for bias in qualitative research as with quantitative research. The 
researcher and participant will both be influenced by the nature of the researcher as a 
doctor and a specialist palliative medicine whether this influence is explicit or not. This 
can be further compounded if the doctor is part of the patient’s usual medical team, even if 
they are not the responsible clinician or directly involved in the patient’s usual medical 
care. There may be the perceived need for loyalty to the patient’s usual medical team and a 
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perceived idea that they should reflect this in the thoughts they share during the semi 
structured interview. 
 
 
It can be very difficult to record and observe without also finding oneself in the role of 
doctor. This was easier when other medical teams were responsible for the care of the 
patient and was more difficult when the researcher was assumed by the patient to have 
some influence or responsibility for their medical care. This was not always so and I tried 
to make it explicit at the start of the participants recruitment to the study and again before 
commencing the qualitative interviews. 
 
 
It may also be that the researcher was part of the palliative medicine team that has 
successfully managed the participant’s symptoms. This can engender a respect and loyalty 
from the patient that alters their responses as research participant. There is a bias that 
successful management of symptoms brings to the study. 
 
 
6.7.4 Future work 
 
 
“Respondent validation” (Pope and Mays, 2000) is a technique to enhance quality of the 
research. Pope and Mays suggest that those who participated in the study review the 
findings and their comments are included in the results. Although this would enhance 
quality it would not have been feasible with this patient group due to the length of time to 
recruit all seventeen participants. By the time recruitment and data analysis was completed 
unfortunately some of those recruited early in the study had passed away.  It may be 
possible though to show the findings to a similar patient group and ask them to reflect on 
the findings and whether they recognise the views expressed. 
 
 
The patients recruited were those who had experienced an episode of opioid toxicity. This 
had been successfully managed and the patients were under the care of specialist palliative 
care teams who were addressing any unresolved symptoms. It would be interesting to see 
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how the themes identified through analysis of qualitative interviews with participants with 
unresolved symptoms or opioid related side effects compared to those with well managed 
symptoms and who were no longer experiencing opioid related side effects. The need to 
assess capacity and ability to give informed consent may make this very challenging 
though. 
 
 
Ethical approval was not sought to seek the views of carers of patients who had previously 
been opioid toxic. The study revealed some of the burden on carers and it would be 
interesting to explore this further. It would also be interesting to see if there were any 
differences between those with cancer and non-cancer pain who have previously been 
opioid toxic. 
 
 
Field notes were not recorded during this study. Non-verbal cues are therefore not 
available for inclusion in the results. They may have added further depth to the data. 
 
 
The use of pain management programmes for patients with cancer would be an interesting 
area to explore given that the participants were already developing coping strategies and 
using covert self-management techniques. Attendance at such a programme may empower 
them further. 
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6.7.5 Conclusion 
 
 
The published literature has not previously revealed the impact of opioid toxicity on the 
patient and their family. It is the first time that the impact of an episode of opioid toxicity 
and in particular the effect of opioids on cognitive function, have been described. This is 
the first study to describe the altered pain and sensation that may be experienced along 
with the symptoms of opioid toxicity and that most likely represents opioid-induced 
hyperalgesia. The opioid-induced hyperalgesia is present with much milder symptoms of 
opioid toxicity and more modest doses of opioid than have been described in the literature. 
Participants engaged in covert self-management and developed coping strategies to 
manage the symptoms. This covert self-management could be the basis of future work to 
help empower the patient and adopt a more patient-centred approach. 
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CHAPTER 7:  CHARACTERISATION OF 
OPIOID INDUCED HYPERALGESIA 
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Outline of Chapter: 
 
 
 
 The pre-clinical and clinical evidence for the existence of opioid-induced 
hyperalgesia (OIH) is discussed 
 A detailed review of the description of opioid-induced hyperalgesia is presented 
 The findings of quantitative sensory testing in patients with cancer pain, non-cancer 
pain and substance misuse are described  
 These findings are compared with published literature to help better define the 
clinical presentation of OIH. 
 
 
7.1 Hypothesis 
 
 
Patients who have pain and who are prescribed opioids will have different sensory 
thresholds when compared to healthy volunteers and those who have a history of substance 
misuse. 
 
 
7.2 Aims 
 
 
The specific aims of this part of the study were to: 
 
 
 Establish the prevalence of features suggestive opioid-induced hyperalgesia 
 Compare the sensory processing of patients with cancer and non-cancer pain with 
other groups of patients 
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 Characterise the clinical presentation of opioid-induced hyperalgesia in order to 
provide guidance in making the diagnosis for clinicians. 
 
 
7.3 Opioid-induced Hyperalgesia and Tolerance 
 
 
Recently there has been evidence that suggests the effect of the opioid is not maintained 
over time.  There are two possible reasons why the analgesic effect of the opioid may 
lessen over time – tolerance and hyperalgesia. It can be difficult to distinguish opioid-
induced tolerance from opioid-induced hyperalgesia particularly in the context of pain due 
to advanced cancer. In patients with advanced cancer it may be that their pain has 
worsened and therefore unrelated to the opioids. Opioid-induced tolerance requires a 
higher dose of opioids to manage the pain. Opioid-induced hyperalgesia “results in a 
paradoxical increase in atypical pain that appear to be unrelated to the original nociceptive 
stimulus.” (DuPen 2007).  
 
 
“Hyperalgesia represents increased sensitivity to pain, whereas tolerance may reflect 
decreased sensitivity to opioids.” (DuPen, 2007) 
 
 
When the two opioid-related phenomena are not recognised it is not possible to manage 
patients’ pain well. Opioid-induced hyperalgesia may be misdiagnosed as uncontrolled 
pain or generalised distress leading to inappropriate management with further escalation of 
opioid doses or the addition of anxiolytics or sedatives to relieve the patient’s distress.  
 
 
7.4 Opioid Physiology 
 
 
The pathophysiology of pain was briefly outlined in the introduction. In this chapter the 
focus is primarily on opioid physiology and the mechanisms thought to underpin the 
development of OIH. 
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There are three groups of opioids prescribed for the management of pain and they have an 
effect by “modulating the endogenous opioid system.” (Levac, 2001) The initial division of 
exogenous opioids is made on the basis of chemical structure. The endogenous opioids are 
the dynorphins, enkephalins, endorphins and endomorphins. For the purpose of this chapter 
the focus will be on the role of opioids in pain management but opioids also have an effect 
on gastrointestinal motility, temperature regulation, mood and respiration amongst others. 
(Levac, 2001) 
 
 
Opioid receptors are found throughout the central nervous system including the 
hypothalamus, rostral ventromedial medulla and spinal cord dorsal horn. (Hutchinson, 
2011) In the peripheral nervous system opioid receptors are found on nociceptors and in 
the spinal cord interneurons. (Stein, 2013) Analgesia results from both peripherally and 
centrally located opioid receptors. (Lee, 2014) 
 
 
All the opioids are mu agonists and derive most of their clinical benefit from this activity. 
Other opioid receptors have also been identified – these are the opioid-like receptor 1 
(ORL-1), delta and kappa receptors. In addition there are seven subtypes of mu receptor. 
The opioids all have varying affinity for the receptors and their subtypes which goes some 
way to explain why individual patients may respond better to particular opioids either in 
terms of analgesia or a better side effect profile. (DuPen, 2007) Genetic polymorphisms 
affect receptor structure and are a further component of the inter-individual variation. 
Genetic polymorphisms are discussed further in the chapter “Future work”. 
 
 
Morphine receptors are G-protein coupled receptors. When the opioid binds to the receptor 
the G-protein is activated and reduces cyclic adenyl phosphatase (cAMP), which in turn 
causes suppression of sodium and calcium channels and a reduction in the hyper 
excitability of the neurones involved in the pain pathway. Analgesia is the result. (DuPen, 
2007) 
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The mechanisms underlying opioid tolerance are not well elicited. It is known that G-
protein and the opioid receptor can uncouple after prolonged exposure to opioids. Beta–
arrestin 2 regulates the uncoupling and lack of beta-arrestin 2 results in longer opioid-
induced analgesia. (Levac, 2001) It is also possible for G-protein to switch to a 
pronociceptive protein so that analgesia is no longer the result of the sequence put in 
motion by the administration of the opioid. (DuPen, 2007) 
 
 
Endocytosis of the opioid receptors by cells appears to have role in regulating receptor 
function. The endocytosis can be down-regulated and one study has shown that if patients 
don’t have the down-regulator they cannot develop tolerance to opioids. Alternatively 
endocytosis may be important in preventing the development of tolerance by facilitating 
the replacement of opioid receptors with new ones that may avoid the uncoupling of the G-
protein or G-protein switch described above. (DuPen, 2007) 
 
 
Within the Central Nervous System (CNS) opioids are further involved in signalling and 
pathways. They have roles beyond the neuronal pathways of pain and have signalling roles 
in the immune system. Astrocytes form the blood-brain barrier, regulate cerebral blood 
flow, can detect the need for repair of nerves and help provide the nutrients and precursors 
of neurotransmitters that the central nervous system requires. In addition astrocytes express 
opioid receptors and appear to have a key role in maintaining opioid homeostasis. If the 
astrocytes respond to local or general changes in the nervous system this can impact on 
pain pathways. Microglia are specialised macrophages that are found in the CNS and 
respond to acute tissue damage. Toll-like receptors are an integral part of their ability to 
respond quickly.  Once microglia have responded to an acute tissue injury they remain 
active and are able to respond more quickly if there is subsequent damage.  (Hutchinson, 
2011) Toll-like receptor 4 is expressed by microglia and has been shown to have a role in 
sepsis and it responds to substances released from damaged cells. It appears that Toll-like 
receptor 4 is able to detect the presence of opioids and transmit a signal within the CNS 
based on their presence. (Hutchinson, 2011) Toll-like receptor 4 is involved in the 
development of allodynia, hyperalgesia and neuropathic pain and is therefore of significant 
interest to researchers trying to unravel the pathophysiology of opioids which leads to 
opioid-induced hyperalgesia.  
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Endogenous opioids are released in response to painful stimuli and activation of the pain 
pathways from nociceptor to cerebral cortex.  
 
 
“Inflammation of peripheral tissue leads to increased expression, axonal transport and 
enhanced G-protein coupling of opioid receptors in DRG (dorsal root ganglia) neurons.” 
(Stein, 2013) 
 
 
The endogenous opioids are released from leukocytes in response to stress, cytokines and 
bacteria. Further inhibition of the pain pathways occurs in the spinal cord where opioids 
and Gamma amino butyric acid (GABA) act to reduce the excitatory ascending pain signal.  
 
 
7.5 Evidence of Opioid-Induced Hyperalgesia 
 
 
There have been several reviews considering opioid-induced hyperalgesia (OIH) and its 
relevance to clinical practice. The authors have differing views and there are some who do 
not feel there is sufficient evidence to consider OIH to be an important clinical 
phenomenon (Fishbain et al, 2009). The conclusion of the review conducted by Fishbain 
and his colleagues was that the evidence of OIH in humans was inconsistent and they 
favoured acute tolerance to opioids rather than OIH as the explanation for study findings. 
Bannister and Dickenson published a very comprehensive review in 2010 in which they 
outlined the mechanisms which may underpin the development of OIH (Bannister and 
Dickenson, 2010). They draw attention to the ability to extrapolate from animal studies 
into human models due to the lack of significant variability in the structure of the mu 
opioid receptor.   
 
 
Three main pathways are thought to be involved in the development of OIH. The dorsal 
horn of the spinal cord is the anatomically most important region in its development (Chu 
et al, 2008).  
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Central sensitisation occurs in the spinal cord and represents a “hypersensitivity of the 
spinal cord to nociceptive inputs from the periphery” (DuPen, Shen, Ersek, 2007, page 
116). The normal response to pain becomes exaggerated in the presence of central 
sensitisation.  NMDA (N-methyl –D –aspartate) is thought to protect against the 
development of OIH (Lee et al, 2011). Central sensitisation and therefore opioid-induced 
hyperalgesia do not develop if the NMDA receptors are antagonised (Colvin and Fallon, 
2009; Silverman, 2009). In animal studies the concomitant use of ketamine and opioid at 
the time of procedure resulted in less thermal hyperalgesia for the four days after the 
procedure (Tompkins and Campbell, 2011) Authors who have suggested ketamine as a 
means of managing OIH are utilising the protective effect of NMDA (Chu, Angst, Clark, 
2008). 
 
 
Spinal dynorphin levels are thought to play an important role in the development of OIH. 
Levels of dynorphin increase after administration of opioids and this in turn causes an 
increased release of excitatory peptides. The increased release of the peptides causes 
increased stimulation of the nociceptors (Lee et al, 2011). Dynorphin is a kappa-opioid 
antagonist and also has non-opioid actions. Studies have suggested that increased levels of 
dynorphin enhance the nociceptive response (Vanderah et al, 2001) 
 
 
The third pathway which has gained interest and support for its involvement in the 
development of OIH is the “activation of facilitative descending pathways from the RVM” 
(Lee et al, 2011, page 148) (RVM, rostral ventromedial medulla). Activation of these 
pathways is thought to enhance the processing of pain by the nociceptors. The descending 
pathways exist in a state of equilibrium which is affected by the administration of opioids 
over time. The opioids cause an increase in the excitatory pathways and a reduction in the 
inhibitory pathways and an overall move to excitation (Bannister and Dickenson, 2010; 
Vanderah et al, 2001). 
 
 
The injection of anti-inflammatory drugs into the intrathecal space reduces OIH. The role 
of spinal inflammation in the development of OIH is a further area of interest to basic 
science researchers (Chu, Angst, Clark, 2008).  
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The evidence for OIH in humans comes from three patient groups. Patients who are on 
methadone maintenance programmes have been shown to have an increased sensitivity to 
cold induced pain (Lee at el, 2011). Angst and Clark outline further studies in support of 
OIH in this patient group (Chu, Angst, Clark, 2008; Angst and Clark, 2006). It does seem 
to be a sensory specific modality in this group of patients. Pain in response to electrical or 
mechanical stimuli is near normal (Chu, Angst, Clark, 2008). 
 
 
There has been some work to suggest patients who are given very high doses of opioids as 
part of general anaesthesia for surgical procedure may have greater intensity of pain after 
the procedure (Lee at el, 2011). However there have also been several studies refuting this 
(Chu, Angst, Clark, 2000). Although the studies recruited patients with a well-defined 
clinical phenotype, the numbers are small. In healthy volunteers there is a suggestion of 
multiple sensory modalities being affected including heat-induced pain and mechanically-
induced pain (Chu, Angst, Clark, 2000). 
 
 
Case studies support the suggestion that OIH is part of the spectrum of opioid toxicity and 
this is discussed further in the section on OIH in patients with cancer pain. There have 
been similar case reports of patients with chronic non-cancer pain developing generalised 
allodynia, sometimes associated with myoclonus, at very high doses of opioids (Angst and 
Clark, 2006). The patients responded to reduction of the opioid dose and / or an opioid 
switch.  
 
 
In healthy volunteers who have been given opioids as part of research studies have shown 
an increased sensitivity to cold-induced pain (Lee at el, 2011). However the studies of 
healthy volunteers may represent hyperalgesia precipitated by acute opioid withdrawal 
rather than OIH. 
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7.6 Opioid-induced Hyperalgesia in Palliative Medicine 
 
 
A literature search was carried out using Ovid Medline (1946 to 2014) and Embase 1947 to 
the present. The search was conducted using the key words opioid$ or opiate$ or morphine 
or oxycodone or fentanyl or methadone and hyperalgesia or paradoxic$ pain or allodynia 
or increased pain and cancer pain or palliative care or palliative medicine or terminal care. 
 
 
Figure 6:  Articles identified of relevance to literature search regarding opioid-
induced hyperalgesia in palliative medicine  
 
 
677 articles 
    Limited to English language 
 
 
622 articles 
Duplicates removed 
 
 
511 articles 
Exclude animal studies 
 
 
405 articles  
 
 
Abstracts reviewed and articles excluded which were relating to non-cancer pain, described OIH in 
children, conference posters or presentations, general opinion papers 
 
 
 
 
17 case studies/ series/small studies  29 review articles which 
discuss OIH in cancer 
patients identified for 
inclusion in discussion 
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7.6.1 Summary of Papers Included in Review 
 
 
Initially seventeen papers were identified which discussed opioid-induced hyperalgesia in 
cancer patients. On reviewing the full text it was evident that the clinical symptoms in 
some cases were that of severe opioid toxicity without hyperalgesia. These papers were 
therefore excluded from this review. Further papers have been identified from the 
reference lists of the initial papers. Data has been extracted from the papers and is 
presented in table 1. 
 
 
All the patients included in this review had a cancer diagnosis. There were many different 
tumour sites and pathologies. Eight (57.1%) of the fourteen patients were male. The ages 
ranged from 31 to 76 years with a median age of 52.9 years. 
 
 
7.6.2 Opioid prescribed 
 
 
The opioids most frequently prescribed by specialist palliative care were all implicated in 
the development of OIH ie morphine, oxycodone, hydromorphone and methadone. 
Morphine was the most frequently prescribed opioid at the time the features suggestive of 
OIH developed. Nine of the patients were prescribed morphine initially; some patients 
were on a combination of opioids. The opioids were prescribed by different routes 
including oral, transdermal, intravenous and intrathecal routes. 
 
 
Seven patients were receiving very high doses of opioids. One of the patients had been 
given an acute overdose of fentanyl. The opioids had been significantly titrated in nine of 
the patients. The time course of titration was short (two to four weeks) in many of the cases 
described. 
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7.6.3 Clinical presentation 
 
 
Ten of the cases outlined had an increase in pain, allodynia or generalised pain described in 
combination with other features of opioid toxicity. There were descriptions of myoclonus, 
hallucinations, sedation, tremor, miosis, delirium, nausea and vomiting. Four patients had 
escalating pain coinciding with escalating opioid doses but had no features of opioid 
toxicity described. 
 
 
7.6.4 Other factors 
 
 
Two patients had a significant history of anxiety and depression and depression, anger and 
benzodiazepine misuse. A further patient was recognised to be very distressed. It is 
possible that these diagnoses affected the presentation of pain and response to opioid. 
 
 
Radiotherapy had been given to two patients as part of the management of their pain and 
disease shortly before the symptoms of OIH and opioid toxicity developed. 
 
 
7.6.5 Management of opioid induced hyperalgesia 
 
 
Dose reduction of the opioid was important in the management of the majority of patients.  
Two patients did not have a significant dose reduction; one of these patients had a further 
episode of the symptoms suggestive of OIH. The only patient for who dose reduction and / 
or opioid switch was not the major factor in managing their OIH was the patient who had 
given the wrong dose of fentanyl. As expected this patient required naloxone as the 
primary intervention. In two patients the dose of opioid was reduced by a factor of 100. 
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Eight patients had an opioid switch. Seven patients were switched to methadone. Three 
patients had more than one opioid switch. 
 
 
7.6.6 Theory postulated by authors 
 
 
The presence of hyperalgesia and allodynia in patients who were opioid toxic was reflected 
upon by the authors of each of the papers. Rapid titration phase and ultra-high doses of 
opioids were both identified as likely to have contributed. Methadone was postulated as 
important to the management, alongside an opioid reduction, as it is the only opioid that 
has an antagonist effect at the NMDA receptor.  
 
 
Failure to recognise pain as a multidimensional experience was also thought to have 
contributed to the development of OIH in one of the cases. The opioids had been titrated 
rapidly with the intention of relieving pain but the extent of the patient’s severe distress 
and anger at her cancer diagnosis and limited prognosis had not been recognised. 
 
 
The patient who received a significant overdose of fentanyl was noted to have features of 
central excitation which responded to naloxone. Naloxone would not be expected to relieve 
these features in patients who receive doses of opioid higher than required for their pain 
over a prolonged period. 
 
 
7.7 Summary of Clinical Evidence from Patients with Cancer Pain 
 
 
These case reports provide a clear link between rapid titration of opioids and the 
development of hyperalgesia as part of the clinical picture of opioid toxicity. The authors 
were able to provide a description of worsening pain with increasing doses of opioids. It 
can be difficult to recognise this link when managing a patient’s overwhelming pain but 
the authors have provided real clarity. 
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The patients who had received radiotherapy had further reason for their opioid 
requirements to change. The radiotherapy may have caused an improvement in their pain 
and therefore rendered them more vulnerable to opioid toxicity. 
 
 
The presence of psychological distress was significant for one of the patients. Another 
patient also had a history of anxiety and depression. The authors recognised her spiritual 
and psychological pain and providing support from the multi-professional team was 
instrumental in relieving her pain. 
 
 
Two other case series have also been published but there was not sufficient clinical 
description to extract themes for the tables. In one series (Sjogren et al, 1993) eight cancer 
patients were described who developed hyperalgesia whilst on treatment with intravenous 
morphine. Seven of the eight patients had neuropathic pain due to direct tumour invasion 
of nerves. Four of the patients also had myoclonus. The authors suggested that the 
neuropathic pain and the use of morphine rather than other opioids had contributed to the 
development of the hyperalgesia. 
 
 
In a further series also by Sjogren (Sjogren et al, 1998) six patients were described – four 
of the patients had malignant disease. There was scant clinical description but when the 
patients developed features which suggested opioid-induced hyperalgesia the levels of 
morphine -3-glucoronide (M3G) were found to be higher than expected. The authors 
suggested this as an interesting finding but recognised that without clear “normal values” 
for M3G concentration and without full clinical descriptions the conclusions were limited. 
 
 
These case reports provide a compelling argument for the relevance of OIH in patients 
with cancer pain. They demonstrate a link between rapid titration and ultra-high doses of 
opioids and the development of hyperalgesia. The patients had features suggestive of OIH 
and symptoms of opioid toxicity suggesting that OIH may form part of the spectrum of 
opioid toxicity. 
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While we continue to rely on anecdotal evidence for the existence of OIH in cancer 
patients it is difficult to guide those who prescribe opioids, and the patients who take them, 
as to which opioids are most likely responsible, when to be cautious about the titration 
phase and how best to manage OIH. 
 
 
Much of the literature published on opioid-induced hyperalgesia is based on small studies 
and some papers are contradictory. No research group has yet studied OIH in a cancer 
population in a systematic way. Studies that have been done have tended to focus on single 
measures or outcomes and there has not been a comparison of comprehensive longitudinal 
data gathered in different patient groups. A longitudinal study of patients with cancer pain 
will provide the answers to some of these questions. 
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Table 65:  Included papers with themes extracted exploring opioid-induced hyperalgesia in patients with cancer pain 
Author, 
Publication 
year 
Demographic 
details 
Opioid prescribed Clinical 
presentation 
Management of 
OIH 
Other relevant 
factors 
Theory 
postulated by 
authors 
Lawlor et al, 1997 52,F 
Recurrent renal cell 
carcinoma 
Morphine; 
PO and IV; 
28,800mg MEDD 
Generalised 
hyperalgesia, 
constipation, 
myoclonus, 
hypoactive – 
agitated delirium, 
cognitive 
impairment, 
hallucinations, 
tonic seizure 
Opioid dose 
reduced by a factor 
of 100. 
Changed to 
methadone. 
Multidisciplinary 
support. 
Resolution of 
symptoms over 
subsequent 6 days 
 
Past history of 
depression, anger 
and benzodiazepine 
misuse 
Failure to 
recognise the 
other dimensions 
of pain ie 
psychological and 
spiritual distress 
resulted in 
escalation of 
opioid doses 
Wilson and 
Reisfield,2003 
39, M 
Testicular cancer. 
L2 bony 
destruction with 
compromise of 
thecal sac 
Morphine, 
IT; 
86,000mg MEDD 
Escalating pain 
despite escalating 
doses of opioid. 
Alert and lucid 
Reduction of IT 
morphine by factor 
of 100. 
Improvement of 
pain 6 hours after 
opioid reduction 
 Opioid induced 
hyperalgesia with 
“a near absence of 
analgesia from 
ultra-high dose 
opioid therapy” 
 
Fainsinger and 
Bruera, 1995 
68, M 
Multiple myeloma, 
bone disease 
Transdermal 
fentanyl and 
morphine, PO; 
MEDD 4800mg at 
max 
Escalating pain 
despite escalating 
doses of opioid.  
Agitation, 
myoclonus, 
hallucinations 
Reduction of opioid 
and several opioid 
switches. Pain 
control achieved on 
methadone, MEDD 
300mg 
 Opioid tolerance 
had developed. 
Symptoms due to 
high M3G 
concentrations 
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Table 66:  Included papers with themes extracted exploring opioid-induced hyperalgesia in patients with cancer pain 
 
Author, 
Publication 
year 
Demographic 
details 
Opioid prescribed Clinical 
presentation 
Management of 
OIH 
Other relevant 
factors 
Theory 
postulated by 
authors 
Okon and George, 
2008 
76, F 
Locally advanced 
leiomyosarcoma of 
uterus 
Fentanyl, 
IV PCA; 
200 mcg / hour 
Hypersensitive to 
light touch on 
lower limbs, 
delirium, 
hallucinations, 
distress, 
intermittent 
sedation 
Fentanyl initially 
reduced by third, 
further reductions 
until fentanyl 
discontinued on 
day 5. 
Symptoms settled 
over 24 hours 
 Although 
moderate dose of 
fentanyl was 
administered 
there had been a 
rapid titration 
phase. Fentanyl 
accumulation may 
also have 
contributed 
 
Davis, Shaiova, 
Angst, 2007 
54, M 
Hepatocellular 
cancer, spinal cord 
compression 
Oxycodone PO; 
Converted to 
methadone PO 
Myoclonus, 
generalised burning 
pain, sensitivity to 
light touch and 
clothing, delirium 
Oxycodone 
converted to 
methadone, dose 
reduction of 
methadone and 
introduction of 
ketamine. 
Symptoms resolved 
over 1 week 
 
Presented 3 weeks 
after radiotherapy 
Escalating doses 
of methadone 
resulted in OIH 
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Table 67:  Included papers with themes extracted exploring opioid-induced hyperalgesia in patients with cancer pain 
 
Author, 
Publication 
year 
Demographic 
details 
Opioid prescribed Clinical 
presentation 
Management of 
OIH 
Other relevant 
factors 
Theory 
postulated by 
authors 
Vorobeychek et al, 
2008 
56,M 
Squamous cell lung 
cancer, spinal 
metastases 
Initially morphine, 
then fentanyl TD 
plus oxycodone PO 
plus morphine 
PCA; 
Then 
hydromorphone 
PCA 
>50,000mg MEDD 
 
Pain escalating 
over a 4 week 
period; sedation, 
fatigue, weakness, 
severe pain, nausea 
and vomiting 
Hydromorphone 
dose reduced by 40 
– 50%; and 
changed to 
methadone. 
Symptoms resolved 
over 4 days 
Recent 
radiotherapy 
OIH postulated 
as scan did not 
show significant 
disease 
progression and 
symptoms 
improved with 
reduced opioid 
dose and 
introduction of 
NMDA 
antagonist 
 
Mercadente et al., 
2010 
 
48, M 
Sarcoma in chest 
wall, metastatic 
disease 
Fentanyl TD 
titrated from 3.6g / 
day to 12g / day in 
2 weeks 
Severe pain despite 
escalating opioid 
doses; myoclonus 
Changed to 
methadone and 
dose reduced by a 
factor of 100. 
Pain controlled by 
day 6 
 
 OIH due to 
opioid dose 
escalation 
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Table 68:  Included papers with themes extracted exploring opioid-induced hyperalgesia in patients with cancer pain 
Author, 
Publication 
Year 
Demographic 
details 
Opioid prescribed Clinical 
presentation 
Management of 
OIH 
Other relevant 
factors 
Theory 
postulated by 
authors 
Bruera and 
Pereira, 1996 
 
 
 
 
 
 
 
62,M 
Adenocarcinoma of 
stomach; advanced 
intra-abdominal 
disease 
Overdose of 
fentanyl iv. 
Received 5000mcg 
in 1 hour (50x 
usual dose) 
Acute confusion, 
hallucinations, 
tremor, myoclonus, 
hyperalgesia of 
limbs, sweating, 
miosis 
Naloxone iv 
administered; 
symptoms resolved 
after 2-3 mins; 
symptoms recurred 
and further naloxone 
bolus and infusion 
needed 
 
 
 Acute opioid 
overdose causes 
central 
excitation which 
responds to 
naloxone and 
contrasts with 
chronic opioid 
overdose which 
causes central 
excitation which 
is not responsive 
to naloxone 
Juba, Wahler, 
Daron, 2012 
43, F 
Metastatic non 
small cell lung 
cancer 
Morphine 200mg / 
day; previously on 
fentanyl TD 
New generalised 
pain 2 weeks after 
starting morphine, 
pain on light touch; 
allodynia and 
hallucinations with 
second episode 
Changed to 
oxycodone tds with 
hydromorphone prn; 
symptoms resolved 
over 1 week. 
Symptoms recurred 
when 
hydromorphone use 
increased. 
Changed to fentanyl 
PCA and symptoms 
resolved over 3 days 
Anxiety and 
depression also 
Opioid rotation 
enabled 
excretion of 
metabolites of 
causative 
opioid. OIH is 
due to 
metabolites. 
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Table 69:  Included papers with themes extracted exploring opioid-induced hyperalgesia in patients with cancer pain 
Author, 
Publication 
Year 
Demographic 
details 
Opioid prescribed Clinical 
presentation 
Management of 
OIH 
Other relevant 
factors 
Theory 
postulated by 
authors 
Mercadente et al, 
2003 
54, M 
Lung cancer with 
thoracic metastases 
 
 
47, M 
Hepatocarcinoma 
Fentanyl, TD 
 
 
 
 
 
Morphine; iv; 
changed to 
methadone and 
morphine 
combination 
 
Worsening pain, 
whole body 
hyperalgesia, 
confusion, agitation 
followed titration 
of methadone 
 
Titration of opioid 
was followed by 
whole body pain 
with no other 
adverse effects 
Trial of ketamine 
bolus was not 
helpful; required 
sedation and 
intrathecal 
bupivacaine 
 
 
Intrathecal catheter 
was placed and 
bupivacaine and 
morphine infused 
Poor compliance 
with treatment 
previously, severe 
psychological 
distress 
 
 
 
 
Opioid-induced 
hyperalgesia due 
to escalating 
opioid doses 
 
 
 
 
Opioid-induced 
hyperalgesia due 
to escalating 
opioid doses 
Sjogren, Jensen, 
Jensen, 1994 
19,F 
Gliosarcoma 
 
 
55, F 
Metastatic breast 
cancer 
68, F 
Metastatic breast 
cancer 
Morphine; PO 
 
 
 
Morphine; PO; then 
methadone then to 
morphine again 
 
 
Morphine; PO 
Whole body 
allodynia, 
myoclonus 
 
 
“Skin burning” 
 
 
 
Allodynia 
Opioid switch   
significant dose 
reduction 
 
Changed to 
ketobemidone 
 
Changes to sufentanil 
subcutaneous 
infusion 
 Opioid-induced 
hyperalgesia due 
to very high 
opioid doses 
 
Opioid-induced 
hyperalgesia 
 
Opioid-induced 
hyperalgesia 
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7.8 Methods 
 
 
Patients were recruited from the different clinical groups that have been outlined 
previously in order to provide comparison between the groups. The different patient groups 
were – patients with cancer pain, patients with chronic non-cancer pain, patients with a 
history of substance misuse, patients with non-cancer pain and co-morbid substance 
misuse, and patients with non-cancer pain who were not on opioids. In addition healthy 
volunteers were recruited to provide comparison with the population from which the 
patients had been recruited rather than normal data from other countries. 
 
 
Patients who were on 60 mg of morphine or an equivalent dose of another opioid were 
eligible to complete more than one series of assessments. Patients with a history of 
substance misuse were asked to complete just one series of assessments. 
 
 
The opioid history was completed in detail at the first assessment providing information 
about the use of opioids in the six months prior to the assessment. At the subsequent 
assessments the opioid history was updated if there had been any changes to the opioid or 
dose prescribed. 
 
 
Patients were asked to complete the Self-Completed Leeds assessment of Neuropathic 
Symptoms and Signs (S-LANSS). The S-LANSS tool asks patients seven questions about 
the nature of their pain and helps to distinguish neuropathic pain from other pain types. 
Patients answered questions regarding the presence of pins and needles or tingling, altered 
sensation and colour change at the site of their pain. Each question is given a score and if 
the total score is 12 or greater it suggests the pain is neuropathic in origin. The validation 
of the S-LANSS was discussed in the methods chapter.  
 
 
Quantitative sensory testing provides a functional assessment of the peripheral nervous 
system. The patients were asked to compare the different sensations between the index and 
control site. For each sensory modality tested they were asked to describe the sensation as 
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increased, significantly increased, reduced, significantly reduced, no difference or not 
detected.  
 
 
The quantitative sensory testing was carried out in a consistent manner and all researchers 
involved ensured they used the same language for each assessment and as other members 
of the research team.  
 
 
The quantitative sensory testing (QST) was carried out with the patient relaxed and 
comfortable. The thermal rollers were at the correct temperature before the QST 
commenced to avoid any delays or the need to change the order of the testing. Each of the 
sensory modalities was explained separately and documented in the case report form. 
 
 
A soft brush was gently applied to the skin at both index and control sites and the patient 
was asked to describe the sensation as indicated above. The patient was also asked to give 
the sensation a pain score from zero to ten. A cool roller at a temperature of 25
0
 was 
applied next followed by a warm roller at 40
0
. The rollers are applied to the skin and the 
same questions are asked as for the brush.  
 
 
Von Frey filaments are calibrated so that they apply a consistent force to the skin. The 
filaments are numbered from three to 19. 
 
 
The filaments are placed on the skin and the handle is depressed just enough to bend the 
filament. Starting at the filament which applies the lowest force the researcher moves 
through the filaments until the patient is just able to detect the force applied. The number 
of the filament is then recorded as the detection threshold. The patient is asked to give a 
pain score from zero to ten and then the sequence of testing each filament in sequence 
continues until the patient reports the force applied causes pain. The number of this 
filament is recorded as the pain threshold and a pain score is recorded. 
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Pinprick sensation was tested at both index and control sites. Patients were asked if they 
could detect the pinprick and whether it caused them any pain. A test for wind-up was the 
final stage of the quantitative sensory testing. The pin was used to cause several skin pricks 
in quick succession. If severe pain resulted, wind-up was present and a pain score was 
attributed. 
 
 
In order to facilitate the statistical analysis of the detection and pain thresholds the filament 
numbers are converted to a force applied according to the manufacturers calibration chart. 
The chart has been included as Appendix L. 
 
 
The findings of the quantitative sensory testing have been explored using descriptive 
statistics to explore possible correlations between sensory processing and either the opioid 
prescribed or recent titration of the dose.   Possible correlations between the presence of 
pain and the type of pain ie cancer or non-cancer pain and the patients’ sensory processing 
were also explored. The data from healthy volunteers were compared with data from the 
control site of the patients. 
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7.9 Results  
 
 
 
 
 
 
The tables below show the results of the quantitative sensory testing. The results are 
presented by patient group, opioid prescribed and opioid titration for each of the sensory 
modalities explored.  
Figure 7:  Number recruited in each patient group and the number of assessments 
completed by patients in each patient group 
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Table 70: Thermal thresholds reported by patients at index and control sites where n 
= 164 at assessment 1 and n = 88 at assessment 2 
  
N (%) 
Assessment 1  
Index cool response  
Decrease 23 (14.0%) 
No change 71 (43.3%) 
Increase 70 (42.7%) 
  
Index warm response  
Decrease 39 (23.8%) 
No change 71 (43.3%) 
Increase 54 (32.9%) 
  
Assessment 2  
Index cool response  
Decrease 17 (19.3%) 
No change 34 (38.6%) 
Increase 37 (42.0%) 
  
Index warm response  
Decrease 21 (23.9%) 
No change 39 (44.3%) 
Increase 28 (31.8%) 
 
 
The thermal thresholds at the index site of all patients are shown above. At assessment one 
23 patients (14.0%) described a decreased response when the cool threshold was tested and 
70 patients (42.7%) described an increased response to the same stimulus. At assessment 
one a larger number of patients (n=39, 23.8%) reported a reduced response to the warm 
stimulus and 54 patients (32.9%) reported an increased response to stimulus. 
 
 
At assessment two, 17 patients (19.3%) reported a reduced response to cool stimulus and 
37 (42.0%) patients reported an increased response to the same stimulus. The number of 
patients reporting altered response to warm stimulus also increased at assessment two. 
Twenty-one patients (23.9%) reported a reduced response and 28 patients (31.8%) reported 
and increased response.  
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Table 71:  Thermal thresholds at assessment no. 1 by patient group where n = 159 
 
Index cool response   
Cancer Decrease 8 (9.5%)  
 No change 37 (44.0%) 
 Increase 39 (46.4%) 
   
Non-cancer Decrease 8 (25%) 
 No change 10 (31.3%) 
 Increase 14 (43.8%) 
   
Substance misuse Decrease 1 (5.7%) 
 No change 12 (63.2%) 
 Increase 6 (31.6%) 
   
Non-opioid Decrease 5 (20.8%) 
 No change 9 (37.5%) 
 Increase 10 (41.7%) 
   
Index warm response   
Cancer Decrease 11 (13.1%) 
 No change 42 (50.0%) 
 Increase 31 (36.9%) 
   
Non-cancer Decrease 14 (43.8%) 
 No change 9 (28.1%) 
 Increase 9 (28.1%) 
   
Substance misuse Decrease 2 (10.5%) 
 No change 10 (52.6%) 
 Increase 7 (36.8%) 
   
Non-opioid Decrease 11 (45.8%) 
 No change 7 (29.2%) 
 Increase 6 (25.0%) 
 
 
The table above provides further details of the thermal thresholds in each patient group. In 
the substance misuse group, the majority of patients had normal threshold responses to the 
cool stimulus. In both the cancer and non-cancer pain groups a significant proportion of 
patients had an increased response to the cool stimulus.  
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Table 72:  Thermal thresholds at assessment no. 2 by patient group where n = 88 
 
Index cool response   
Cancer Decrease 8 (16.3%) 
 No change 20 (40.8%) 
 Increase 21 (42.9%) 
   
Non-cancer Decrease 6 (26.1%) 
 No change 8 (34.8%) 
 Increase 9 (42.9%) 
   
Substance misuse No change 1 (100.0%) 
   
Non-opioid Decrease 3 (20.0%) 
 No change 5 (33.3%) 
 Increase 7 (46.7%) 
Index warm response   
Cancer Decrease 10 (20.4%) 
 No change 25 (51.0%) 
 Increase 14 (28.6%) 
   
Non-cancer Decrease 6 (26.1%) 
 No change 9 (39.1%) 
 Increase 8 (34.8%) 
   
Substance misuse Decrease 1 (100.0%) 
   
Non-opioid Decrease 4 (26.7%) 
 No change 5 (33.3%) 
 Increase 6 (40.0%) 
 
 
The responses to the cool stimulus do not appear to have changed much between 
assessment one and two in any of the patient groups. There is only one patient in the 
substance misuse group though. The responses to the warm threshold appear to have 
changed significantly in those patients with non-cancer pain and those patients with non-
cancer pain who are not on opioids when assessments one and two are compared. There are 
smaller changes seen at assessment two in the cancer pain group. Between the assessments 
the percentage of patients in the non-cancer group who have a decreased response to the 
warm stimulus has reduced from 43.8% to 26.1% with an increase in the percentage of 
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patients who had either no change or an increased response. The same pattern was seen in 
the patients who were not on opioids but had chronic non-cancer pain. 
 
 
Table 73:  Thermal thresholds at assessment no. 1 by regular drug where n = 129 and 
the most frequently prescribed drugs are shown 
Index cool response   
Fentanyl Decrease 1(6.7%) 
 No change 5(33.3%) 
 Increase 9(60.0%) 
   
Methadone Decrease 2(10.0) 
 No change 12(60.0%) 
 Increase 6(30.0%) 
   
Morphine                 Decrease 8(14.3%) 
 No change 26(46.4%) 
 Increase 22(39.3%) 
   
Oxycodone Decrease 6(15.8%) 
 No change 14(36.8) 
 Increase 18(47.4%) 
Index warm response   
Fentanyl Decrease 1(6.7%) 
 No change 6(40.0%) 
 Increase 8(53.3%) 
   
Methadone Decrease 3(15.0%) 
 No change 12(60.0%) 
 Increase 5(25.0%) 
   
Morphine       Decrease 10(17.9%) 
 No change 29(63.0%) 
 Increase 17(34.7%) 
   
Oxycodone Decrease 10(26.3%) 
 No change 13(34.2%) 
 Increase 15(39.5%) 
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Fentanyl has the largest proportion of patients with an increased response to the warm 
stimulus. Patients who were prescribed methadone were most likely to report no change in 
their response to warm threshold. Patients who were prescribed morphine and oxycodone 
either reported no change or an increase in response to the warm stimulus with a small 
number of patients who were prescribed each drug reporting a decreased warm response. 
 
 
Similar patterns were seen when patients were asked to describe their response to the cold 
stimulus. Again patients who were prescribed methadone were most likely to have no 
change in their response to the warm stimulus. Patients who were prescribed morphine also 
were most likely to have no change in the description of the warm stimulus. 
 
 
Table 74:  Change in temperature thresholds by mean change in morphine equivalent 
dose (MEDD) between assessments 1 and 2 where n = 88 
 Change in 24 hour MEDD 
 
 N Mean SD SE Min Max 
 
Change in cool response       
Reduced 25 0.2 60.7 12.9 -120.0 139.5 
Same 42 7.9 61.4 11.2 -120.0 200.0 
Elevated 21 -7.1 76.9 18.1 -160.0 205.0 
       
All 88 1.6 64.8 7.7 -160.0 205.0 
       
Change in warm response       
Reduced 18 4.2 54.1 12.7 -120.0 110.0 
Same 54 -0.6 70.2 11.2 -160.0 205.0 
Elevated 15 2.4 68.4 19.8 -120.0 180.0 
       
All 87 1.2 65.2 7.8 -160.0 205.0 
 
 
The table shows the patients divided into three groups according to the change in their 
response to the cool stimulus between assessments one and two. The responses were either 
reduced, the same or increased between the two assessments. “N” shows the number of 
patients in each group. There is a very wide range of opioid dose changes as shown by the 
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maximum and minimum values. The mean changes are very small with large standard 
deviations. 
 
 
The same information is also presented for the patients description of their response to the 
warm threshold.  
 
 
Table 75: Temperature thresholds at the index site by mean opioid titration from 7 
days ago & from 4 weeks ago at assessment 1 where n = 164 
 Dose change (%) from 7 
days ago 
Dose change (%) from 4 
weeks ago 
 
 N Mean Min Max Mean Min Max 
Index cool response at assessment 1 
Decrease 23 -6.4 -33.3 0.0 -8.4 -57.1 40.0 
No change 71 9.6 -66.7 525.0 31.6 -66.7 525.0 
Increase 70 1.4 -44.4 66.7 9.1 -52.0 200.0 
        
Index warm response at assessment 1 
Decrease 39 -1.8 -33.3 50.0 -1.9 -57.1 80.0 
No change 71 8.9 -66.7 525.0 23.9 -66.7 525.0 
Increase 54 0.9 -44.4 66.7 18.4 -28.6 200.0 
        
All 164 4.0 -66.7 525.0 16.8 -66.7 525.0 
 
 
The table shows the patients divided into three groups according to the change in their 
response to the cool stimulus between assessments one and two. The responses were either 
reduced, the same or increased between the two assessments. “N” shows the number of 
patients in each group. There is a wide range of opioid dose changes and these ranges are 
greater over the longer time period. The mean changes are very small with large standard 
deviations. 
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Table 76:  Brush Response at the index site for all patients in the study where n = 163 
Assessment 1  
Decrease 40(24.5%) 
No change 97(59.5%) 
Increase 26(16.0) 
  
Assessment 2  
Decrease 16(18.2%) 
No change 61(69.3%) 
Increase 11(12.5%) 
 
 
In the study group as a whole at assessment one and two the majority of patients reported a 
normal response to the brush stimulus. 
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Table 77:  Brush response at the index site by patient group and assessment where n 
= 158 at assessment one 
 
Assessment 1   
Cancer Decrease 17(20.2%) 
 No change 56(66.7%) 
 Increase 11(13.1%) 
   
Non-cancer Decrease 9(29.0%) 
 No change 13(41.9%) 
 Increase 9(29.0%) 
   
Substance misuse Decrease 5(26.3%) 
 No change 12(63.2%) 
 Increase 2(10.5%) 
   
Non-opioid Decrease 8(33.3%) 
 No change 13(54.2%) 
 Increase 3(12.5%) 
   
Assessment 2   
Cancer Decrease 5(10.0%) 
 No change 40(80.0%) 
 Increase 5(10.0%) 
   
Non-cancer Decrease 5(22.7%) 
 No change 13(59.1%) 
 Increase 4(18.2%) 
   
Substance misuse No change 1(100.0%) 
   
Non-opioid Decrease 6(40.0%) 
 No change 
Increase 
7(46.7%) 
2(13.3%) 
 
 
At assessment one the majority of patients in each of the different groups described an 
unchanged response to the brush at the index site. In patients with non-cancer pain and 
those with non-cancer pain who were not on opioids this majority was less than in the other 
two patient groups. Patients with non-cancer pain who were prescribed opioids had a more 
even distribution between those patients who described an increased and a decreased 
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response to the brush. In patients with non-cancer pain, not on opioids only a small 
minority had an increased response to the brush at the index side. 
 
 
At assessment two, the majority of patients with cancer pain have an unchanged response 
to the brush at the index site with 56 patients (80.0%) reporting a normal experience. In the 
non-cancer pain group the same pattern is seen at assessment two and assessment one. In 
the group of patients who were on not on opioids but had chronic non-cancer pain there is 
again a more even distribution between those patients who had an unchanged response to 
the brush and those with a reduced response to the stimulus. A minority of two (13.3%) of 
patients in this group had an increased response.  
 
 
Table 78:  Brush response at assessment no. 1 by regular drug where the most 
frequently prescribed opioids are shown and n = 128 
Fentanyl   Decrease 4 (26.7%) 
 No change 6 (40.0%) 
 Increase 5 (33.3%) 
   
Methadone Decrease 5 (25.0%) 
 No change 13 (65.0%) 
 Increase 2 (10.0%) 
   
Morphine Decrease 8 (14.5%) 
 No change 44 (80.0%) 
 Increase 3 (5.5%) 
   
Oxycodone Decrease 11 (28.9%) 
 No change 16 (42.1%) 
 Increase 11 (28.9%) 
 
 
As in the previous tables where the results are presented by regular opioid prescribed, 15 
patients were prescribed fentanyl, 20 patients were prescribed methadone, 55 patients were 
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prescribed morphine and 38 patients were prescribed oxycodone. The majority of patients 
who were on methadone reported no change in response to the brush. Patients who were 
prescribed morphine had the greatest majority (80%) of patients with an unchanged 
response to the brush. 
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Table 79:  Von Frey detection thresholds in units of force (g) at index and control site by patient group where n = 140 at assessment one 
 Detection threshold:  index Detection threshold:  control 
 N Mean Median Min Max N Mean Median Min Max 
Assessment No 
1 Cancer 83 3.8 0.4 0 110 84 2.8 0.7 0 34 
Non-cancer 33 16.0 1.1 0 110 31 4.5 0.4 0 110 
Non-opioid 24 5.5 0.2 0 110 24 1.0 0.3 0 8 
All 140 7.0 0.4 0 110 139 2.9 0.4 0 110 
            
2 Cancer 50 4.9 1.4 0 34 50 2.5 1.1 0 17 
Non-cancer 23 7.5 1.1 0 110 20 0.8 0.3 0 5 
Non-opioid 15 15.5 0.4 0 110 15 0.8 0.4 0 3 
All 88 7.4 1.1 0 110 85 1.8 0.4 0 17 
 
The table above shows the detection thresholds at the index and control sites for patients with cancer pain, non-cancer pain and those patients with non-
cancer pain who were not on opioids. The thresholds are given as forces in grams. At the index site patients with non-cancer pain had the highest mean 
detection threshold with a mean of 16.0 g. This is much higher than patients in the other groups. At the control site patients with non-cancer pain again 
had the highest mean detection threshold. At assessment two it is the patients with non-cancer pain who were not on opioids who had the highest mean 
detection threshold at the index site.  
278 
 
Table 80:  Difference between index and control sites in Von Frey detection 
thresholds in units of force (g) by patient group where n = 138 at assessment one 
 Detection threshold index - control 
 N Mean SE Min Max 
Assessment No 
1 Cancer 83 1.0 1.4 -19 107 
 Non-cancer 31 9.0 4.9 -5 110 
 Non-opioid 24 4.6 4.5 -5 108 
 All 138 3.4 1.6 -19 110 
       
2 Cancer 49 2.4 1.1 -7 29 
 Non-cancer 20 7.6 5.4 -1 108 
 Non-opioid 15 14.7 9.8 -3 110 
 All 84 5.9 2.3 -7 110 
 
 
The table above shows the detection threshold at the index site minus the detection 
threshold at the control site. At assessment one it is the patients with non-cancer pain who 
had the greatest difference between sites. At assessment two it is the patients with non-
cancer pain who were not on opioids. Patients with cancer pain had the smallest difference 
between thresholds at both assessments. In all patients together detection threshold are 
significantly difference between index and control sites. There is no significant difference 
between the sites in the different patient groups. 
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Table 81:  Von Frey pain thresholds in units of force (g) at index and control site by patient group where n = 139 at assessment one 
 Pain threshold:  index Pain threshold:  control 
 N Mean Median Min Max N Mean Median Min Max 
Assessment No 
1 Cancer 82 46.4 24.0 0 110 84 49.6 24.0 0 110 
Non-cancer 33 49.6 24.0 0 110 31 39.9 17.0 0 110 
Non-opioid 24 35.2 12.7 0 110 24 29.6 12.7 2 110 
All 139 45.2 17.0 0 110 139 44.0 24.0 0 110 
            
2 Cancer 50 47.3 24.0 0 110 51 41.7 24.0 1 110 
Non-cancer 23 54.8 34.0 0 110 21 66.2 110.0 0 110 
Non-opioid 15 33.9 5.1 2 110 15 29.1 8.3 1 110 
All 88 46.9 24.0 0 110 87 45.4 24.0 0 110 
 
 
The table above shows the pain thresholds at the index and control sites for patients with cancer pain, non-cancer pain and those patients with non-cancer 
pain who were not on opioids. The thresholds are given as forces in grams. At the index site patients with non-cancer pain had the highest mean pain 
threshold and those patients with non-cancer pain who were not on opioids had a much lower threshold. At assessment one the mean pain threshold at the 
control site in patients with cancer pain was higher than at the index site.  
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Table 82:  Difference between index and control sites in Von Frey pain thresholds in 
units of force (g) by patient group where n = 137 at assessment one 
 Pain threshold index - control 
 N Mean SE Min Max 
Assessment No 
1 Cancer 82 -1.8 4.2 -107 102 
 Non-cancer 31 9.4 9.0 -107 109 
 Non-opioid 24 5.6 5.1 -23 102 
 All 137 2.0 3.3 -107 109 
       
2 Cancer 50 7.0 4.8 -93 102 
 Non-cancer 21 -8.7 14.1 -110 110 
 Non-opioid 15 4.9 11.0 -86 102 
 All 86 2.8 4.8 -110 110 
 
 
The table above shows the pain threshold at the index site minus the pain threshold at the 
control site. At assessment one, patients with cancer pain had a negative mean reflecting 
the higher pain threshold at the control site than the index site. At assessment two, it is the 
patients with non-cancer who were not on opioids who had a negative mean.  
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Table 83:  Visual Analogue Scores for the pain threshold detected using the Von Frey filaments where n = 141 at assessment 1 
 
 Pain threshold  VAS:  index Pain threshold VAS:  control 
 N Mean Median Min Max N Mean Median Min Max 
Assessment No 
1 Cancer 84 2.3 1.0 0 10 85 1.9 1.0 0 10 
Non-cancer 33 2.3 1.0 0 9 32 2.4 1.0 0 8 
Non-opioid 24 2.0 1.0 0 7 24 2.0 1.0 0 6 
All 141 2.2 1.0 0 10 141 2.0 1.0 0 10 
            
2 Cancer 50 2.1 1.0 0 9 51 2.3 1.0 0 10 
Non-cancer 23 2.2 1.0 0 8 21 0.8 0.0 0 5 
Non-opioid 15 2.3 1.0 0 8 15 3.1 3.0 0 8 
All 88 2.1 1.0 0 9 87 2.1 1.0 0 10 
 
 
The pain scores range from the minimum to the maximum possible values on the visual analogue scales indicating some patients did not feel pain even at 
the strongest force exerted by the Von Frey filaments. The mean and median pain scores appear similar throughout the patient groups. 
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Table 84:  Difference between index and control sites in Von Frey detection and pain 
thresholds in units of force (g) by regular opioid where n = 107 at assessment one 
 Detection threshold 
index – control 
Pain threshold 
index - control 
Assessment 
No 
Drug N Mean SE N Mean SE 
1 Fentanyl 14 0.4 1.0 14 -2.3 3.3 
Morphine 57 4.0 2.7 57 -4.7 5.5 
Oxycodone 36 3.9 3.1 35 10.6 7.6 
        
2 Fentanyl 9 3.5 3.3 9 -13.4 18.8 
Morphine 34 5.7 3.3 35 8.4 6.8 
Oxycodone 22 1.5 1.0 23 -0.2 8.9 
 
 
Fentanyl had the lowest mean difference between detection thresholds at the index and 
control sites. Oxycodone had the highest mean difference between pain thresholds at the 
index and control sites.  
 
 
Table 85:  Pearson correlations between dose change from assessment 1 to 2, and 
change in thresholds (index - control) between assessments 1 & 2 for cancer and non-
cancer pain patients 
 Correlation with dose 
change 
P 
Cancer Detection threshold 0.285 0.052 
 Pain threshold 0.165 0.267 
Non-cancer Detection threshold -0.061 0.799 
 Pain threshold 0.165 0.474 
All Detection threshold 0.195 0.113 
 Pain threshold 0.154 0.210 
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Table 86:  Comparison of Control results at assessment 1 with results for 102 healthy volunteers 
Grp Mean (SE) 
Detection 
Threshold 
Mean (SE) 
Difference 
from 
Healthy 
volunteers 
t ratio of 
difference 
Mean (SE) 
Pain 
Threshold 
Mean (SE) 
Difference 
from 
Healthy 
volunteers 
t ratio of 
difference 
Mean (SE) 
Pain VAS 
Painvasdiff t ratio of 
difference 
Healthy 
volunteers 
0.29 (0.05)  . 66.48 (4.55)  . 2.88 (1.43)  . 
Cancer 2.78 (0.62) 2.49 (0.62) 4.01 49.62 (5.11) -16.86 (6.84) -2.46 1.91 (0.27) -0.97 (1.45) -0.67 
Non-cancer 4.51 (3.53) 4.22 (3.53) 1.20 39.91 (7.89) -26.56 (9.11) -2.92 2.41 (0.47) -0.47 (1.50) -0.32 
Substance 
misuse 
0.48 (0.15) 0.19 (0.16) 1.18 60.83 (10.41) -5.65 (11.36) -0.50 1.13 (0.40) -1.76 (1.48) -1.18 
Non-opioid 0.98 (0.39) 0.69 (0.39) 1.76 29.61 (7.85) -36.87 (9.07) -4.06 2.04 (0.37) -0.84 (1.48) -0.57 
 
All 2.50 (0.74) 2.21 (0.75) 2.97 46.47 (3.63) -20.00 (5.82) -3.44 1.91 (0.19) -0.97 (1.44) -0.67 
 
 
The table shows the mean detection thresholds using Von Frey filaments in healthy volunteers and then the difference between mean detection thresholds 
in healthy volunteers and the other patient groups. The table also shows the mean pain thresholds using Von Frey filaments in healthy volunteers and then 
the difference between mean detection thresholds in healthy volunteers and the other patient groups. 
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T ratios greater than two are unlikely to be due to chance. Pain thresholds are 
‘significantly’ lower than healthy volunteers in the cancer, non-cancer and non-opioid 
groups, but detection thresholds are significantly higher in the patients with cancer pain 
and for all patient groups combined.  
 
Table 87:  Wind-up frequencies by patient group at assessment 1 where n = 50 
Patient Group Wind-up at Index Site Wind-up at Control site 
Cancer 8 (9.1%) 3(3.6%) 
Non-cancer 13 (39.4%) 9 (27.3%) 
Substance misuse 4 (16%) N/A 
Non-cancer pain, Non opioid 9 (36%) 4 (16%) 
 
 
The table above shows the number of patients with wind-up in each patient group. At the 
control site which is a non-painful area it is surprising to note the number of patients who 
have wind-up. Nine (27.3%) out of 33 patients with non-cancer pain reported wind-up at 
the control area.  
 
 
Table 88:  Mean pain (VAS) of patients with wind-up detected at the index site by 
patient group and assessment at assessment 1 
  Index Control 
 
  N Mean pain 
(VAS) 
N Mean pain 
(VAS) 
 
Assessment Patient group     
1 Cancer 8 2.5 3 0.3 
 Non-cancer 13 4.6 9 3.8 
 Substance misuse 3 3.0 N/A N/A 
 Non-opioid 8 2.5 4 1.1 
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Table 88 shows the mean pain visual analogue scale (VAS) of those patients who reported 
wind-up. The results are shown for each patient group and at each assessment. Patients 
were asked to score their pain from zero to ten. The mean pain VAS for those patients with 
non-cancer pain was 4.6 at the index pain site and 3.8 at the control site. The mean pain 
scores for patients in the non-cancer pain group were higher than the mean pain scores 
reported by patients in the other groups.  
 
 
Table 89:  Mean pain differences (Index minus Control) for patients with wind-up 
detected at the index site by patient group and assessment at assessment one 
  Index Control Index minus 
Control 
  Mean pain 
(VAS) 
Mean pain 
(VAS) 
Mean pain 
(VAS) 
 
Assessment Patient group    
1 Cancer 2.5 0.3 2.3 
 Non-cancer 4.6 3.8 1.0 
 Non-opioid 2.5 1.1 1.4 
 All 3.4 2.2 1.5 
 
 
 
Patients with substance misuse were excluded from this table of results as wind-up was 
only sought at the index site in that patient group. The table shows there is little difference 
in mean pain scores at index and control sites for those patients with non-cancer pain who 
detected wind-up. There is a greater difference between wind-up associated pain at the 
index and control sites for those patients with cancer pain. 
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 Table 90:  Mean pain (VAS) of index and control wind-up by regular drug at 
assessment 1 for patients with wind-up detected at the index site and who were 
prescribed one of the four most frequently prescribed opioids where n = 22 
 Index Control 
 
 N Mean pain (VAS) N Mean pain (VAS) 
 
Fentanyl 5 3.2 4 2.8 
Methadone                4 3.8 1 3.0 
Morphine 8 4.0 8 2.1 
Oxycodone 5 4.6 5 1.8 
 
 
The table above shows the number of patients who were prescribed the most frequently 
used opioids who detected wind-up at index and control sites. The mean pain score at the 
index site of patients who were prescribed oxycodone is higher than the mean pain score 
reported by patients prescribed other opioids. However at the control site the mean pain 
score of patients who were prescribed oxycodone is lower than the other corresponding 
scores for patients on other opioids.  
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Table 91:  Wind-up frequencies at assessment 1, by patient group and most used 
regular opioid (last 24h) where n = 83 and only the four top opioids are shown 
 
  Index Wind-up Control Wind-up 
 
   D N  D N 
 
Cancer Fentanyl . 2 6 7 . 1 
 Morphine 1 1 39 25 . 16 
 Oxycodone 1 4 29 17 . 17 
 All 2 7 74 49 . 34 
        
Non-cancer Fentanyl 1 3 3 3 2 2 
 Methadone . 1 . . 1 . 
 Morphine . 7 10 3 4 10 
 Oxycodone . 1 4 3 1 1 
 All 1 12 17 9 8 13 
        
Substance 
misuse 
Methadone . 4 16    
 Oxycodone . . 1    
 All . 4 17    
 
 
The table above shows the number of patients who detected wind-up by opioid prescribed 
and in each patient group. In the cancer pain group oxycodone is the most frequently 
prescribed opioid in those patients who detected wind-up.  In the non-cancer pain group 
morphine is most commonly associated with wind-up. 
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7.10 Summary of Main Findings 
 
 
7.10.1 Wind-up 
 
 
The most striking result is the presence of wind-up at the control site. Patients with chronic 
non-cancer pain were more likely than patients with cancer pain to have wind-up at the 
control site. Patients with wind-up were asked to score the pain from zero to ten and the 
mean pain score at the index site was 3.4 in all patient groups and 2.0 at the control site. In 
patients with cancer pain oxycodone was the opioid most often associated with wind-up at 
the control site. In patients with non-cancer pain morphine was the opioid most commonly 
associated with wind-up.  
 
 
7.10.2 Thermal Thresholds  
 
 
Patients with chronic non-cancer pain had altered thermal thresholds. This change 
appeared to be exaggerated when the patients were prescribed opioids to manage the pain. 
Patients with substance misuse were least likely to have altered thermal thresholds. 
Patients with cancer pain and non-cancer pain had either no change in thermal thresholds 
or an increase in both cool and warm responses. Patients who were not on opioids and had 
non-cancer pain showed an increased proportion of patients with reduced thermal 
thresholds and this was most pronounced at assessment two. Methadone was the opioid 
prescribed which appeared least likely to alter the patients’ response to thermal thresholds. 
Fentanyl was the most likely to increase the response to the warm stimulus. 
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7.10.3 Brush Allodynia 
 
 
Overall there was less consistency between patient groups in their response to the brush 
being applied to the skin. Patients with cancer pain were most likely to have an unaltered 
response to the brush. Patients with non-cancer pain reported an increased and decreased 
response in almost equal proportions. Patients who were prescribed morphine and 
methadone were most likely to have an unaltered response to the brush. Fentanyl was the 
opioid most likely to induce a change however the change was split between increased and 
decreased response. 
 
 
7.10.4 Pain and Detection Thresholds 
 
 
Patients with non-cancer pain had the highest mean Von Frey detection threshold and the 
greatest difference between detection thresholds at the index and control sites. Patients 
with non-cancer pain also had the highest mean pain threshold at the index site. Although 
the numbers are small there does appear to be a difference between the opioid. Fentanyl 
had a smaller difference between detection threshold at the index and control sites. The 
healthy volunteers had higher pain thresholds than any of the patient groups but were able 
to detect Von Frey filaments at lower forces than the patient groups.  
 
 
7.11 Discussion 
 
 
In a study comparing patients with pain but not on opioids and patients with pain Lucy 
Chen and colleagues found no evidence of mechanical hyperalgesia in any of the patient 
groups. They found heat-induced wind-up was present in patients with pain and on opioids 
but not in the other patient groups. They found a correlation between morphine equivalent 
daily dose and both the heat pain threshold and the presence of heat-induced hyperalgesia 
(Chen et al, 2009). The results of this study are very comparable to our own findings but 
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highlight the difficulties in comparing quantitative sensory testing results between studies 
when the parameters used are so different. 
 
 
Wind-up at the control site indicated a significant proportion of patients in our study were 
developing central sensitisation.  Central sensitisation occurs when normal inhibitory 
controls are reduced or stopped (Dickenson, 1995). This has been recognised in 
experimental studies in both animal and human models (Bannister et al, 2011). Thus the 
presence of the wind-up may be an early means of identifying patients at risk of 
developing OIH. Testing for wind-up is possible for clinicians in all care settings and 
requires no specialist equipment or training. The recognition of a hyper-excitable state is 
helpful in terms of making a diagnosis of hyperalgesia but it does not necessarily lead us to 
conclude the opioids are responsible. Our results suggest that pain and chronic exposure 
are both playing a role with overlap in patients who have chronic pain and are prescribed 
opioids.  
 
 
In our patient groups there was also altered thermal sensitivity. 32.9% of the patients 
reported an increased response to the warm stimulus and this was maintained over time to 
the second assessment. Altered thermal thresholds have also been recognised in both 
animal and human models. Anne Vardanyan and colleagues discussed the role of the 
TRPV1 receptor in opioid-induced hyperalgesia. In a study involving rats with implanted 
morphine pellets they were able to demonstrate thermal and touch hypersensitivity in rats 
with TRPV1 receptor expressed and this was absent in TRPV1 knock-out mice. TRPV1 is 
known to play a role in inflammatory mediated pain and in the presence of inflammation 
the expression of TRPV1 increases. The ability to block the hyperalgesia with a TRPV1 
antagonist further supports its importance in the OIH pathway (Vardanyan et al, 2009). 
Further weight was given to the role of the TRPV1 receptor by the findings of Rowan’s 
work (Rowan et al, 2014). The altered thermal threshold was also demonstrated in patients 
with COMT val
158
met polymorphism (Jensen et al, 2009) which is discussed in the chapter 
on future work. 
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Sensitivity to cold-induced pain has also been described and attributed to exposure to 
morphine. This has been demonstrated in methadone maintenance patients in particular 
(Compton et al, 2010; Cleeland et al, 1995). Again patients in our study groups described 
altered response to the cool stimulus with 42.7% describing an increased response to the 
cool roller.     
 
 
In a study published in 2014 Wasserman and colleagues described a cohort of patients on 
long-term opioids and had persistent pain. They found that some patients who were on 
opioids had persistent pain and wondered if his clinical finding may indicate OIH or that 
the patients had a central pain which was less likely to respond to the opioids (Wasserman 
et al, 2014). One aspect that certainly warrants further exploration in our group is the 
presence of neuropathic features of the pain and whether there is any association between 
pain which is predominantly neuropathic and the development of the features of OIH. 
 
 
Our results add to the published literature and provide valuable comparison between 
patient groups. The data are also provided at different time points which are of benefit. We 
have provided comparison between different patient groups which are highly relevant to 
clinicians. While there will be limitations on comparison due to different quantitative 
sensory testing protocols it will be possible for other research groups to compare our 
results to their own findings. Although our results are consistent with the literature in terms 
of altered thermal threshold we need to explore in more detail whether  individual patients 
have both altered warm and cool sensory processing and whether it is the patients with 
altered thermal threshold who also have wind-up at the control site. When this further 
analysis has been carried out we will be much closer to defining the clinical phenotype of 
OIH. 
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CHAPTER 8:  PATIENTS WITH CHRONIC 
NON-CANCER PAIN AND A HISTORY OF 
SUBSTANCE MISUSE 
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8.1 Hypothesis 
 
 
Patients with chronic non-cancer pain and co-morbid substance misuse will have a 
different response to opioids. This will result in different opioid-related side effects and 
sensory thresholds when compared to patients who are taking opioids for the management 
of either chronic non-cancer pain or substance misuse. 
 
 
8.2 Introduction 
 
 
Much has been written about the risks of patients becoming addicted to opioids which have 
been prescribed for the management of their pain. Less has been written about the 
management of chronic pain in those patients with a current history of substance misuse. In 
an editorial in Pain in 2009 Alford highlighted the importance of knowing whether the 
patient had a history of substance misuse when managing chronic non-cancer pain. He 
called for specialists in pain management and addiction to work together to achieve the 
best outcomes for patients. As well as the need for vigilance when prescribing opioids for 
this group of patients he also highlights the altered and often increased pain responses that 
patients who are substance misusers display (Alford, 2009, Ballantyne and LaForge, 2007). 
 
 
While it is important to be cautious of the risks involved when managing pain in patients 
with substance misuse, it would not be ethical to withhold analgesia from patients with 
chronic pain, including opioids where these are an appropriate therapeutic option. It should 
be noted however, that the risk/ benefit balance that needs to be considered before starting 
any patient on a strong opioid is different in this group of patients. Patients with a history 
of substance misuse will have a higher risk of iatrogenic dependence, but uncontrolled pain 
may be a stressor that can contribute to relapse.  
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8.2.1 Definition of Addiction 
 
 
Physical dependence will occur after prolonged use of an opioid and is a physiological 
response to exposure. It will manifest with symptoms when the drug is withdrawn 
suddenly or the dose is significantly reduced. Symptoms are those covered by the short 
opioid withdrawal scale and will include yawning, sweating, abdominal pain and muscle 
aches. Physical dependence is not the same as, or a precursor for, addiction. The definition 
of addiction requires that the patient has a pre-occupation with the need to obtain the drug. 
Loss of control over the use of the opioid is important in both the development of addiction 
and in making the diagnosis (Lingford-Hughes et al, 2010). Portenoy (quoted in Hojsted 
and Sjogren, 2007, page 492) describes addiction as “a psychological and behavioural 
syndrome characterised by evidence of psychological dependence, and evidence of 
compulsive drug use, and/or evidence of compulsive drug use, and/or evidence of other 
aberrant drug-related behaviours.” 
 
 
There is a “spectrum of substance misuse behaviours” including harmful use and substance 
abuse (Lingford-Hughes et al, 2004). Methadone maintenance programmes are effective at   
keeping patients in management programmes, reducing the use of other non-prescription 
drugs, reducing patient involvement in crime and preventing drug related deaths (Lingford-
Hughes et al, 2004). 
 
 
“Addiction stems from the progressive adaptation of the brain to repeated exposure to 
drugs of abuse” (Lutz and Kieffer, 2013, page 473). Initially patients gain a reward from 
use of the drug whether this is an opioid, cannabis, or alcohol or another substance with 
potential for misuse. After the experience of reward the patient starts to seek the reward 
again and enters a cycle of reward, withdrawal and craving which deteriorates into 
addiction. The mu-opioid receptor is involved in the sensation of reward associated with 
opioids and it is possible that genetic variation in the mu opioid receptor affects responses 
to social behaviour which have also been implicated in the development of addiction. 
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Conversely the kappa receptor has been shown to block the experience of reward to both 
opioids and social experiences (Lutz and Kieffer, 2013). 
 
 
Several brain areas are key in the addiction pathways and these include the nucleus 
accumbens, the orbitofrontal cortex and the amygdala. Dopamine is one of the main 
mediators involved in dependence developing. (Lingford-Hughes et al, 2010) 
 
 
8.2.2 Drugs used to manage addiction to opioids 
 
 
In the UK methadone and buprenorphine are the drugs most frequently used to maintain 
patients with substance misuse. Methadone is a synthetic opioid which binds at the mu 
opioid receptor which will relieve pain for four to six hours but will suppress withdrawal 
and craving for up to 36 hours due to a long half-life. Buprenorphine is also a synthetic 
opioid which is a partial agonist at the mu opioid receptor and has a ceiling effect which 
prevents the risk of respiratory depression if larger doses are taken. It dissociates slowly 
from the opioid receptor which gives the added benefit of a long duration of action. 
(Chapter 3, Pharmacology of medications used to treat opioid addiction in Center for 
Substance Abuse Treatment. Medication–Assisted Treatment for Opioid Addiction in 
Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. HHS 
Publication No. (SMA) 12-4214. Rockville, MD: Substance Abuse and Mental Health 
Services Administration, 2005.) 
 
 
8.2.3 Chronic Non-cancer Pain and Co-morbid Substance Misuse 
 
 
Substance misuse exists with other psychiatric illnesses including depression, anxiety and 
psychosis. (Lingford-Hughes et al, 2004) Patients may also have physical health problems. 
Pain may be the reason patients seek opioids initially and pain can cause loss of physical 
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and social functioning that drives vulnerable patients to seek drugs as a means of coping 
and escape. (Trafton et al, 2004; Cicero et al, 2008) 
 
 
It is difficult to ascertain the prevalence of chronic non-cancer pain in those with substance 
misuse as the patients may not engage with health services or their pain may not be 
recognised and there can be a tendency to over-diagnose prior to substance misuse 
(Weisner et al, 2009). However in 2012 a meta-analysis conducted by Fischer and 
colleagues provided an estimate of the prevalence of pain as 48% with the prevalence of 
anxiety as 16% and of depression 17%. It is noted that the prevalence of the diagnoses is in 
patients who are using prescription opioids illicitly and does not necessarily reflect the 
prevalence of co-morbidities in those patients who are enrolled in methadone maintenance 
programmes.  
 
 
In a large study in the USA Constance Weisner and colleagues looked at data from two 
health plans and found that patients who were prescribed opioids for chronic non-cancer 
pain who also had a history of substance misuse were younger than other patients who 
were prescribed opioids. (Weisner et al, 2009) In another large study, Cicero and 
colleagues reviewed 1408 patients who were admitted for management of substance 
misuse. In this study there were many different substances used prior to admission for 
treatment. Patients were found to have significantly lower physical well-being across 
several domains including chronic pain, mental health and social functioning when 
compared to the national norms. In the study 45% of the patients reported that their first 
contact with opioids had been as part of the management of pain rather than as part of 
experimentation with drugs or seeking highs. This study neatly demonstrated the overlap 
of chronic pain and substance misuse. (Cicero et al, 2008) 
 
 
The management of patients with chronic pain and a history of substance misuse relies on 
making an accurate diagnosis of all co-morbidities. It is important to obtain collateral 
history from family members and other health professionals where possible in case they 
have concerns about on-going use of other substances. Opioid contracts and written 
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treatment plans may also be helpful. (Wesson et al, 1993) Joint working between addiction 
and pain specialists is very important. It is likely that healthcare professionals will be wary 
of managing chronic pain in those patients with a history of substance misuse and there is a 
risk that adequate pain relief will be delayed. (Baldacchino et al, 2009) 
 
 
8.3 Aims 
 
 
The specific aims of this part of the study were to 
 
 
 Establish the impact of opioids on the cognitive function of patients with chronic 
pain and substance misuse 
 Compare the sensory processing of patients with chronic pain and substance misuse 
with the other patient groups. 
 Compare the side effect burden of patients with chronic pain and substance misuse 
with the other patient groups. 
 
 
8.4 Methods 
 
Patients were recruited from a specialist clinic. After they had provided written consent 
they were asked to complete the research assessment on one occasion. Demographic data 
was collected and a detailed opioid history was obtained. Patients completed the same 
series of assessments as outlined in methods chapter. A detailed opioid history was taken 
and patients completed Likert scales which detailed the frequency of opioid-related side 
effects in the last week. The Brief Pain Inventory provided a measure of pain severity and 
the Self-completed Leeds Assessment of Neuropathic Symptoms and Signs provided an 
indication of the quality of the pain. Both objective and subjective measures of cognitive 
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function were used. Quantitative sensory testing provided information on the function of 
the peripheral nervous system. 
 
 
8.5 Results 
 
 
Only six patients were recruited with chronic non-cancer pain and a history of substance 
misuse. The patients in this group were all recruited from the specialist clinic in NHS 
Lothian at which patients are managed jointly by specialists in addiction and pain 
medicine. The clinic runs twice each month. 
 
 
Table 92:  Demographic details of the patients recruited with a history of chronic 
pain and substance misuse where n = 6 
Patient 
Identification 
Number 
 
Age, Sex Pain Site Pain Type 
Patient 1 
 
36, M Lower abdomen Mixed 
Patient 2 
 
41, M Flank and inguinal 
region 
Visceral 
Patient 3 
 
36, M Neck, phantom arm 
pain 
Muscular 
Patient 4 
 
22, M Bilateral whole leg 
pain 
Neuropathic 
Patient 5 
 
36, M Back Musculoskeletal 
Patient 6 
 
40, F Forehead Neuropathic 
 
 
The patients were predominantly male with an age range of 22 to 41 years and a mean age 
of 35.2 years. There are several different types and sites of pain in the patient group. 
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Table 93:  Opioid history and morphine equivalent daily dose (MEDD) of each 
patient with a history of chronic pain and substance misuse where n = 6 
Patient 
Identification 
Number 
 
Primary Opioid 
Prescribed 
 
MEDD Duration of 
Opioid Use 
Patient 1 
 
Dihydrocodeine 
 
66 mg 10 years 
Patient 2 
 
Methadone 
 
960 mg Not stated 
Patient 3 
 
Methadone 
 
1500 mg 12 years 
Patient 4 
 
Methadone 
 
600 mg 1.5 years 
Patient 5 
 
Methadone 
 
975 mg 8 years 
Patient 6 
 
Methadone 
 
1050 mg 4 years 
 
 
Methadone was the most frequently prescribed opioid in this patient group.  The MEDD 
ranged from 66 mg to 1500 mg with a mean of 858.5 mg and a median of 967.5 mg. The 
duration of use ranged from 1.5 years to 12 years with a mean of 7.1 years and a median of 
8 years. 
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Table 94:  Use of adjuvant analgesics and non-pharmacological pain management 
techniques of each patient with a history of chronic pain and substance misuse where 
n = 6 
 
Patient 
Identification 
Number 
 
Adjuvant Analgesics Non-pharmacological 
Interventions 
Patient 1 
 
Diclofenac, Methocarbamol Acupuncture, Heat, Massage, 
Physiotherapy, Psychology, 
TENS 
Patient 2 
 
Gabapentin, Hyoscine 
butylbromide 
Relaxation, Heat 
Patient 3 
 
No Acupuncture, Massage, 
Aromatherapy, Reiki 
Patient 4 
 
Sodium Valproate, Gabapentin, 
Amitriptyline 
Physiotherapy, TENS 
Patient 5 
 
No Physiotherapy 
Patient 6 
 
Paracetamol, Ibuprofen Acupuncture, TENS 
 
 
Four of the six patients were also prescribed adjuvant analgesia and all the patients had 
engaged with non-pharmacological interventions as part of the approach to managing their 
pain.  
 
 
Three of the patients had a co-existing psychiatric disorder – two patients had anxiety and 
depression and one patient had bipolar disorder. 
 
 
301 
 
Table 95:  Median symptom severity scores and Number (percentage) of patients 
experiencing symptoms either very or quite often, or less frequently than this, in 
patients with a history of chronic pain and substance misuse where n = 6 
 
 
 
Median Severity 
of Symptom 
N (%) of patients 
Experiencing 
Symptom Very / 
Quite Often 
N (%) of patients 
Experiencing Symptom 
Occasionally / Never 
Nausea 
 
2.0 1 (16.7%) 5 (83.3%) 
Vomiting 
 
2.0 0 (0%) 6 (100%) 
Dry Mouth 
 
4.0 3 (50%) 3 (50%) 
Myoclonus 
 
1.0 1 (16.7%) 5 (83.3%) 
Hallucinations 
 
2.0 0 (0%) 6 (100%) 
 
 
The table above shows dry mouth was the most frequent symptom in this patient group. 
The median symptom severity score for dry mouth was dry mouth. Nausea, vomiting and 
myoclonus were the most frequently reported symptoms in patients with a history of 
chronic pain and substance misuse. 
 
 
Using the constipation score, three patients (50%) were constipated. Only one of the 
patients was prescribed a laxative. 
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Table 96:  S-LANSS and Brief Pain Inventory Scores for patients with a history of 
chronic pain and substance misuse where n = 6 
 
 
S-LANSS Score Brief Pain Inventory Scores 
 
 
Patient 
Identification 
Number 
 
 Mean Pain Severity Mean Pain 
Interference 
Patient 1 
 
12 
 
8.0 9.1 
Patient 2 
 
2 
 
5.5 5.9 
Patient 3 
 
5 
 
3.8 6.0 
Patient 4 
 
16 7.0 3.3 
Patient 5 
 
8 
 
3.8 3.4 
Patient 6 
 
0 2.8 3.1 
 
 
Two of the six patients scored 12 or greater on the S-LANSS indicating symptoms and 
signs consistent with neuropathic pain. The Brief Pain Inventory scores revealed the 
severity of the patient’s’ pain. The mean pain severity ranged from 2.8 to 8.0 out of 10, 
with a mean of 5.2. The mean pain interference ranged from 3.1 to 9.1 out of 10, with a 
mean of 5.1.  
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Table 97:  MMSE and ACE-R scores for each patient with a history of chronic pain 
and substance misuse where n = 6 
 
Patient 
Identification 
Number 
 
MMSE Score  ACE-R Score 
Patient 1 
 
28 74 
Patient 2 
 
28 91 
Patient 3 
 
30 97 
Patient 4 
 
30 98 
Patient 5 
 
28 73 
Patient 6 
 
30 94 
 
 
Cognitive function was assessed using the Addenbrooke’s Cognitive Examination – 
Revised.  Two of the patients had scores below 85 out of 100 indicating impaired cognitive 
function. All six patients had normal Mini-Mental State Scores. 
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Table 98:  Thermal thresholds, brush response and presence of wind-up as detected 
by Quantitative Sensory Testing in patients with a history of chronic pain and 
substance misuse where n = 6 
 
Patient 
Identification 
Number 
 
Cool Response at 
Index Site 
Warm Response 
at Index Site 
Brush Response 
at Index Site 
Wind-up 
at Control 
Site 
Patient 1 
 
Increased Increased Increased No 
Patient 2 
 
Unchanged Unchanged Unchanged Yes 
Patient 3 
 
Reduced Reduced Reduced No 
Patient 4 
 
Reduced Reduced Reduced No 
Patient 5 
 
Missing Missing Missing Yes 
Patient 6 
 
Unchanged Unchanged Unchanged No 
 
 
One patient had missing QST data at the index site.  Of the remaining five patients three 
had altered thermal thresholds and response to brush stimulus. Two of six patients had 
wind-up at the control site indicating sensitisation beyond the site of the pain. 
 
 
8.6 Discussion 
 
 
8.6.1 Summary of Main Findings 
 
 
Only six patients were recruited with a history of chronic non-cancer pain and substance 
misuse. Recruitment for the study overall had been relatively straightforward however this 
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group of patients proved difficult to identify despite one of the research team being present 
at the specialist clinic. 
 
 
Given the small number of patients recruited the pragmatic decision was taken to present 
descriptive results obtained for the patients. This has ensured transparency of findings. 
 
 
The patients have varied pain histories. They are most frequently prescribed opioids and 
most of the patients have been on opioids for several years. Dry mouth and constipation 
were the most frequently reported symptoms. Two of the six patients had impaired 
cognitive function when assessed using the ACE-R. All patients had preserved cognitive 
function when assessed using the MMSE. 
 
 
Four of the six patients have altered thermal thresholds and response to brush at the site of 
their pain on Quantitative Sensory Testing. Two patients had wind-up at the control site 
suggesting a general sensitisation. 
 
 
8.6.2 Comparison with Other Patient Groups from this Study 
 
 
Dry mouth is the most frequently reported symptom in all patient groups. The median 
severity is highest in patients with pain and a history of substance misuse but this is based 
on only six patients. The frequency of each of the symptoms appears very similar across 
the different patient groups. Constipation is more frequent in patients with substance 
misuse and a history of substance misuse than in other patient groups. The mean pain 
interference score in this group of patients is lower than in the other groups. As in other 
patient groups the ACE-R detected cognitive impairment which was not detected by the 
MMSE. 
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In this sample it was most common to have reduced sensitivity to cool and warm stimulus 
at the site of the pain. This is different to the other patient groups where a minority had 
reduced sensitivity to thermal stimuli. 
 
 
8.6.3 Comparison with Published Literature 
 
 
The patients had a significant side effect burden. In a study of 48 patients on methadone 
39.6% reported dry mouth, 20.8% reported nausea and 18.7% reported constipation. The 
patents in this study were on a mean daily methadone dose of 99.5 mg which is a Morphine 
Equivalent Daily Dose of 746.3 mg ie slightly lower than the MEDD in this patient group. 
(Rhodin et al, 2006) 
 
 
In a literature review published in 2013 Garland comments that altered working memory,  
 
 
“reduced cognitive flexibility and increased impulsivity in long-term opioid users” can 
be “compounded with those associated with chronic pain, may compromise the patient’s 
ability to exert cognitive control needed to cope through non-pharmacological means, 
thereby inadvertently promoting dependence on opioids as a means of obtaining relief 
from pain.” 
 
 
(Garland et al, 2013) In this patient group it will not be possible to determine how much 
cognitive impairment is due to the opioids and how much is due to the substance misuse or 
other –co-existing psychiatric disorder. However cognitive impairment is to be expected in 
this patient group. The patients in this small sample have again shown the ACE-R to be 
superior to the MMSE in detecting cognitive impairment in patients who are prescribed 
opioids. (Karasz et al, 2004) 
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In a qualitative study which recruited 12 patients several themes emerged.  Patients were 
already on methadone maintenance programmes but were not yet involved with pain 
management services. They described the severity of their pain and a subsequent loss of 
physical abilities which resonates with the patients in this study. The six patients in this 
study had a mean pain interference score of 5.1 reflecting the impact of the pain on their 
ability be active and carry out daily activities. Four (66.6%) of the six patients had a mean 
pain interference score greater than five which is almost  the same as the findings of 
Rosenblum et al who found that 65% of patients with chronic pain who were in a 
methadone maintenance programme had a mean pain interference score of five or greater.  
The results in the paper were based on 143 patients. (Rosenblum et al, 2003) 
 
 
Patients with a history of substance misuse have been shown to have reduced pain 
tolerance and report higher levels of pain in general and to thermal stimulus in particular. 
Patients with chronic pain who were identified as high risk for substance misuse had lower 
pain thresholds and higher pain ratings to mechanical and thermal stimuli which were not 
otherwise accounted for by variables which included age, sex or opioid use. (Edwards RR 
2011) Patients with substance misuse have also been shown to have lower pain tolerance 
than healthy volunteers. (Compton et al, 2000) In this study only one of the six patients 
exhibited increased sensitivity at the site of pain but two of the patients had wind-up at the 
control site indicating sensitisation. In the qualitative study published by Alison Karasz in 
2004 patients also described worsening of their pain which they had attributed to the 
methadone. The possibility that the quotes described opioid-induced hyperalgesia was not 
recognised or discussed by the authors. (Karasz et al, 2004) 
 
 
8.7 Conclusions 
 
 
Limited conclusions can be drawn from a sample of six patients. However this is a difficult 
patient group to recruit and there is little published literature on the burden of side effects 
and cognitive impairment which they may experience. The importance of using an 
assessment tool which assesses the relevant domains of cognitive function more fully have 
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been shown in this patient group and are consistent with the larger numbers recruited in the 
rest of the study. The Addenbrooke’s Cognitive Examination appears to be superior to the 
Mini-Mental State Examination in detecting cognitive impairment. Two of the six patients 
had wind-up which may reflect general sensitisation due to opioids. A larger sample size 
would be needed to explore this finding and there may be benefit in conducting qualitative 
interviews with this patient group to explore their views on their pain and the effects of the 
methadone. 
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CHAPTER 9:  FUTURE WORK 
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9.1 Summary of Main Findings 
 
 
The results of this study are exciting and highly clinically relevant. In the context of 
increasing opioid use and increasing recognition of the potential complications the data 
presented here adds to our understanding of the adverse effects of opioids. 
 
 
Patients who are prescribed opioids for the management of pain, either cancer or non-
cancer related, and substance misuse experience opioid-related side effects. The results 
revealed the burden of the side effects. Our results were consistent with some published 
studies with persistent side effects over time and not just at initiation or titration of the 
opioid. Understanding that side effects are likely to be present over prolonged time periods 
helps clinicians take a more proactive approach. Ensuring opioid-related side effects are 
discussed and specifically sought during patient reviews should avoid patients feeling they 
must cope alone. 
 
 
The prevalence of impaired cognitive function has highlighted a significant issue for 
patients and clinicians. The patients who participated in the qualitative interviews 
eloquently discussed the impact of the problem. They described the coping strategies they 
had developed to manage their memory loss and word-finding difficulties. Clinicians need 
to ask patients about their memory and ability to cope in everyday situations for example 
managing their medications. Patients may not volunteer information about memory loss. 
The perceived stigma of memory loss was clear from the qualitative interviews. 
 
 
The qualitative interviews also revealed that patients are aware of altered pain sensation 
and sensitivity of the skin along with other features suggestive of opioid toxicity. This 
study is the first to recognise that opioid-induced hyperalgesia may be present and the 
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symptoms recognised by the patient. Taking a full and thorough history from patients who 
are on opioids could identify those with OIH.  
 
 
The quantitative sensory testing revealed evidence of central sensitisation in patients who 
are on opioids. The central sensitisation was signalled by the presence of wind-up at a non-
painful site. Thermal thresholds were altered which has been described in the literature 
previously. Detection thresholds were higher in patients with pain compared to healthy 
volunteers and pain thresholds were lower in the patients with pain. 
 
 
We have made some progress to defining the clinical phenotype of OIH. Further analysis 
of the data collected will refine this further. 
 
 
9.2 Bias and Limitations 
 
 
There was no power calculation for this study. The decision was made at the start of the 
study after discussion with the statistician to recruit as many patients as possible but 
without a sample size calculation. This was felt to be an appropriate approach for an 
exploratory study. The number of patients recruited was 178 and many of them completed 
assessments at two or three time points which are a significant number especially in the 
palliative medicine patient population where patients are likely to become frailer during 
participation in a study.  
 
 
The research team were all members of either specialist palliative care or chronic pain 
teams with both clinical and research roles. It may be that some of the patents under-
reported symptoms and side-effects due to a loyalty to clinicians from the same team.  
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The study was conducted at several sites in Glasgow, Edinburgh and Forth Valley. The 
geography of the area and the number of patients recruited for the study required the 
involvement of several team members in conducting research assessments. This may have 
introduced observer bias particularly with the quantitative sensory testing. Other research 
tool used such as the Brief Pain Inventory and the Self-completed Leeds Assessment of 
Neuropathic Symptoms and Signs should have been more robust in terms of inter-observer 
bias. They rely on subjective responses from the patient but have still been shown to have 
validity. 
 
 
It was difficult to recruit patients with chronic non-cancer pain who were not on opioids. 
Most patients were prescribed an opioid before being referred to the specialist clinic. It 
may have been easier to recruit this group of patients through primary care. Patients with a 
history of substance misuse were keen to participate in the study but were clear in their 
preference to complete the assessments whilst attending clinic. This was a practical 
arrangement as the assessments were only required at one time point for this patient group. 
Patients with chronic pain and a co-morbid history of substance misuse were the most 
challenging to recruit. They may have other health issues which preclude regular 
attendance at the clinic. 
 
 
The majority of the patients were seen in their own home according to their preference. 
This probably contributed to a more comfortable environment for the patient. Many of the 
patients enjoyed participating in the study and reported they enjoyed the visits and valued 
the additional contact. 
 
 
The time interval between study assessments was six to eight weeks. For patients with 
metastatic cancer there can be significant change in their well-being and medications 
during a period of weeks. Although a pragmatic choice the time interval will have affected 
our ability to detect changes in the study outcomes. The provision of longitudinal data has 
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affected the ability to detect smaller changes. It is also likely that during the time interval 
malignant disease progressed and the confounding factors changed. 
 
 
Patients were asked about the presence of side-effects in the week prior to the assessment 
and this was recorded using the Likert scales. Many of the published studies have used 
side-effect severity as the outcome measure rather than frequency. This limits the ability to 
compare our results with the published literature. However the information does give a 
very meaningful description of the burden of side-effects.  It is likely that patients will 
differ in their opinion of the relative importance of frequency and severity of side-effects 
and this opinion will have been affected by their own experience. It would have given even 
more depth and meaning if the history of both frequency and severity of opioid-related 
side-effects had been sought. 
 
 
Overall patients were able to complete the assessments required by the study without 
difficulty. They did not find the study too burdensome and welcomed the chance to 
participate. Many patients commented on the first question of the Brief Pain Inventory 
which askes about “pains other than everyday aches and pains”. Many patients found this 
question confusing. They lived with pain each day and for them even very severe pain had 
become part of everyday life. 
 
 
Patients seemed to have the most difficulty when completing the Bond and Lader scales. 
Several of the patients needed support and clarification before being able to complete the 
scales. Patients appeared more familiar with the use of numerical rating scales which were 
used to record the pain severity at various times in the assessments for example during 
completion of the Brief Pain Inventory.  If subjective measures of cognitive function were 
needed for future studies either numerical rating scales or verbal rating scales to assess 
specific aspects of cognitive function would be used. It may be that if the study had 
focussed on particular aspects of cognitive function – those that are most meaningful to 
patients in terms of everyday functioning –the results of the subjective measures of 
cognitive function would have had more meaning to the patients. 
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9.3 Future Work 
 
 
There are still further explorations of the data that will clarify findings already discussed 
and help to refine the conclusions reached. There are many confounders for both the 
opioid-related side effects and the effect of opioids on cognitive function. The possible 
contribution of chemotherapy to the impaired cognitive function has not yet been explored. 
Another possible analysis of the data already collected could explore the impact of 
socioeconomic factors on the cognitive function of the patients for example. It would also 
be interesting to compare the affective component of the Brief Pain Inventory with the 
Hospital Anxiety and Depression Scale results and how they correlate with the 
Addenbrooke’s Cognitive Examination and the Mini-Mental State Examination. 
 
 
The prevalence of cognitive function revealed by the Addenbrooke’s Cognitive 
Examination is fascinating. It is likely that the cognitive impairment is due to multiple 
factors including the opioids, other drugs such as anti-cholinergics, chemotherapy, pain 
and co-morbidities. However recognising the extent of the cognitive impairment is the first 
step. We have used an objective measure of cognitive function that does not require 
specialist training and was acceptable to patients. Future work would ideally recruit 
patients with cancer-related pain who are opioid-naïve and assess their cognitive function 
prior to introducing opioids. The project would have a flexible approach so that patients 
can be reviewed soon after changes in their opioids have been made. This future project 
would offer the responsiveness lacking in the current study. Due consideration would need 
to be given to the assessment of patients at times when they had needed a change in their 
opioids which implies an increase in pain (or breathlessness) as the pain itself may also 
impact on their cognitive function. Having identified the extent of cognitive function it 
would also be interesting to explore this further with patients through qualitative 
interviews. Some themes were highlighted during the interviews with patients who had 
previously been opioid toxic but exploring the cognitive impairment further with both 
patients and their main carers may help clinicians understand better how their patients 
cope. 
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Some of the patients in the study had a significant side-effect burden and were managing 
their symptoms, opioid-related side effects and pain covertly. This was highlighted by 
some of the participants in the qualitative part of the study. A project being considered is 
the introduction and evaluation of a pain management programme for patients with cancer-
related pain in order to provide them with a better understanding of their pain, the drugs 
they have been prescribed, the management of the side effects and how to obtain further 
information and support.  
 
 
9.4 Impact of other Drugs on Cognitive Function 
 
 
Patients with cancer and non-cancer pain are likely to be on several different medications. 
We are keen to explore the impact of these medications and will explore possible 
correlation between other medications and objective and subjective measures of cognitive 
function. 
 
 
The drug burden index will be used to explore the possible role of other drugs. The index 
was developed to understand some of the risks to patients from the medications they are 
taking. The index takes into account the sedative effects and the anti-cholinergic side-
effects of drugs. The index has been shown to correlate with physical frailty and poor 
function on a specific test of cognitive function – the digit symbol substitution test. We 
will explore how the drug burden index correlates with the Addenbrooke’s Cognitive 
Examination and whether it helps separate the role of opioids and drugs from the other 
factors affecting cognitive function (Hilmer et al, 2007; Kouladjian et al, 2014). 
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Appendix B 
 
Patient Information Sheet 
 
Study Title: Opioid-induced side-effects and hyperalgesia 
 
Explanation of the title 
 
Opioids are strong painkillers which may be prescribed for different reasons including 
longstanding non-cancer pain and cancer pain. Opioids are a class of drug which include 
morphine and drugs similar to morphine. Methadone is another example of an opioid drug. 
It is sometimes prescribed for pain and sometimes to help people who have previously had 
a drug misuse problem.  
 
All the strong painkillers can have side-effects. There is also a small risk that the painkiller 
can cause an increase in the type or severity of pain which is reported. This is known as 
opioid-induced hyperalgesia. 
 
Some patients who have chronic pain but are not taking morphine or any of the drugs 
similar to morphine will also be invited to take part to help us understand the effects of the 
strong painkillers. 
 
Introduction 
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of this study? 
 
This study is being done so that we can learn more about the side-effects and potential 
problems that can happen when people are prescribed strong painkillers such as morphine 
for their pain. Some of these problems affect only a very small number of people but it is 
still important that we learn as much as possible about the risks so that we can help those 
affected. For some people there is a chance that taking the strong painkiller will make their 
pain worse or change the type of pain they experience. 
 
Why have I been invited to take part in the study? 
 
You have been invited to take part in the study because you are on strong painkillers for 
your pain or other reasons. About 250 people who are taking morphine or drugs similar to 
morphine will take part in the study. Some people will also be asked to take part because 
they have experienced pain over a long period of time. The type of pain they experience 
may be different and it is likely there will be many different causes of the pain. 
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Do I have to take part?  
 
It is up to you to decide. Before you decide to take part, please read this information sheet 
carefully.  Ask us to explain anything that is not clear or if you would like more information about 
any part of the study. If you decide to take part, we will ask you to sign a consent form to show 
you have agreed to take part.  You are not obliged to take part in this study; it is your choice 
whether you take part or not.  If you do take part, you may change your mind and leave the study at 
any time.  Leaving the study or not taking part will have no effect on your usual medical care and 
you will continue to be treated by your doctor(s) as before. 
 
 
What will happen to me if I take part? 
 
There are different parts to this study. You may choose to take part in one aspect of the 
study or you may be eligible for all three parts.  
 
The first part of the study involves a single assessment of your pain and any side-effects 
you may be experiencing as a result of the painkillers you are taking. The assessment 
process is described below. 
 
The second part of the study involves a more detailed interview for those people who have 
experienced more severe side-effects of the painkillers. The doctor who usually looks after 
you will let us know that you have had this experience. The interviews will be conducted 
on an individual basis and will be recorded. This should take no more than 60 minutes. 
 
The third part of the study involves repeating the assessments (as described below) every 4 
to 8 weeks. This will tell us if your pain is changing and whether this change could in any 
way be due to the painkillers you are taking. We can also review any side-effects you may 
be experiencing. If you are happy to be involved in this part of the study, we will continue 
to see you for a maximum of 18 months. 
 
All patients who participate in the study will be asked if they would provide a blood 
sample or mouth swab. This will be stored and analyzed in the future to try and understand 
in more detail the link between genetics and side-effects of the drugs. You do not have to 
provide a blood sample even if you are helping with other parts of the study. 
 
The assessment undertaken in the first and third parts of the study involves a series of 
questionnaires which should take no more than 60 minutes to complete. They will provide 
us with information on the type of pain you are experiencing and how the pain is affecting 
you generally for example your mood and intellectual functioning. We will also test the 
sensation in the skin at the site of your pain. This involves very briefly pressing fine plastic 
fibres and warm and cool rollers against your skin.  Most of the tests are not 
uncomfortable, but if it produces a very mild discomfort, this shouldn’t last for more than a 
few seconds.   
 
The first part of the study is open to anyone who is taking strong painkillers such as 
morphine. The third part of the study is open to those who are taking more than 60mg of 
morphine each day (or an equivalent dose of another strong painkiller). 
 
The detailed assessment of your pain is in addition to your normal treatment. The doctors 
looking after you will continue to manage your pain and to adjust your painkillers as 
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needed. This study does not affect the medication you can take for your pain. 
 
What will I have to do?  
 
If you decide to take part in the study we will ask that you complete the questionnaires and 
examination whilst you are attending the hospital for your usual clinic appointments or 
treatment.  
 
What are the possible advantages and disadvantages of taking part? 
 
We cannot promise the study will help you but the information we get from the study will 
help those who experience side-effects or a worsening or change in the type of pain as a 
result of taking strong painkillers. You will have a very detailed assessment of your pain 
on a regular basis and if there are problems we will contact your doctor who normally 
looks after your pain to make any necessary changes. The main disadvantage to you is the 
additional time that will be required to complete the study although we will make every 
effort to ensure this coincides with your routine visits to the hospital clinic and, if it is more 
convenient for you, a researcher can arrange to visit you at home. 
 
What if there is a problem? 
  
Any complaint about the way you have been dealt with during the study will be addressed. 
The detailed information on this is given in part 2. 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. Information from the assessments you complete will be identified 
by your initials and a number, rather than by your name. All information will be securely 
stored. Occasionally regulatory authorities need to check that research is being done 
properly. In this case they may need to access your medical records. 
 
If the information in part 1 has interested you please read the additional information 
in part 2 before making any decision. 
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Part 2 
 
What if relevant new information becomes available? 
 
If during the course of the study it becomes clear that you are someone who is 
experiencing side-effects of the strong painkillers or that the drugs are changing the pain 
you are experiencing, we will contact the doctors who usually look after your pain. They 
will arrange for any necessary changes to be made to your medications. 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any point. Questionnaires that you have already 
completed will remain part of the study but you will not need to complete any further 
assessments. The researcher may suggest that you stop the study, for example if there is a 
change in your medical condition. 
 
What happens if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (0141 211 3418/ 0131 777 
3518). If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. Details can be obtained from the hospital. 
 
Involvement of the General Practitioner / Hospital Consultant 
 
We will inform your general practitioner and hospital consultant of your involvement in 
the study. They will receive a letter which explains the study and explains who they can 
contact if they have any questions. 
 
What will happen to the results of the research study? 
 
The results of the study will be published in journals and presented at conferences. There 
will be no way of identifying you in any of the publications. If you would like to be 
informed of the results of the study once it is completed we can explain them to you. 
 
Who is organising and funding the study? 
 
The Beatson Oncology Centre Fund (A registered charity) in Glasgow is funding the study. 
The study is being organised by a team of researchers who work in Glasgow and 
Edinburgh as part of the Edinburgh Translational Research in Pain Group. 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee to protect your safety, rights, well-being and dignity.  
 
Contact: Dr Ruth Isherwood (0141 211 3418) 
Dr Suzanne Carty (0131 777 3518) 
 
Thank you for taking the time to read this Patient Information Sheet. 
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Appendix C 
Consent Form 
4
th
 November 2010 (Version 4) 
 
Title of project: Opioid-induced side-effects and hyperalgesia. 
 
Researchers: 
Dr Ruth Isherwood, Senior Clinical Research Fellow 
Dr Suzanne Carty, Advanced Pain Trainee 
Dr Lesley Colvin, Consultant in Anaesthesia and Pain Medicine 
Prof Marie Fallon, Consultant in Palliative Medicine 
Dr Michaell Orgel, Consultant in Substance Misuse 
 
Patient Identification Number for Trial: …………… 
 
Please initial each statement to confirm your consent. 
 
1. I confirm that I have read the patient information leaflet and have had the opportunity to ask 
questions regarding this study.                                                                                                          
 
2. I understand that members of the research team will need access to my medical records as part of 
this study and I give permission for them to look at the records. I also understand that regulatory 
authorities may need access to my medical records where it is relevant to my participation in 
research.                                                                                                               
 
3. I agree to my GP and hospital consultant being informed that I am participating in this study and 
to them being contacted if it may improve the management of my pain.                                  
 
4. I understand that participation in the study is voluntary and that I am free to withdraw from the 
study at any time. If I withdraw from the study I understand that any assessments I have already 
completed as part of the study will remain in the study database. I understand that withdrawing 
from the study does not affect my medical care or legal rights.                                                             
 
5. I consent to take part in the assessments described in the patient information leaflet.  
1.One series of assessments only as part of the study                                                                     
2. Repeat series of assessments every 4 to 8 weeks as part of the study                              
 
6. I understand that if I participate in the interview about my experiences of having side-effects of 
the strong painkillers (opioids), the interview will be recorded and transcribed ie a written copy will 
be made which will remain confidential.                                                                                              
                        
7. I understand that if I participate in the interview about my experiences of having side-effects of 
the strong painkillers (opioids), quotes from this interview may be used in publications or 
submitted thesis. I will not be identifiable from any quotes used.                                                    
 
8. I agree to provide a blood sample or mouth swab which will be stored and analysed in the future 
to provide more information on the link between genetics and side-effects of the strong painkillers 
(opioids)            
 
                                         
……………………………….                   ……………          ..…………………… 
Name of Patient                                          Date                       Signature 
 
……………………………….                   ……………              …………………. 
Name of researcher taking consent            Date                           Signature 
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Appendix D 
 
Short Opioid Withdrawal Scale 
 
Please put a tick in the appropriate box if you have suffered from any of the following 
conditions in the last 24 hours: 
 
 None 
 
Mild Moderate Severe 
Feeling sick 
 
    
Stomach cramps 
 
    
Muscle spasms / twitching 
 
    
Feelings of coldness 
 
    
Heart pounding 
 
    
Muscular tension 
 
    
Aches and Pains 
 
    
Yawning 
 
    
Runny nose 
 
    
Insomnia / Problems sleeping                           
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Appendix E 
 
 
ORAL Morphine 
Equivalency Factor 
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 -
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N
 -
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 E
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a
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I
T
 -
 I
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a
l 
C1 - Co-codamol 30/500 Divide by 6 
           C1 - Co-codamol B1 
8/500 Divide by 6 
           C1 - Co-codamol B2 
15/500 Divide by 6 
           C2 - Codeine Phosphate  Divide by 8 
           C3 - Co-proxamol  Divide by 8 
           C4 - Dihydrocodeine Divide by 10 
           
C5 - Tramadol  
Divide by 
13.3 
           D1 - Alfentanil 
 
MC 
 
x30 
     
MC 
  D2 - Buprenorphine 
 
x80 
     
x2.1 
    D3 - Diamorphine x3 
  
x3 
      
MC MC 
D4 - Fentanyl 
 
Divide by 
20 
Divide by 
20 
    
x3 
Divide by 
33 MC MC MC 
D5 - Hydromorphone x7.5 
  
x25 
      
MC MC 
D6 - Methadone x7.5 
  
MC 
      
MC MC 
D7 - Morphine x1 
  
x2 x2 
 
Divide by 
2 
   
MC MC 
D8 - Oxycodone x2 
  
x4 
                        
             KEY: 'MC' = drug can be given by this route but will require manual conversion for individual patients
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Appendix F 
 
 
 
 The Presence and Severity of Symptoms 
 
1. Please read and answer each question about symptoms that you may have noticed. 
2. If you are experiencing the problem, please rate the severity of the problem. 
3. Answer the questions while thinking about the last week. 
 
 
 
 
 
Very 
often 
Quite 
often 
Occasionally Very 
rarely 
Never 
1. Have you felt sick or 
nauseated? 
 
 
4 3 2 1 0 
2. Have you been sick? 
 
 
4 3 2 1 0 
3. Does your mouth feel 
dry?                      
 
 
4 3 2 1 0 
4. Have you noticed any 
jerking or twitching of your 
arms or legs (e.g. spilling 
drinks or whilst reading a 
book or whilst trying to go 
to sleep)? 
 
4 3 2 1 0 
5. Have you thought you 
have seen or heard anything 
that may not have been real 
or that seemed strange? 
  
 
4 3 2 1 0 
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Appendix G 
 
 
 
The Presence and Severity of Constipation 
 
 
1. Please read the following questions about your bowel function. 
2. Answer the questions while thinking about the last week. 
3. Please tick the answer which best represents your bowel function in the last week. 
 
 
 
 
 
1. How often have 
your bowels moved 
in the last week? 
 
 
 
Twice less 
than usual 
 
 
 
As usual or 
once more or 
less than usual 
 
 
 
Twice more 
than usual 
 
 
 
 
2. How easy has it 
been to move your 
bowels? 
 
 
 
Difficult 
 
 
 
Normal 
 
 
 
Easy 
 
 
 
 
3. What has been 
the consistency of 
your motions? 
 
 
 
No motion 
 
 
 
Hard 
 
 
 
Normal 
 
 
 
Loose 
 
 
 
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Appendix H 
 
Hospital Anxiety and Depression Scale 
 
Doctors are aware that emotions play an important part in most illnesses. If your doctors 
know about theses feelings he will be able to help you more. This questionnaire is designed 
to help your doctor know how you feel. Read each item and place a firm tick in the box 
opposite the reply which comes closest to how you have been feeling in the past week. 
Don’t take too long over your replies; your immediate reaction to each item will probably 
be more accurate than a long thought out response.  
Tick only one box in each section 
 
I feel tense or “wound up”: 
Most of the time 
 
 
A lot of the time 
 
 
Time to time, 
Occasionally 
 
 
Not at all 
 
 
I still enjoy the things I used to enjoy: 
Definitely as 
much 
 
Not quite so much 
 
Only a little 
 
 
Not at all 
 
I get a sort of frightened feeling like something awful is about to happen: 
Very definitely 
and quite badly 
 
Yes, but not too 
badly 
 
A little but it 
doesn’t worry me 
 
 
Not at all 
 
 
I can laugh and see the funny side of things: 
As much as I 
always could 
 
Not quite so much 
now 
 
Definitely not so 
much now 
 
 
Not at all 
 
 
I feel as if I am slowed down: 
Nearly all of the 
time       
 
Very often 
 
Sometimes 
 
Not at all 
 
I get a sort of frightened feeling like “butterflies in the stomach” 
Not at all 
 
Occasionally 
 
Quite often 
 
 
Very often 
 
I have lost interest in my appearance: 
Definitely 
 
 
I don’t take as 
much care as I 
should     
 
 
I may not take 
quite as much care 
 
I take just as much 
care as ever 
 
I feel restless as if I have to be on the move: 
Very much indeed 
 
Quite a lot 
 
 
Not very much 
 
Not at all 
 
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Hospital Anxiety and Depression Scale 
(Continued) 
 
 
 
Worrying thoughts go through my mind: 
A great deal of the 
time 
 
 
A lot of the time 
 
 
From time to time 
but not too often 
 
 
Only occasionally 
 
 
I feel cheerful: 
Not at all 
 
Not often 
 
Sometimes 
 
 
Most of the time 
 
I look forward with enjoyment to things: 
As much as I ever 
did 
 
Rather less than I 
used to 
 
Definitely less than 
I used to 
 
 
 
Hardly at all 
 
 
I get sudden feelings of panic: 
Very often indeed 
 
 
Quite often  
 
 
Not very often 
 
 
 
Not at all 
 
 
I can sit at ease and feel relaxed: 
Definitely 
      
 
Usually 
 
Not often 
 
Not at all 
 
I can enjoy a good book or radio or TV programme: 
Often 
 
Sometimes 
 
Not often 
 
 
Very seldom 
 
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Appendix I 
 
Brief Pain Inventory (Short Form) 
 
1. Throughout our lives, most of us have had pain from time to time (such as minor 
headaches, sprains and toothaches). Have you had pain other than these everyday kinds of 
pain today? 
 
 1. Yes     2. No 
 
2. Please rate your pain by circling the one number that best describes your pain at its 
worst in the last 24 hours. 
0 1 2 3 4 5 6 7 8 9 10 
No          Pain as bad  
Pain          as you can  
          imagine 
 
3. Please rate your pain by circling the one number that best describes your pain at its least 
in the last 24 hours. 
0 1 2 3 4 5 6 7 8 9 10 
No          Pain as bad  
Pain          as you can  
          imagine 
 
4. Please rate your pain by circling the one number that best describes your pain on the 
average. 
0 1 2 3 4 5 6 7 8 9 10 
No          Pain as bad  
Pain          as you can  
          imagine 
 
5. Please rate your pain by circling the one number that tells how much pain you have right 
now. 
0 1 2 3 4 5 6 7 8 9 10 
No          Pain as bad  
Pain          as you can  
          imagine 
 
6. What treatments or medications are you receiving for your pain? 
………………………………………………………………………………………………
…………………………………………………………………………………… 
 
 
7.In the last 24 hours, how much relief have pain treatments or medications provided? 
Please circle the one percentage that most shows how much relief you have received. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No          Complete 
Relief          Relief 
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Brief Pain Inventory (continued) 
 
 
8. Circle the one number that describes how, during the past 24 hours, pain has interfered 
with your: 
 
A. General Activity 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
B. Mood 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
C. Walking Ability 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
D. Normal Work (includes both work outside the home and housework) 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
E. Relations with other people 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
F. Sleep 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
 
G. Enjoyment of life 
0 1 2 3 4 5 6 7 8 9 10 
Does not                  Completely 
Interfere                  Interferes 
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Appendix J 
Quantitative Sensory Testing 
 
Spontaneous pain score (0 - 10)                 
 
Does the patient have an area with abnormal sensation?      Yes                 No       
 
If yes, map area on paper. Mark index and control areas on chart below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index area Control area 
 
 
 
Result VAS Result VAS 
Brush     
Rolltemp 
Cool     
Warm     
Von Frey filaments 
Detection 
threshold 
    
Pain threshold     
Pinprick 
(Record if not 
detected) 
    
Wind-up  
 
 
 
 
 
 
 
Key  No change  0 Decrease   3 
 Increase  1 Significant decrease  4 
Significant increase 2 Not detected   5 
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Appendix K 
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Appendix L 
 
The Use of Analogue Scales to Rate Subjective Feelings 
 
1. Please rate the way you feel in terms of the dimensions given below. 
2. Regard the line as representing the full range of each dimension. 
3. Rate your feelings as they are at the moment. 
4. Mark clearly and perpendicularly across each line. 
 
 
Alert  Drowsy 
 
Calm  Excited 
 
Strong  Feeble 
 
Muzzy  Clear- headed 
 
Well-
coordinated 
 Clumsy 
 
Lethargic  Energetic 
 
Contented  Discontented 
 
Troubled  Tranquil 
 
Mentally 
slow 
 Quick-witted 
 
Tense  Relaxed 
 
Attentive  Dreamy 
 
Incompetent  Proficient 
 
Happy  Sad 
 
Antagonistic  Amicable 
 
Interested  Bored 
 
Withdrawn  Gregarious 
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Appendix M 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE S-LANSS PAIN SCORE Leeds Assessment of Neuropathic Symptoms 
and Signs (self-complete)  
Dr Mike Bennett MD FRCP  
Senior Clinical Lecturer in Palliative Medicine, St Gemma’s Hospice and University of Leeds  
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale has seven items 
consisting of five symptom items and two examination items. Usually, the examination items are done by a 
doctor but the modified version (the S-LANSS or self-report LANSS) allows people to do this themselves. 
The purpose of these scales is to assess whether the pain that is experienced is predominantly due to nerve 
damage or not. Both the LANSS and S-LANSS are scored out of 24; a score of 12 or more is strongly 
suggestive of neuropathic pain. Please note, however, that although the S-LANSS is a useful guide to the 
type of pain, it should only be viewed as an indicator, and not as a diagnosis. Always consult your doctor 
for a qualified opinion.  
Read more … http://www.neurocentre.com/nep.php  
NAME:_______________________________________________ DATE:________  
• This questionnaire can tell us about the type of pain that you may be experiencing. This 
can help in deciding how best to treat it.  
• Please draw on the diagram below where you feel your pain. If you have pain in more than 
one area, only shade in the one main area where your worst pain is.  
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• On the scale below, please indicate how bad your pain (that you have shown on the above 
diagram) has been in the last week where :'0' means no pain and '10' means pain as severe as 
it could be.  
• Below are 7 questions about your pain (the one in the diagram).  
• Think about how your pain that you showed in the diagram has felt over the last week. 
Put a tick against the descriptions that best match your pain. These descriptions may, or may not, 
match your pain no matter how severe it feels.  
• Only circle responses that describe your pain.  
NONE 0 1 2 3 4 5 6 7 8 9 10 SEVERE PAIN  
1. In the area where you have pain, do you also have 'pins and needles', tingling or 
prickling sensations?  
a) NO - I don't get these sensations (0)  
b) YES - I get these sensations often (5)  
2. Does the painful area change colour (perhaps looks mottled or more red) when the 
pain is particularly bad?  
a) NO - The pain does not affect the colour of my skin (0)  
b) YES - I have noticed that the pain does make my skin look different (5) from normal  
3. Does your pain make the affected skin abnormally sensitive to touch? Getting 
unpleasant sensations or pain when lightly stroking the skin might describe this.  
a) NO - The pain does not make my skin in that area abnormally sensitive (0) to touch  
b) YES - My skin in that area is particularly sensitive to touch (3)  
4. Does your pain come on suddenly and in bursts for no apparent reason when you are 
completely still? Words like 'electric shocks', jumping and bursting might describe 
this.  
a) NO - My pain doesn't really feel like this (0)  
b) YES - I get these sensations often (2)  
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5. In the area where you have pain, does your skin feel unusually hot like a burning 
pain?  
a) NO - I don't have burning pain (0)  
b) YES - I get burning pain often (1)  
6. Gently rub the painful area with your index finger and then rub a non-painful area (for 
example, an area of skin further away or on the opposite side from the painful area). How 
does this rubbing feel in the painful area?  
a) The painful area feels no different from the non-painful area (0)  
b) I feel discomfort, like pins and needles, tingling or burning in the (5) painful area that is 
different from the non-painful area  
7. Gently press on the painful area with your finger tip then gently press in the same way 
onto a non-painful area (the same non-painful area that you chose in the last question). 
How does this feel in the painful area?  
a) The painful area does not feel different from the non-painful area (0)  
b) I feel numbness or tenderness in the painful area that is different from (3) the non-
painful area  
Scoring: a score of 12 or more suggests pain of a predominantly neuropathic origin  
SCORE___________  
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Appendix N 
 
 
The SOMEDIC von Frey set consist of a specially designed case, containing 17 
monofilaments, marked 3 to 19 and a built-in-thermo-hygrometer. 
Manufacturing details for SENSELab monofilaments (hairs) are as follows: 
 
Hair No Diameter 
(mm) 
Length 
(mm) 
Nominal Force 
(g) 
Pressure 
(g/mm2) 
     
3 0.12 46 0.026 5 
4 0.12 40 0.034 8 
5 0.15 46 0.064 7 
6 0.17 46 0.085 11 
7 0.20 46 0.145 11 
8 0.23 46 0.320 14 
9 0.25 43 0.390 18 
10 0.30 46 1.10 23 
11 0.35 46 1.70 38 
12 0.40 46 3.30 49 
13 0.45 43 5.10 53 
14 0.50 43 8.30 90 
15 0.55 43 17.0 90 
16 0.65 40 24 122 
17 0.70 40 34 133 
18 0.80 40 50 169 
19 1.00 40 110 178 
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